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Prolactin is a polypeptide hormone that is synthesized in and secreted from the 
lactotrophs of the anterior pituitary gland. We are now aware that synthesis and 
secretion of prolactin is not restricted to the anterior lobe of the pituitary gland, but 
other organs and individual cells can also produce it. This book provides the headlines to 
follow a course of cumulated knowledge on prolactin research during the last two-three 
decades and it may also help us understand some of the concerns that we face today.
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Prolactin is a polypeptide hormone that is synthesized in and secreted from the 
lactotrophs of the anterior pituitary gland. The name of the hormone was originally 
given 80 years ago based on the fact that bovine pituitary extract causes growth of the 
crop sac and stimulate the elaboration of crop milk in pigeons[1]. Nowadays, we 
already know that prolactin plays multiple pivotal roles in control of general 
homeostasis[2-5]. Without giving a detailed list, rather some of them will be highlighted 
here. The classical role can be seen in mammals where prolactin stimulates the 
mammary glands to produce milk during lactation and the development of corpus 
luteum of the ovary to secrete its hormone i.e. progesterone.  
Its osmoregulatory role is also well defined. It has a critical role in fish, so it is also 
called a “freshwater-adapting” hormone[6]. Plasma prolactin levels may follow the 
changes of environmental milieu, i.e. be lower in seawater fish, but increased in 
freshwater.  
During the last two decades we have learned that prolactin has a prominent and well 
defined role in the regulation of immune function[7,8]: as an immune modulator it 
enhances the proliferative response, but also has a role in certain autoimmune diseases 
as a pathoclinical indicator in multi-organ and organ specific autoimmune diseases (e.g. 
in lupus erythematosus (SLE), rheumatoid arthritis (RA), Sjogren's syndrome, 
Hashimoto's thyroiditis, multiple sclerosis (MS), psoriasis, etc)[9, 10, 11].  Prolactin may also 
participate in the development of immune tolerance between the fetus and the maternal 
organism during pregnancy[12]. Several experimental and also clinical evidences 
confirming the relationship between prolactin and the immune system have required to 
open new “sub-folder” for the role of prolactin in “immune-biology”, “immune-
endocrinology” and “neuroimmune-modulation”, as well as for non-clinical and clinical 
contributions to the search for potential new drugs in the development process.  
The physiological role of prolactin is still important in the classical fields of 
reproduction. Prolactin seems to be involved in the central control of sexual behavior 
and activity. There is a brief and sudden elevation of prolactin during orgasm 
indicating that it may have a role in the “gratification” during sexual acts as well[13]. 
On the other hand, a nondrug related female sexual dysfunction (FSD), affecting up to 
1 in 10 US women, manifested with a decreased sexual desire could also be associated 
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with increased prolactin levels [14]. A chronic hyperprolactinemia is clinically 
associated with hypogonadotropic hypogonadism and sexual dysfunction as well, 
while treatment of hyperprolactinemia restores normal sexual function both in men 
and women[15]. 
Moreover, prolactin levels and our behavior are potentially also connected. Prolactin is 
higher during periods of nursing in some species, but also in human during 
“maternal” as well as “paternal” behavior: fathers of infants have elevated prolactin 
levels [16]. 
Prolactin stimulates proliferation of oligodendrocyte precursor cells (they are cells that 
differentiate into oligodendrocytes, and they are responsible for the formation of 
myelin sheet of axons in the central nervous system (CNS)[17,18]. Interestingly, high 
prolactin levels stimulate the proliferation of olfactory epithelium[19]. 
Prolactin can also be found in amniotic fluid and contributes to surfactant synthesis of 
fetal lungs at the end of pregnancy[20].  
Since pituitary prolactin is under a close and mainly inhibitory control of hypothalamic 
dopaminergic system, it is predictable that drugs attenuating pathological 
neurotransmitter levels (like in schizophrenia, mood disturbances, etc) may have 
potential side effect resulting in clinical signs associated with or caused by 
hyperprolactinemia. Some of the effective antipsychotic treatments may have medication 
related adverse drug reactions appear in more than two-thirds of the patients [21, 22, 23], 
indicating the continuous need to search for prolactin-sparing solutions.  
Furthermore, we are now aware that synthesis and secretion of prolactin is not 
restricted to the anterior lobe of the pituitary gland, but other organs and individual 
cells can also produce it. Indeed, the multiple roles and sources of prolactin had led 
Bern and Nicoll (1968), to suggest renaming it to “omnipotin” or “versatilin” [24]. This 
book provides the headlines to follow a course of cumulated knowledge on prolactin 
research during the last two-three decades and it may also help us understand some of 
the concerns that we face today.   
 
György M. Nagy and Dr Bela Ernest Toth 
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1. Introduction 
Prolactin (PRL) was discovered in 1928. It is found in all vertebrates including humans. The 
name ‘prolactin’ is derived from its established role, in female mammals, in mammopoiesis. 
That raised the first mystery regarding its role in the human male and in non-mammalian 
vertebrates. More than 300 effects have been produced by injecting PRL into animals of all 
phylogenic groups. That raised the second mystery i.e. absence of any reliable and relevant 
bio assay for PRL till today. Following the approaches of Reductionist Biology, prolactin has 
been purified and characterized from a number of vertebrate groups. That raised the third 
mystery i.e. extensive microheterogeneity in structure and its doubtful relevance to 
physiology. The mechanism of action of prolactin has been studied extensively and that 
gave rise to the fourth mystery as to why it does not follow the second messenger model in 
signaling pathways, as in the case of other membrane receptor acting hormones like 
epinephrine or Luteinizing hormone (LH) or FSH etc. Prolactin behaves more like a cytokine 
and growth factor than like a hormone! In spite of exhibiting multiple physiological effects 
on a variety of tissues like brain (behavior), gonadal and mammary tissues, accessory sex 
organs like ventral prostate, immune system of phagocytes and lymphocytes etc, no disease 
whose origin can be ascribed to mutations in PRL or PRL receptor genes has yet been 
discovered. That is the fifth mystery. There is no known clinical model of prolactin 
deficiency. Hyperprolactinemia due to tumors of pituitary lactotrophs is the only known 
pathological condition. Long term hyperprolactinemia can lead to amenorrhea in women, 
loss of libido in men and infertility in both. 
2. Relevant biochemistry and biology of prolactin 
The first observation related to prolactin was made in 1928 (Stricker and Grueter, 1928). 
These French scientists injected a bovine pituitary extract into pseudopregnant rabbits and 
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bio assay for PRL till today. Following the approaches of Reductionist Biology, prolactin has 
been purified and characterized from a number of vertebrate groups. That raised the third 
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gave rise to the fourth mystery as to why it does not follow the second messenger model in 
signaling pathways, as in the case of other membrane receptor acting hormones like 
epinephrine or Luteinizing hormone (LH) or FSH etc. Prolactin behaves more like a cytokine 
and growth factor than like a hormone! In spite of exhibiting multiple physiological effects 
on a variety of tissues like brain (behavior), gonadal and mammary tissues, accessory sex 
organs like ventral prostate, immune system of phagocytes and lymphocytes etc, no disease 
whose origin can be ascribed to mutations in PRL or PRL receptor genes has yet been 
discovered. That is the fifth mystery. There is no known clinical model of prolactin 
deficiency. Hyperprolactinemia due to tumors of pituitary lactotrophs is the only known 
pathological condition. Long term hyperprolactinemia can lead to amenorrhea in women, 
loss of libido in men and infertility in both. 
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observed that such rabbits started lactating. Thereafter Riddle et al (1933) reported that the 
crude extract could stimulate the production of “milk” by the crop sac of pigeons. Later it 
was established that the same pituitary principle was responsible for both the crop “milk” 
production and mammary gland secretion. The same component of pituitary was purified 
using a pigeon crop sac development as bioassay from bovine pituitary and termed as 
“Prolactin” (Riddle et al 1933). Thirty years after its discovery, the first amino acid sequence 
of ovine Prolactin was completed in 1970 (Li et al. 1970). Prolactin from different species of 
fishes to mammals has since been sequenced (Sinha, 1995).   
Prolactin and growth hormone from buffalo pituitaries have been purified and 
characterized in our laboratory (Muralidhar, et al., 1994; Khurana and Muralidhar, 1997; 
Maithal et al, 2001).  The molecular size of buPRL monomer was 22,664 Da as determined by 
MALDI-TOF analysis (Panchal and Muralidhar, 2008). Enhancement of Nb2 rat lymphoma 
cell proliferation by the hormone has been studied (Khurana and Muralidhar, 1997). 
Prolactin from number species of different classes of vertebrate has been purified and 
characterized. Primary structure of PRL from about 45 species is known either by protein 
sequence directly or deduction from gene sequence or cDNA sequence (Sinha, 1995). In 
most of the mammalian species prolactin contains three intra-disulfide bridges between 
Cysteine residues 4-11, 58-174 and 191-199. Teleost PRLs, however, lack the amino terminal 
disulfide loop (Sinha, 1995).                                                                 
The major role of prolactin in eutherians and marsupials is regulation of milk secretion and 
growth of mammary gland. The binding specificity of prolactin receptors does vary between 
species, however (Amit et al, 1997). Prolactin also plays other roles in mammals, like in 
immunomodulation, osmoregulation and control of parental behavior and it may be that 
variation in the relative importance of one or more of these provide the drive for adaptive 
change (Wallis, 2000). 
Prolactin is biosynthesized as a larger precursor protein but processed into a ~23 kDa 
protein in most of the species. Many different molecular size isoforms as well as forms of 
PRL with post translational modifications like glycosylation, phosphorylation and sulfation 
have been described in literature. Dimerisation and polymerization of prolactin or 
aggregation with binding proteins, such as immunoglobulins, by covalent and non covalent 
bonds may result in high-molecular-weight forms. In general, the high-molecular weight 
forms have reduced biological activity (Sinha, 1995). The role of prolactin-IgG 
macromolecular complex in the detection and differential diagnosis of different 
prolactinemias is targeted primarily in clinical studies (Cavaco et al 1995). 
Tyrosine sulfation is not a very common post-translational modification. Recently a review 
on this modification has listed 62 proteins which have been identified as tyrosine sulfated. 
For the majority of these, a role for sulfation in the function(s) of the proteins has not been 
described. In some cases sulfation is important in optimal receptor-ligand interactions 
(e.g.chemokine receptor binding), optimal proteolytic processing (e.g. gastrin processing), 
and proteolytic activation of extra cellular proteins (e.g. factor V and VIII activation) (Moore 
2003). 
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There is only one pituitary hormone known to have sulfation of tyrosine and this is 
prolactin. It was found that a prolactin containing fraction had very high radioactivity when 
pituitary cells were incubated with radio labeled sulfate. Later it was proved that prolactin 
was the protein which was containing this radioactivity. Chemical analysis proved the 
sulfation is on the tyrosine residue/s of prolactin. Role of this tyrosine sulfated prolactin is 
still an unanswered question (Kohli et al 1987, Kohli et al 1988). Thus the key feature of PRL 
is structural microheterogeneity in various forms. The microheterogeneous isoforms of 
prolactin and growth hormone have been reported by our laboratory earlier. These isoforms 
reported included tyrosine sulphated prolactin (Kohli, et al., 1987; 1988; Chadha, et al., 
1991), lower sized (19 kDa and 13 kDa) iso forms (Khurana and Muralidhar, 1997) and 
glycosylated isoforms (Khurana and Muralidhar, 1997) in buPRL. Similar size and charge 
isoforms of buffalo growth hormone have also been reported by our laboratory earlier 
(Maithal et al, 2001) However, the unique biological functions of the heterogeneous forms, if 
any, are not known yet. To serve as a frame work for investigations, we postulated two 
hypotheses with regard to biological significance of microheterogeneity in PRL. One was 
that microheterogeneous forms have different potencies in a given bioassay during 
ontogeny. Two, that microheterogeneous forms exhibit different biological activities in 
different phylogenic groups of animals during phylogeny. It was observed that the non-
glycosylated isoform of buPRL was 4-5 times more potent than the glycosylated isoform of 
buPRL in the Nb2 rat lymphoma cell growth assay in vitro (Khurana and Muralidhar, 1997). 
Similarly it was observed that the PRL with higher isoelectric point (i.e. more basic isoform) 
had a higher potency than the PRL isoform with lower isoelectric point (i.e. more acidic 
isoform) in the same assay. 
2.1. Prolactin from peripheral tissues 
The cells of the anterior pituitary gland which synthesize and secrete prolactin were initially 
described by light microscopy using conventional staining techniques (Herlant 1964). These 
cells designated lactotrophs or mammotrophs comprise 20-50% of the cellular population of 
the anterior pituitary gland depending on the sex and physiological status of the animal. 
The first observation that prolactin is produced in the brain was by Fuxe (Fuxe et al 1977) 
who found prolactin immuno reactivity in hypothalamic axon terminals. Prolactin immuno 
reactivity was subsequently found in the telencephalon in the cerebral cortex, hippocampus 
amygdala, septum (Devito 1988), caudate putamen (Emanuele et al 1992), brain stem 
(Devito 1988), cerebellum (Seroogy et al 1988), spinal cord (Siaud et al 1989), choroids plexi, 
and the circum ventricular organs (Thompson 1982). 
Several approaches have been taken to prove that prolactin is found in the hypothalamus 
and that it is synthesized locally, independent of prolactin synthesis in the pituitary gland. 
Indeed, hypophysectomy has no effect on the amount of immuno reactive prolactin in the 
male hypothalamus and only diminishes but does not abolish the quantity of immuno 
reactive prolactin in the female rat hypothalamus (Devito 1988). With the use of 
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conventional peptide mapping and sequencing of a polymerase chain reaction (PCR) 
product of hypothalamic cDNA from intact and hypophysectomized rats (Wilson  et al 
1992), it has been established that the primary structure of prolactin of hypothalamic origin 
is identical to that of the prolactin of the anterior pituitary (Wilson et al 1992). The deciduas 
produce a prolactin-like molecule that is indistinguishable from pituitary prolactin in 
human (Andersen 1990, Riddick et al 1978), Finally, the non pregnant uterus has been 
shown to be a source of prolactin as well. Indeed a decidual-like prolactin, indistinguishable 
from pituitary prolactin (Gellersen et al 1989) has been identified in the myometrium of 
nonpregnant rats (Ben-Jonathan et.al, 2008). In addition to uptake of prolactin from the 
blood, the mammary epithelial cells of lactating animals are capable of synthesizing 
prolactin. The presence of prolactin mRNA (Kurtz et al 1993) as well as synthesis of 
immunoreactive prolactin by mammary epithelial cells of lactating rats has been described 
(Lkhider et al 1996). A great deal of evidence suggests that lymphocytes can be a source of 
prolactin as well (Gala et al 1994, Montgomery et al 1990). 
2.2. Receptors to Prolactin (PRLR) 
The PRLR was identified as a specific, high-affinity, membrane–anchored protein (Kelly et al 
1974). The cDNA encoding the rat PRLR has been prepared. As is true for their respective 
ligands, receptors for PRL and GH (GHR) are also closely related (Boutin et al 1988, Kelly et 
al 1991). Both are single–pass transmembrane chains and despite a relatively low degree 
(~30%) of sequence identity, they share several structural and functional features (Kelly et al 
1991, Goffin et al 1998). The gene encoding human  PRLR is located on chromosome 5 (p13-
14) and contains at least 10 exons for an overall length exceeding 100 kb (Arden et al 1990). 
multiple isoforms of membrane-bound PRLR resulting from alternative splicing of the 
primary transcript have been identified in several species (Boutin et al 1988).. 
3. Prolactin and angiogenesis 
Angiogenesis has been described well. A number of factors regulate this process in the body 
(Iyer and Acharya, 2002). We report here that naturally occurring lower size isoforms of 
buPRL, Cathepsin derived peptide fragments of prolactin and synthetic peptide from the 
internal sequence of both prolactin and growth hormone were found to exhibit anti-
angiogenic activity in endothelial cell migration and CAM assays. Further using in silico 
methods, the three dimensional structure of buffalo prolactin was arrived at including the 
location of the anti angiogenic peptide sequence. A 16 K PRL as a newly generated N-
terminal 16 K fragment resulting from the proteolysis of rat PRL by acidified mammary 
extracts was discovered and reported in 1980 (Mittra 1980a and 1980b). Since then, this PRL 
fragment has received considerable attention from the scientific community. The protease 
responsible for the cleavage of rat PRL into 16K was identified as Cathepsin D, The 16K PRL 
was shown to have lost PRL receptor binding ability but otherwise to have acquired the 
ability to specifically bind another membrane receptor (Clapp and Weiner 1992)  through 
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which it exerts antiangiogenic activity (Clapp et al 1993). Although this receptor is still not 
identified, some of its downstream signaling targets have been elucidated (D’Angelo et al 
1999, Corbacho et al 2000).However; many questions related to the biology of 16K PRL 
remain unanswered. First, although the majority of investigations have used rat 16K PRL, 
results are much less clear for other species, especially humans, in which PRL was recently 
reported to be resistant to Cathepsin D (Khurana et al 1999a and 1999b). This contrasts with 
the findings indicating that hPRL yields partial, but reproducible, proteolysis leading to N-
terminal 16K like PRL fragments when incubated with this protease. Second, because it may 
be generated both centrally (Clapp et al 1994) and at the periphery, such as in pulmonary 
fibroblasts (Corbacho et al 2000) and endothelial cells (Corbacho et al 2000), the site/s of 16K 
PRL generation remains to be clearly identified. Hence, whether all sites of extra pituitary 
PRL synthesis can generate 16K PRL from endogenous 23K PRL or alternatively, whether 
circulating PRL is internalized before the proteolyzed form is exported (or both) remains 
open to investigation. Also, the sub-cellular compartment/s in which appropriate proteolysis 
conditions are found remain/s to be identified, although one can not discard the possibility 
that the cleavage of takes place in extra cellular milieu. In humans, although various 
recombinant forms of 16K hPRL were shown to be antiangiogenic, no insight into the 
biological relevance of hPRL in vivo was provided. It is relevant to ask also whether, the 
effects of PRL on tumors in vivo should be viewed from a new angle, considering a balance 
between the mitogenic and angiogenic (pro-tumor) activities of full-length PRL versus the 
antiangiogenic (anti tumor) activity of 16K-PRL (Goffin et al 1999). 
3.1. Purification of buffalo PRL monomer from a discarded acid pellet 
Buffalo pituitary prolactin in monomeric form can be prepared (Panchal and Muralidhar, 
2008). The lower size isoforms of buffalo PRL can be separated from the monomer as well as 
the higher sized isoforms by differential alcohol fractionation (Panchal and Muralidhar, 
2008) This lower size isoform containing fraction was designated as (AP) P-190-70. The APP-
I, a semi-pure buPRL from buffalo pituitaries (Chaudhary, et al., 2004), has higher sized 
forms (>34.9 kDa, 34.9 kDa and 25.9 kDa (26 K)) and lower sized forms (18.4 kDa (18 K), 14.5 
kDa (14 K) and <14.5 kDa) as well as buPRL monomer (23.4 kDa).  The lower sized forms, 
approximately 18 K and 14 K under non-reducing conditions transform into 19 K and 13 K 
bands under reducing conditions (Khurana and Muralidhar, 1997). The 26 K PRL under 
non-reducing condition is probably the isoform nicked in the large loop of intact form but 
with intact disulfide bonds (Mittra I, 1980a; 1980b). Khurana and Muralidhar (1997) reported 
that 25 K buPRL (under non-reducing condition of SDS-PAGE) disappeared under reducing 
condition of the gel. The size isoform mixture, APP-I could be separated by differential 
alcohol precipitation. APP-I 70 (higher sized form mixture) and APP-I 90-70 (lower sized 
form mixture) were checked by SDS-PAGE analysis. The lower sized form mixture, APP-I 
90-70, was confirmed to be free from higher sized forms by immunoblotting analysis. The 
reason for the successful separation is that the two different sized mixtures had different pI. 
Buffalo PRL monomer has pI 5.1~5.45 (Chadha, et al., 1991). The higher sized forms and 
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monomer are probably soluble in the alkaline ethanol. The buPRL lower sized peptides had 
opposite property.  
3.2. Anti-angiogenic activity of (AP) P-I 90-70 fraction, lower size isoforms 
mixture 
It has been known that N-terminal 16K PRL fragment had an inhibitory effect on 
angiogenesis i.e. the formation of new blood vessels (Folkman and Shing 1992), in rat 
(Ferrara, et al 1991) and in human (Clapp, et al 1993)  both  in vitro and ex vivo. Thus, it was 
of interest to know whether the lower size forms mixture including 18K and 14K size forms 
i.e. naturally occurring PRL peptides, have the anti-angiogenic activity or not. Hence (AP) P-
I 90-70 fraction was tested with endothelial cell migration assay (in vitro) and chick egg yolk 
membrane assay (ex vivo) (Figure 1). Approximately 7 % inhibition of cell migration 
compared to control was observed after 4 hrs and 8 hrs, when 30 pg/ml of (AP)P-I 90-70 was 
added to human immortalized umbilical vein endothelial cells, EAhy926. The exact amount 
of the active peptide(s) in this mixture is difficult to estimate. It is, therefore, clearly proved 
that the physiologically cleaved buPRL fragments (i.e. naturally occurring lower size 
isoforms) had an anti-angiogenic function. The C-terminal 16 K hPRL does not appear to 
have the anti angiogenic activity (Khurana et al 1999). Extrapolating this fact to buffalo PRL, 
the present PRL lower size isoforms have to be mostly N-terminal fragments. If C-terminal 
fragments were in the mixture of isoforms, their presence is much less than that of N-
terminal ones. Or those fragments may include specific anti-angiogenic active site. This 
(AP)P-I 90-70 fraction needs to be further characterized. Struman et al. (1999) reported that 
intact human PRL, GH and PL exhibited angiogenic activity. However, our results indicate 
unequivocally that the buPRL monomer had no significant stimulatory or inhibitory effect 
on blood vessel formation in CAM and endothelial cell migration assays.            
3.3. Peptides derived from buffalo PRL by enzymatic digestion have anti 
angiogenic activity 
Most of the studies about the antiangiogenic N-terminal fragment cleaved by Cathepsin D 
(CD) have been done in the case of rat and human PRLs (Ferrara et al. 1991). It was therefore 
hypothesized that buffalo pituitary PRL can be cleaved by Cathepsin D, and that the 
fragment could inhibit angiogenesis via endothelial interference. Here, we demonstrate that 
buPRL size isoform produced by CD have an inhibitory action on angiogenesis. However, it 
was not clear which sequence in the N-terminal fragment plays a role in antiangiogenesis. 
Highly pure buPRL monomer was obtained from pituitary glands with the protocol 
standardized in our laboratory designed with differential ethanol extractions to separate 
both different sized forms followed by a single Sephacryl S-200 chromatography (Panchal 
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Figure 1. Antiangiogenic activity by ex vivo and in vitro assays. A, Results of CAM assay. Eggs at 6th 
day of incubation were used for the assay. B, Analysis of the results of A. C, Results of endothelial cell 
migration assay. Values are means ± SEM. P < 0.05 vs control. **Significantly different from control cells 
(P < 0.001). 
with distilled water and 20 mM citrate/phosphate buffer including salt (i.e. pH 3.0) at 37°C, 
respectively, and then analyzed by electrophoresis at frequent intervals. When the intact 
buPRL was incubated in distilled water for 6 h, no lower-sized fragments were detected in 
SDS-PAGE either under non-reducing or reducing conditions. However, when the intact 
buPRL was incubated under the acidic conditions, a lower-sized form, approximately 
21 kDa, was observed in SDS-PAGE under reducing conditions.. The lower form did not 
significantly increase in type and quantity during the incubation time, up to 12 h.  Protease-
free intact buPRL was incubated with bovine spleen CD (the ratio of substrate vs enzyme = 
100:1) in acidic condition (pH 3.0) 37°C,and then the peptide mixture was separated in  a 
15% SDS-PAGE under reducing conditions.. Results indicated that the intact buPRL was 
cleaved by CD at pH 3.0 and the molecular weight of cleaved peptides were approximately 
18.39 kDa (18K), 14 kDa (14K), 11.16 kDa (11K) and 7.47 kDa (7K). These sizes were 
identified by immunological analysis using buPRL antiserum (Figure 2B). The mixture did 
not show a significant contamination of CD (42.12 kDa and 29 kDa) (Fig. 2A) This enzymatic 
cleavage was confirmed when in the presence of pepstatin A (Marks et al. 1973), a known 
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monomer are probably soluble in the alkaline ethanol. The buPRL lower sized peptides had 
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acidic protease inhibitor, CD did not generate lower-sized peptides from the monomer 
under non-reducing conditions to just below monomer under reducing conditions (Fig.2D 
and 2E, L1). The amount of cleaved isoform under non-reducing condition decreased at 6 h 
incubation (Fig. 2D, L6). 
 
Figure 2. (A) Results of SDS-PAGE analysis after colloidal Coomassie blue staining. Lane C, buPRL 
monomer (5 μg); Lane +, buPRL monomer (5 μg) incubated with CD; Lane M, molecular weight marker; 
Lane CD, Cathepsin D (7.49 μ g); Msc, mature single chain (42.12 kDa); Mlc, mature large chain 
(29 kDa). (B) Immunoblot of A with anti-buPRL serum indicating the cleaved fragments of buPRL by 
CD. (C) Effect of pepstatin A on buPRL cleavage by CD. (D) Time course of action by CD on buPRL 
monomer. L1–L6 represent analysis of reaction mixture by SDS-PAGE under non-reducing conditions 
after 0 and 30 min, and 1, 2, 3 and 6 h, respectively. Lane C is the control where no enzyme was added; 
Lane M represents marker. (E) Same as D except that the gel was run under the reducing conditions.  
(Taken from Jaeok Lee  et al 2011 with permission). 
Cell migration analysis by wound healing assay was performed in EAhy926. The cell line 
expresses factor VIII-related antigen and has the same morphological distribution as 
primary endothelial cells with a doubling time of 12 h (Edgell et al. 1983). 
A dose-dependent (3.3 pg/mL to 330 μg/mL) inhibition by buPRL peptide mixture including 
intact form on migration of EAhy926 cells was observed. Hence, 33 pg/mL of the peptide 
mixture was used for early stage (on the day 4) CAM assay, one of the ex vivo methods to 
study angiogenesis (Ribatti et al.1996).The blood vessel generation reduced with the dose of 
the peptide mixture in a time-dependent fashion. These studies were done with the peptide 
mixture which was not separated from the undigested PRL, if any.  This meant that in our 
hands the PRL monomer had neither antiangiogenic nor angiogenic activity. Further intact 
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PRL was not binding to the putative receptors to which the peptides were supposed to bind 
and exhibit their antiangiogenic activity. Prolactin is known to bind to PRL- specific 
receptors. Hence it can also be concluded, tentatively at least, that Cathepsin digested PRL –
derived peptides do not work through PRL receptors for their anti angiogenic activity.   
3.4. The peptide mixture separated from PRL retains antiangiogenic activity 
The results described above were confirmed when the peptide mixture was separated from 
the undigested intact PRL on an FPLC column and then tested for antiangiogenic activity 
(Jaeok Lee et al 2011). It is interesting to note the cleavage pattern of prolactins from 
different species when exposed to Cathepsin D is different. For example, the sizes of  
fragments obtained by CD from buffalo prolactin are different from the sizes of cleaved 
fragments of PRL from : rat pituitary (16K and 8K) (Mittra, 1980a, b), mouse pituitary (16K 
and 8K) (Sinha and Gilligan, 1984), and human pituitary (17K, 16.5K, 15K, 11K, 8K and 5K) 
(Piwnica et al. 2006) PRL (Fig.3) These different patterns of cleavage could be due to micro-
variation in the primary structure among species. Comparing the cleaved sequences 
between human and rat PRLs, Tyr147-Pro148-Val149-Trp150-Ser151 of human and Tyr145-
Leu146-Val147-Trp148-Ser149 of rat are homologous (Piwnica et al. 2006) (Fig.3B). The 
presence of Pro148 and Leu132 controls the cleavage pattern in hPRL (Piwnica et al 2006). 
Pro148 prevented high cleavage efficiency at 147–148 and 150–151 sites, while Leu132 
produced the additional cleavage at 132–133 sites (Piwnica et al. 2006). Buffalo PRL has the 
same sequence at 147–151 site as in hPRL, but not at residue 132 (Fig. 3B). The Pro148 in 
buPRL also seems to link to a specific cleavage pattern. Hence, 18K and 14K of buPRL were 
considered homologous to 17K and 15K of hPRL, respectively. We could not detect a 
fragment similar to the 16.5K fragment of hPRL. 
Angiogenesis, the process of developing new blood vessels from preexisting vessels, is 
crucial to reproduction, growth and wound healing (Folkman and Shing 1992). In the last 
two decades, numerous studies reported novel angiogenic regulators (Iyer and 
Acharya, 2002). Among the angiogenic regulators, hPRL fragment is one of the very 
paradoxical molecules. Its intact form has pro-angiogenic action (Struman et al. 1999), 
inducing cell proliferation and motility, and relates to breast carcinogenesis (Clevenger et 
al. 2003). The PRL fragments as well as intact PRL were are also known to be secreted from 
vascular endothelial cells (Ochoa et al. 2001). The antiangiogenic and anti mitogenic effects 
of peptide fragments were observed in BBBE and HUVE cells, even in the presence of PRL 
antibody. This suggested the possibility that they act as autocrine regulators of 
angiogenesis, (Clapp et al. 1998; Corbacho et al. 2000). 
3.5. Buffalo pituitary PRL derived peptides are active at pico gram level 
In the present study, the antiangiogenic activity of buPRL-derived peptides was 
demonstrated in vitro and ex vivo. Endothelial cell migration is fundamental to angiogenesis 
(Lamalice et al. 2007), because endothelial cells, derived from meso dermal cells, form 
capillary blood and lymphatic vessels (Venes and Thomas 2001).  
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Figure 3. CD and thrombin cleavage site in the primary sequences of rat, human, buffalo and cattle 
PRLs. (A) In human PRL three N-termini by CD and C-terminus by thrombin (figure from Piwnica, et 
al. 2004). (B) CD cleavage sites in rat, human, buffalo and cattle PRLs. (C) The SST aligned sequences of 
buPRL and buGH are partially or completely involved in the sequence of N-terminus fragment known 
as antiangiogenic factor. Triple * in hSST is the specific binding site to SSTRs. The square window 
indicates the considered sequence has an antiangiogenic action. Arrows indicate the cleavage sites. (D) 
hSST in SWISS-Pdb viewer 4.0. Blue arrows and alphabets represent SST receptor binding sites. (E) The 
synthetic peptide derived from buPRL. Molecular size and pI of each peptide were gained from 
ExPASy Proteomics tools. (Taken from Jaeok Lee et al, 2011 with permission) 
Earlier reports found antiangiogenic activity of r16K (Ferrara et al. 1991) and recombinant 
h16K (Clapp et.al. 1993; D’Angelo et.al. 1999) in micromolar concentrations. The present 
study demonstrates that buPRL-derived peptides have an antiangiogenic activity in 
nanomolar concentration. Even the cleaved fragments mixed with intact buPRL, considered 
a pro-angiogenic factor (Struman et al. 1999), are effective at the lower concentration level. 
The results of our study prove that buPRL peptides cleaved by CD have the antiangiogenic 
action, and these peptides must have come from N-terminal side. Mechanistic studies were 
undertaken and it was observed that the peptide mixture obtained by Cathepsin D digestion 
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of prolactin was capable of antagonizing the action of Bradykinin (BK) in terms of NO 
production.  
NO, produced by NO synthase (NOS), is a second messenger in the regulation of 
physiological and pathophysiological process in the cardiovascular, nervous and immune 
systems (Moncada and Higgs 1993; Nathan and Xie 1994). NO is involved in cell migration 
and cell protection (Lee et al. 2005; Kolluru et al. 2008). NO-mediated pathway is a well 
known signaling mechanism of angiogenesis, vasopermeability and vasorelaxation in 
relation to VEGF (Ferreira and Henzel, 1989; Ishikawa et al. 1989), BK (Regoli and 
Barabe 1980; Ferreira et al. 1992) and Acetyl choline (Ach) actions (Palmer et al. 1989). 
Gonzalez et al. (2004) reported that human and rat 16K PRL fragments inhibited NOS 
activation induced not only by VEGF and BK but also by Ach, in endothelial cells. Buffalo 
PRL fragments seem not to be correlated to the pathway stimulated by Ach in EAhy926 (Jaeok 
Lee et al, 2011). Moreover, the buPRL peptides were more effective in inhibiting the BK-
mediated NO mechanism than that by VEGF. It is not known, however, how this peptide 
blocks the NO pathway. We envisage two possible mechanisms. One is that the peptides act as 
receptor antagonists of angiogenic factors, and the other is that the peptides induce another 
pathway to inhibit NO production driven by these angiogenic factors. Besides, the role of 
individual amino acid residues in the antiangiogenic action is not yet clear.  
It has been observed that these proteolytically derived peptides from buffalo PRL are more 
potent than Somatostatin (Jaeok Lee et al, 2011). Somatostatin, a small peptide (14 amino 
acids) secreted from hypothalamus, is a negative regulator of growth hormone (GH) release 
(Norman 1997). Widely distributed throughout the body, SST binds to five different 
subtypes of its cognate receptors (SSTR1-5), one of them being a G-protein-coupled receptor 
present on the cell membrane (Patel et al. 1990; Lahlou et al. 2004). While the five SSTRs bind 
the natural peptide, SSTR2, SSTR3, and SSTR5 can bind its synthetic analogues (Lahlou et 
al. 2004). SST and its analogues inhibit angiogenesis and also the production and secretion 
of angiogenic factors including VEGF (Barrie et al. 1993). It was reported that SST blocked 
Kaposi sarcoma (KS) cells (KS-Imm), isolated from a kidney-transplanted, immuno 
suppressed patient and also highly angiogenic, xenografts into nude (nu/nu) mice through 
angiostasis (Albini et al. 1999). SST also induced cell death of human somatotrph tumor cells 
(SSTR2) (Ferrante et al. 2006). In the study with vascular endothelial cell (dominated by 
SSTR3) by Reisine and Bell 1995), SST inhibited cell proliferation through blocking of both 
endothelial NOS (eNOS) and MAPK activations. SST is a powerful anti-tumour angiostatic 
agent. The results of our work confirm that SST and 14K buPRL are significant 
antiangiogenic factors, and 14K is more effective than SST in the antiangiogenesis assays. 
The antiangiogenesis brought about by buPRL fragment seems to be related to the inhibition 
of vasopermeability of endothelial cells. 
It is interesting to note that a synthetic peptide corresponding to the Somatostatin sequence 
within the amino acid sequence of buffalo pituitary Growth hormone is capable of 
antagonizing Bradykinin induced angiogenesis in terms of nitric oxide production 
(Syamantak Majumder et al, 2009). To what receptors do these lower size isoforms of buPRL 
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production.  
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Lee et al, 2011). Moreover, the buPRL peptides were more effective in inhibiting the BK-
mediated NO mechanism than that by VEGF. It is not known, however, how this peptide 
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receptor antagonists of angiogenic factors, and the other is that the peptides induce another 
pathway to inhibit NO production driven by these angiogenic factors. Besides, the role of 
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It has been observed that these proteolytically derived peptides from buffalo PRL are more 
potent than Somatostatin (Jaeok Lee et al, 2011). Somatostatin, a small peptide (14 amino 
acids) secreted from hypothalamus, is a negative regulator of growth hormone (GH) release 
(Norman 1997). Widely distributed throughout the body, SST binds to five different 
subtypes of its cognate receptors (SSTR1-5), one of them being a G-protein-coupled receptor 
present on the cell membrane (Patel et al. 1990; Lahlou et al. 2004). While the five SSTRs bind 
the natural peptide, SSTR2, SSTR3, and SSTR5 can bind its synthetic analogues (Lahlou et 
al. 2004). SST and its analogues inhibit angiogenesis and also the production and secretion 
of angiogenic factors including VEGF (Barrie et al. 1993). It was reported that SST blocked 
Kaposi sarcoma (KS) cells (KS-Imm), isolated from a kidney-transplanted, immuno 
suppressed patient and also highly angiogenic, xenografts into nude (nu/nu) mice through 
angiostasis (Albini et al. 1999). SST also induced cell death of human somatotrph tumor cells 
(SSTR2) (Ferrante et al. 2006). In the study with vascular endothelial cell (dominated by 
SSTR3) by Reisine and Bell 1995), SST inhibited cell proliferation through blocking of both 
endothelial NOS (eNOS) and MAPK activations. SST is a powerful anti-tumour angiostatic 
agent. The results of our work confirm that SST and 14K buPRL are significant 
antiangiogenic factors, and 14K is more effective than SST in the antiangiogenesis assays. 
The antiangiogenesis brought about by buPRL fragment seems to be related to the inhibition 
of vasopermeability of endothelial cells. 
It is interesting to note that a synthetic peptide corresponding to the Somatostatin sequence 
within the amino acid sequence of buffalo pituitary Growth hormone is capable of 
antagonizing Bradykinin induced angiogenesis in terms of nitric oxide production 
(Syamantak Majumder et al, 2009). To what receptors do these lower size isoforms of buPRL 
bind in their antiangiogenic activity? In our hands, intact buffalo PRL had neither pro- nor 
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anti- angiogenic activity. The peptides may act through PRL receptors or through other 
receptors like those to Bradykinin or VEGF. They may also have their own distinct 
receptors. As they are capable of inhibiting VEGF or Bradykinin induced angiogenesis, it 
can be safely concluded that the peptides might work through VEGF or Bradykinin 
receptors rather than PRL- specific receptors. 
3.6. Antiangiogenic activity of the Synthetic peptides 
Generally, the conformation of the cleaved fragment is either new and unstable or native-
like which is less stable than that of the original (Creighton, 1993). No experimental details 
are available on the conformation of the cleaved fragment. Nevertheless, a significant 
difference in the N-terminal 14K PRL structure from the intact PRL was that the loop 
between the first and the second α-helices were loosened and more opened to the 
environment. In the intact form, the loop was close to the fourth α-helix.  
The disulfide bond between the loop and the fourth α-helix, between Cys58 and Cys174, in 
the centre of the loop might be giving more compact configuration. 
We have cloned and expressed cDNA for buffalo prolactin in E.coli and the bacterially 
expressed buffalo prolactin was biologically active in stimulating Nb2 rat lymphoma cells in 
vitro to divide (Manoj Panchal and Muralidhar, 2010). From the nucleotide sequence of the 
cDNA, the aminoacid sequence was deduced and from the available 3- dimensional 
structure of human prolactin, the 3-dimensional structure of buffalo prolactin was obtained 
by homology modelling. Somatostatin is a known inhibitor of angiogenesis. Using 
bioinformatics tool of BLAST search, we could locate a similar peptide in both prolactin and 
growth hormone. The peptides were synthesized through commercial sources. It was 
observed that the synthetic peptides, both the 13-mer and the 14-mer were active in 
pictogram range in all the in vitro and ex vivo bioassays. 
Small ligands tend to bind, relatively speaking, the interior of globular proteins, while linear 
ligands tend to bind in clefts on the surface of proteins (Creighton 1993). The small and 
linear structure of the synthesized peptide (Figure 3E) enables it to bind to both the interior 
of putative receptors and to the clefts on the surface of receptors. The synthetic peptide, 
Ala45-Gly47-Lys48-Gly49-Phe50-Ile51-Thr52-Met53-Ala54-Leu55-Asn56-Ser57-Cys58, also 
showed more active than SST in the antiangiogenic action. This SST-matching sequence 
peptide had a structure (linear) different from SST, which had α-helix structure (Figure 3D). 
This active motif for antiangiogenesis is not involved in binding to the PRLR sites, especially 
the second half of loop 1 (His59, Pro66 and Lys69) of site 1 (Goffin et al. 1992). This result 
also demonstrates that Ala45 to Met53 can be the active sites for angiostatic function. The C-
terminal 16K peptide (54–199 residues) of hPRL does not appear to have the function of 
antiangiogenesis (Khurana et al. 1999b). In the C-terminal 16K fragment of hPRL, the fourth 
helix is still close to the partial second loop, which becomes exposed to environment in the 
N-terminal 16K fragment of hPRL. Because of this, the C-terminal 16K fragment of hPRL 
may not have antiangiogenic action. Three residues, Phe7-Trp8-Lys9, in SST sequence 
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appear to have the crucial role in binding with high affinity to all SST receptors, SSTR1 to 
SSTR5 (Poitout et al. 2001). However, in the synthetic sequence derived from buPRL, Ala1-
Gln2-Gly3-Lys4-Gly5-Phe6-Ile7-Thr8-Met9-Ala10-Leu11-Asn12-Ser13-Cys14, ‘Ile7-Thr8-
Met9’ is found instead of ‘Phe7-Trp8-Lys9’. In the SST-matching sequence of hPRL, ‘Ile51-
Thr52-Lys53’ replaces the SST tri-peptide sequence (‘Phe7-Trp8-Lys9’) positions (Figure 3C). 
This leads to the question of whether buPRL fragments bind to SSTR3 or not, and if the 
fragments bind to SSTR3, which residues in the sequence of the fragments bind to the 
receptor and mediate the antiangiogenic action? In the PRL fragments- and SST-mediated 
inhibition of the angiogenesis, there are similar mechanistic patterns. Both factors blocked 
VEGF-induced cell proliferation, which is known to be through the MAPK pathway in 
vascular endothelial cells (D’Angelo et al. 1999). 
The hPRL and hGH tilted peptides (14-amino-acid sequence) consisting of 9 hydrophobic 
amino acids induce endothelial cell apoptosis and inhibit endothelial cell proliferation and 
capillary formation (Nguyen et al. 2006). The tilted peptide has been known to destabilize 
membrane and lipid core and is characterized by an asymmetric distribution of hydrophobic 
residues along the axis when helical. However, the synthetic tilted peptides derived from 
hPRL and hGH show 4 times and 32 times less activity, respectively, than the 16K hPRL in 
vitro (Nguyen et al. 2006). The synthetic peptide related to buPRL represents differences in 
structure and functional sensitivity from those of the tilted peptides. This peptide has 
similar sensitivity with 14K buPRL in the inhibition of angiogenesis in vitro and ex vivo. 
Although the peptide includes 9 hydrophobic amino acids, it does not form a helix 
(Figure 3E). These differences imply that the synthetic peptide related to buPRL has a 
receptor-binding mediated antiangiogenic function, rather than protein-membrane-
interaction-mediated function. 
4. Summary and speculation 
The present study suggests that naturally occurring size iso forms of buPRL have 
antiangiogenic activity. Further, buPRL gives upon Cathepsin digestion a 16K-like fragment, 
but of 14K size and more cleaved fragments which have an antiangiogenic action. The 
antiangiogenic action of the fragments is, at least, related to the initial part of the sequence 
of the second loop between first and second α-helices. Furthermore, the synthetic peptide 
(derived by hSST matching area of buPRL) can be a potential anticancer therapeutic agent as 
well as for treatment of vascular, rheumatoid and other diseases whose etiology necessarily 
involves angiogenesis (Folkman 1995). Confirming the relevance of this idea requires 
demonstrating whether the buPRL fragments have N-terminal structure, and whether there 
are other sequences between Thr1 and Tyr44 having anti angiogenic action. Further work is 
required to explore whether SSTR3 is the specific receptor for 14K and other cleaved 
peptides, and if not, what is the specific receptor to the peptides, and what sequence part 
plays a crucial role in this antiangiogenic action? The biology of PRL is fascinating but very 
intriguing. More than 300 biological activities have been ascribed to PRL from various 
species. We have proposed two hypotheses to guide research on this hormone with regard 
 
Prolactin 12 
anti- angiogenic activity. The peptides may act through PRL receptors or through other 
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the centre of the loop might be giving more compact configuration. 
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linear structure of the synthesized peptide (Figure 3E) enables it to bind to both the interior 
of putative receptors and to the clefts on the surface of receptors. The synthetic peptide, 
Ala45-Gly47-Lys48-Gly49-Phe50-Ile51-Thr52-Met53-Ala54-Leu55-Asn56-Ser57-Cys58, also 
showed more active than SST in the antiangiogenic action. This SST-matching sequence 
peptide had a structure (linear) different from SST, which had α-helix structure (Figure 3D). 
This active motif for antiangiogenesis is not involved in binding to the PRLR sites, especially 
the second half of loop 1 (His59, Pro66 and Lys69) of site 1 (Goffin et al. 1992). This result 
also demonstrates that Ala45 to Met53 can be the active sites for angiostatic function. The C-
terminal 16K peptide (54–199 residues) of hPRL does not appear to have the function of 
antiangiogenesis (Khurana et al. 1999b). In the C-terminal 16K fragment of hPRL, the fourth 
helix is still close to the partial second loop, which becomes exposed to environment in the 
N-terminal 16K fragment of hPRL. Because of this, the C-terminal 16K fragment of hPRL 
may not have antiangiogenic action. Three residues, Phe7-Trp8-Lys9, in SST sequence 
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appear to have the crucial role in binding with high affinity to all SST receptors, SSTR1 to 
SSTR5 (Poitout et al. 2001). However, in the synthetic sequence derived from buPRL, Ala1-
Gln2-Gly3-Lys4-Gly5-Phe6-Ile7-Thr8-Met9-Ala10-Leu11-Asn12-Ser13-Cys14, ‘Ile7-Thr8-
Met9’ is found instead of ‘Phe7-Trp8-Lys9’. In the SST-matching sequence of hPRL, ‘Ile51-
Thr52-Lys53’ replaces the SST tri-peptide sequence (‘Phe7-Trp8-Lys9’) positions (Figure 3C). 
This leads to the question of whether buPRL fragments bind to SSTR3 or not, and if the 
fragments bind to SSTR3, which residues in the sequence of the fragments bind to the 
receptor and mediate the antiangiogenic action? In the PRL fragments- and SST-mediated 
inhibition of the angiogenesis, there are similar mechanistic patterns. Both factors blocked 
VEGF-induced cell proliferation, which is known to be through the MAPK pathway in 
vascular endothelial cells (D’Angelo et al. 1999). 
The hPRL and hGH tilted peptides (14-amino-acid sequence) consisting of 9 hydrophobic 
amino acids induce endothelial cell apoptosis and inhibit endothelial cell proliferation and 
capillary formation (Nguyen et al. 2006). The tilted peptide has been known to destabilize 
membrane and lipid core and is characterized by an asymmetric distribution of hydrophobic 
residues along the axis when helical. However, the synthetic tilted peptides derived from 
hPRL and hGH show 4 times and 32 times less activity, respectively, than the 16K hPRL in 
vitro (Nguyen et al. 2006). The synthetic peptide related to buPRL represents differences in 
structure and functional sensitivity from those of the tilted peptides. This peptide has 
similar sensitivity with 14K buPRL in the inhibition of angiogenesis in vitro and ex vivo. 
Although the peptide includes 9 hydrophobic amino acids, it does not form a helix 
(Figure 3E). These differences imply that the synthetic peptide related to buPRL has a 
receptor-binding mediated antiangiogenic function, rather than protein-membrane-
interaction-mediated function. 
4. Summary and speculation 
The present study suggests that naturally occurring size iso forms of buPRL have 
antiangiogenic activity. Further, buPRL gives upon Cathepsin digestion a 16K-like fragment, 
but of 14K size and more cleaved fragments which have an antiangiogenic action. The 
antiangiogenic action of the fragments is, at least, related to the initial part of the sequence 
of the second loop between first and second α-helices. Furthermore, the synthetic peptide 
(derived by hSST matching area of buPRL) can be a potential anticancer therapeutic agent as 
well as for treatment of vascular, rheumatoid and other diseases whose etiology necessarily 
involves angiogenesis (Folkman 1995). Confirming the relevance of this idea requires 
demonstrating whether the buPRL fragments have N-terminal structure, and whether there 
are other sequences between Thr1 and Tyr44 having anti angiogenic action. Further work is 
required to explore whether SSTR3 is the specific receptor for 14K and other cleaved 
peptides, and if not, what is the specific receptor to the peptides, and what sequence part 
plays a crucial role in this antiangiogenic action? The biology of PRL is fascinating but very 
intriguing. More than 300 biological activities have been ascribed to PRL from various 
species. We have proposed two hypotheses to guide research on this hormone with regard 
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to the significance of microheterogeneous isoforms. Our work has provided experimental 
evidence in support of these two hypotheses. Much more work needs to be done to 
understand and demystify prolactin actions. 
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1. Introduction 
Growth hormone, prolactin and somatolactin belong to the same hormone family and have a 
similar structure in teleost fishes [1]. Each of these three hormones appear to have opposite or 
specific functions in electrolyte balance in teleosts [2]. Teleost fish in freshwater environment 
face two primary challenges: preventing the loss of ions to the external hypoosmotic 
environment and preventing the influx of water. Prolactin plays a central role in these 
activities during the adaptation of fish to fresh water, as evidenced by its ability to increase 
plasma ion concentrations (primarily Na+ and Cl-) and decrease the permeability of 
osmoregulatory organs, such as gill, kidney and intestine [3]. In seawater environment, in 
contrast, diffusive water loss is counteracted by drinking seawater and actively taking up Na+, 
Cl- and water across the gastrointestinal tract, and the gill actively secretes Na+ and Cl- through 
chloride cells. Growth hormone activates these gill chloride cells with ion transporters (e.g., 
Na+, K+-ATPase and the Na+,K+,2Cl- cotransporter) involved in secretion of Na+ and Cl- across 
the branchial epithelium [3], and appears to stimulate the intestinal absorption [4]. On the 
other hand, somatolactin is proposed to be involved in regulation of acid-base, calcium and 
phosphate levels in several species [2, 3, 5-7], but the role of somatolactin in the intestine is 
unknown. Although the presence of receptors for these hormones in ion-transporting organs 
has been reported in a variety of teleost species [8-14] and several studies have investigated the 
direct effects of the teleost hormones on osmoregulatory organs [5, 15-18], the modes of action 
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of the hormones are still unclear. In particular, the opposite in-vitro effects of growth hormone 
and prolactin have not been reported, and there is little information on the cellular and 
biochemical mechanisms of the osmoregulatory actions of these hormones. 
In our in-vivo studies on esophagi from euryhaline fish, prolactin stimulated cell 
proliferation in the epithelium [14, 19]. This effect seems to be related to increased cell 
proliferation for the stratified epithelium to reduce permeability in fresh water [20]. We 
have also found the increased apoptosis for the simple epithelium to give high permeability 
in seawater [14, 19]. A large number of reported effects of prolactin are associated with cell 
proliferation and/or apoptosis [21]. Thyroid-hormone induced apoptosis of the 
metamorphosing amphibian tail is directly prevented by prolactin and enhanced by  
glucocorticoid [22]. Using recently developed techniques for the culture of esophagus from 
the euryhaline medaka, Oryzias latipes, we have demonstrated that cortisol directly induced 
both cell proliferation and apoptosis [23]. In this study, we compared the effects of prolactin, 
growth hormone and somatolactin in this system, and found the first evidence that prolactin 
and growth hormone have opposite effects on the osmoregulatory organ in vitro. 
2. Materials and methods 
2.1. Animals 
Adult medaka (Oryzias latipes, 0.1-0.2 g in weight) of both sexes were kept in indoor 
freshwater tanks at 27 ± 2°C and fed on Tetrafin flakes (Tetra Werke, Melle, Germany) daily 
for more than two weeks. Osmoregulation, differentiation of gill chloride cells, hormonal 
status during adaptation to different salinities, and the in-vivo effects of osmoregulatory 
hormones in this species have been described in our previous reports [23, 24]. Fish were 
exposed to 0.1% Fungizone (Amphotericin B, Invitrogen, Tokyo, Japan) for two days 
without food to avoid contamination before isolation of the esophagus. All fish were 
handled, maintained, and used in accordance with the Guidelines for Animal 
Experimentation established by Okayama University in accordance with international 
standards on animal welfare and in compliance with national regulations. 
2.2. Tissue culture 
As previously described [23], esophagi were gently sliced open along the long axis and cut 
into halves. Each explant was placed in a individual well of 96-well culture plates containing 
preincubation medium (MEM with Hanks' salts, 25 mM HEPES, 5 mg/ml BSA, 250 U/ml 
penicillin G, and 250 µg/ml streptomycin sulfate, adjusted to pH 7.8 at 25°C). After several 
hours, the medium was replaced with MEM containing Earle's salts, 4 mg/ml BSA, 292 
µg/ml L-glutamine, 50 U/ml penicillin G and 50 µg/ml streptomycin sulfate adjusted to pH 
7.8 when saturated with 99% O2 / 1% CO2. The medium osmolarity was adjusted to 300 
mOsm/kg with NaCl. Explants were randomly assigned to control and treatment groups (N 
= 4-6), and incubated at 27°C in an airtight humidified chamber and gassed daily. Chum 
salmon prolactin, growth hormone and somatolactin was (1, 10, 100 ng/ml) or was not 
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added to the culture medium. The concentrations were chosen based on the published 
effective physiological doses [5, 15-17, 25-27], plasma hormone concentrations [14, 28-30], 
and our preliminary studies. These salmonid hormones have approximately 60% amino-acid 
identities to the medaka counterparts (NCBI accession no. or Ensemble medaka genomic 
database browser ID: medaka growth hormone: ENSORLP00000024332, prolactin: AAP33052, 
somatolactin: AAT58046; [1, 13]) and have high specificities for their respective receptors in 
fish, unlike mammalian hormones which bind equally to other hormone receptors in fish [13, 
31, 32]. The use of these salmonid hormones to study the specific physiological roles in many 
teleost species has been well established [25, 27, 29, 33, 34]. All the culture medium was 
replaced with freshly prepared medium daily. Although explants were occasionally found to 
adhere to the bottom of the plate well, they typically remained unattached during culture. 
The tissue culture maintained structural integrity for 8 days based on the presence of 
intact nuclei and cell-to-cell borders [23]. The cultured esophageal explants were fixed in 
4% paraformaldehyde in phosphate-buffered saline (PBS) at 4°C for 4 h for histological 
analysis (N = 3-5) or snap frozen in liquid nitrogen for quantification of apoptosis. 
2.3. Cell proliferation assay 
At given time points, cultured explants were pulsed with an oxidation-reduction indicator 
WST-1 (10% vol/vol, Roche, Tokyo, Japan) for 4 h and color development (A450 nm-A600 nm) 
was quantified to measure the activity of mitochondrial dehydrogenases. This activity is 
proportional to the number of viable cultured cells and is expressed as the cell proliferating 
index [35]. The result after pre-incubation (on day 0) was used to correct for differences in 
initial tissue content per esophageal slice, and also for quantification of apoptosis. 
2.4. Quantification of apoptosis 
DNA internucleosomal fragmentation in the esophagus was assessed using a cell death 
detection ELISA kit (Roche, Tokyo, Japan) according to the manufacturer’s instructions. This 
kit uses a quantitative sandwich ELISA that specifically measures the histone region (H1, H2A, 
H2B, H3, and H4) of mono- and oligonucleosomes [36] in teleosts [37] that are released during 
apoptosis, but not during necrosis [38]. After a 10-minute reaction, color development (A405 
nm-A492 nm) was quantified using an MTP-300 microplate reader (Corona, Ibaragi, Japan).  
2.5. Proliferating cell nuclear antigen (PCNA) immunohistochemistry 
To label proliferating cells in the esophagus, we used a mouse monoclonal antibody (clone 
PC10; Sigma, Tokyo, Japan) against proliferating cell nuclear antigen (PCNA), as described 
previously for teleosts [14, 19, 33]. In our previous study on the teleost esophagus [19], the 
level of PCNA immunoreactivity was in agreement with the uptake of [3H]-thymidine. 
Slides were immersed in 0.3% H2O2 in methanol at 20°C for 30 min to inactivate endogenous 
peroxidase activity. After washing in PBS, the sections were placed in 5% normal goat 
serum in PBS at room temperature for 1 h to block non-specific binding. Sections were 
subsequently incubated at 4°C overnight with the primary antibody diluted 1:100 in a 
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µg/ml L-glutamine, 50 U/ml penicillin G and 50 µg/ml streptomycin sulfate adjusted to pH 
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apoptosis, but not during necrosis [38]. After a 10-minute reaction, color development (A405 
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subsequently incubated at 4°C overnight with the primary antibody diluted 1:100 in a 
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solution containing 0.5% Triton X-100 and 1% BSA (Sigma, Tokyo, Japan) in PBS. Sections 
were then washed 3 times in PBS, incubated with peroxidase-labeled goat anti-mouse 
secondary antibody (Sigma, Tokyo, Japan) diluted 1:70 in PBS containing 0.5% Triton X-100 
and 1% BSA at room temperature for 1 h, and then developed for 5 min with DAB substrate 
solution (Roche, Tokyo, Japan). Controls omitting the PCNA primary antibody were 
performed and yielded no immunoreactivity. 
2.6. In situ 3'-end labeling of DNA (TUNEL) 
Nuclei of apoptotic cells were detected by the TUNEL method [39] using an in situ cell death 
detection kit (Roche, Tokyo, Japan; [14, 19, 33]). The TUNEL procedure produces results that 
are similar to those obtained with analysis of internucleosomal DNA fragmentation in the 
esophagus using gel electrophoresis, and appears to discriminate apoptosis from necrosis 
[19]. Fixed tissue samples were dehydrated through graded alcohol concentrations and 
embedded in Paraplast. Sections were cut at 5 µm and attached to 3-
aminopropyltriethoxysilane-coated slides. The sections were then treated with 20 µg/ml 
proteinase K (Roche, Tokyo, Japan) at 20°C for 30 min, washed in PBS for 15 min, and 
immersed in 0.3% H2O2 in methanol at 20°C for 30 min to inactivate endogenous peroxidase 
activity. After washing in PBS, the sections were incubated with TdT and fluorescein-labeled 
dUTP at 37°C for 1 h in a humidified chamber. The reaction was terminated by transferring 
the slides to PBS for 15 min. The sections were then incubated with peroxidase-labeled anti-
fluorescein antibody at 37°C for 30 min and then for 5 min with DAB substrate solution 
(Roche, Tokyo, Japan). Omission of TdT gave completely negative results. 
2.7. Statistical analysis 
The significance of differences between the means for cell proliferation were analyzed using 
two-way repeated measures analysis of variance (ANOVA), with time within groups (after 
application of treatment) as one factor and treatment among or between groups as the other 
factor. Since there was a significant interaction between treatment and time, each time was 
analyzed separately to identify differences among the treatments using the appropriate 
post-hoc test. The significance of differences among means for concentration-response 
relationships for apoptosis was also tested using ANOVA followed by a post-hoc test. All 
data were checked for normality and equal variances. Where assumptions of normality or 
equal variances were not satisfied, equivalent non-parametric tests were used. Results were 
considered significant for P < 0.05. 
3. Results 
The effects of growth hormone, prolactin and somatolactin (1, 10 and 100 ng/ml) on 
esophageal cell proliferation for 8 days in culture are shown in Figures 1 and 2. Addition of 
prolactin at 10 ng/ml to the culture medium significantly (P < 0.001) enhanced cell proliferation 
after 4 and 8 days (Figs. 1A and 2). Significant (P < 0.05) induction of cell proliferation was also 
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observed at 1 day after treatment with 10 ng/ml growth hormone. In contrast, the esophagus 
did not respond significantly (P > 0.05) to treatment with somatolactin at any concentration. 
Similar results were obtained from six separate trials. Based on the highly significant results 
for prolactin treatment in the cell proliferation assays, the localization of the proliferating cells 
was examined in esophagi cultured for 8 days with or without 10 ng/ml prolactin (Fig. 1B). In 
control esophagi, labeling with an antibody against PCNA revealed few proliferating cell 
nuclei in the epithelium. In contrast, esophagi treated with prolactin had many PCNA-labeled 
nuclei in the epithelium and mucus cells in the epithelium were seemed to be more abundant 
than those in control tissue. No obvious longitudinal regionalization of the epithelial structure, 
including localization of proliferating cells, was observed. 
 
Figure 1. Effects of 1-100 ng/ml growth hormone (GH), prolactin (PRL) and somatolactin (SL) on cell 
proliferation of esophageal explants cultured for 1-8 days (A). Values are means ± SEM (N = 4-6) and are 
expressed in arbitrary units normalized to the results on day 0 (initial tissue content). * P < 0.05, *** P < 
0.001 vs. the control on the same day. Proliferating cell (dark muclei, arrowheads) based on labeling by 
PCNA immunocytochemistry in the esophageal epithelium after 8 days in culture (B). A few PCNA-
positive nuclei were detected in the epithelium in control esophagi, whereas many labeled nuclei 
appeared in the epithelium in esophagi treated with 10 ng/ml prolactin. L: lumen. Representative results 
are shown. Scale bar = 50 µm. 
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Figure 1. Effects of 1-100 ng/ml growth hormone (GH), prolactin (PRL) and somatolactin (SL) on cell 
proliferation of esophageal explants cultured for 1-8 days (A). Values are means ± SEM (N = 4-6) and are 
expressed in arbitrary units normalized to the results on day 0 (initial tissue content). * P < 0.05, *** P < 
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Figure 2. Effects of 10 ng/ml growth hormone (GH), prolactin (PRL) and somatolactin (SL) on cell 
proliferation of esophageal explants cultured for 1-8 days (redrawn from Fig. 1). Values are means ± 
SEM (N = 4-6) and are expressed in arbitrary units normalized to the results on day 0 (initial tissue 
content). * P < 0.05, *** P < 0.001 vs. the control on the same day.  
 
Figure 3. Effects of growth hormone (GH), prolactin (PRL) and somatolactin (SL) on esophageal 
apoptosis after 8 days of culture. Values are means ± SEM (N = 4-5) and are expressed in arbitrary units 
normalized to the initial tissue content. * P < 0.05 vs. control. Apoptosis in the esophageal epithelium 
detected in a TUNEL assay after 8 days in culture (left and right insets). A few TUNEL-positive nuclei 
were observed in the epithelium in control esophagi (left inset), whereas numerous labeled nuclei 
appeared in the epithelium of esophagi treated with 10 ng/ml growth hormone (right inset). L: lumen. 
Representative results are shown. Scale bar = 50 µm. 
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We examined the effects of growth hormone, prolactin and somatolactin (1, 10 and 100 
ng/ml) on esophageal apoptosis after 8 days of culture, since esophageal apoptosis has been 
shown to be induced significantly 5-10 days after salinity acclimation and hormonal 
treatment of fish [14, 19, 33]. Addition of growth hormone (10 ng/ml) to the culture medium 
significantly induced esophageal apoptosis (P < 0.05), whereas prolactin and somatolactin 
showed no significant effects at any doses (Fig. 3). Similar results were obtained from three 
separate trials. Based on these results, the localization of apoptotic cells was examined in 
esophagi cultured for 8 days with or without 10 ng/ml growth hormone. In control esophagi 
cultures, there were few apoptotic cells based on TUNEL staining of DNA fragments (Fig. 3, 
left inset), whereas a large number of apoptotic cells were observed in esophageal epithelia 
treated with 10 ng/ml growth hormone for 8 days (Fig. 3, right inset). No obvious 
longitudinal regionalization of apoptotic cells was observed. 
4. Discussion  
Prolactin is an important hormone for freshwater adaptation in teleost species, whereas 
growth hormone is involved in seawater adaptation in several euryhaline fishes [3]. In 
accord with the greater permeability of the esophagus in seawater-acclimated euryhaline 
fish than in freshwater-acclimated fish [20], we have previously shown that apoptosis 
throughout the esophageal epithelium occurs for the simple columnar epithelium in 
seawater and that cell proliferation is induced for the stratified epithelium, which is 
composed of numerous mucus cells, in fresh water [14, 19]. We have also shown that 
injection of prolactin stimulates cell proliferation in the esophageal epithelium [33], but 
neither the mode nor specificity of the action of prolactin is clear. The present study shows 
that the esophagus of medaka is responsive to prolactin and growth hormone after several 
days in culture, with induction of cell proliferation and apoptosis, respectively. This is the 
first demonstration of opposite in-vitro effects of prolactin and growth hormone on the 
teleost osmoregulatory organ. The 10-ng/ml concentrations of prolactin and growth 
hormone required for these specific responses were similar to the physiologically increased 
levels observed in the plasma of several teleost fishes during acclimation to different 
salinities [14, 29, 30]. The time course is also similar to those for esophageal cell proliferation 
and apoptosis as well as for plasma prolactin and growth hormone in euryhaline fishes 
during salinity acclimation and after in-vivo hormonal treatment [14, 19, 33]. The in-vitro 
response to prolactin in the esophagus is consistent with the localization of prolactin 
receptors in proliferating cells of esophageal epithelia found in our previous study [14]. The 
growth hormone receptor is also expressed in the gastrointestinal tracts of fishes, which 
accounts for the ability of growth hormone to act on these organs [8, 11, 40-42]. Taken 
together, these results suggest that the osmoregulatory esophagus is one of the primary 
targets for the actions of prolactin and growth hormone during acclimation of euryhaline 
fishes to fresh water and seawater, respectively. 
The in-vitro effects of prolactin on the permeability of trout gill epithelia [16, 43] may also be 
associated with direct stimulation of cell proliferation by prolactin, as proposed above for 




Figure 2. Effects of 10 ng/ml growth hormone (GH), prolactin (PRL) and somatolactin (SL) on cell 
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Figure 3. Effects of growth hormone (GH), prolactin (PRL) and somatolactin (SL) on esophageal 
apoptosis after 8 days of culture. Values are means ± SEM (N = 4-5) and are expressed in arbitrary units 
normalized to the initial tissue content. * P < 0.05 vs. control. Apoptosis in the esophageal epithelium 
detected in a TUNEL assay after 8 days in culture (left and right insets). A few TUNEL-positive nuclei 
were observed in the epithelium in control esophagi (left inset), whereas numerous labeled nuclei 
appeared in the epithelium of esophagi treated with 10 ng/ml growth hormone (right inset). L: lumen. 
Representative results are shown. Scale bar = 50 µm. 
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esophagi cultured for 8 days with or without 10 ng/ml growth hormone. In control esophagi 
cultures, there were few apoptotic cells based on TUNEL staining of DNA fragments (Fig. 3, 
left inset), whereas a large number of apoptotic cells were observed in esophageal epithelia 
treated with 10 ng/ml growth hormone for 8 days (Fig. 3, right inset). No obvious 
longitudinal regionalization of apoptotic cells was observed. 
4. Discussion  
Prolactin is an important hormone for freshwater adaptation in teleost species, whereas 
growth hormone is involved in seawater adaptation in several euryhaline fishes [3]. In 
accord with the greater permeability of the esophagus in seawater-acclimated euryhaline 
fish than in freshwater-acclimated fish [20], we have previously shown that apoptosis 
throughout the esophageal epithelium occurs for the simple columnar epithelium in 
seawater and that cell proliferation is induced for the stratified epithelium, which is 
composed of numerous mucus cells, in fresh water [14, 19]. We have also shown that 
injection of prolactin stimulates cell proliferation in the esophageal epithelium [33], but 
neither the mode nor specificity of the action of prolactin is clear. The present study shows 
that the esophagus of medaka is responsive to prolactin and growth hormone after several 
days in culture, with induction of cell proliferation and apoptosis, respectively. This is the 
first demonstration of opposite in-vitro effects of prolactin and growth hormone on the 
teleost osmoregulatory organ. The 10-ng/ml concentrations of prolactin and growth 
hormone required for these specific responses were similar to the physiologically increased 
levels observed in the plasma of several teleost fishes during acclimation to different 
salinities [14, 29, 30]. The time course is also similar to those for esophageal cell proliferation 
and apoptosis as well as for plasma prolactin and growth hormone in euryhaline fishes 
during salinity acclimation and after in-vivo hormonal treatment [14, 19, 33]. The in-vitro 
response to prolactin in the esophagus is consistent with the localization of prolactin 
receptors in proliferating cells of esophageal epithelia found in our previous study [14]. The 
growth hormone receptor is also expressed in the gastrointestinal tracts of fishes, which 
accounts for the ability of growth hormone to act on these organs [8, 11, 40-42]. Taken 
together, these results suggest that the osmoregulatory esophagus is one of the primary 
targets for the actions of prolactin and growth hormone during acclimation of euryhaline 
fishes to fresh water and seawater, respectively. 
The in-vitro effects of prolactin on the permeability of trout gill epithelia [16, 43] may also be 
associated with direct stimulation of cell proliferation by prolactin, as proposed above for 
the medaka esophagus. Prolactin has also been shown to induce cell proliferation in jejunal 
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explants from fetal rat [44], and several studies have shown direct effects of prolactin on cell 
proliferation throughout vertebrates [21]. In teleosts, prolactin induces proliferative 
responses in cultured salmonid leukocytes [25, 26], and promotes osteoblastic activities in 
goldfish scales in vitro [27]. However, the epithelium appears to be the major target, as in 
human keratinocytes and prostate epithelial cells [3, 45, 46], and it is likely that a primary 
function of prolactin in teleost osmoregulation is direct stimulation of cell proliferation in 
osmoregulatory epithelia. On the other hand, prolactin has also been shown to stimulate 
apoptosis in newt spermatogonia and rat luteal tissues [47, 48]. In addition, we suggested 
that the inhibitory effect of prolactin on osteoclastic activity in goldfish scales is mediated in 
part through osteoclast apoptosis [27]. Further studies of intracellular signaling pathway 
will elucidate how prolactin regulates these cell turnover. At any rate, one of prolactin’s 
primary functions may be control of cell proliferation/apoptosis. Indeed, the prolactin 
receptors belong to the large superfamily of class 1 “cytokine” receptors. 
There are few reports on the in vitro actions of growth hormone on teleost osmoregulatory 
organs, although growth hormone appears to be an important hormone for seawater 
adaptation. Direct regulatory roles of growth hormone on the gill Na+,K+-ATPase and heat-
shock protein 70 in climbing perch and silver sea bream have been described [15, 17, 18]. 
Our experiment reveals direct effects of growth hormone on esophageal cell turnover. 
Induction of cell proliferation was observed 1 day after addition of 10 ng/ml growth 
hormone, whereas epithelial apoptosis was stimulated after 8 days. The direct action of growth 
hormone on cell proliferation may occur through locally produced insulin-like growth factor I 
(IGF-I), since IGF-I has been suggested to mediate the direct proliferative effects of growth 
hormone in mammalian gastrointestinal tracts [49, 50]. On the other hand, the stimulation of 
apoptosis by long-term growth hormone exposure is at variance with the commonly reported 
protective role of the growth hormone /IGF-I axis against cell death [51]. However, increases in 
myocyte apoptosis are associated with high levels of growth hormone in patients with 
acromegaly [52] and in 9-month-old transgenic mice overexpressing growth hormone [53]. 
Furthermore, coho salmon implanted with growth hormone for 2 weeks showed stimulated 
Na-dependent proline absorption in the intestine [4], which may reflect increased permeability 
of the apoptotic intestinal epithelia in seawater. 
At 100 ng/ml prolactin or growth hormone, the above significant effects on esophageal cell 
turnover were disappeared. Very high doses of these hormones may also activate receptors 
for the other hormones even in homologous systems. It is reported that prolactin can bind to 
growth hormone receptor in tilapia (Oreochromis mossambicus) [54], and that growth hormone 
has an ability to bind to somatolactin receptor in salmon (Oncorhynchus masou) [13]. In 
addition, our results may also be related to the functional distinction of multiple prolactin 
receptor isoforms in teleost fish [55]. These receptors have different sensitivities to prolactin 
and may have the distinct physiological functions as described above [27, 49, 50, 55-57].  
In our previous study using this esophagus culture system, low levels of cortisol stimulate 
epithelial apoptosis through glucocorticoid receptors in seawater, whereas high levels of 
cortisol induce epithelial cell proliferation also via glucocorticoid receptors in freshwater 
[23]. Interactions of prolactin/growth hormone with glucocorticoid may play an important 
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role in the cell turnover in osmoregulatory esophageal epithelia during acclimation to 
different salinities. In the gill, cortisol is suggested to promote the differentiation of the ion-
secretory chloride cell (seawater-form) with growth hormone, and also expedite the 
differentiation of ion-uptake chloride cell (freshwater-form) by interacting with prolactin [3, 
58]. In the amphibian metamorphosis, on the other hand, thyroid hormones with 
glucocorticoid signaling induce apoptosis in the regression of tadpole tail, whereas prolactin 
prevents this apoptosis [22](Fig. 4B). Although apoptosis by glucocorticoid appear to be 
conserved throughout the vertebrates, thyroid hormone has no significant effect on 
esophageal cell proliferation or apoptosis in euryhaline fish [33]. Therefore, we hypothesize 
that thyroid hormones are involved only in irreversible metamorphosis and/or 
developmental processes. 
 
Figure 4. The summary representation of the epithelial differentiation in the esophagus of an 
euryhaline teleost during adaptation to different salinities. During freshwater (FW) adaptation, 
glucocorticoid signaling (cortisol-glucocorticoid receptor) and prolactin (PRL) stimulate epithelial cell 
proliferation for the stratified epithelium, resulting in the low permeability. During seawater (SW) 
adaptation, growth hormone (GH) and glucocorticoid signaling induce epithelial apoptosis for the 
simple epithelium with the high permeability (A). In the amphibian metamorphosis, thyroid hormones 
with glucocorticoid signaling induce apoptosis in tadpole tail whereas prolactin inhibits the apoptosis 
induced by thyroid hormones in regression of tadpole tail (B). 
5. Conclusions 
Our in vitro study in medaka esophagi indicates that prolactin directly induces the epithelial 
cell proliferation for the stratified epithelium and this response appears to be important in 
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Figure 4. The summary representation of the epithelial differentiation in the esophagus of an 
euryhaline teleost during adaptation to different salinities. During freshwater (FW) adaptation, 
glucocorticoid signaling (cortisol-glucocorticoid receptor) and prolactin (PRL) stimulate epithelial cell 
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5. Conclusions 
Our in vitro study in medaka esophagi indicates that prolactin directly induces the epithelial 
cell proliferation for the stratified epithelium and this response appears to be important in 
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the freshwater adaptive process. Furthermore, growth hormone directly stimulates the 
apoptosis for the simple epithelium and seems to be a key factor in seawater acclimation 
(Fig. 4A). To clarify the mechanism of prolactin/growth hormone actions in osmoregulation, 
future investigations using molecular tools are required to examine the relationship among 
the esophageal proliferating/apoptotic cells and important gene/protein expression patterns 
(e.g. prolactin/ growth hormone receptors, IGF-I and IGF-I receptor as well as 
transporters/pumps and intercellular junctions such as Na+,K+,ATPase, Na+,K+,2Cl- 
cotransporter, aquaporins., tight junctions, gap junctions and claudins. A further study is 
also required determine if the apoptosis induced by growth hormone in medaka esophagus 
is also characteristic of other species. 
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1. Introduction 
Prolactin is a protein hormone mainly, but not exclusively produced by lactotroph cells of 
the anterior pituitary. Its role in lactogenesis and galactopoiesis (maintenance of milk 
secretion) is well demonstrated [1, 2]. Therefore, the gene encoding it (PRL) is considered to 
be one of the key links in the gene network constituting the hereditary component of milk 
productivity. Test systems for cattle breeding have been developed based on the 
associations of the PRL gene polymorphism with milk yield and quality. 
Inbreeding, which decreases the genetic variation and viability of animals, is a well-known 
negative consequence of artificial selection. Its impact is further aggravated by the recent 
trend towards globalization of some cattle breeds [3]. Therefore, conservation of aboriginal 
breeds adapted to local conditions (which are not infrequently extreme) is necessary in 
countries with wide zonal climatic variations. 
This is especially important when a breed in question has pronounced adaptive 
characteristics and its population is small. Yakut cattle represent one of such breeds (Figure 
1a); it is unique among Russian breeds in terms of ecological plasticity. These cattle live in 
the northernmost part of the Bos taurus species range, a hardly accessible region of the 
subarctic zone of the Republic of Sakha (Yakutia), Russia, surrounded with mountain ridges. 
The morphological and physiological characteristics of Yakut cattle and their biochemical 
and behavioral adaptations allow free grazing almost round the year despite a severe 
continental climate, with the mean air temperatures usually varying from –43°C in winter to 
+25°C in summer (the lowest and highest temperatures on record are –65°C and +38°C, 
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Prolactin is a protein hormone mainly, but not exclusively produced by lactotroph cells of 
the anterior pituitary. Its role in lactogenesis and galactopoiesis (maintenance of milk 
secretion) is well demonstrated [1, 2]. Therefore, the gene encoding it (PRL) is considered to 
be one of the key links in the gene network constituting the hereditary component of milk 
productivity. Test systems for cattle breeding have been developed based on the 
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characteristics and its population is small. Yakut cattle represent one of such breeds (Figure 
1a); it is unique among Russian breeds in terms of ecological plasticity. These cattle live in 
the northernmost part of the Bos taurus species range, a hardly accessible region of the 
subarctic zone of the Republic of Sakha (Yakutia), Russia, surrounded with mountain ridges. 
The morphological and physiological characteristics of Yakut cattle and their biochemical 
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respectively). These animals can live on rough foods. Their body, including the udder, is 
covered with long, thick hair protecting them from cold and gnats. The color of aboriginal 
Yakut cattle varies from black and red to a leopard pattern with white spots on the head and 
lower trunk. This breed is exceptionally resistant to tuberculosis, leukemia, and brucellosis. 
Yakut cattle are small, with the shoulder height shorter than 1 m and the live weights of 
bulls and cows of 500–550 and 350–400 kg, respectively. The milk yield is low (2100–2350 kg 
in the breeding stock), but the fat content of milk is as high as 7.3% [4]. Yakut cattle have 
long been providing local residents (mostly Yakuts) with beef and dairy products. Cattle 
leather is widely used in Yakut ethnic handicrafts; Yakuts traditionally make comfortable, 
durable, beautiful leather clothes. Excavations in the Olekminsk district of Yakutia have 
revealed remnants of nomad camps containing fossil bones of domestic cattle, which 
suggests an ancient origin of this breed [5]. 
Bestuzhev and Kostroma cattle are dual-purpose breeds. Bestuzhev cattle selected for both 
beef and milk production were bred from local cattle in Samara province, Russia, in the late 
18th century (Figure 1b). English Shorthorn cattle were used for its improvement, the 
offspring being crossed with the Holland, Shorthorn, Simmental, and some other breeds. 
The breed was completely formed by the mid-19th century. Bestuzhev cattle are well 
adapted to the continental climate of the Volga basin. The animals are red; the color 
intensity varies from light-red to dark-red or cherry-red. Some animals have white spots, 
mostly on the lower trunk, udder, and head. The mean milk yield of Bestuzhev cattle is 
5502–8250 kg; the mean fat content of milk is 3.82–4.0% (the maximum content is 5.5%) [4]. 
Bestuzhev cattle are especially valuable because they are almost free of hereditary diseases 
and abnormalities and are resistant to tuberculosis and leukemia. 
Kostroma cattle are classified with the group of brown cattle (Figure 1c). The breed was 
registered in 1944. These cattle are characterized by a high growing capacity, strong 
constitution, and steady inheritance of commercially valuable traits, including a good milk 
quality. The Kostroma breed is regarded as one of the most productive dual-purpose breeds. 
The live weights of Kostroma bulls and cows are 800–900 and 550–650 kg, respectively; the 
fat and protein contents of milk are as high as 3.9 and 3.6%, respectively. The milk yield 
varies from 6000–8000 to 10,500 kg [4]. The Kostroma breed is characterized by a high total 
frequency of the BoLA–DRB3 gene alleles determining the leukemia resistance (on average, 
35.9%) [6]. 
Yaroslavl cattle, formed as a native cattle breed in the 16th century, have the highest milk 
yield and the best milk composition among all native Russian breeds (Figure 1d). Their milk 
contains, on average, 4.37% of fat (maximum content, 5.0%) and 3.4–3.6% of protein; the dry 
matter content is 13.6% (compared to 12.3–12.5% in other breeds) [4]. Yaroslavl cattle are 
usually black, except the white head with a black mask around the eyes and the white lower 
trunk. Yaroslavl cattle were first mentioned in the literature in the mid-19th century. 
Bestuzhev cattle were named after the original breeder; Yaroslavl, Yakut, and Kostroma 
cattle, after the region of origin. 
The balance between the increase in the milk yield and quality of cattle breeds and 
preservation of diversity both within and between breeds of B. taurus is a complicated 
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problem. Therefore, analysis of the variation of the gene markers that are affected by 
artificial selection because of their associations with milk yield and composition would be 
useful for breed monitoring. 
The bovine prolactin gene (bPRL) is traditionally regarded as a good candidate gene for 
marker-assisted selection (MAS) [7] for milk production parameters, because it has been 
located to chromosome 23 at 43 cM, close to the quantitative trait loci (QTLs) (36, 41, and 42 
cM) [8-11]. In addition, it is known that the binding of the bPRL gene product with its 
receptor (PRLR) initiates a signaling cascade that activates the transcription of a number of 
genes, including the genes of milk proteins (caseins and lactalbumin). 
 
Figure 1. (a) Yakut, (b) Bestuzhev, (c) Kostroma, and (d) Yaroslavl cattle breeds [12, 13, 14, 15]. 
Note that this regulatory cascade involves growth hormone (Figure 2), because it is 
recognized not only by its own receptor (GHR), but also by PRLR [16]. The prolactin and 
growth hormone genes are very similar to each other, because they have resulted from 
duplication of a common ancestral gene. They have the same general structure (five exons 
and four introns) [17] and a common positive transcription factor (PITI) [18]. 
The specifics of the bPRL and bGH genes suggest their combined effect on milk production; 
however, this has been paid little attention until now. Most studies on the polymorphism of 
milk production genes deal with isolated effects of individual genes. Many data on the 
polymorphisms of both bPRL and bGH genes and their relationship with the milk yield and 
composition have been accumulated. For example, a synonymous A–G transition has been 
found in the codon of amino acid residue 103 of bPRL in the third exon of its gene; this 
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cattle, after the region of origin. 
The balance between the increase in the milk yield and quality of cattle breeds and 
preservation of diversity both within and between breeds of B. taurus is a complicated 
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problem. Therefore, analysis of the variation of the gene markers that are affected by 
artificial selection because of their associations with milk yield and composition would be 
useful for breed monitoring. 
The bovine prolactin gene (bPRL) is traditionally regarded as a good candidate gene for 
marker-assisted selection (MAS) [7] for milk production parameters, because it has been 
located to chromosome 23 at 43 cM, close to the quantitative trait loci (QTLs) (36, 41, and 42 
cM) [8-11]. In addition, it is known that the binding of the bPRL gene product with its 
receptor (PRLR) initiates a signaling cascade that activates the transcription of a number of 
genes, including the genes of milk proteins (caseins and lactalbumin). 
 
Figure 1. (a) Yakut, (b) Bestuzhev, (c) Kostroma, and (d) Yaroslavl cattle breeds [12, 13, 14, 15]. 
Note that this regulatory cascade involves growth hormone (Figure 2), because it is 
recognized not only by its own receptor (GHR), but also by PRLR [16]. The prolactin and 
growth hormone genes are very similar to each other, because they have resulted from 
duplication of a common ancestral gene. They have the same general structure (five exons 
and four introns) [17] and a common positive transcription factor (PITI) [18]. 
The specifics of the bPRL and bGH genes suggest their combined effect on milk production; 
however, this has been paid little attention until now. Most studies on the polymorphism of 
milk production genes deal with isolated effects of individual genes. Many data on the 
polymorphisms of both bPRL and bGH genes and their relationship with the milk yield and 
composition have been accumulated. For example, a synonymous A–G transition has been 
found in the codon of amino acid residue 103 of bPRL in the third exon of its gene; this 
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mutation results in an RsaI polymorphic site [19]. The AA and AB genotypes have been 
shown to be associated with the milk yield and protein content in Polish Black & White, 
Holstein Friesian, and Brown Swiss cattle [19-21]. Other associations have been found in 
Russian Red Pied cattle [22]. The C–G transversion in the third exon of the bGH gene 
(nucleotide position 2141) is known to be related to milk production traits. This SNP entails 
the disappearance of an AluI restriction site and the substitution of valine for leucine (Leu → 
Val) at position 127 of the bGH amino acid sequence. There is evidence for a stronger 
dependence of the milk yield on the LL genotype than the LV genotype in Black Pied and 
Holstein Friesian cattle [23, 24]. However, Mitra et al. [25] and Dybus et al. [20] note a 
positive dependence of the milk yield and both fat and protein contents on the V allele in 
Holstein and Polish Black & White cattle. Study of the combined effect of the bPRL and bGH 
genes might explain some contradictions about the associations of individual markers of 
these genes. Although associations of the bPRL(RsaI) and bGH(AluI) polymorphisms with 
milk yield and quality have been extensively studied, the combined effect of SNPs of these 
genes has been hardly considered at all. 
 
Top: an anterior pituitary cell. Chromosomes carrying the transcription factor (Pit-1), growth hormone (GH), and 
prolactin (PRL) genes are shown in the nucleus (a green oval). The product of Pit-1 (TF Pit-1) activates the transcription 
of the prolactin and growth hormone genes. The corresponding hormones (GH and PRL, shown in dark blue and light 
blue, respectively) enter the bloodstream and reach mammary cells, where they are recognized by transmembrane 
receptors (GHR and PRLR, respectively). This initiates regulatory cascades activating the transcription of the milk 
protein (β-casein and α-lactalbumin) genes. The prolactin and growth hormone receptors are shown in yellow and 
green, respectively. The growth hormone competes with prolactin for the prolactin receptor. 
Figure 2. Schematic representation of the regulatory cascade involving the prolactin gene. 
The goal of this study was twofold. First, we compared the Kostroma, Bestuzhev, Yakut, 
and Yaroslavl breeds both with one another and with some other Russian and foreign 
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breeds (literature data) with respect to genetic variation as estimated from the RsaI 
polymorphism of the prolactin gene. Second, we estimated the effect of the RsaI 
polymorphism of the bPRL gene, as well as the effect of its combination with the AluI 
polymorphism of the bGH gene, on milk production in Yaroslavl cattle. 
2. Materials and methods 
We used PCR–RFLP analysis to study the RsaI polymorphism of the bPRL gene in Yakut 
cattle (n = 41) in the Republic of Sakha (Yakutia), Bestuzhev cattle (n = 57) in Samara region, 
Kostroma cattle (n =124) in Kostroma region, and Yaroslavl cattle (n = 113) in Yaroslavl 
region of Russia. The possible effects of the bPRL(RsaI) polymorphism and its combination 
with the bGH(AluI) polymorphism on milk production in Yaroslavl cattle were estimated. 
DNA was isolated from 200-μl samples of whole blood using a DiatomTM DNA Prep kit 
(IsoGeneLab., Russia). Fragments of bPRL (156 bp) and bGH (223 bp) [25] were amplified in 
a Tertsik thermal cycler by the standard methods using a GenePakTMPCR Core kit (IsoGene 
Lab., Russia). The DNA digestion with the RsaI and AluI restriction endonucleases was 
performed as recommended by the manufacturer (MBI Fermentas, Lithuania). The 
oligonucleotides FPRL (5'-CGAGTCCTTATGAGCTTGATTCTT-3') and RPRL (5'-
GCCTTCCAGAAGTCGTTTGTTTTC-3') served as primers for the bPRL gene fragments; FGH 
(5'-GCTGCTCCTGAGGGCCCTTCG-3') and RGH (5'-GCGGCGGCACTTCATGACCCT-3'), 
for the bGH gene fragments. The following amplification profiles were used: for the bPRL 
gene fragments, one cycle of 94°C for 4 min; 35 cycles of 94°C for 30 s, 58°C for 30 s, and 
72°C for 30 s; and one cycle of 72°C for 10 min; for the bGH gene fragments, one cycle of 
94°C for 4 min; 35 cycles of 94°C for 45 s, 67°C for 45 s, and 72°C for 45 s; and one cycle of 
72°C for 10 min. The amplification products were detected by means of 2% agarose gel 
electrophoresis (0.5 μg/ml ethidium bromide in 1X TBE buffer). The restriction products 
were visualized in 2% agarose gel (the bGH gene) or 6% polyacrylamide gel (the bPRL gene) 
(0.5 μg/ml ethidium bromide in 1X TBE buffer). The results of electrophoresis were recorded 
by means of a UVT-1 transilluminator (312 nm) and a ViTran-1 photodocumentation system 
(Biokom, Russia). The alleles were identified as follows: RsaI(–) and RsaI(+) corresponded to 
the A and B alleles of the bPRL gene, respectively; AluI(–) and AluI(+), to the V and L alleles 
of the bGH gene, respectively. 
The PopGene [26] and STATISTICA 8.0 [25] software packages were used for statistical 
treatment of the results. Pairwise comparisons of the allele and heterozygote frequencies 
(observed heterozygosity, Hobs) in the group of breeds studied were performed using the 
Fisher exact test. For similar comparisons using published data on other Russian and foreign 
breeds, we additionally calculated the expected heterozygosity (Hexp) where its values were 
not presented. The G2 test was used for pairwise comparisons of the breeds with respect to 
the genotype frequencies and Hexp. The fit of the observed frequencies of heterozygous 
genotypes to those expected from the Hardy–Weinberg equilibrium was tested using the 
PopGene software. The dependence of the milk yield (in kilograms) and fat and protein 
contents (in percent) on the bPRL and bGH genotypes in Yaroslavl cattle was estimated by 
one-way and two-way ANOVA with the use of the STATISTICA 8.0 software. 
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breeds (literature data) with respect to genetic variation as estimated from the RsaI 
polymorphism of the prolactin gene. Second, we estimated the effect of the RsaI 
polymorphism of the bPRL gene, as well as the effect of its combination with the AluI 
polymorphism of the bGH gene, on milk production in Yaroslavl cattle. 
2. Materials and methods 
We used PCR–RFLP analysis to study the RsaI polymorphism of the bPRL gene in Yakut 
cattle (n = 41) in the Republic of Sakha (Yakutia), Bestuzhev cattle (n = 57) in Samara region, 
Kostroma cattle (n =124) in Kostroma region, and Yaroslavl cattle (n = 113) in Yaroslavl 
region of Russia. The possible effects of the bPRL(RsaI) polymorphism and its combination 
with the bGH(AluI) polymorphism on milk production in Yaroslavl cattle were estimated. 
DNA was isolated from 200-μl samples of whole blood using a DiatomTM DNA Prep kit 
(IsoGeneLab., Russia). Fragments of bPRL (156 bp) and bGH (223 bp) [25] were amplified in 
a Tertsik thermal cycler by the standard methods using a GenePakTMPCR Core kit (IsoGene 
Lab., Russia). The DNA digestion with the RsaI and AluI restriction endonucleases was 
performed as recommended by the manufacturer (MBI Fermentas, Lithuania). The 
oligonucleotides FPRL (5'-CGAGTCCTTATGAGCTTGATTCTT-3') and RPRL (5'-
GCCTTCCAGAAGTCGTTTGTTTTC-3') served as primers for the bPRL gene fragments; FGH 
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for the bGH gene fragments. The following amplification profiles were used: for the bPRL 
gene fragments, one cycle of 94°C for 4 min; 35 cycles of 94°C for 30 s, 58°C for 30 s, and 
72°C for 30 s; and one cycle of 72°C for 10 min; for the bGH gene fragments, one cycle of 
94°C for 4 min; 35 cycles of 94°C for 45 s, 67°C for 45 s, and 72°C for 45 s; and one cycle of 
72°C for 10 min. The amplification products were detected by means of 2% agarose gel 
electrophoresis (0.5 μg/ml ethidium bromide in 1X TBE buffer). The restriction products 
were visualized in 2% agarose gel (the bGH gene) or 6% polyacrylamide gel (the bPRL gene) 
(0.5 μg/ml ethidium bromide in 1X TBE buffer). The results of electrophoresis were recorded 
by means of a UVT-1 transilluminator (312 nm) and a ViTran-1 photodocumentation system 
(Biokom, Russia). The alleles were identified as follows: RsaI(–) and RsaI(+) corresponded to 
the A and B alleles of the bPRL gene, respectively; AluI(–) and AluI(+), to the V and L alleles 
of the bGH gene, respectively. 
The PopGene [26] and STATISTICA 8.0 [25] software packages were used for statistical 
treatment of the results. Pairwise comparisons of the allele and heterozygote frequencies 
(observed heterozygosity, Hobs) in the group of breeds studied were performed using the 
Fisher exact test. For similar comparisons using published data on other Russian and foreign 
breeds, we additionally calculated the expected heterozygosity (Hexp) where its values were 
not presented. The G2 test was used for pairwise comparisons of the breeds with respect to 
the genotype frequencies and Hexp. The fit of the observed frequencies of heterozygous 
genotypes to those expected from the Hardy–Weinberg equilibrium was tested using the 
PopGene software. The dependence of the milk yield (in kilograms) and fat and protein 
contents (in percent) on the bPRL and bGH genotypes in Yaroslavl cattle was estimated by 
one-way and two-way ANOVA with the use of the STATISTICA 8.0 software. 
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3. Results and discussion 
3.1. Genetic structure 
The genotype and allele frequencies of the bPRL gene studied in four Russian cattle breeds 
are shown in Table 1. 
 
Breed  bPRL(RsaI) genotypes RsaI alleles of the bPRL gene 
Yakut 
(n = 41) 
(n) AA (23) AB (14) BB (4) A (60) B (22) 
p±s.e. 0.561±0.078 0.341±0.074 0.098±0.046 0.732±0.098 0.268±0.098 
 Hexp± s.e. 0.393±0.120    
Yaroslavl 
(n = 113) 
(n) AA (48) AB (50)  BB (15)  A (146)  B (80)  
p±s.e. 0.425±0.047 0.442±0.047 0.133±0.032 0.646±0.064 0.354±0.064 
 Hexp± s.e. 0.461±0.066    
Bestuzhev 
(n = 57) 
(n) AA (27) AB (24) BB (6) A (78) B (36) 
p±s.e. 0.474±0.066 0.421±0.065 0.105±0.041 0.684±0.087 0.316±0.087 
 Hexp± s.e. 0.432±0.085    
Kostroma 
(n = 124) 
(n) AA (69) AB (48) BB (7) A (186) B (62) 
p±s.e. 0.556±0.045 0.387±0.044 0.056±0.021 0.750±0.055 0.250±0.055 
 Hexp± s.e. 0.375±0.133    
Notes: p± s.e. is the genotype (allele) frequency and its standard error; the number of animals with the given genotype 
is indicated in parentheses; n is the sample size; Hexp ± s.e. is the expected heterozygosity and its standard error. 
Table 1. The frequencies of the RsaI restriction genotypes and alleles of the bPRL gene in four Russian 
cattle breeds 
The G2 test did not show significant differences between the breeds studied with respect to 
the genotype or allele frequencies for the bPRL gene. The genotype frequency distributions 
in the breeds studied fit the Hardy–Weinberg equilibrium. The A allele was prevailing in all 
breeds studied; its frequency was two to three times higher than the B allele frequency. 
Thus, these breeds had similar genetic structures in terms of the given SNP despite their 
different origins and directions of artificial selection. 
The distribution of the RsaI alleles of the bPRL gene is characterized by a higher frequency of 
the A allele in most breeds studied (Figure 3). In Indian Jersey cattle [28], the frequencies of 
the two alleles were approximately equal. The A allele frequency was lower in Polish Jersey 
cattle [29], which deserves special attention. These differences in allele frequencies may have 
resulted from different histories of selection for milk yield in different breeds. The breeds of 
B. taurus exhibit a considerable genotypic variation with respect to the bPRL gene marker 
used in this study. This can be seen in the diagram of the genotype frequency distribution 
(Figure 4). The group of four Russian cattle breeds studied here significantly differed in the 
genotype frequency distribution from Russian Black & White [31] and Russian Red Pied 
[22], but not Lithuanian Black & White [30]; (p < 0.006 with the Bonferroni correction). 
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Designations: A and B, alleles of the bPRL gene; P, Polish; J, Jersey; I, Indian; L, Lithuanian; B&W, Black and White; R, 
Russian; Holstein Friesian; Mont, Montebeliard; R.R.P., Russian Red Pied; Kostr, Kostroma; Yar, Yaroslavl; Best, 
Bestuzhev. 
The diagram is based on published data on Polish Jersey [29], Indian Jersey, Indian Holstein Friesian [28], Lithuanian 
Black & White, Lithuanian Red [30], Russian Black & White [31], Montebeliard [32], and Russian Red Pied [22] cattle. 
Figure 3. Distribution of bPRL(RsaI) allele frequencies in the four breeds studied and in other Russian 
and foreign breeds. The abscissa shows the breeds; the ordinate shows the allele frequencies (in 
fractions of unity). 
 
Designations: AA, AB, and BB, bPRL genotypes. For designations of the breeds, see Figure 2. 
Figure 4. Distribution of bPRL genotype frequencies in the four breeds studied and in other Russian 
and foreign breeds. The radial axes show the breeds and the corresponding genotype frequencies. 
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Thus, these breeds had similar genetic structures in terms of the given SNP despite their 
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cattle [29], which deserves special attention. These differences in allele frequencies may have 
resulted from different histories of selection for milk yield in different breeds. The breeds of 
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used in this study. This can be seen in the diagram of the genotype frequency distribution 
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genotype frequency distribution from Russian Black & White [31] and Russian Red Pied 
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3.2. Genetic variation 
The observed (Hobs) and expected (Hexp) heterozygosities (Table 1) for the bPRL gene did not 
differ significantly from each other in any breed studied; nor did any two breeds differ in 
these parameters. This was unexpected, considering the substantial differences between 
these breeds in the HinfI site of the bPit-1 transcription factor gene (exon 6) and the AluI site 
of the bGH growth hormone gene (exon 5) (our unpublished data), which are also associated 
with milk productivity. 
In order to compare the genetic diversity in the Russian cattle breeds studied here with 
those in other Russian and foreign breeds (Figure 5), we calculated the Hexp for all breeds 
analyzed. The observed and expected heterozygosities for the bPRL gene did not differ 
significantly in most breeds (Figure 5). The Indian Jersey breed was an exception (χ2 = 13.77, 
ν = 1, p = 0.00021); the excess of heterozygotes in these cattle apparently resulted from 
artificial selection. 
 
Designations: Hobs and Hexp, the observed and expected heterozygosities, respectively. For designations of the breeds, 
see Figure 2. The diagram is based on the expected heterozygosity levels calculated from published data on 
Montebeliard [32], Russian Red Pied [22], Polish Jersey [29], Lithuanian Black & White, Lithuanian Red [30], Indian 
Jersey, and Indian Holstein Friesian [28] cattle. 
Figure 5. The observed and expected heterozygosities for the bPRL gene markers in Russian and 
foreign cattle breeds. The abscissa shows the breeds; the ordinate shows the heterozygosity coefficients 
(in fractions of unity). 
Four Russian breeds studied did not differ from one another in the genetic variation (Hexp). 
At the same time, as can be seen in Figure 5, this group had significantly higher Hexp values 
compared to Russian Red Pied [22] Indian Holstein Friesian [28], and Montebeliard [32], 
cattle (G2 =36.13, ν = 4, p =3.0∙10–7; G2 =39.19, ν = 4, p = 1.0∙10–7; G2 =16.72, ν = 4, p = 0.0022; and 
G2 =19.41, ν = 4, p = 0.0007, respectively; after the Bonferroni correction). 
Thus, the heterozygosity levels in the Kostroma, Bestuzhev, Yakut, and Yaroslavl breeds are 
significantly higher than in the breeds used for comparison. This indicates a stable state of 
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the breeds studied. However, since artificial selection alters genetic variation, regular 
monitoring of cattle breeds for the given RsaI genetic marker is advisable. 
3.3. Search for associations of SNPs of the prolactin and somatotropin genes 
with milk production traits in Yaroslavl cattle 
Advances in molecular genetic analysis based on PCR have given rise to novel marker 
systems for direct genotyping at the DNA level that are independent of the animal's sex and 
age. This makes the procedures less time-consuming and more accurate. 
The RsaI polymorphism of the bPRL gene (Table 1), as well as the AluI polymorphism in 
exon 5 of the bGH gene, was used to search for associations of these genes with milk 
production traits, including the milk yield and milk fat and protein contents, in Yaroslavl 
cattle. We found the following frequency distribution of genotypes: LL (n = 32), 0.283 ± 0.042; 
LV (n = 63), 0.558 ± 0.047; VV (n = 18), 0.159 ± 0.034. The genotype frequency distribution in 
these breeds fit the Hardy–Weinberg equilibrium. Table 1 shows the frequency distribution 
of bPRL genotypes. AAVL (n = 29) and ABVL (n = 27) are the most frequent combined 
genotypes of these genes; the AALL and ABLL genotypes are somewhat rarer (n = 12 and n = 
16, respectively). 
We used ANOVA to estimate the isolated effect of the bPRL gene and the combined effect of 
the bPRL and bGH genes on milk production traits (the milk yield in kilograms and the 
percentage fat and protein contents for the first three lactations) in Yaroslavl cattle. Table 3 
shows the dependence of these parameters for the third lactation on the bPRL(RsaI) 
polymorphism as estimated by one-way ANOVA. The bPRL gene was found to affect the fat 
content of milk (F(2;63) = 3.18, p = 0.048) but not the milk yield or protein content. 
 
 Lactation 3 
  Milk Yield (kg) Fat (%) 
Factor D. F. SS MS F P SS MS F P 
PRL(Rsa1) 2 0.03 0.015 0.5 0.629 0.002 0.001 3.19 0.0478 
Error 63 2.021 0.032   0.0232 0.0004   
  Protein (%) 
  SS MS F P 
Rsa1(PRL) 2 0.0005 0.0003 2.34 0.104 
Error 63 0.0073 0.0001   
Designations: d.f., number of degrees of freedom; SS, sum of squares; MS, mean sum of squares, F, Fisher's test; p, 
probability; Error, residual variance. 
Table 2. Results of one-way ANOVA showing the dependence of milk production traits for the third 
lactation on the PRL(RsaI) polymorphism in Yaroslavl cattle 
Figures 6a–6c show the dependences of three milk production traits on the bPRL genotypes 
in Yaroslavl cattle. As can be seen in Figure 6a, cows with the AA genotype exhibited a 
significantly higher fat content of milk compared to BB cows (p = 0.037). 
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cattle (G2 =36.13, ν = 4, p =3.0∙10–7; G2 =39.19, ν = 4, p = 1.0∙10–7; G2 =16.72, ν = 4, p = 0.0022; and 
G2 =19.41, ν = 4, p = 0.0007, respectively; after the Bonferroni correction). 
Thus, the heterozygosity levels in the Kostroma, Bestuzhev, Yakut, and Yaroslavl breeds are 
significantly higher than in the breeds used for comparison. This indicates a stable state of 
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the breeds studied. However, since artificial selection alters genetic variation, regular 
monitoring of cattle breeds for the given RsaI genetic marker is advisable. 
3.3. Search for associations of SNPs of the prolactin and somatotropin genes 
with milk production traits in Yaroslavl cattle 
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age. This makes the procedures less time-consuming and more accurate. 
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exon 5 of the bGH gene, was used to search for associations of these genes with milk 
production traits, including the milk yield and milk fat and protein contents, in Yaroslavl 
cattle. We found the following frequency distribution of genotypes: LL (n = 32), 0.283 ± 0.042; 
LV (n = 63), 0.558 ± 0.047; VV (n = 18), 0.159 ± 0.034. The genotype frequency distribution in 
these breeds fit the Hardy–Weinberg equilibrium. Table 1 shows the frequency distribution 
of bPRL genotypes. AAVL (n = 29) and ABVL (n = 27) are the most frequent combined 
genotypes of these genes; the AALL and ABLL genotypes are somewhat rarer (n = 12 and n = 
16, respectively). 
We used ANOVA to estimate the isolated effect of the bPRL gene and the combined effect of 
the bPRL and bGH genes on milk production traits (the milk yield in kilograms and the 
percentage fat and protein contents for the first three lactations) in Yaroslavl cattle. Table 3 
shows the dependence of these parameters for the third lactation on the bPRL(RsaI) 
polymorphism as estimated by one-way ANOVA. The bPRL gene was found to affect the fat 
content of milk (F(2;63) = 3.18, p = 0.048) but not the milk yield or protein content. 
 
 Lactation 3 
  Milk Yield (kg) Fat (%) 
Factor D. F. SS MS F P SS MS F P 
PRL(Rsa1) 2 0.03 0.015 0.5 0.629 0.002 0.001 3.19 0.0478 
Error 63 2.021 0.032   0.0232 0.0004   
  Protein (%) 
  SS MS F P 
Rsa1(PRL) 2 0.0005 0.0003 2.34 0.104 
Error 63 0.0073 0.0001   
Designations: d.f., number of degrees of freedom; SS, sum of squares; MS, mean sum of squares, F, Fisher's test; p, 
probability; Error, residual variance. 
Table 2. Results of one-way ANOVA showing the dependence of milk production traits for the third 
lactation on the PRL(RsaI) polymorphism in Yaroslavl cattle 
Figures 6a–6c show the dependences of three milk production traits on the bPRL genotypes 
in Yaroslavl cattle. As can be seen in Figure 6a, cows with the AA genotype exhibited a 




Figure 6. Dependence of (a) the milk yield (in kilograms), (b) the fat content, and (c) the protein 
content of milk of the third lactation on the bPRL genotypes in Yaroslavl cattle. The abscissas show 
the bPRL genotypes; the ordinates show the mean values of the traits; vertical bars are 0.95 
confidence intervals. 
Considering that quantitative traits, including milk production traits, are each determined 
by a number of genes, we also estimated the possible combined effect of two factors, the 
bPRL and bGH genes, on the milk production traits using two-way ANOVA. The analysis 
did not reveal a significant isolated effect of any one-locus genotype for any lactation. Still it 
showed that the bPRL genotype tended to affect the third-lactation milk fat content (p = 
0.064), which was in contrast to the results of one-way ANOVA showing its significant effect 
(Table 2). Like one-way ANOVA, the two-way analysis demonstrated that AA cows were 
characterized by a higher fat content of milk than BB cows. However, the main result 
concerning the relationship between the bPRL and bGH gene polymorphisms and milk 
production was that we found combined effects of these two genes on the fat and protein 
contents of first-lactation milk in Yaroslavl cattle (F(4;104) = 2.59, p = 0.041 and F(4;104) = 2.93, p = 
0.024, respectively) (Table 3). 
In order to identify the genotypes whose carriers significantly differed in the mean 
percentage fat and protein contents of milk, we performed post-hoc pairwise comparisons of 
these traits in cows with different combined genotypes of the bPRL and bGH genes. Table 4 
shows the results of this analysis. In terms of the milk fat content, cows with the ABLL 
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genotype significantly differed from those with the AAVL, AALL, ABVV, and BBVL 
genotypes; and cows with the BBVV genotype significantly differed from those with the 
ABVV and BBVL genotypes. In terms of the milk protein content, AALL cows significantly 
differed from AAVV, ABVL, ABLL, and BBLL cows; and BBVV cows, from BBLL ones. 
 
Effect Lactation 1 
Trait Milk Yield Fat (%) 
D.f. SS MS F P SS MS F P 
PRL(RsaI) 2 0.006 0.003 0.2 0.858 4.0E-05 2.0E-05 0.060 0.939 
GH(AluI) 2 0.084 0.042 2.1 0.123 0.001 2.6E-04 0.920 0.401 
PRL(RsaI) 
*GH(AluI) 
4 0.064 0.016 0.8 0.520 0.003 0.001 2.590 0.041 
Error 104 2.049 0.020   0.029 2.8E-04   
 Lactation 1 
 Trait Protein (%) 
Effect D.f. SS MS F P 
PRL(RsaI) 2 2.4E-05 1.2E-05 0.100 0.908 
GH(AluI) 2 2.3E-04 1.1E-04 0.890 0.412 
PRL(RsaI) 
*GH(AluI) 
4 0.001 3.7E-04 2.930 0.024
Error 104 0.013 1.3E-04   
Designations are the same as in Table 2. 
Table 3. Results of two-way ANOVA showing the dependence of the milk production parameters on 
the bPRL and bGH genes and their interaction in Yaroslavl cattle 
Figure 7 graphically shows the combined effects of the bPRL and bGH genes. The milk yield 
(in kilograms) and the fat and protein contents of milk of the first lactation in Yaroslavl cows 
are plotted in Figures 7a, 7b, and 7c, respectively, against the bPRL genotypes (AA, AB, and 
BB). The bGH genotypes are indicated by dots of different colors. The points corresponding 
to the same bGH genotype but different bPRL genotypes are connected by dotted lines. As 
evident from Figure 7, there was no consistent dependence of the fat or protein content on 
the dose of any allele of any gene. Let us consider how the mean milk fat content depended 
on the bPRL genotypes in combination with different bGH genotypes (Figure 7b). The 
combinations of the AA genotype of the bPRL gene with different bGH genotypes did not 
differ significantly from one another, and neither did the combinations of the BB genotype 
of the bPRL gene with different bGH genotypes. In contrast, the mean percentage fat content 
of milk of AB cows was significantly lower if they had the LL genotype of the bGH gene than 
if they had the VV genotype. This indicates gene interaction, which should be taken into 
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account because otherwise the effects of individual genes on the formation of these traits 
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would be incorrectly estimated. Note that, among the combined genotypes of the bPRL and 
bGH genes shown in Figure 7, the AALL, AAVL, ABVV, and BBVL genotypes were 
characterized by a significantly higher milk fat content of milk compared to the ABLL gene 
(Figure 7b). 
 
Combined bPRL and bGH genotypes (bPRL(RsaI)–bGH(AluI)) 
 AAVV AAVL AALL ABVV ABVL ABLL BBVV BBVL BBLL 
AAVV  0.933 0.725 0.243 0.945 0.182 0.272 0.267 0.968 
AAVL 0.102  0.701 0.163 0.809 0.041 0.175 0.186 0.984 
AALL 0.038 0.378  0.336 0.572 0.044 0.139 0.369 0.806 
ABVV 0.067 0.484 0.986  0.125 0.008 0.038 0.955 0.339 
ABVL 0.432 0.181 0.058 0.125  0.069 0.218 0.143 0.919 
ABLL 0.733 0.086 0.029 0.068 0.570 0.882 0.009 0.259 
BBVV 0.058 0.343 0.725 0.736 0.108 0.064 0.042 0.312 
BBVL 0.559 0.368 0.153 0.208 0.960 0.727 0.159  0.36 
BBLL 0.713 0.086 0.036 0.054 0.293 0.491 0.045 0.387  
Table 4. Results of post-hoc comparisons of the mean first-lactation fat (above the diagonal) and protein 
(below the diagonal) contents of milk of Yaroslavl cows with different combined bPRL–bGH genotypes 
Regarding the dependence of the mean protein content of milk in Yaroslavl cattle on the 
bPRL genotypes combined with different bGH genotypes (Figure 7c), the combined AALL 
genotype differs from AAVV, and BBVV differed from BBLL. In contrast, no combination of the 
AB genotype of bPRL with a bGH genotype differed from its combination with any other bGH 
genotype in this respect. Note that, in the given sample of Yaroslavl cattle, the AAVV, ABLL, 
and BBLL genotypes were preferable over the AALL genotype in terms of the percentage 
protein content of milk, as was the BBLL genotype over the BBVV genotype. 
Thus, in Yaroslavl cattle, the AA genotype of the bPRL gene was characterized by a 
significantly higher percentage fat content of milk than the BB genotype, in contrast to 
Russian Red Pied cattle, where AB cows had a higher milk fat content than AA and BB cows 
(p < 0.05) [22]. Our study has been the first to demonstrate the combined effect of the bPRL 
and bGH genes (i.e., their combined genotypes) on the milk fat and protein contents. A 
number of other authors have also studied the relationship of milk production with 
combined genotypes of SNPs in the same or different genes; however, the possibility of their 
combined effect has almost never been considered. One exception is the study on the effects 
of the combined genotypes of the AluI and MspI polymorphic sites in exon 5 and intron 3, 
respectively, of the growth hormone gene in Polish Black & White cattle [20]. However, 
these authors studied combined bGH genotypes as a single factor; hence, they did not 
consider the effect of interaction between individual SNPs on the traits studied. In addition, 
the marker system used by them was hardly suitable for revealing the interaction of these 
SNPs because they were located in the same gene. 
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by dotted lines. 
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We have found that four Russian cattle breeds, Yakut, Bestuzhev, Kostroma, and Yaroslavl 
cattle, are similar in genetic structure. All of them are characterized by a low frequency of 
the BB genotype of the RsaI polymorphic site in the bPRL gene (from 0.056 ± 0.021 to 0.133 ± 
0.031) and high frequencies of heterozygotes and homozygotes for the A allele. The breeds 
of B. taurus exhibit a considerable genotypic variation with respect to the bPRL gene marker 
used in this study. The group of these four Russian cattle breeds significantly differs in the 
genotype frequency distribution from other breeds, such as Russian Black & White and 
Russian Red Pied. At the same time, these four breeds do not differ significantly in the 
observed or expected heterozygosity for the bPRL gene either from each other or from other 
breeds used for comparison. 
We have demonstrated a combined effect of the bPRL and bGH genes on the percentage 
protein and fat contents of milk. Each trait has been found to be significantly positively 
associated with some of the combined genotypes. No genotype has been found to positively 
affect both traits. At the same time, some genotypes are associated positively with one trait 
and negatively with the other one: ABVV cows are characterized by a high fat content and 
low protein content of milk, while this is the other way round with ABLL cows. This could 
be used for selecting cattle for high individual productivity traits. Note that only one 
combined genotype (BBVV) is unfavorable in terms of both traits. However, being doubly 
homozygous, it may serve as a reserve for obtaining genotypes that are valuable in terms of 
either fat (ABVV and BBVL) or protein (AAVV and BBLL) content of milk. Thus, the study of 
the combined effects of the bPRL and bGH genes and the breeding practice taking these 
effects into account allow the cattle productive potential to be analyzed in more detail. In 
addition, involvement of epistatic gene interaction in the formation of selectively valuable 
quantitative traits has been further confirmed. 
We believe that data on the bPRL(RsaI) SNP marker and the heterozygosity estimates 
calculated from its allele frequencies may be used in programs for conservation of aboriginal 
breeds while maintaining the optimal balance between the goals of artificial selection and 
preservation of the genetic diversity, which is necessary for sustained reproduction of cattle 
breeds with all their unique characters. This is especially important because of the rapid 
decrease in the stocks of cattle breeds and the related threat of partial loss of the genetic 
resources for stockbreeding on a global scale. [33]. 
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1. Introduction 
Prolactin (PRL) is a protein hormone, as well as a cytokine, which is synthesized and 
secreted from specialized cells of the anterior pituitary gland, named lactotrophs. More than 
300 functions exerted by PRL in vertebrates have been recognized; and they reflect the 
ubiquitous distribution of its receptors, as well as the fact that PRL is synthesized in many 
extrapituitary tissues. Among these sites of PRL synthesis are cells of the immune system, 
such as macrophages, natural killer cells, and T- and B-lymphocytes. Regulation of PRL 
synthesis is organ specific, which confers additional complexity to the spectrum of PRL 
actions. In the physiology of the immune system, PRL acts by stimulating the secretion of 
other cytokines and the expression of cytokine receptors, and also as a growth and survival 
factor. In pathological conditions, increased levels of PRL could cause deterioration of the 
subject’s condition. In this review, we integrate the information on regulation of PRL 
synthesis with that concerning its physiological and pathological actions in extrapituitary 
tissues, highlighting those in the immune system. 
2. Regulation of prolactin expression and secretion in the pituitary and at 
extrapituitary sites 
PRL was originally identified as a neuroendocrine hormone of pituitary origin; however, its 
synthesis is not limited to the hypophysis since numerous extrapituitary tissues also express 
this protein, including the placenta, ovary, testis, mammary gland, skin, adipose tissue, 
endothelial cells, and immune cells [1]. This wide-spread PRL expression might explain its 
involvement in very different processes such as reproduction, metabolism, immunology, 
and behavior. 
PRL expression and secretion are regulated by different stimuli provided by the 
environment and the internal milieu. Although pituitary PRL secretion is under a tonic and 
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predominantly inhibitory control exerted by dopamine of hypothalamic origin, other factors 
within the brain, pituitary gland, and peripheral organs have been shown to inhibit or 
stimulate PRL secretion as well [2-5]. Therefore, pituitary PRL expression depends on the 
balance between inhibitory and stimulatory molecules such as hormones, cytokines, and 
other factors that orchestrate the cascade of intracellular events involving numerous 
signaling pathways. Prominent among these signaling cascades are the cAMP/protein 
kinase A (PKA), the phosphatidylinositol/Ca++/protein kinase C (PKC), and the mitogen-
activated protein kinase (MAPK) pathways. In addition, the PRL gene seems to follow a 
pulsatile transcription dynamic with refractive phases in the transcription cycles [4]. In the 
pituitary, a direct relation between transcribed mRNA and released protein cannot be easily 
established, since different, post-transcriptional processes may alter the final protein 
production; these include mRNA degradation, protein storage, and regulation of secretion. 
Pituitary PRL secretion depends on the action of secretagogues which act on the cell 
membrane of lactotrophs, rapidly releasing stored PRL by means of calcium-dependent 
exocytosis. In contrast, extrapituitary cells seem to have little storage capacity and 
consequently, PRL is released after synthesis [2, 5]. Therefore, extrapituitary PRL is basically  
 
Figure 1. Schematic representation of the human PRL gene. A) The alternative and proximal promoters, 
as well as the coding region are depicted. Exons are represented by black boxes with corresponding 
exon numbers (1a, 1b, 2-5). Exon 1a, located 5.8 kb upstream of the proximal start site, drives 
extrapituitary PRL expression. B) Extended diagram of human PRL alternative promoter showing the 
location of predicted transcription factor binding sites. The superdistal promoter is about 3.0 kb in 
length. Consensus sequences for transcription factors are depicted and shown in different colors. The 
figure is not drawn to scale. AP1: activator protein 1; C/EBP: CCAAT/enhancer binding protein; Pit-1: 
pituitary-specific transcription factor 1; CRE: cyclic-AMP response element; HoxA-11: homeobox A11; 
FOXO1A: forkhead box protein O1A; HNF-1: hepatocyte nuclear factor 1; ETS: E-twenty six; ERE: 
estrogen response element. Enhancer regions are represented in green. 
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regulated at the level of transcription. The regulation of PRL gene expression is quite 
complex, due to the presence of several enhancer and silencer domains as well as the 
formation of chromatin loops with consequences for transcription dynamics. Two 
independent promoters with differential responses to regulatory mediators direct PRL 
transcription in a cell-type specific manner [4]. 
The human PRL locus consists of a single gene containing 5 coding exons transcribed 
directly from a pituitary-specific promoter (proximal promoter) and a non-coding exon (1a) 
transcribed from an alternative promoter (also known as the decidual or superdistal 
promoter) with a transcriptional start site located 5.8 kb upstream of exon 1b (Figure 1). This 
alternative promoter drives expression in extrapituitary tissues [4, 5] and seems to have 
evolved from a long terminal repeat transposable element, previously described as primate 
specic [6]. The differential promoter usage produces different sized gene products, which 
may vary in a cell-specific manner depending on the functional elements used within the 
particular promoter. In general, extrapituitary PRL mRNA is 150 bp longer than pituitary 
PRL mRNA; however, mRNA identical to that in the pituitary gland has been found in 
normal and tumoral breast tissues, breast cell lines, and prostate [7, 8]. Therefore, the 
dichotomy of promoter usage in pituitary versus extrapituitary sites is not absolute [9]. 
As a consequence of the distal transcription start site, the alternative promoter does not 
respond to the same regulators of gene expression that operate with the proximal promoter, 
such as the pituitary transcriptional factor-1 (Pit-1), which is paramount for the activation of 
pituitary PRL transcription. An exception to this generalization is the hormonal form of 
vitamin D, calcitriol, which stimulates PRL expression in pituitary cells as well as in decidua 
and resting lymphocytes. Other cell-specific cases will be further discussed below. 
2.1. Regulation of PRL in the immune system 
In the immune system, PRL is thought to act as a locally produced cytokine with relevance 
for immune regulation and modulation of T- and B-cell function. Nevertheless, the 
molecular mechanisms regulating PRL expression in the immune system and the factors 
implicated are still not fully understood. Within the immune system, PRL is produced by T- 
and B-lymphocytes, macrophages, thymocytes, mononuclear and natural killer cells. 
However, in peripheral blood-mononuclear cells (PBMC), PRL production is mainly 
associated with the T-lymphocyte fraction [2, 10]. Because it uses the alternative promoter, 
lymphocyte PRL expression is independent of Pit-1, progesterone, estrogen, thyrotropin-
releasing hormone (TRH), dihydrotestosterone, and insulin, among other classical 
modulators of PRL in the hypophysis. In contrast, PRL expression in T-lymphocytes is 
stimulated by cAMP, retinoic acid, and calcitriol, while it is inhibited by dexamethasone and 
some interleukins [10-15].  
2.1.1. cAMP and modulators of the cAMP/CREB pathway 
Consistent evidence, including studies in different leukemic cell lines as well as PBMC from 
normal patients, has shown that PRL gene expression is significantly stimulated by cAMP, 
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its analogues and first messengers that signal through the cAMP/PKA pathway [12, 13, 16]. 
The second messenger cAMP induces PRL gene expression by activating PKA, which 
migrates to the nucleus and phosphorylates target proteins such as the cAMP response 
element binding protein (CREB). However, in the eosinophilic leukemia cell line EoL-1, it 
seems that cAMP induces PRL expression by two different signaling cascades: the classic 
PKA-dependent pathway leading to the phosphorylation of CREB, and a PKA-independent 
pathway leading to the phosphorylation of p38 [12]. Known first messengers that activate 
the cAMP/PKA pathway are prostaglandin-E2 and terbutaline, a 2-adrenergic agonist that 
enhances PRL expression in PBMC and some leukemic cell lines either alone or in 
combination with PMA or ionomycin [17]. These observations are most likely explained by 
the cAMP response element (CRE) located -25 bp upstream of the PRL alternative promoter 
(Figure 1). Furthermore, this CRE encourage additional studies of the regulation of PRL by 
other physiological modulators of the immune system that operate through cAMP as a 
second messenger. This would be especially relevant in pathological conditions associated 
with increased PRL levels such as autoimmune diseases and cancer, where alterations in 
extrapituitary PRL promoter regulation might play a role in the pathophysiology of these 
disorders. 
2.1.2. Dopamine and cell-activating factors 
Quite interestingly, the nervous and the immune systems use a common chemical language 
for intra- and inter-system communication. Indeed, both systems produce a common set of 
neurotransmitters and cytokines that act on a shared repertoire of receptors [18]. Regarding 
dopamine, which is the primary neuroendocrine inhibitor of PRL secretion in the anterior 
pituitary gland, some evidence supports the involvement of this neurotransmitter in the 
regulation of lymphocyte PRL production and release [3]. Indeed, differential expression of 
all dopamine receptor subtypes has been detected by flow cytometry in human immune 
cells [19]. Specifically in lymphocytes, pharmacological studies indicate expression of the 
dopamine receptors D2, D3, D4, and D5 [3, 20, 21]. In the secondary lymphoid tissues, D3 is 
the predominant dopamine receptor and it is highly and selectively expressed in naive 
CD8+T cells of both humans and mice [22]. The differential expression of dopamine receptor 
subtypes in the lymphocyte subsets as well as the alterations in dopamine-mediated effects 
under conditions of stress [23]; need to be taken into consideration when studying 
regulatory mechanisms involved in cell activation/suppression processes. Indeed, since D1 
and D5 couple with Gs proteins increasing cAMP, while D2, D3, and D4 couple with Gi 
proteins, inhibiting the production of cAMP, a different cell response is to be expected 
depending on the receptor subtype that is expressed, as seen in activated T cells [24].  
In addition, some immune cells such as lymphocytes produce endogenous dopamine, which 
may induce autocrine/paracrine actions. The effects of dopamine in the immune system are 
highly dependent on the context and dopamine concentration [25]; moreover, its effects on 
immune cells also depend on their activation state, which, at the same time, is modulated by 
dopamine itself [25, 26]. Indeed, dopamine interacts directly with dopaminergic receptors 
on normal human T-cells, triggering characteristic features of activated lymphocytes [26]. 
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These data are in agreement with unpublished observations from our group which 
indicated that dopamine regulates prolactin expression in PBMC, as well as expression of its 
own receptor [27]. Moreover, our results showed that activation of PBMC with 
phytohemagglutinin (PHA), concanavalin-A (Con-A), or phorbol myristate acetate (PMA) 
significantly reduced PRL mRNA in all cases. Notably, the inhibitory effect of Con-A upon 
PRL mRNA expression persisted in the presence of a cAMP analogue (Figure 2), suggesting 
that cell activation with this lectin disrupts the cAMP/PKA signaling pathway, which is 
involved in PRL upregulation in lymphocytes as previously mentioned. In accordance with 
our results, Gerlo et al showed that PMA and ionomycin inhibited PRL gene expression in 
normal PBMC, but elicited differential effects in several leukemic cell lines [17]. Altogether, 
these observations suggest that under an in vivo scenario, modification of the lymphocytes 
activation status by dopamine might alter their PRL expression, an idea which warrants 
further investigation. In vitro, even if PRL gene expression is decreased by cell activation, the 
final PRL concentration in the culture media might be elevated due to the larger number of 
PRL-producing cells. This agrees with several other studies showing that mitogen 
stimulation is not required for PRL mRNA expression and exerts no appreciable effect on 
the level of PRL transcripts [10]. 
 
Figure 2. Effect of lymphocyte activators on PRL mRNA levels. PBMC from 3 pregnant women were 
incubated for 24 h in the presence of 8-Bromo-cAMP (8Br, 1 mM), concanavalin-A (Con-A, 1 mg/mL), or 
both. PRL mRNA expression was evaluated after normalization against L-32 mRNA by real time PCR. a 
= P < 0.05 vs control (C); b = P < 0.05 vs 8Br. An arbitrary value of 1 was given to control data.  
2.1.3. Calcitriol 
Previous findings in human lymphocytes suggested that calcitriol effects were exerted only 
after cell activation, which is necessary for the induction of the 50-kDa classic vitamin D 
receptor (VDR). Nevertheless, recent findings from our group clearly showed VDR-
mediated effects in resting lymphocytes. We also described a constitutive, 75-kDa VDR 
species that might participate in calcitriol-dependent PRL upregulation in these cells. 
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2.1.3. Calcitriol 
Previous findings in human lymphocytes suggested that calcitriol effects were exerted only 
after cell activation, which is necessary for the induction of the 50-kDa classic vitamin D 
receptor (VDR). Nevertheless, recent findings from our group clearly showed VDR-
mediated effects in resting lymphocytes. We also described a constitutive, 75-kDa VDR 
species that might participate in calcitriol-dependent PRL upregulation in these cells. 
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Indeed, as in the case of decidua and the pituitary, calcitriol stimulated both, PRL mRNA 
expression and protein production in resting PBMC through a VDR-mediated mechanism 
[15]. Interestingly, this effect was only seen in quiescent lymphocytes and was not detected 
in Jurkat T-lymphoma cells. Genomic effects of calcitriol upon the alternative PRL promoter 
are likely to occur in lymphocytes, in view of previous results in decidua [28] together with 
the fact that the decidual form of the PRL transcript is expressed in human blood 
lymphocytes [10, 29]. Nevertheless, further studies are required to clarify the specific 
interaction of the VDR with the PRL promoter region in lymphocytes, since it is known that 
the pituitary promoter contains functional sequences that confer VDR responsiveness. 
Indeed, calcitriol stimulated PRL promoter activity in cultured pituitary GH3 cells [30, 31], 
an effect that was further corroborated in vivo [32]. The fact that calcitriol regulates PRL in 
immune cells might be relevant in specific physiological contexts, considering the 
immunomodulatory actions of this secosteroid. Certainly, calcitriol effects in the immune 
system appear to occur at the level of T-helper (Th) cells, where it acts as an 
immunosuppressive factor. Calcitriol inhibits mainly Th1 cytokines [33], as confirmed by its 
abilities to prevent or ameliorate autoimmune diseases and to inhibit allograft rejection 
responses [34, 35]. The upregulation of lymphocyte-derived PRL by calcitriol could help 
explain the condition of hyperprolactinemia reported in some granulomatous disorders 
such as sarcoidosis, a disease associated with increased calcitriol production by 
macrophages, and characterized by abnormal accumulation of inflammatory cells such as T-
lymphocytes [36, 37]. Indeed, calcitriol is synthesized by macrophages, dendritic cells, and 
both T- and B-cells by means of expressing the enzyme CYP27B1, which catalyzes the 
synthesis of the secosteroid from its inactive precursor, calcidiol [38]. Thus, in immune cells, 
PRL secretion might be regulated by locally produced calcitriol providing, at this level, 
paracrine and or autocrine immunomodulatory effects. 
2.1.4. Cytokines 
Structural analyses of PRL and its receptors have revealed their relation to the 
cytokine/hematopoietin family. Standing as a leukocyte-derived cytokine in the immune 
system, PRL is regulated by other cytokines in an autocrine and paracrine manner. In T-
lymphocytes, interleukin (IL)-2, IL-1 and IL-4 reduced PRL mRNA, while IL-10 and 
interferon- had no effect [11]. On the other hand, in myeloid leukemic cells, the PRL 
alternative promoter was activated by the proinflammatory cytokine tumor necrosis factor 
alpha (TNF-). A TNF--responsive region was located between -1842 and -1662 of the 
extrapituitary PRL promoter. Interestingly, the stimulatory effect of TNF- upon PRL was 
blocked by a protein kinase C (PKC) inhibitor [14]. Since TNF- is a master 
proinflammatory cytokine, its involvement in PRL stimulation might have clinical relevance 
in view of several studies indicating that leukocyte-derived PRL is involved in autoimmune 
and hematological disorders [39-41]. Indeed, hyperprolactinemia and increased secretion of 
lymphocyte PRL have been reported in systemic lupus erythematosus (SLE) [42], which is 
an autoimmune disease characterized by abnormal production of autoantibodies and 
proinflammatory cytokines [43]. Moreover, hyperprolactinemia has been associated with 
SLE disease activity [41, 42, 44, 45]. 
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2.2. Regulation of PRL in the placenta and endometrium 
PRL functions in reproduction vary within species. For example, while in rodents the presence 
of PRL is mandatory to achieve a normal estrous cycle, support the corpus luteum for 
progesterone production and maintenance of gestation, in humans the role of PRL is more 
likely relevant during lactation, since it does not support the corpus luteum nor significantly 
participates in the menstrual cycle [5]. The decidua develops from the uterine lining 
throughout the late luteal phase of the menstrual cycle, and during pregnancy the decidua 
constitutes the maternal component of the placenta. Considered a marker of decidualization, 
PRL is one of the most dramatically induced genes in decidualized endometrial cells. The 
placental decidua secretes very large amounts of PRL that accumulates in the amniotic fluid, 
peaking between 16 and 22 weeks of gestation (5000 ng/mL) and falling to 500 ng/mL at 
term [46]. Regarding PRL regulation, activation of the cAMP/PKA pathway is known to 
induce the activity of the alternative PRL promoter in human decidual cells through the 
transcription factors CREB and CCAAT/enhancer-binding protein (C/EBP) [47, 48]. In this 
regard, eight C/EBP binding sites have been described in the decidual PRL promoter (Figure 
1). Decidualization is mainly triggered and supported by progesterone. Accordingly, 
upregulation of PRL gene expression steadily increases due to high progesterone levels during 
pregnancy. Indeed, progesterone potently stimulates decidual PRL production [49, 50], which 
is achieved in part  by cross-talk with the cAMP/PKA signaling pathway [51], and is 
synergized by a number of factors such as prostaglandin E, corticotropin releasing factor, and 
the free -subunit of gonadotropin [52-54]. Furthermore, in human endometrium explants and 
endometrial stromal (ES) cells, progesterone and relaxin induced stromal differentiation 
(decidualization) and PRL secretion [50, 55]. Interestingly, in primary ES cell cultures, cAMP 
activated the alternative PRL promoter in a biphasic manner, with an initial, weak induction 
during the first 12 hours, followed by a more intense induction afterwards. It was concluded 
that the early response depended upon the CRE located at approximately -12 bp upstream of 
the PRL alternative promoter, whereas the major activation depended upon a region between 
positions -332 and -270 bp, which kinetics differed from classic CRE-mediated responses [55]. 
In addition to the decidualized endometrium of the late luteal phase and of pregnancy, the 
human myometrium, which is the muscle layer of the uterus, is considered to be a 
secondary source of PRL. Nevertheless, the regulation of myometrial PRL differs 
significantly from that of the decidua. Indeed, myometrial PRL expression seems to be 
under inhibitory control in vivo, as concluded from experimental findings showing that 
myometrial PRL release increased with time in culture. Moreover, in myometrial explant 
cultures, medroxyprogesterone acetate inhibited PRL production [2, 56]. This observation, 
together with the fact that PRL circulating levels are unchanged throughout the human 
menstrual cycle, suggests that further studies are needed to completely clarify the 
mechanistic details of PRL regulation by progesterone in the human myometrium.  
Besides progesterone, other stimulators of decidual PRL synthesis and release are insulin, 
insulin-like growth factor-1, and calcitriol [28, 57, 58]. Since the human decidua is able to 
synthesize calcitriol and express the VDR, PRL regulation by this secosteroid is more likely 
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autocrine in nature. However, considering that inflammatory cytokines such as TNF-, IL-
1, IL-1, IL-2, IL-8, and transforming growth factor- (TGF-1) inhibit decidual PRL 
expression [59, 60], and that calcitriol is a potent inhibitor of placental inflammatory 
cytokine production [61, 62], calcitriol might also be acting as a paracrine upregulator of 
decidual PRL. In addition, IL-4 decreased both the level of PRL mRNA and its release from 
myometrial tissue, whereas IL-6 exerted no effect [63]. Recently, the transcriptional 
regulators HoxA-10, HoxA-11, and FOXO1A, which are essential for decidualization, have 
been shown to interact physically and functionally to upregulate the expression of a gene 
battery in differentiating endometrium. In particular, this core set of transcription factors 
cooperatively upregulate PRL in differentiating ES cells by binding to an enhancer region 
located between positions −395 and −148 of the decidual prolactin promoter (Figure 1) [64]. 
2.3. Regulation of PRL in the breast and adipose tissue 
In addition to uptake of PRL from the blood, mammary epithelial cells synthesize PRL 
during pregnancy and lactation. It has been suggested that the production of mammary PRL 
requires a systemic trophic factor, because PRL mRNA declined with time in cultured rat 
mammary gland explants [65]; however, this proposal requires further investigation since 
PRL regulation is thought to differ between species. Interestingly, the number of PRL 
variants in human milk exceeds that found in serum, indicating that the breast may be a 
post-transcriptional processing site [66]. In support of this possibility, incubation of 
mammary slices in the presence of PRL resulted in the formation of fragments of PRL [67]. 
Although there are two Pit-1 consensus sequences located at -2186 and -2800 bp within the 
alternative promoter (Figure 1), the expression of extrapituitary PRL is thought to be 
independent of Pit-1. However, Pit-1 expression in normal and cancerous human breast 
tissue has been reported [68]. Moreover, the experimental over-expression of Pit-I in MCF-7 
cells significantly increased expression of PRL mRNA, while PRL protein expression was 
significantly reduced after Pit-I knockdown, suggesting that in this cell line, PRL 
transcription is driven by the proximal pituitary promoter and is due to Pit-I binding to this 
region [69]. Alternatively, distal upstream Pit-1 consensus sequences could also be 
participating. 
As in the case of the pituitary, studies performed in the human mammary cell line T47D 
showed that estrogen directly induces PRL gene expression [70]. A functional, non-
canonical, estrogen responsive element (ERE) and an AP1 site have been located in the PRL 
distal promoter (Figure 1). Moreover, both estrogen receptors  and  bind directly to this 
ERE, which suggests that estrogens regulating autocrine PRL in the human breast may 
contribute to breast development and cancer progression. 
It is noteworthy that most local PRL production in the breast occurs in adipose rather than 
in glandular tissue [71]. Whereas PRL release from glandular explants was suppressed by 
progesterone, neither estrogen nor progesterone altered PRL expression in adipose explants 
[71]. This dissimilar regulation of PRL in adjacent tissues is not unusual, and was also 
observed in decidua and myometrium. Therefore, the interactions between stromal, 
glandular, and adipose tissue should be taken into consideration for PRL regulation studies 
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in the mammary gland. Even if the main source of PRL in breast adipose tissue seems to 
be the mature adipocyte, both the subcutaneous and visceral adipose depots also produce 
PRL [72]. As in other locations, the regulation of PRL release from primary human breast 
preadipocytes is stimulated by activators of the cAMP/PKA pathway. Indeed, recent 
studies have shown that, similar to its action in the pituitary, dopamine suppresses PRL 
gene expression and release in adipocytes through inhibition of cAMP, followed by the 
suppression of PKA activity [73]. Moreover, in primary human breast preadipocytes, 
isoproterenol, a -adrenergic receptor agonist, and the pituitary adenylate cyclase 
activating peptide, increased PRL mRNA expression and release. This effect was 
suppressed by several protein kinase inhibitors, suggesting involvement of multiple 
signaling cascades [74].  
Another interesting issue to be addressed is whether regulators of metabolic and endocrine 
activities of adipocytes such as insulin and cytokines affect PRL secretion in these cells. This 
question is particularly relevant in conditions such as obesity and inflammation. Contrary to 
results obtained in cultured rat mammary gland explants [65], PRL release from human 
adipose explants and mature adipocytes increased with time, indicating removal from 
inhibition [72]. Interestingly, insulin suppressed PRL expression and release from 
differentiated adipocytes but moderately stimulated PRL release from non-differentiated 
cells. Nevertheless, considering that preadipocytes represent only a small fraction of the 
total cell population within adipose tissue, the overall effect of insulin on PRL is likely 
inhibitory [72]. 
3. Prolactin in the physiology of the immune system 
PRL is a highly versatile hormone/cytokine that displays a wide spectrum of effects in a 
variety of tissues. In fact, more than 300 actions by PRL have been described in vertebrates. 
In pancreatic beta cells, pancreas, liver, and T-lymphocytes, PRL can regulate proliferation 
[75, 76] while in prostate, pancreatic beta cells, lymphocytes, ovarian carcinoma cells, breast 
cancer cells, and others, PRL acts as an antiapoptotic factor. [77-81]. These effects are 
mediated by its receptors, which are members of the class I hematopoietin/cytokine receptor 
family [76]. In the immune system, PRL receptors expression have been detected in several 
cells such as splenocytes, thymocytes, bone marrow cells, PBMC, lymphocytes, and 
monocytes [76]. Both PRL and the PRL receptor are constitutively expressed by resting T-
cells [29], which indicates that PRL may influence the immune system even during steady-
state conditions.  
PRL has a wide range of effects on the regulation of the immune system. Administration of 
PRL to hypophysectomised rats provokes weight gain of two lymphoid tissues, spleen and 
thymus [82]. In lymphocytes, PRL reverses anemia, leukopenia, and thrombocytopenia 
induced by hypophysectomy [83], and it increases antibody production [84]. PRL has also 
been reported to increase receptor levels for interleukin (IL)-2 and PRL [76]. Using PRL 
receptor knockdown, autocrine PRL actions could be elucidated. In T- lymphocytes in which 
the PRL receptor was silenced, proliferation induced by phytohemagglutinin (PHA) was 
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autocrine in nature. However, considering that inflammatory cytokines such as TNF-, IL-
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in the mammary gland. Even if the main source of PRL in breast adipose tissue seems to 
be the mature adipocyte, both the subcutaneous and visceral adipose depots also produce 
PRL [72]. As in other locations, the regulation of PRL release from primary human breast 
preadipocytes is stimulated by activators of the cAMP/PKA pathway. Indeed, recent 
studies have shown that, similar to its action in the pituitary, dopamine suppresses PRL 
gene expression and release in adipocytes through inhibition of cAMP, followed by the 
suppression of PKA activity [73]. Moreover, in primary human breast preadipocytes, 
isoproterenol, a -adrenergic receptor agonist, and the pituitary adenylate cyclase 
activating peptide, increased PRL mRNA expression and release. This effect was 
suppressed by several protein kinase inhibitors, suggesting involvement of multiple 
signaling cascades [74].  
Another interesting issue to be addressed is whether regulators of metabolic and endocrine 
activities of adipocytes such as insulin and cytokines affect PRL secretion in these cells. This 
question is particularly relevant in conditions such as obesity and inflammation. Contrary to 
results obtained in cultured rat mammary gland explants [65], PRL release from human 
adipose explants and mature adipocytes increased with time, indicating removal from 
inhibition [72]. Interestingly, insulin suppressed PRL expression and release from 
differentiated adipocytes but moderately stimulated PRL release from non-differentiated 
cells. Nevertheless, considering that preadipocytes represent only a small fraction of the 
total cell population within adipose tissue, the overall effect of insulin on PRL is likely 
inhibitory [72]. 
3. Prolactin in the physiology of the immune system 
PRL is a highly versatile hormone/cytokine that displays a wide spectrum of effects in a 
variety of tissues. In fact, more than 300 actions by PRL have been described in vertebrates. 
In pancreatic beta cells, pancreas, liver, and T-lymphocytes, PRL can regulate proliferation 
[75, 76] while in prostate, pancreatic beta cells, lymphocytes, ovarian carcinoma cells, breast 
cancer cells, and others, PRL acts as an antiapoptotic factor. [77-81]. These effects are 
mediated by its receptors, which are members of the class I hematopoietin/cytokine receptor 
family [76]. In the immune system, PRL receptors expression have been detected in several 
cells such as splenocytes, thymocytes, bone marrow cells, PBMC, lymphocytes, and 
monocytes [76]. Both PRL and the PRL receptor are constitutively expressed by resting T-
cells [29], which indicates that PRL may influence the immune system even during steady-
state conditions.  
PRL has a wide range of effects on the regulation of the immune system. Administration of 
PRL to hypophysectomised rats provokes weight gain of two lymphoid tissues, spleen and 
thymus [82]. In lymphocytes, PRL reverses anemia, leukopenia, and thrombocytopenia 
induced by hypophysectomy [83], and it increases antibody production [84]. PRL has also 
been reported to increase receptor levels for interleukin (IL)-2 and PRL [76]. Using PRL 
receptor knockdown, autocrine PRL actions could be elucidated. In T- lymphocytes in which 
the PRL receptor was silenced, proliferation induced by phytohemagglutinin (PHA) was 
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significantly reduced. Moreover, the expression of certain co-stimulatory molecules (CD137, 
CD154) and the secretion of cytokines (IL-2 and IL-4) induced by PHA activation were 
suppressed in these cells [85]. Although PRL has been observed to act in a cooperative 
fashion with IL-2 to influence proliferation in the immune system, there is evidence 
indicating that PRL can act as a T-cell growth factor, independently of IL-2 [86-88]. In 
addition to stimulating proliferation, PRL has been shown to inhibit apoptosis of 
lymphocytes [79, 89, 90]. In BALB/c mice expressing a transgene for the heavy chain of a 
pathogenic anti-DNA antibody, inducing moderate hyperprolactinemia (a 2-fold increase in 
the serum PRL concentration) increases the number of autoreactive B-cells with the follicular 
phenotype and leads to their activation, with subsequent anti-DNA antibody production as 
well as IgG deposition in the kidneys [91]. The induction of hyperprolactinemia promotes 
autoreactivity inasmuch as it breaks B-cell tolerance, acting on the mechanisms of B-cell 
tolerance induction at three levels: B cells receptor-mediated deletion, receptor editing, and 
anergy [91]. 
Despite evidence of an immunomodulatory role of PRL, it has been shown that the 
development of the immune system was unaffected in both PRL and PRL-receptor knockout 
mice [92]. The effects due to the lack of PRL action were probably compensated by 
redundancy of the cytokine network. Data support the immunomodulatory role of PRL in 
normal murine and human cells and in in vivo models after procedures such as 
hypophysectomy and ovariectomy. More studies are needed to determine the involvement 
of PRL in physiological and/or pathological conditions, and to explore its therapeutic 
potential in diseases of the immune system. 
4. Prolactin in the pathology of the immune system. 
4.1. Prolactin and autoimmunity 
The interrelationship between PRL and the immune system has been elucidated over the 
last 2 decades, opening important new horizons in the field of immunoendocrinology [93]. 
The autoimmune diseases are more common in females, and sex hormones could have an 
important role in this gender bias. Estrogens and PRL modify the immune phenotype and 
functions; furthermore, they are able to modulate both the innate and adaptive 
immunological response. PRL exerts an immunostimulatory effect and might promote the 
development of autoimmune diseases by different mechanisms, such as impairing the 
negative selection of auto reactive B-lymphocytes occurring during B-cell maturation into 
fully functional B-cells [94]. Moreover, PRL induces an anti-apoptotic effect, enhances the 
proliferative response to antigens and mitogens, and increases the production of 
immunoglobulin, cytokines, and autoantibodies. In murine models of some autoimmune 
diseases there is a clear association between hyperprolactinemia and disease progression. 
Indeed, moderate hyperprolactinemia has been found in a cohort of patients with 
autoimmune diseases like SLE, rheumatoid arthritis (RA), Sjogren´s syndrome (SS), 
Hashimoto´s thyroiditis (HT), and multiple sclerosis (MS) [95-98]. These data are 
controversial, since some studies have not found a consistent correlation between PRL levels 
 
Prolactin in the Immune System 63 
and disease activity in humans [99]. These discrepancies could be explained by genetic, 
environmental, and hormonal factors related to susceptibility; these factors might influence 
the progression of autoimmune disorders, might alter PRL circadian rhythm thereby 
contributing to disease by modifying the immune response [100], and could even change 
PRL isoforms and anti-PRL antibodies that reduce the biological activity of PRL [101]. The 
PRL molecule undergoes posttranslational modifications generating several molecular 
species. In contrast to high molecular weight PRL species (>100 kDa), monomeric PRL (23 
kDa) is associated with SLE clinical activity [102]. An association of PRL levels with anti-
dsDNA antibodies and with anti-Ro and anti-La antibodies has been reported [94]. 
The physiology of the immune system involves a balance between the two arms of the 
cellular immune response. T-helper cells type 1 (Th1) and type 2 (Th2) elicit cell- and 
humoral-mediated responses, respectively. PRL is involved in regulating both Th1 and Th2 
responses, particularly the former. Altered PRL levels associated with either Th1 or Th2 
dominance often characterize autoimmune diseases [103]. Evidence observed in animal 
models and human disorders suggest that Th1 cytokines (IFN-, IL-2 and TNF-) are 
involved in the genesis of organ-specific autoimmune diseases, such as RA, MS, insulin-
dependent diabetes mellitus (IDDM), and thyroid autoimmunity. In contrast, Th2 responses 
tend to dominate in circumstances such as SLE, and in systemic and allergic conditions, 
such as HT (Figure 3) [103]. 
 
Figure 3. The role of PRL in autoimmune diseases. PRL induces monocytes maturation to dendritic 
cells (DC) through increasing major histocompatibility complex and co-stimulatory molecules. 
Furthermore, PRL induces T-cell activation and production of pro-inflammatory cytokines. Imbalances 
between Th1 and Th2 result in different autoimmune diseases. BC, B-cells; SLE, systemic lupus 
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4.1.1. Systemic lupus erythematosus 
SLE is an autoimmune disease nine times more common in young women of reproductive 
age than in men. The expected rate of hyperprolactinemia is 0.4% in healthy adults [104, 
105], whereas mild to moderate hyperprolactinemia occurs in 15-33% of SLE patients of both 
genders [102, 106]. Furthermore, elevated lymphocyte PRL gene expression has been 
identified in a cohort of female SLE subjects [42, 44]. In the majority of SLE - 
hyperprolactinemia patients the cause of the enhanced PRL levels is unknown, which 
suggests impaired regulation of PRL synthesis in SLE. In this regard, observations from our 
group showed an increased central dopaminergic tone in SLE and normoprolactinemic 
female patients, but with enhanced levels of PRL from lymphocytes; this finding suggests 
that lymphocyte-derived PRL might contribute to altering the functional activity of the 
hypothalamic dopaminergic system in order to maintain serum PRL within a physiological 
range in SLE [42]. In this study, after metoclopramide administration, mRNA expression 
and secretion of lymphocyte-derived PRL increased only in PBMC from control women and 
not in those from SLE patients. These observations indicate that dopamine could have a 
direct effect on PRL synthesis in normal lymphocytes that is absent in SLE lymphocytes. 
Murine SLE encompasses several strains of inbred mice and hybrids (NZB, NZB x NZW F1, 
MRL lpr/lpr, BXSB) that variably manifest autoimmune disturbances such as accelerated 
hypergammaglobulinemia, immune complex glomerulonephritis and mortality, increased 
anti-DNA antibody levels and immune complex formation, as well as suppression of 
lymphoproliferation, symptoms that closely resemble those of human SLE [107]. In this 
model, induced hyperprolactinemia exacerbates disease activity, which leads to premature 
death regardless of the gender. Interestingly, in non-lupus prone BALB/c mice, treatment 
with high or physiological doses of PRL favours the development of an SLE-like phenotype, 
because this hormone breaks down the B-cell tolerance [91]. In addition, administration of 
bromocriptine, a dopamine receptor agonist that blocks prolactin secretion by the anterior 
pituitary ameliorates disease progression in murine SLE models [108, 109], indicating a 
potential role of PRL in the pathogenesis of SLE. Furthermore, clinical trials treating SLE 
with bromocriptine, have suggested a beneficial effect in patients with mild and moderate 
disease activity. Bromocriptine suppresses the levels of immunoglobulins, autoantibodies, 
and immune complexes in lupus glomerulonephritis, both in animal models and SLE 
patients [103, 107]. This drug is also associated with lower cytokine secretion and 
proliferation of T- cells. Furthermore, a clinical trial using bromocriptine in pregnant SLE 
patients suggests that it may help prevent maternal-fetal complications secondary to this 
disease [110, 111]. 
4.1.2. Rheumatoid arthritis 
Clinical observations in humans and experimental data in animal models have also 
implicated PRL in other autoimmune diseases such as RA. This common autoimmune 
condition is an inflammatory disease that presents a diurnal rhythm of disease activity. An 
imbalance in favor of proinflamatory hormones like PRL, as opposed to levels of anti-
inflammatory hormones, could be responsible for this diurnal rhythm of disease [112]. In 
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both genders, however, associations between RA and PRL have been inconsistent [98, 100, 
113-118]. A recent study shows an increase of PRL in serum and synovial fluid from subjects 
affected with RA perhaps indicating that this cytokine acts as a proinflammatory factor to 
increase disease severity and joint damage in RA [119]. However, further studies are still 
needed in this area. 
4.1.3. Multiple Sclerosis 
Patients with MS, a Th1-dominated autoimmune disease, have slightly, but significantly 
higher PRL levels than normal subjects, and an association between this biomarker and the 
course of the disease course should be considered [120]. One-third of MS subjects exhibit 
hyperprolactinemia, which is claimed to be a sensitive indicator for hypothalamic lesions 
[97]. In experimental animal models of MS, treatment with bromocriptine decreases both 
PRL secretion and disease severity [121]. These data support the idea that PRL is involved in 
the pathogenesis of MS. 
4.1.4. Hashimoto thyroiditis 
In HT, an endocrine autoimmune disease, hyperprolactinemia and low serum cortisol levels 
have been found [122]. In addition, the high prevalence of anti-thyroid antibodies in the 
presence of hyperprolactinemia in HT suggests a role for PRL in this autoimmune disease, 
particularly since hyperprolactinemia correlates with HT only in subjects with 
hypothyroidism, suggesting a role of PRL in this autoimmune disease. Furthermore, another 
association between PRL and endocrine autoimmune diseases has been noted in subjects 
with a combined deficiency of pituitary hormones (GH; PRL; TSH) due to antibodies against 
Pit-1 [123].  
4.1.5. Prolactin and diabetes 
Diabetes mellitus (DM) is a complex disease characterized by hyperglycemia, dyslipidemia 
and disorders of protein metabolism. High levels of glucose in serum are a consequence of 
defects in insulin secretion, insulin action, or both. Indeed, DM is classified as type 1 (DM1) 
with an autoimmune etiology that causes a total absence of insulin secretion, or as type 2 
(DM2) caused by a combination of resistance to insulin action and an inadequate 
compensatory insulin secretion response [124, 125].  
Studies in human and murine experimental models have demonstrated a stimulatory effect 
of PRL and other structurally related hormones (placental lactogen and growth hormone) on 
both insulin secretion and proliferation of -cells [126, 127]. Furthermore, studies in PRL 
receptor-deficient mice highlight the importance of these hormones in pancreatic islet 
development. PRLR-deficient mice had a 26-42% lower islet-cell density (P < 0.01), and beta-
cell mass and insulin mRNA levels in pancreatic cells were 20-30% lower compared with 
wild-type mice [75]. Furthermore, insulin secretion in response to glucose was blunted in 
PRLR-deficient males in vivo. The precise mechanism by which PRL induces insulin gene 
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transcription is still unclear since PRL binding induces low promoter activation of STAT5b, 
indicating that other pathways might be involved. The effects of many of the insulin 
signaling inhibitors occur downstream of PRL signaling pathways; however, the mechanism 
by which PRL impairs insulin signaling remains to be elucidated [128].  
The effects of PRL have been studied in subjects with DM. For example, hyperprolactinemia 
has been identified in patients with DM1; however, the precise role of PRL in the 
progression of this disease is unclear. In contrast, PRL is one factor that can modify the 
clinical course of diabetic retinopathy (DR), one of the main complications of DM2 and a 
leading cause of blindness in working-age adults. The DR is associated with an excessive 
retinal vasopermeability and this could be inhibited by intraocular vasoinhibins, a family of 
peptides derived from proteolysis of PRL. Indeed, in a case-controlled study of diabetic 
patients, decreased serum PRL levels contributed to the development and progression of DR 
[129]. Furthermore, in a pharmacologically induced murine model of DM, 
hyperprolactinemia led to vasoinhibins accumulation within the retina, which reduced 
retinal vasopermeability induced by the vascular endothelial growth factor (VEGF) or 
streptozotocin, and this phenomenon is reversed by bromocriptine [130]. Therefore, 
circulating PRL influences the progression of DR after its intraocular conversion to 
vasoinhibins [130]. This important observation may provide a novel approach to protect DM 
subjects against the development of DR [131] , which was recently demonstrated in a murine 
model using gene therapy [132]. In summary, in vitro experiments and in vivo studies 
revealed that vasoinhibins are potent inhibitors of angiogenesis in the retina by several 
mechanisms, inhibiting proangiogenic effects of VEGF. 
5. Effects of prolactin, circadian rhythms, and sleep on immune function 
5.1. Background 
Circadian rhythms are defined as ~24-h fluctuations in a variety of behavioral, physiological, 
and metabolic parameters driven by biological pacemakers and oscillators. The rhythmic 
changes are endogenous, meaning they are independent of environmental clues. At the 
same time, circadian rhythms are entrained by external inputs that are classified as photic 
(light–darkness alternation) and non-photic (food availability, pheromones, social 
interactions). Although they have been described across the entire phylogenetic scale (from 
prokaryotes to vertebrates), the various mechanisms that underlie circadian rhythms are 
better understood in mammals. In this group the principal pacemaker is the suprachiasmatic 
nucleus (SCN), which is a hypothalamic structure situated above the optic chiasm and close 
to the third ventricle. The SCN is synchronized by means of the conduction of photic stimuli 
from the melanopsin-enriched ganglionar retinal cells directly to the dorsal section of the 
SCN. Experiments done in vitro with isolated SCN preparations have demonstrated that this 
oscillator can show 24-h rhythmicity in electrical and metabolic activity for several weeks. 
The capacity for self-sustained oscillatory activity is based on the cyclic expression of a set of 
specialized genes and proteins that form the core of the molecular clock. The set of “clock” 
gene proteins interact in a network of positive and negative feedback loops, ultimately 
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giving the SCN the ability to measure ~24-h time periods. The circadian rhythmicity elicited 
by the SCN is eventually communicated to other tissues and organs through several output 
pathways that enable the circadian variations in endocrine patterns, physiological 
responses, metabolic activities, and behavior [133]. 
The circadian system is hierarchical; it is formed by the SCN as principal pacemaker, but 
also includes a set of peripheral oscillators which are dependent on SCN activity to 
accomplish a coordinated and harmonized overall day-to-day response. These peripheral 
oscillators are present, not only in thoracic and abdominal organs (heart, lungs, liver, 
pancreas, and others), but also in cerebral regions different from the SCN (amigdala, 
hippocampus, other hypothalamic nuclei, etc). Many of these peripheral oscillators are 
endocrine glands and biological targets for the secreted hormones. The coordination 
between SCN and peripheral oscillators is lost in some circumstances, such as restricted 
feeding schedules [134]. It has been proposed that a state of good fitness involves the 
appropriate coordination between the SCN (as a master pacemaker) and the other oscillators 
(slave clocks). Hence, a lack of communication among oscillators could promote adverse 
symptoms such as jet-lag and maladies associated with shift work [135].  
Many biological functions are under the command of the circadian system. In the end, the 
evolutive explanation considers the 24-h rhythmic fluctuations as adaptations that allow 
biological tasks to be performed at a most appropriate time for the organisms, according to 
their diurnal or nocturnal profile. Some examples illustrating this concept are: 1) cortisol in 
humans is secreted a short time before awakening as a response to the fasting condition and 
in preparation for wakefulness; 2) growth hormone is released during the non-REM stage of 
sleep; 3) for predators, the search for food occurs when prey are most likely available and is 
coordinated with the time for rest and sleep. 
Sleep is a complex process that is modulated by both circadian and homeostatic regulation. 
This dual control is evident in situations of sleep deprivation. In this circumstance, the 
animal will compensate for the lack of sleep regardless of the time of day, and the subject 
will fall sleep as a function of the amount of previous time awake. Not very much is known 
about the brain structures and neurotransmitters involved in the coordination and interplay 
between the circadian and homeostatic control of the sleep activity. The functions that have 
been attributed to sleep are diverse, but some of the principal ones are: energy restoration, 
memory processing, and neural plasticity [136]. 
In mammals and some birds, sleep is divided into 2 principal phases: sleep without rapid 
eye movement (NREM) and sleep with rapid eye movement (REM). These 2 stages are 
characterized mainly by polysomnographic criteria: for example, NREM sleep shows brain 
waves of high amplitude and low frequency and a clear muscular tone. In contrast, during 
REM sleep the brain waves become desynchronized, have low voltage, and the muscular 
tone is lost. Interestingly, the muscles that allow the ocular movements are the only ones 
that can become active. In humans, 75-80% of sleep time is dedicated to NREM and the rest 
to REM sleep, with the episodes of REM sleep becoming more frequent at the end of the 
night [137]. Because some characteristics of REM sleep and the wakeful state are similar, 
REM has been called paradoxical sleep.  
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Multiple factors have been invoked as having some role in the control of circadian 
rhythmicity, including the physiological adaptations in the sleeping activity. This section 
will be focused on the role of PRL in modulating both processes, acting as an endocrine 
signal and as an immunological mediator. 
5.2. Circadian profile of prolactin in physiological and pathological conditions 
PRL displays ultradian and circadian variations in humans [138]. On average, PRL is 
significantly higher at night, with a clear acrophase or peak close to midnight. However, 
between 6 and 8 peaks of PRL are also observed during the 24-h period, indicating a 
concurrent ultradian pattern [139]. The amplitude of the PRL diurnal rhythm is reduced 
during aging [140]. Hypothalamic PRL secretion is highly dependent on the suppression of 
the inhibitory input of dopamine. In rats, it has been shown that dopamine control of PRL 
release is modulated by circadian action from the SCN. In experimental animals, circulating 
PRL was reported to show complex rhythmicity under the regulation of several 
hypothalamic factors, including   that is exerted by the vasoactive intestinal peptide (VIP) 
secreted by the SCN [141]. Levels of PRL produced by the lactotrophs of the anterior 
pituitary gland increase in the afternoon, but this PRL peak is abolished when VIP is not 
released from the SCN, indicating a circadian contribution to the temporal PRL profile. PRL 
secretion is also regulated by sexual activity, mainly in female rats. Mating promotes the 
release of oxytocin, which favors PRL synthesis and release. Hence, circadian modulation of 
blood PRL is coordinated with ultradian events and also with sporadic physiological 
responses. Most of the genes that show circadian rhythmicity contain a specific response 
element known as the E-box. However, PRL is an exception, since the circadian fluctuations 
involve daily chromatin remodeling carried out by the factors NONO (Non-POU domain-
containing octamer-binding protein) and SFPQ (splicing factor proline-glutamine rich) [142]. 
PRL has also been implicated in circannual rhythmicity in rams. In this context, the role of 
PRL in reproductive physiology, which fluctuates according to the photoperiodic regulation 
during the year, is dependent mainly on the pineal gland, and it persists after the 
hypothalamo-pituitary connection is severed [143]. 
In patients with Parkinson´s disease, the rhythmic pattern of PRL secretion is not altered 
[139], but schizophrenic patients under treatment with atypical antipsychotic drugs such as 
perospirone show larger daily fluctuations of PRL [144]. However, loss of PRL rhythmicity 
during hyperprolactinemia episodes has been associated with obesity. One of the apparent 
causes of increased adipose tissue reservoirs is inhibition of the lipolytic enzyme lipoprotein 
lipase by PRL [145]. Hyperprolactinemia also affects daily changes of GABA and taurine 
concentrations in various hypothalamic areas, with potential consequences for eating and 
drinking behaviors [146]. Hypersecretion of PRL has been associated with the Carney 
complex (a syndrome of spotty skin pigmentation, myxomas, endocrine overactivity, and 
schwannomas), which is a multiple neoplasia condition with various endocrine 
abnormalities [147]. Elevation of PRL at night has also been associated with the worsening 
of a pathological condition known as SUNCT (recurrent short-lasting unilateral 
neuralgiform headache attacks with conjunctival injection and tearing) [148]. High PRL 
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concentrations are involved in the pathogenesis of SLE in human beings and experimental 
animals by an unknown mechanism [149]. A hypothesis related to the onset of winter 
depression in women has postulated a defect of neural pathways afferent to the 
paraventricular nucleus that promote a reduction of serum PRL concentration. In this 
perspective, winter depression would also under the influence of estrogen responses [150]. 
Reduced PRL at night has also been associated with women suffering from fibromyalgia, a 
medical disorder characterized by chronic, widespread pain, and allodynia (pain due to a 
stimulus which does not normally provoke painful response) [151]. 
5.3. Prolactin and sleep 
PRL concentrations are elevated during sleep, even if sleep is delayed [152], and short 
periods of sleep deprivation in humans are associated with lower nocturnal PRL levels in 
comparison to normal sleep [153]. PRL has been shown to be a hypnogenic factor, acting as 
a promoter of REM sleep: systemic or intracerebroventricular injection of PRL in rats and 
rabbits increased REM episodes, but in rats, only during the light period [154]. Supporting 
this observation, it was reported that antiserum against PRL and genetically PRL-deficient 
rodents showed reduced frequency of REM sleep [155]. It has been suggested that PRL may 
enhance a REM-promoting mechanism rather than initiate REM episodes. A putative 
mechanism by which PRL enhances REM sleep is the activation of the mitochondrial 
enzyme pyruvate dehydrogenase, which catalyzes the synthesis of acetyl-coenzyme A. This 
metabolic intermediate may favor the generation of acetylcholine in cholinergic terminals of 
brain areas that are involved in promoting REM sleep [156]. 
Besides its action in REM episodes, PRL has been postulated to be a modulator of NREM 
sleep in lactating women [157]. The predominant underlying hormonal alteration occurring 
in lactation is a marked increase in circulating PRL. Because the PRL concentration is 
elevated for several months in women that breastfeed, the increase in NREM sleep in this 
situation has been explained as a result of chronic hyperprolactinemia [158]. 
5.4. The circadian system and the sleep–wake cycle as modulators of the immune 
function. Role of prolactin 
The immunological network is influenced by the physiological timing organization, but at 
the same time, the circadian rhythmicity is regulated by factors elicited by the immune 
system. This reciprocal modulation has been documented in physiological and pathological 
conditions in humans, and some related molecular and cellular mechanisms have been 
explored in experimental animals. It has been reported that the number and properties of 
cellular components of the immune system show circadian variations, for example: 1) IgE-
dependent activation by mast cells [159], 2) cell-adhesion molecule expression by human 
leukocytes [160], 3) activation of natural killer cells [161], 4) deterioration of clinical 
symptoms associated with rheumatoid arthritis in the morning following the diurnal 
rhythm of the pro-inflammatory cytokine IL-6 [162].   
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The timing regulation of the immunological function is also influenced by the numerous 
changes that occur during the sleep period. Sleep promotes a striking increase in the 
number of myeloid dendritic cell precursors producing IL-12, which implies an induction of 
the Th1 responses. In addition, sleep reduces plasmacytoid dendritic cells and T-cell counts 
without affecting the production of IFN. Sleep also substantially decreases the number of 
certain subpopulations of monocytes (CD14 and CD16+), probably reflecting margination of 
these cells upon a sleep-related drop in catecholamine release [163]. The number of 
undifferentiated naïve T cells and the production of pro-inflammatory cytokines exhibit 
peaks during the first hours of sleep, whereas the number of circulating immune cells with 
immediate effector functions and the anti-inflammatory cytokine activity peak during 
wakefulness. Sleep also facilitates the extravasation of T-cells and their redistribution to 
lymph nodes. In general, sleep enhances cytokines (such as IL-12) that promote the 
interaction between antigen-presenting cells and T-helper cells [164]. 
It has been postulated that NREM sleep facilitates the transfer of antigenic information from 
antigen-presenting cells to antigen-specific Th cells; as a consequence, sleep after vaccination 
has been observed to boost immunological memory [165]. The daily profile of circulating 
PRL, with elevated levels during the rest periods in mammals, raises the possibility that PRL 
could be one of the factors involved in the enhanced immunological response associated 
with sleep. This role could be related in particular to the stage of NREM sleep and its 
accompanying pro-inflammatory endocrine milieu with the high levels of growth hormone 
and PRL and low concentrations of glucocorticoids and catecholamine that occur during 
sleep [165]. This same idea provides a rationale for the chronobiological treatment of RA. In 
this protocol, a low-dose, chronotherapeutic application of prednisone at night (~03:00 h) 
has been suggested to improve the benefits and reduce the adverse side-effects of 
glucocorticoid treatment in patients with RA. The low dose of prednisone during the night 
is as effective as a higher dose applied during the day. Again, this pharmacological scheme 
could be favorable because of the conjunction between PRL and other immunological 
supportive peptides and the proven clinical drugs [166]. 
6. Conclusion 
The multiple actions of PRL and its diverse sites of synthesis evidence the versatility of this 
hormone/cytokine in the homeostasis of the organism. Besides the well-known actions of 
PRL on reproduction, it exerts multiple actions unrelated to the reproductive area. In the 
immune system PRL functions as a survival factor inasmuch as it promotes proliferation 
and inhibits apoptosis. This important role could help to maintain the appropriate number 
of immune cells in physiological conditions, and to maintain immune tolerance. Abnormal 
synthesis and secretion of PRL could lead to the breakdown of balance in the immune 
system, and consequently, could promote autorreactivity and bursting or aggravation of the 
clinical condition in autoimmune diseases. A deregulation in the mechanisms that control 
PRL synthesis could lead to enhanced PRL secretion. Nowadays, available information is 
limited on the biological significance of posttranslational modifications of the PRL in vivo, 
such as glycosylation or cleavage, which may exert different biological functions related to 
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the immune function. In agreement with current knowledge, PRL at normal levels could be 
a permissive molecule, while at abnormal levels it could affect the organism homeostasis. 
Additional studies of PRL and its regulation, especially in the extrapituitary tissues, are 
needed in order to understand better the role of PRL in the physiology and pathophysiology 
of autoimmune diseases. 
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1. Introduction 
1.1. Definition and structure of Neuregulin-1 (Nrg1) 
Hypothalamus-derived dopamine and thyrotrophin-releasing hormone (TRH) have long 
been considered the main sources of prolactin (PRL) regulators in the anterior pituitary, 
whereas other substances also modulate PRL expression and secretion (Borrelli et al., 1992; 
Cai et al., 1999; Spuch et al., 2006). Recently, Vlotides for the first time observed that 
recombinant Nrg1 can control PRL secretion from rat RPL and growth hormone (GH) 
secreting lactosomatotroph GH3 cells, suggesting the emerging role of Nrg1 as a PRL 
regulator (Vlotides et al., 2009).  
Neuregulins are homologous to epidermal growth factor (EGF) and are mainly encoded by 
four alternatively spliced genes: NRG-1 to -4 (Orr-Urtreger et al., 1993). Diverse splicing of 
the NRG-1 gene gives rise to at least six main types of Nrg1 (types I–VI) with ectodomain 
variation, whereas type I to III Nrg1. are the most intensively investigated. All types of Nrg1 
contain an EGF-like domain, which can be classified as either α or β (Jacobsen et al., 1996; 
Rosnack et al., 1994). Distinct from soluble Nrg1, a membrane-tethered Nrg1 precursor has 
been identified that contains a transmembrane (TM) domain and an intracellular domain 
(ICD). The ICD can be further characterized as ICD a, b and c. The structure that links the 
ectodomain and the transmembrane (TM) domain is called a stalk (S), which can be further 
classified as S1, S2 and S4. Proteolysis of the Nrg1 precursor, a tightly regulated process, 
releases the soluble domains and leads to formation of autocrineparacrine loops. However, 
recruitment of S3, which contains the stop codon, terminates the extension of the 
ectodomain into the cytoplasm and thus leads to the formation of non-membrane anchored 
Nrg1α/β (See Fig 1).  
 T e Author(s). Licensee InTech. This chapter i distributed under the terms of he Creative Commons 
Attribution License http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, 
and reproduction in any medium, provided the original work is properly cited.
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Figure 1. Schematic of type I- III Nrg1 Diverse splicing of NRG-1 gene gives rise to Type I-III Nrg1s, 
whose structures were schematically diagrammed. α, EGF-like domain α; β, EGF-like domain β; Ig, Ig-
like domain; s, stalk domain; sp, spacer domain.   
1.2. Interaction of Nrg1 with its cognate receptors and related biological 
functions 
The bioactivity of Nrg1 is mainly mediated by homodimers comprised of their cognate 
receptors ErbB4 (Hahn et al., 2006) or ErbB3/ErbB2 and ErbB4/ErbB2 heterodimeric 
complexes (Liu et al., 2002) (See Fig 2). Nrg1 was found to specifically activate the tyrosine 
kinase receptor ErbB2 as a growth factor extracted from the conditioned medium of a 
human breast tumor cell line (Holmes et al., 1992). It exerts mitogenic activity on cultured 
Schwann cells as type II Nrg1 (Glial growth factor, GGF) purified from the brain and bovine 
pituitary anterior lobe (Lemake et al., 1984). The acetylcholine receptor-inducing activity 
protein (ARIA), another Nrg1 type, was shown to promote acetylcholine receptor synthesis 
in cultured skeletal muscle and myotubes (Jessell et al., 1979; Usdin et al., 1986). The ligand-
receptor interaction initiates a complex intracellular signaling cascade in which extracellular 
signal-regulated kinase (ERK), serine/threonine protein kinase (AKT), mitogen-activated 
protein kinase (MAPK), phosphatidyl-inositol 3-kinase γ (PIK3γ), protein kinase C (PKC), 
and Janus kinase-signal transducers and activators of transcription (Jak-STAT) are activated. 
Activation of this signaling pathway leads to, among other events, tumorigenic 
development, cell cycle arrest, cell proliferation, differentiation, and anti-apoptotic processes 
(Peles et al., 1993; Liu and Kern et al., 2002; Puricelli et al., 2002). Recently, Nrgβ1 has been 
reported to signal mitogenesis of cortical astrocytes through ErbB1ErbB3 heterodimeric 
complex (Sharif et al., 2009).  
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Figure 2. Schematic of type I- III Nrg1 interaction with their receptors. The initial proteolysis site was 
indicated by the arrow, and the site for second proteolysis was indicated by the arrow head. 
2. Endogenous expression of Nrg1 in the anterior pituitary and rat 
lactosomatotroph GH3 cells 
2.1. Expression and localization of Nrg1 and its receptor in the anterior pituitary 
of rat and non-human primates 
The Nrg1-ErbB signaling pathway has a critical role in organ development, cell 
differentiation and tumorigenesis. Neuregulins have previously been described in the 
nervous system, especially in the cortex, spinal cord and hypothalamus. In the 
hypothalamus, ARIA (or Nrg1α and β) was expressed in neurons with processes projecting 
to the posterior pituitary gland but not in those without these projections, suggesting that 
hypothalamus-derived Neuregulin regulates certain functions of the pituitary (Bernstein et 
al., 2006; Corfas et al., 1995). Furthermore, Nrg1 receptors were reported to be expressed in 
hypothalamic astrocytes, where their activation as a result of paracrine Nrg1 stimulation is 
essential for stimulating secretion of luteinising hormone-releasing hormone (LHRH), 
intrapituitary gonadotrophin secretion and normal sexual puberty (Bernstein et al., 2006; 
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2. Endogenous expression of Nrg1 in the anterior pituitary and rat 
lactosomatotroph GH3 cells 
2.1. Expression and localization of Nrg1 and its receptor in the anterior pituitary 
of rat and non-human primates 
The Nrg1-ErbB signaling pathway has a critical role in organ development, cell 
differentiation and tumorigenesis. Neuregulins have previously been described in the 
nervous system, especially in the cortex, spinal cord and hypothalamus. In the 
hypothalamus, ARIA (or Nrg1α and β) was expressed in neurons with processes projecting 
to the posterior pituitary gland but not in those without these projections, suggesting that 
hypothalamus-derived Neuregulin regulates certain functions of the pituitary (Bernstein et 
al., 2006; Corfas et al., 1995). Furthermore, Nrg1 receptors were reported to be expressed in 
hypothalamic astrocytes, where their activation as a result of paracrine Nrg1 stimulation is 
essential for stimulating secretion of luteinising hormone-releasing hormone (LHRH), 
intrapituitary gonadotrophin secretion and normal sexual puberty (Bernstein et al., 2006; 
Prevot et al., 2003).  
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Neuregulin has also been reported to be expressed in the endocrine organs, including the 
adrenal gland and the adult pancreas (Harari et al., 1999; Orr-Urtreger et al., 1993). 
Additionally, thyroid-derived cell lines and corresponding papillary carcinomas also 
express Nrg1 and ErbB receptors ErbB2 and ErbB4 (Fluge et al., 2000; Mincione et al., 1998). 
By contrast, Nrg1 expression and localization, as well as its role in the adenohypophyseal 
structure, have not been fully defined for a long time. Recently, exogenous Nrg1 has been 
reported to modulate PRL mRNA expression and PRL secretion from the rat 
lactosomatotroph GH3 cells, where the ErbB3 receptor was shown to correlate with 
malignant transformation of prolactinomas (Vlotides et al., 2009). Thus, it is essential to 
elucidate (i) whether the anterior pituitary gland endogenously expresses Nrg1, (ii) whether 
intrahypophyseal Nrg1ErbB receptor can regulate PRL secretion and (iii) its relevance to the 
development of prolactinoma. 
2.1.1. Multiple Nrg1 isoforms are expressed in the anterior pituitary and GH3 cells 
Based on a domain RT-PCR method systematically used by Cote et al. (2005), multiple 
isoforms of Nrg1 were amplified. In our work, we first amplified a 392-bp band from the rat 
cortex and anterior pituitary cDNA, corresponding to the spacer domain (SP)-containing Ig-
EGFα segment in type I Nrg1 (Fig 3A). When primers spanning the Ig-like domain and the 
EGFβ domain were used, a band at 401 bp was amplified from the cortex, hypothalamus 
and anterior pituitary cDNA, representing type I Nrg1β. A 299-bp band was amplified from 
the cortex and hypothalamus, but not from the anterior pituitary cDNA, which represents 
the SP free Ig- EGFβ segment exclusively contained in type II Nrg1 (Fig 3B). With primers 
specific to both the Ig domain and S1, S3 or S4, we found that S1 and S3 are present in type I 
Nrg1 in rat cortex, hypothalamus and anterior pituitary (Fig 3C-E). When primers against 
the CRD-EGFα domain was employed, an 833-bp band was weakly amplified from the 
cortical cDNA and strongly amplified from the anterior pituitary and GH3 cells (Fig 3G). 
Using primers against the CRD-EGFβ domain, an 842-bp band was amplified in all tested 
samples (Fig 3H ). With primers specific to CRD and S1, S3 or S4, we found that S1 and S3 
are present in both forms of type III Nrg1 in rat cortex, hypothalamus, anterior pituitary and 
GH3 cells (Fig 3I, J), whereas S4 was present in rat cortex and undetectable in the other 
samples tested (Fig 1K). GAPDH signals were equal in each group, suggesting the equal 
loading of samples (Fig 3F). To confirm the expression of membrane-anchored Nrg1, 
transmembrane segments were amplified by using primers specific to the different types of 
cytoplasmic domains. All samples tested showed two similar bands, in which the upper 
band represents the TM-cytoplasmic a tail segment and the lower band represents the TM-
cytoplasmic b tail segment (Fig 3L).  
By contrast to previous studies depicting type II Nrg1 (GGF I-III) expression in the pituitary 
(Goodearl  et al., 1993), other studies do not support this idea as a result of the absence or 
extremely low levels of GGF mRNA in rat pituitary with in situ hybridization (ISH) or RT-
PCR (Marchionni et al., 1993). In line with the letter, the rat anterior pituitary expresses both 
type I Nrg1α β and type III Nrg1α β, whereas the GH3 cells only express type III Nrg1α β 
(Tab 1). This suggests that Nrg1 may have specific functions there. Furthermore, the 
 
Neuregulin-1 (Nrg1): An Emerging Regulator of Prolactin (PRL) Secretion 87 
presence of both membrane-tethered Nrg1 and soluble Nrg1 may function in an autocrine  
paracrine manner. 
 
Type sample α β S1 S3 S4 ICD-a ICD-b ICD-c 
I AP + + + + - + + + 
 GH3 - - - - - - - - 
II AP - - - - - - - - 
 GH3 - - - - - - - - 
III AP + + + + - + + + 
 GH3 + + + + - + + + 
Table 1. Nrg1 domain identification in the anterior pituitary (AP) and GH3 cells (GH3) based on 
domain RT-PCR. α, EGF-like domain α; β, EGF-like domain β; S, stalk domain; ICD, intracellular 
domain.  
 
Figure 3. Domain RT-PCR for multiple Nrg1 isoforms in the rat cortex, hypothalamus, anterior 
pituitary and GH3 cells. Reverse transcriptase-PCR with several sets of domain specific primers 
amplified the expression of Nrg1 isoforms in the hypothalamus (HP) and anterior pituitary (AP) and 
GH3 cells (GH3). Rat cortex (Cor) serves as positive control. D-Glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) was used to indicate the equal loading of samples. The schematic diagrams 
right to the RT-PCR results indicate domains that the RT-PCR products contain. α, EGF-like domain α; 
β, EGF-like domain β; s, stalk domain; CRD, cysteine-rich domain; ICD, intracellular domain; TM, 
transmembrane domain. (Zhao et al., 2011a) 
At the protein level based on Western blot, the anterior pituitary give rise to a group of 
bands with a wide range of molecular weights as a result of alternative splicing and post-
translational modification such as hyperglycosylation. In the anterior pituitary cell lysates, 
bands at 140, 110, 95 and 90 kDa, representing the main Nrg1 precursors, were observed, 
whereas, in the hypothalamus cell lysates, a weak band at 110 kDa was observed. Soluble 
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Neuregulin has also been reported to be expressed in the endocrine organs, including the 
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(Goodearl  et al., 1993), other studies do not support this idea as a result of the absence or 
extremely low levels of GGF mRNA in rat pituitary with in situ hybridization (ISH) or RT-
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At the protein level based on Western blot, the anterior pituitary give rise to a group of 
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whereas, in the hypothalamus cell lysates, a weak band at 110 kDa was observed. Soluble 
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Nrg1s at 36 and 30 kDa were detected in the anterior pituitary, whereas only the 36 kDa 
Nrg1 was detected in the hypothalamus. 
In the anterior pituitary, Nrg1αβ was co-localized with Nrg1α, further confirming the 
domain RT-PCR and western blotting results and indicating that Nrg1α is the predominant 
intrapituitary Nrg1. However, Nrg1αβ was not co-localized with S-100, GH and ACTH, 
which serve as markers for folliculo-stellate cells, somatotrophs and corticotrophs, 
respectively. Notably, neighbouring localization of Nrg1 with PRL was observed, 
suggesting a potential interaction between lactotrophs and Nrg1 positive cells. In addition, 
Nrg1 was weakly detected in partial PRL positive lactotrophs. Further 
immunofluoresecence investigation demonstrated Nrg1αβ were co-stained with FSH or LH, 
both of which are markers for gonadotrophs. Significant co-localization of Nrg1αβ with 
either FSH or LH was noted in the transition zone between pars tuberalis and pars distalis. 
However, in the pars distalis, such co-localization was relatively weak. This suggests that 
gonadotrophs in the pars tuberalis adjacent to the pars distalis are the major source of 
intrapituitary Nrg1α/β (Fig 4) (Zhao et al., 2011a). 
 
Figure 4. Gonadotrophs are the main source of Nrg1 in the anterior pitutiary. PL, posterior lobe; IL, 
intermediate lobe; AL, anterior lobe. A, pars tuberalis; B, pars distalis. (Zhao et al., 2011a) 
In addition, RT-PCR demonstrated varying expression patterns of Nrg 1 isoforms at the 
mRNA level during the estrous cycle. Type I Nrg1α was expressed at a low level during the 
proestrous (PE) phase and at a constant level in other phases. In contrast, low levels of type I 
Nrg1β were observed in the metestrous (ME) and diestrous (DE) phases. Type II Nrg1 was 
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expressed at the highest level during the E1 phase. Both type III Nrg1α and type III Nrg1β 
were expressed at higher levels during the E1 and E2 phases, when an estrogen surge 
occurred in response to hypophyseal gonadotrophic hormones. At the protein level, the 
expression of both 110 kDa and 95 kDa Nrg1s in the anterior pituitary were significantly 
higher in E1 and E2 phases. No similar expression pattern was observed in the posterior 
pituitary (Zhao et al., 2011c). In spite of these observations, it is still unclear whether Nrg1 
functions in an sex-dependent manner or not in the anterior pituitary, and unfortunately, 
little is known about the sex-specific expression and function of Nrg1 in the brain (Taylor et 
al., 2012). 
2.1.2. Localization of Nrg1 and ErbB4 receptor in the anterior pituitary of male Rhesus 
monkeys 
In male Rhesus monkeys aged 5-7 years, the existence of Nrg1 and ErbB4 was observed, 
which showed a partial adjacent pattern, suggesting the existence of Nrg1/ErbB4 juxtacrine 
signaling in the anterior pituitary in non–human primates (See Figure 5) (Zhao et al., 2011c).  
 
Figure 5. Nrg1 and ErbB4 receptor are expressed in the anteior pituitary of the rhesus monkey. The 
anterior pituitary of Rhesus monkey was subjected to immunofluorescence staining for both Nrg1 and 
ErbB4 (Green: Nrg1; Red: ErbB4; Blue: DAPI).  
2.2. Expression and Localization of Nrg1 in GH3 cells 
Exogenous Nrg1 was first shown to increase PRL mRNA expression and PRL secretion from 
GH3 cells by activating the ErbB3 receptor and intracellular AKT. In addition, the ErbB3 
receptor has been shown to correlate with the malignant transformation of prolactinomas 
(Vlotides et al., 2008, 2009).  
Subsequent investigation demonstrated that administration of siRNA against Nrg1 reduced 
the expression of multiple isoforms, including the 110-, 60-, 36-, 33-, and 30-kDa proteins, 
indicating that these bands potentially represented alternatively spliced Nrg1 gene 
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higher in E1 and E2 phases. No similar expression pattern was observed in the posterior 
pituitary (Zhao et al., 2011c). In spite of these observations, it is still unclear whether Nrg1 
functions in an sex-dependent manner or not in the anterior pituitary, and unfortunately, 
little is known about the sex-specific expression and function of Nrg1 in the brain (Taylor et 
al., 2012). 
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In male Rhesus monkeys aged 5-7 years, the existence of Nrg1 and ErbB4 was observed, 
which showed a partial adjacent pattern, suggesting the existence of Nrg1/ErbB4 juxtacrine 
signaling in the anterior pituitary in non–human primates (See Figure 5) (Zhao et al., 2011c).  
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anterior pituitary of Rhesus monkey was subjected to immunofluorescence staining for both Nrg1 and 
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2.2. Expression and Localization of Nrg1 in GH3 cells 
Exogenous Nrg1 was first shown to increase PRL mRNA expression and PRL secretion from 
GH3 cells by activating the ErbB3 receptor and intracellular AKT. In addition, the ErbB3 
receptor has been shown to correlate with the malignant transformation of prolactinomas 
(Vlotides et al., 2008, 2009).  
Subsequent investigation demonstrated that administration of siRNA against Nrg1 reduced 
the expression of multiple isoforms, including the 110-, 60-, 36-, 33-, and 30-kDa proteins, 
indicating that these bands potentially represented alternatively spliced Nrg1 gene 
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products, post-translationally modified forms, and/or the shed ectodomains from their 
initial precursors. Immunofluorescence staining also demonstrated the reduced expression 
of Nrg1α/β in GH3 cells. Nrg1 was detected, with the ErbB2 receptor partially expressed in 
some human prolactinoma samples. This suggests the existence of Nrg1/ErbB receptor 
autocrine/paracrine signaling during the development of prolactinoma. 
In addition, type III Nrg1 (SMDF) is distinct from the other two types of Nrg1 and contains 
an extra N terminal transmembrane structure. In type III Nrg1, initial proteolysis frees the 
EGF-like domain from the membrane, leading to juxtacrine signalling characterised by 
reciprocal intercellular communication (Bao et al., 2003; Hancock et al., 2008). Further 
cleavage releases a shorter EGF-like domain-containing peptide, which functions in 
autocrine  paracrine interactions. Indeed, high levels of ErbB4 receptor and Nrg1 have also 
been reported to be expressed in K-ras transformed thyroid Kimol and A6 cells, where Nrg1 
signals through the ErbB2/ErbB4 heterodimeric complex in an autocrine manner (Mincione 
et al., 1998). Although Nrg mRNA was present in both tumor and non-tumor tissue, Nrg 
precursor isoform immunohistochemically showed nuclear immunostaining in most human 
papillary carcinomas but not in normal thyroid tissue. Cytoplasmic Nrgα, β1 and β3 were 
also exclusively detected in papillary carcinomas (Fluge et al., 2000). Significant expression 
of the ErbB2, ErbB3 and ErbB4 receptors, in addition to Nrg1 isoforms, was also detected in 
the developing murine fetal pancreas, where they potentially contribute to islet 
development and regrowth (Kritzik et al., 2000). The strong expression of Nrg1 in 
lactosomatotroph GH3 tumor cells was in sharp contrast with that observed in the anterior 
pituitary, where Nrg1 was almost undetectable in the prolactotroph (Zhao et al., 2011b). 
Thus, overexpression of Nrg1 may play a vitally functional role in prolactinoma 
development. 
3. Autocrine/juxtacrine modulation of prolactin (PRL) secretion via 
Nrg1/ErbB receptor pathway 
3.1. Modulating role of Nrg1 on PRL secretion in the anterior pituitary 
Previous studies have described the morphological relationship between prolactotrophs and 
gonadotrophs, which is characterised by conditional gap junctions, and have reported the 
functional roles of LH on PRL secretion in response to GnRH (Andries et al., 1995; Denef et 
al., 1983). More recently, Henderson et al. (2008) described GnRH-induced PRL release 
independent of gonadotrophins.  
FSH positive gonadotrophs can form contacts with ErbB3 positive cells and ErbB3 was also 
shown to be localized on the prolactotroph membrane. These observations, altogether, 
raised the hypothesis that Nrg1 present in gonadotrophs may function by modulating 
lactotrophs by interacting with ErbB3 receptor on the membrane. Thus, intrapituitary 
gonadotrophs and prolactotrophs may partially use gap junctions to form contacts, allowing 
the binding of gonadotroph-derived membrane-tethered type III Nrg1 to ErbB3 receptors on 
the prolactotrophic membrane. In addition, both prolactotrophs and gonadotrophs may 
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form contacts through cell adhesion molecules widely distributed in the anterior pituitary, 
including L1 cell adhesion molecule and neural cell adhesion molecule (Zhao et al., 2010). 
These molecules may increase the interaction between Nrg1 and ErbB receptors, such as 
ErbB3 and ErbB4, a process that may activate a series of intracellular signals and also 
increase enzymatic cleavage of the PRL precursor.  
In one study, type I and type III Nrg1αβ as well as membrane-tethered type III Nrg1 were 
able to be identified using domain-specific primers-based RT-PCR in the mouse 
gonadotroph αT3-1 cells. Using Western blot assays with an anti-Nrg1 antibody, a cluster of 
proteins were observed with molecular weights in the range 30–114 kDa. Proteins at 70, 60 
and 45 kDa were also detected in serum-free culture medium conditioned by αT3-1 cells. 
However, commonly recognized soluble Nrg1 with molecular weight ranging from 40–25 
kDa were rarely observed, suggesting the precursor is the main form of Nrg1 in this 
gonadotroph cell line, which may be the base for juxtacrine interaction between Nrg1 and its 
cognate receptors. Subsequently, PRL and GH secreting GH3 cells were co-cultured with 
gonadtroph αT3-1 cells pretreated with siRNA against Nrg1. Administration of siRNA 
against mouse Nrg1 significantly reduced the staining intensities of intracellular Nrg1αβ, as 
well as their co-localization, as observed with immunofluorescence assays. Nrg1 reduction 
in αT3-1 cells reduced PRL expression in co-cultured GH3 cells. Co-culturing of GH3 cells 
with αT3-1 cells treated with siRNA against Nrg1 significantly reduced the secretion of an 
18 kDa form of PRL from GH3 cells at 48 h, although it had no significant effect on the 
secretion of 23-kDa PRL and 22-kDa GH. This result, coupled with the observation that 
membrane-tethered type III Nrg1 is mainly expressed in the gonadotrophs, suggests the 
existence of a type III Nrg1-mediated juxtacrine mechanism that affects secretion of a subset 
of PRL, a process that may also occur in the normal anterior pituitary. 
Cleaved full-length PRL has been reported to be a vascular function modulator mainly in 
the 16-kDa form (Clapp et al., 2006, 2008; Macotela et al., 2006). However, an 18- kDa form 
was also reported as an intermediate form of the final cleavage product in vitro (Lkhider et 
al., 2004; Nicoll et al., 1997). We reported that Nrg1 can modulate the release of an 18-kDa 
cleavage form of PRL, which is typical to GH3 cells. This process may be related to the 
modulation of Nrg1 on enzymes specific for PRL cleavage, such as cathepsin D and matrix 
metalloprotease (MMP) family members (Clapp et al., 2006, 2008; Macotela et al., 2006). 
Indeed, Nrg1 has been shown to promote the expression of MMP-7 and -9 in an ErbB 
receptor dependent manner in cancer cells (Ueno et al., 2008; Yuan et al., 2006). 
3.2. Modulating role of Nrg1 on PRL secretion in rat   lactosomatotroph GH3 
cells 
In one study, siRNA method was used to investigate the autocrine/paracrine effect of Nrg1 
on PRL secretion. siRNA of Nrg1 significantly downregulated the release of a soluble form 
of 36 kDa Nrg1 into the conditioned culture medium. Western blotting analysis showed 
significantly reduced secretion of both the 23-kDa and the 18-kDa PRLs into the conditioned 
culture medium in response to the reduced secretion of 36 kDa Nrg1, and a reduction in 
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products, post-translationally modified forms, and/or the shed ectodomains from their 
initial precursors. Immunofluorescence staining also demonstrated the reduced expression 
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form contacts through cell adhesion molecules widely distributed in the anterior pituitary, 
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These molecules may increase the interaction between Nrg1 and ErbB receptors, such as 
ErbB3 and ErbB4, a process that may activate a series of intracellular signals and also 
increase enzymatic cleavage of the PRL precursor.  
In one study, type I and type III Nrg1αβ as well as membrane-tethered type III Nrg1 were 
able to be identified using domain-specific primers-based RT-PCR in the mouse 
gonadotroph αT3-1 cells. Using Western blot assays with an anti-Nrg1 antibody, a cluster of 
proteins were observed with molecular weights in the range 30–114 kDa. Proteins at 70, 60 
and 45 kDa were also detected in serum-free culture medium conditioned by αT3-1 cells. 
However, commonly recognized soluble Nrg1 with molecular weight ranging from 40–25 
kDa were rarely observed, suggesting the precursor is the main form of Nrg1 in this 
gonadotroph cell line, which may be the base for juxtacrine interaction between Nrg1 and its 
cognate receptors. Subsequently, PRL and GH secreting GH3 cells were co-cultured with 
gonadtroph αT3-1 cells pretreated with siRNA against Nrg1. Administration of siRNA 
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well as their co-localization, as observed with immunofluorescence assays. Nrg1 reduction 
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with αT3-1 cells treated with siRNA against Nrg1 significantly reduced the secretion of an 
18 kDa form of PRL from GH3 cells at 48 h, although it had no significant effect on the 
secretion of 23-kDa PRL and 22-kDa GH. This result, coupled with the observation that 
membrane-tethered type III Nrg1 is mainly expressed in the gonadotrophs, suggests the 
existence of a type III Nrg1-mediated juxtacrine mechanism that affects secretion of a subset 
of PRL, a process that may also occur in the normal anterior pituitary. 
Cleaved full-length PRL has been reported to be a vascular function modulator mainly in 
the 16-kDa form (Clapp et al., 2006, 2008; Macotela et al., 2006). However, an 18- kDa form 
was also reported as an intermediate form of the final cleavage product in vitro (Lkhider et 
al., 2004; Nicoll et al., 1997). We reported that Nrg1 can modulate the release of an 18-kDa 
cleavage form of PRL, which is typical to GH3 cells. This process may be related to the 
modulation of Nrg1 on enzymes specific for PRL cleavage, such as cathepsin D and matrix 
metalloprotease (MMP) family members (Clapp et al., 2006, 2008; Macotela et al., 2006). 
Indeed, Nrg1 has been shown to promote the expression of MMP-7 and -9 in an ErbB 
receptor dependent manner in cancer cells (Ueno et al., 2008; Yuan et al., 2006). 
3.2. Modulating role of Nrg1 on PRL secretion in rat   lactosomatotroph GH3 
cells 
In one study, siRNA method was used to investigate the autocrine/paracrine effect of Nrg1 
on PRL secretion. siRNA of Nrg1 significantly downregulated the release of a soluble form 
of 36 kDa Nrg1 into the conditioned culture medium. Western blotting analysis showed 
significantly reduced secretion of both the 23-kDa and the 18-kDa PRLs into the conditioned 
culture medium in response to the reduced secretion of 36 kDa Nrg1, and a reduction in 
 
Prolactin 92 
ErbB3 receptor activation was also observed. However, downregulation of Nrg1 has no 
effects on GH secretion. Thus, Nrg1 may modulate PRL secretion from GH3 cells in an 
autocrine, paracrine/juxtacrine manner (See Fig 6). 
 
Figure 6. Schematic diagram illustrating the hypothesized model for Neuregulin-1 (Nrg1) on PRL 
regulation. A, autocrine; P, paracrine; J, juxtacrine. 
4. Nrg1/ErbB receptor inhibition as a potential clinical management of 
prolactinoma 
The role of Nrg1-mediated autocrine, paracrine, or juxtacrine signaling in several aspects of 
cancer biology suggests that it is a potential target for tumor therapy. Success with a 
combined therapeutic antibody and sheddase inhibitor treatment has been demonstrated in 
the mammary cancer MCF- 7 cell line, in which the administration of INCB7839 (a second 
generation sheddase inhibitor) with Lapatinib prevents the growth of ErbB2 positive BT474-
SC1 human breast cancer xenografts in vivo (Witters et al., 2008). Gefitinib, a tyrosine kinase 
inhibitor, has also been reported to suppress Nrg1-mediated ErbB2/ErbB3 signaling to PRL 
(Vlotides et al., 2008, 2009). A recent investigation has also revealed that Lapatinib, an ErbB2 
inhibitor, possesses additional effects in the suppression of PRL expression, and oral 
Lapatinib treatment triggers the shrinkage of estrogen-induced prolactinomas in rats 
(Fukuoka et al., 2010). Thus, the co-localization of Nrg1 with ErbB2 in partial prolactinomas 
suggests that inhibiting Nrg1 expression or abolishing its binding ability might also have 
similar effects in inhibiting Nrg1-dependent ErbB receptor activation and prolactinoma 
progression. In one of our studies, five human prolactinoma tissues were stained for both 
Nrg1 and ErbB2. All samples demonstrated positive staining for Nrg1, and co-expression of 
both molecules was observed in one sample (Zhao et al., 2011b). Additional prolactinoma 
samples should be recruited to stress further the role of Nrg1/ErbB receptor singling in 
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future investigations. The findings regarding the endogenous expression of Nrg1 and an 
Nrg1-mediated autocrine/paracrine mechanism in GH3 cells have expanded previous 
results and reveal Nrg1 as a potential diagnostic serological marker for prolactinoma. In 
addition, a therapeutic approach involving the direct functional inhibition of Nrg1 might be 
a viable clinical treatment for PRL-secreting pituitary tumors. 
5. Conclusions and perspectives 
Among a series of regulators of PRL, the emerging role of Nrg1 is rather new, but important. 
Overexpression of Nrg1 and its cognate receptor ErbB2, as well as their co-localization 
provides the promising therapeutic method to control prolactinoma and 
hyperprolactinemia. Such a clinical purpose can be achieved by 1) Nrg1 receptor inhibitor, 
such as Erlotinib, Lapatinib et al.; 2) neutralizing antibody against Nrg1 and 3) their 
combination. Additionally, Nrg1-mediated autocrine/paracrine mechanism in GH3 cells 
have expanded previous results and reveal Nrg1 as a potential serological marker not only 
for prolactinoma diagnosis, but for prognosis evaluation post operation. In addition, a 
therapeutic approach involving the direct functional inhibition of Nrg1 might be a viable 
clinical treatment for PRL-secreting pituitary tumors. To avoid the side effects, such as 
affecting the physiological function of circulating Nrg1 brought by intravenous 
administration of anti-Nrg1 antibody, the therapeutic hypothesis may be established by 
intratumoral (i.t.) injection of the therapeutic antibody in patients, whose prolactinomas are 
highly resistant to chemotherapy or in whom the tumor location can lead to high surgery 
risk.  It has recently been reported that experimental i.t. injections with ErbB2 targeted gold 
nanoparticles (AuNPs) resulted in high tumor retention with low systemic exposure and 
represents an attractive delivery strategy (Chattopadhyay et al., 2012). 
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addition, a therapeutic approach involving the direct functional inhibition of Nrg1 might be 
a viable clinical treatment for PRL-secreting pituitary tumors. 
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1. Introduction 
The synthesis and release of prolactin (PRL) by lactotrophs in the anterior pituitary (AP) are 
regulated by factors produced in the hypothalamus as well as in the posterior and 
neurointermediate pituitary lobes, by autocrine and paracrine signals from the anterior 
pituitary itself (Ben-Jonathan & Hnasko, 2001; Kordon, 1985; Denef, 1988; Denef, 2008; 
Freeman et al., 2000; Lorenson and Walker, 2001; Schwartz & Cherny, 1992; Schwartz, 2000; 
Wang & Walker, 1993; Sinha, 1992; Sinha 1995; Moore et al., 2002; Bollengier et al., 1989; 
Bollengier et al., 1996; Kadowaki et al., 1984; MacLeod et al., 1966; Sgouris & Meites, 1953; 
Chen et al., 1968; Welsch et al., 1968) and also by gonadal steroids (Maurer & Gorski, 1977; 
Maurer, 1982). In addition, it has been reported that total PRL and PRL variants (Denef, 
2008; Shah & Hymer, 1989) are secreted under different physiological conditions (Denef, 
2008; Wang & Walker, 1993; Sinha, 1992; Sinha 1995; Mena et al., 1984; Mena et al., 1992; 
Boockfor & Frawley, 1987). And, it is known that functional interactions and cytological 
differences exist among pituitary lactotrophs within the anterior pituitary gland (Denef, 
1988; Schwartz & Cherny, 1992; Schwartz, 2000; Boockfor & Frawley, 1987) and that 
functional variations (Boockfor & Frawley, 1987; Boockfor et al., 1986; Frawley & Boockfor, 
1991; Nagy & Frawley 1990), as well as autoregulation (Nagy et al., 1991) and interactions 
with other pituitary cells (Denef, 2008; Sinha, 1992; Moore et al., 2002; Kadowaki et al., 1984) 
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with other pituitary cells (Denef, 2008; Sinha, 1992; Moore et al., 2002; Kadowaki et al., 1984) 
and with hypothalamic hormones (Ben-Jonathan & Hnasko, 2001; Chen et al., 1968) occur in 
different circumstances. For instance, lactotrophs from the central AP region of lactating 
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to dopamine; and interact with lactotrophs in the peripheral region of the gland (Boockfor & 
Frawley, 1987; Boockfor et al., 1986; Frawley & Boockfor, 1991; Nagy et al., 1991; Nagy & 
Frawley 1990; Diaz et al., 2002). In these studies, it is possible that the release of PRL variants 
may have influenced the regulation of PRL release.  
In previous reports (Huerta-Ocampo et al., 2007; Mena et al., 2010) we showed that 
conditioned media (CM) and PRL variants i.e., from 7-14 and 70-97 kDa, from lactating rat 
APs, characterized by Western blotting and eluted from SDS-PAGE, promoted the in vitro 
vesicular release of the hormone from preformed, mature PRL granules of male rat APs, and 
that such release was independent of PRL synthesis (Huerta-Ocampo et al., 2007). Autocrine 
and paracrine types of actions have also been shown to occur within the AP (Denef, 2008; 
Freeman et al., 2000; Lorenson and Walker, 2001; Schwartz & Cherny, 1992; Schwartz, 2000; 
Welsch et al., 1968; Diaz, et al., 2002; Huerta-Ocampo et al., 2007; Mena et al., 2010), and 
were demonstrated when the central and peripheral AP regions of lactating rats were 
incubated in vitro with CM from pituitaries of lactating, pregnant and steroid-treated 
castrated males or females, but not from untreated castrated rats, intact male rats or by a 
PRL Standard (Huerta-Ocampo et al., 2007; Mena et al., 2010). Also, more potent effects 
occurred with CM from APs of early- than from mid- or late- lactating rats and from rats 
non-suckled for 8 or 16 h than from those non-suckled for 32 h (Mena et al., 2010). These 
results suggest that, under certain conditions, PRL variants released from lactating and non-
lactating rat APs may regulate the release of PRL variants from the lactotrophs. 
In the present study, CM proteins, i.e., PRL variants, that were released in vitro from the AP 
regions of lactating rats were separated and electroeluted from SDS-PAGE and tested using 
in vitro incubation techniques. We sought to determine first, whether PRL variants, which 
are known to occur within the AP (Schwartz & Cherny, 1992; Schwartz, 2000; Wang & 
Walker, 1993; Sinha, 1992; Bollengier et al., 1989; Huerta-Ocampo et al., 2007; Mena et al., 
2010; Mena & Grosvenor, 1972; Asawaroengchai et al., 1978; Nicoll et al., 1969; Mansur & 
Hymer, 1985), and are released in vitro (Mena et al, 1984; Mena et al., 1992; Huerta-Ocampo 
et al., 2007; Mena et al., 2010; Mena & Grosvenor, 1972; Grosvenor et al., 1967; Grosvenor et 
al., 1979; Mena et al., 1989; Mena et al., 1993) after the suckling-induced PRL transformation 
i.e., the transfer of the hormone from a pre-releasable to a releasable state (Mena & 
Grosvenor, 1972; Grosvenor et al., 1967; Mena et al., 1993) would influence the release of 
PRL variants from lactating rat lactotrophs; and second, whether the effects of dopamine 
(DA), thyrotropin-releasing hormone (TRH) and oxytocin (OT) upon PRL release would 
manifest their effects upon PRL secretion by regulating the release of PRL variants from 
lactating rat lactotrophs (Mena et al., 2011).  
Several reports indicate that PRL has some neuro and gliatrophic properties, and that it 
mediates the development and maturation of dopaminergic neurons in the hypothalamo-
pituitary system (Möderscheim et al., 2007). We showed previously (Morales et al., 2001) 
that intrathecal injection of PRL in the spinal cord promoted the sympathetic inhibition of 
milk ejection in lactating rats, and that prolactin variants in CM from the central and 
peripheral regions of the anterior pituitary from lactating, but not from male rats promoted 
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the in vitro release of PRL from pituitary glands of male rats in a dose-dependent manner 
(Huerta-Ocampo et al., 2007; Mena et al., 2010). 
Our results suggest that PRL variants are released into the CM from the central and 
peripheral AP regions of lactating rats, that they interact and selectively and specifically 
stimulate or inhibit the in vitro release of other PRL variants from lactotrophs of lactating rat 
APs; that hypothalamic hormones selectively regulate and interact with PRL variants 
released from AP lactotrophs, and finally, whether in response to CM’s from lactating rats, 
changes in electrical activity (EA) occur in male lactotrophs, as well as in astrocytes from the 
central nervous system, and in intracellular calcium concentration in sympathetic neurons 
(Mena et al, 2012b). 
2. Materials and methods 
2.1 General 
Animal studies were performed under a protocol similar to the USPHS Guide for the Care 
and Use of Laboratory Animals and the Official Mexican Guide from Secretary of 
Agriculture (SAGARPA NOM-062-Z00-1999) published in 2001. Wistar primiparous 
lactating rats (8-10 pups per litter) were housed individually in a room with a reversed light-
dark cycle (14 h light, 10 h darkness) and constant temperature (23-25°C) and were fed ad 
libitum (Purina Chow, Ralston Purina Co., Chicago IL, USA). On postpartum days 10-12 (7 
am, local time) groups of mothers had their pups removed, and 6 h later their pups were or 
were not returned to the mothers and suckled for 15 min. At the end of the suckling or non-
suckling periods, the mothers were killed by decapitation after light ether anesthesia. From 
all animals employed (see below), the pituitary was removed under a dissecting microscope, 
the posterior lobe was discarded and, using fine forceps as originally described by Papka et 
al. 1986, and by Bookfor & Frawley, 1987, the central region around the neurointermediate 
lobe and the peripheral region i.e., the rest of the AP tissue (Boockfor & Frawley, 1987; Diaz 
et al., 2002) were dissected independently, and incubated in Earle’s medium as described 
below. 
2.2. Preparation of concentrated conditioned media 
In individual flasks containing 300 μl of Earle’s medium, media were conditioned by 
incubating tissue fragments corresponding to the central (CR) and peripheral (PR) pituitary 
regions from lactating rats. The pituitary fragments were incubated immediately after 
removal to prevent disruption of hormone storage dynamics (Mena et al., 1992; Diaz et al., 
2002). Flasks containing the pituitary fragments were gassed with 95% O2, 5% CO2, sealed 
with rubber stoppers and incubated at 37°C in a water bath shaker (American Optical, 
Buffalo NY, USA) for 1h. CM from pituitary fragments of each group of rats employed was 
concentrated and desalted in a Centricon micro-concentrator (Centripep, Millipore, 
Bredford MA, USA) and stored frozen until assayed, along with the corresponding primary 
cultures of pituitary cells or with cultures of sympathetic neurons.  
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The dose-response effects of DA (0.5, 1.0, 1.5 μM), TRH (0.1, 1.0, 10 μM) and OT (0.1-10 μM), 
upon the in vitro release of PRL variants previously exposed to the electroeluted PRL variants 
from NS and S lactating rat APs were determined by Enzyme-linked immunoabsorbant assay 
(ELISA).  
2.3. SDS-PAGE  
The PRL released into the media was determined by non-denaturing SDS-PAGE (12.5% 
gels) and Western blotting. The gels of SDS-PAGE were divided into 6 fractions which 
encompassed PRL variants from 6 to 97 kDa. The proteins in each fraction were 
electrophoretically eluted, dialyzed, lyophilized, and then assayed by ELISA for PRL 
content, as well as for their effects upon PRL secretion on primary culture of pituitary cells 
from the lactating rats, different concentrations of hypothalamic hormones, and in central 
and peripheral cultures of sympathetic neurons and astrocytes from hippocampus.  
2.4. Primary cultures of pituitary cells  
Pituitary fragments from male APs, or from NS and S lactating rats (n=5) corresponding to 
the central and peripheral regions of the anterior pituitary were dissected and processed 
separately. Primary cultures (lactotrophs) were prepared as described by Fiordelisio & 
Hernandez-Cruz, 2002. The tissue fragments were gently triturated with a Pasteur pipette; 
the cells were collected by centrifuging for 10 min at 185 x g, and washed twice with 
Dulbecco’s Modified Eagle’s Medium (DMEM) containing 10% BSA. The pellet was 
resuspended in DMEM medium, supplemented with 10% horse serum, 2% Fetal Bovine 
Serum, 10,000 U penicillin, 10 mg/ml streptomycin, all from Gibco BRL, Grand Island NY, 
USA. The cultures were maintained for 24 h at 37°C in a humidified atmosphere (95% air 
and 5% CO2). The primary cultures were placed in the bottom of 24-multiwell culture plates 
(Costar, Cambridge, MA, USA) at a density of 2 x104 cells per well and three replicates were 
used in each experiment. 
2.5. Cultures of astrocytes from the hippocampal and medial preoptic areas 
Astrocyte cultures were obtained as shown previously by Hernández-Morales and García-
Colunga, 2009. Two newborn Wistar rats were killed by decapitation and their brains 
removed. Slices from hippocampal CA1 region, or medial preoptic area were dissected and 
then the tissue was dissociated (5000 cells/mL). The suspended cells were placed on a glass 
coverslip in a 35-mm Petri dish coated with poly-L-ornithine with DMEM supplemented 
with 10% FBS, 100 U/mL penicillin, 0.1 mg/mL streptomycin and 11 μg/mL piruvate was 
added. After 24 h, the medium was changed by Neurobasal medium supplemented with G5 
(specific for growing astrocytes) and 100 U/mL penicillin, and 0.1 mg/mL streptomycin and 
2 mM of L-glutamine. Cultures were kept under controlled air and temperature. 
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2.6. Cultures of sympathetic neurons 
Cultures of sympathetic neurons were obtained as previously reported by Fiordelisio & 
Hernandez-Cruz, 2002. Briefly, ganglia from 10-day-old rats were removed under aseptic 
conditions after ether anaesthesia and cervical dislocation. After cleaning and chopping, the 
neurons were incubated in Ca2+/Mg2+-free Hanks solution with 1 mg/ml trypsin 
(Worthington Biochem Co.) and 2 mg/ml DNAse I for 30 min at 37ºC. After digestion, trypsin 
was inactivated by dilution in DMEM containing 10% fetal bovine serum (FBS) and 1 mg/ml 
trypsin inhibitor (Sigma) and the tissue was incubated in Hanks solution with 2 mg/ml 
collagenase and 2 mg/ml DNAse I for 30 min at 37ºC. After trituration with a Pasteur pipette, 
the cell suspension was centrifuged, washed twice in Hanks solution, and resuspended in 
fresh control culture medium. Cells were seeded on poly L-lysine-treated #1 round glass 
coverslips (1r105 cells per well), and maintained in control culture medium supplemented 
with 30 ng/ml of 7S NGF (Sigma) at 37ºC in a humidified atmosphere of 95% air and 5% CO2. 
Culture medium was changed three times per week. All experiments were carried out with 
cultures less than 5 days old. 
2.7. Electrophysiology 
Astrocyte ion currents were recorded using the whole-cell voltage-clamp technique, as 
shown previously by Hernández-Morales and García-Colunga, 2009. Primary astrocytes 
between 4-7 days of culture were placed in a recording chamber and continuously 
superfused with control solution containing (mM): 136 NaCl, 2.5 KCl, 10 HEPES, 4 CaCl2, 0.5 
MgCl2, 10 glucose, pH 7.2. Pipettes were filled with a solution containing (mM): 130 K-
gluconate, 10 NaCl, 10 EGTA, 10 HEPES, 2 ATP, 0.2 GTP, pH 7.2, having a resistance of 3-5 
M. Astrocytes were held at a potential of -60 mV. The data were analyzed with pClamp 8.2 
software and Origin 7. We determined changes in electrical activity (EA) in response to 
CM’s from lactating and from male rats in male lactotrophs, as well as in neurons from the 
central nervous system. 
2.8. Measurements of intracellular Ca2+ concentration  
Primary astrocytes from hippocampus, medial preoptic area, sympathetic neurons or male 
rat lactotrophs, between 4-7 days of culture, were incubated for 30 min with the Ca2+ 
indicator Fluo 4-AM. Following this, cells were washed out three times for 10 min with 
solution containing (mM): 136 NaCl, 2.5 KCl, 10 HEPES, 4 CaCl2, 0.5 MgCl2, 10 glucose, pH 
7.2. Cells were recorded on a Confocal Microscope LSM-510. Local application of CM was 
carried on with U-tube system placed at 250 μm from the recorded cell. Cells were excited 
at 488 nm-Ar laser. Fluorescent intensity represents the change in intracellular calcium 
concentration and is measured in the whole soma. Data are expressed as a change from 
basal intensity (F0) to maximum intensity reached (%ΔF), %ΔF/F0. Then, we determined 
fluctuations in intracellular Ca2+ concentration, [Ca2+]i, in male lactotrophs in response to CM 
from lactating and from male rats. 
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then the tissue was dissociated (5000 cells/mL). The suspended cells were placed on a glass 
coverslip in a 35-mm Petri dish coated with poly-L-ornithine with DMEM supplemented 
with 10% FBS, 100 U/mL penicillin, 0.1 mg/mL streptomycin and 11 μg/mL piruvate was 
added. After 24 h, the medium was changed by Neurobasal medium supplemented with G5 
(specific for growing astrocytes) and 100 U/mL penicillin, and 0.1 mg/mL streptomycin and 
2 mM of L-glutamine. Cultures were kept under controlled air and temperature. 
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2.6. Cultures of sympathetic neurons 
Cultures of sympathetic neurons were obtained as previously reported by Fiordelisio & 
Hernandez-Cruz, 2002. Briefly, ganglia from 10-day-old rats were removed under aseptic 
conditions after ether anaesthesia and cervical dislocation. After cleaning and chopping, the 
neurons were incubated in Ca2+/Mg2+-free Hanks solution with 1 mg/ml trypsin 
(Worthington Biochem Co.) and 2 mg/ml DNAse I for 30 min at 37ºC. After digestion, trypsin 
was inactivated by dilution in DMEM containing 10% fetal bovine serum (FBS) and 1 mg/ml 
trypsin inhibitor (Sigma) and the tissue was incubated in Hanks solution with 2 mg/ml 
collagenase and 2 mg/ml DNAse I for 30 min at 37ºC. After trituration with a Pasteur pipette, 
the cell suspension was centrifuged, washed twice in Hanks solution, and resuspended in 
fresh control culture medium. Cells were seeded on poly L-lysine-treated #1 round glass 
coverslips (1r105 cells per well), and maintained in control culture medium supplemented 
with 30 ng/ml of 7S NGF (Sigma) at 37ºC in a humidified atmosphere of 95% air and 5% CO2. 
Culture medium was changed three times per week. All experiments were carried out with 
cultures less than 5 days old. 
2.7. Electrophysiology 
Astrocyte ion currents were recorded using the whole-cell voltage-clamp technique, as 
shown previously by Hernández-Morales and García-Colunga, 2009. Primary astrocytes 
between 4-7 days of culture were placed in a recording chamber and continuously 
superfused with control solution containing (mM): 136 NaCl, 2.5 KCl, 10 HEPES, 4 CaCl2, 0.5 
MgCl2, 10 glucose, pH 7.2. Pipettes were filled with a solution containing (mM): 130 K-
gluconate, 10 NaCl, 10 EGTA, 10 HEPES, 2 ATP, 0.2 GTP, pH 7.2, having a resistance of 3-5 
M. Astrocytes were held at a potential of -60 mV. The data were analyzed with pClamp 8.2 
software and Origin 7. We determined changes in electrical activity (EA) in response to 
CM’s from lactating and from male rats in male lactotrophs, as well as in neurons from the 
central nervous system. 
2.8. Measurements of intracellular Ca2+ concentration  
Primary astrocytes from hippocampus, medial preoptic area, sympathetic neurons or male 
rat lactotrophs, between 4-7 days of culture, were incubated for 30 min with the Ca2+ 
indicator Fluo 4-AM. Following this, cells were washed out three times for 10 min with 
solution containing (mM): 136 NaCl, 2.5 KCl, 10 HEPES, 4 CaCl2, 0.5 MgCl2, 10 glucose, pH 
7.2. Cells were recorded on a Confocal Microscope LSM-510. Local application of CM was 
carried on with U-tube system placed at 250 μm from the recorded cell. Cells were excited 
at 488 nm-Ar laser. Fluorescent intensity represents the change in intracellular calcium 
concentration and is measured in the whole soma. Data are expressed as a change from 
basal intensity (F0) to maximum intensity reached (%ΔF), %ΔF/F0. Then, we determined 
fluctuations in intracellular Ca2+ concentration, [Ca2+]i, in male lactotrophs in response to CM 
from lactating and from male rats. 
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3. Statistical analysis 
The PRL concentration was calculated by linear regression and values of PRL concentration 
obtained by ELISA were averaged for each experimental group. Statistical differences were 
determined by a one-way analysis of variance (ANOVA), using Dunnett’s test, and all 
treatments were compared versus the control (Earle’s medium or Total PRL). Comparisons 
were analysed with the Graph Pad 5.0 Software, Inc. (San Diego, CA). The significance level 
was set at p<0.05. Each control or test compound was assayed in duplicate, and the assays 
were performed three times (n=3). 
4. Experiments 
4.1. Autocrine regulation of prolactin secretion 
4.1.1. PRL content of electroeluted (EE) PRL variants released from AP regions of lactating 
non-suckled (NS) and suckled (S) rats 
The PRL variants released from each AP region of NS and S rats were analyzed previously by 
SDS-PAGE and by Western blotting (32, 33). In the present study these PRL variants were 
electroeluted i.e., EE PRL from fractions 1-6 after SDS-PAGE; and the PRL content of each 
fraction was determined by ELISA, as shown in Fig. 1 A-D, and subsequently, to determine 
whether their increased and/or decreased release of PRL variants, each electroeluted PRL 
fraction (EE PRL) was incubated with lactotrophs of each AP region of non-suckled and 
suckled rat APs i.e., Figs. 2-3 (A-D). The fractions contained bands of 7-23 to 97 kDa under 
NR conditions, and 7-16 to 42 kDa under R conditions, and between 1 and more than 20 ng/μl 
of PRL variant protein. However, in spite of these variations, similar amounts of total PRL 
(about 60 ng/μl right panels), were released from each AP regions of NS and S rat, except for 
the higher amount (80 ng/μl) released from the central AP region of NS rats.  
4.1.2. Effects of electroeluted PRL variants (EE PRL), released from AP regions of lactating 
non-suckled (NS) rats, upon the in vitro release of PRL variants from lactotrophs of NS rats 
The EE PRL variants that were released from each AP region of NS rats (Figs. 1 A-B) were 
tested for their effects upon the amount of PRL release by lactotrophs from AP regions of NS 
rats, and the results are shown in Fig. 2A-B. CM from the PR region of NS rat APs (Fig. 1 A) 
contained a low concentration of PRL (< 3 ng/μl) in fraction 2 and high (about 10 ng/μl) in 
fractions 1 and 3-6; after incubation with the EE PRL variants, lactotrophs of the same region, 
i.e., the peripheral AP region of NS rats, exhibited increased release i.e., 5-7 ng/μl of PRL 
variants 1, 2, 4, and 6, and decreased release of PRL variants 3 and 5. When incubated with 
EE fractions from CM of the central AP region of NS rats, lactotrophs from the same region 
showed increased release of PRL variants in fractions 1 and 6, and lower release in fractions 2, 
3, 4 and 5. Thus, except for the amounts of PRL released from fractions 1 and 6, whose levels 
were higher or similar to those of the other EE PRL variants, the amounts of other PRL 
variants released were significantly lower than those of the EE variants. When the central AP  
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Figure 1. (A-B). SDS-PAGE (left panels) and prolactin (PRL) content (ng/μl) of PRL variants 
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determined by a one-way analysis of variance (ANOVA), using Dunnett’s test, and all 
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electroeluted i.e., EE PRL from fractions 1-6 after SDS-PAGE; and the PRL content of each 
fraction was determined by ELISA, as shown in Fig. 1 A-D, and subsequently, to determine 
whether their increased and/or decreased release of PRL variants, each electroeluted PRL 
fraction (EE PRL) was incubated with lactotrophs of each AP region of non-suckled and 
suckled rat APs i.e., Figs. 2-3 (A-D). The fractions contained bands of 7-23 to 97 kDa under 
NR conditions, and 7-16 to 42 kDa under R conditions, and between 1 and more than 20 ng/μl 
of PRL variant protein. However, in spite of these variations, similar amounts of total PRL 
(about 60 ng/μl right panels), were released from each AP regions of NS and S rat, except for 
the higher amount (80 ng/μl) released from the central AP region of NS rats.  
4.1.2. Effects of electroeluted PRL variants (EE PRL), released from AP regions of lactating 
non-suckled (NS) rats, upon the in vitro release of PRL variants from lactotrophs of NS rats 
The EE PRL variants that were released from each AP region of NS rats (Figs. 1 A-B) were 
tested for their effects upon the amount of PRL release by lactotrophs from AP regions of NS 
rats, and the results are shown in Fig. 2A-B. CM from the PR region of NS rat APs (Fig. 1 A) 
contained a low concentration of PRL (< 3 ng/μl) in fraction 2 and high (about 10 ng/μl) in 
fractions 1 and 3-6; after incubation with the EE PRL variants, lactotrophs of the same region, 
i.e., the peripheral AP region of NS rats, exhibited increased release i.e., 5-7 ng/μl of PRL 
variants 1, 2, 4, and 6, and decreased release of PRL variants 3 and 5. When incubated with 
EE fractions from CM of the central AP region of NS rats, lactotrophs from the same region 
showed increased release of PRL variants in fractions 1 and 6, and lower release in fractions 2, 
3, 4 and 5. Thus, except for the amounts of PRL released from fractions 1 and 6, whose levels 
were higher or similar to those of the other EE PRL variants, the amounts of other PRL 
variants released were significantly lower than those of the EE variants. When the central AP  
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Figure 1. (A-B). SDS-PAGE (left panels) and prolactin (PRL) content (ng/μl) of PRL variants 
(middle and right panels) released from the peripheral (PR) and central (CR) adenohypophyseal 
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(AP) regions of non-suckled (NS) rats, and electroeluted (EE PRL) from fractions 1-6 of SDS-
PAGE. Data are means ± SEM. Letters (a-d) indicates P < 0.05 difference between fractions of EE 
PRL.  
(C-D). SDS-PAGE (left panels) and prolactin (PRL) content (ng/μl) of PRL variants (middle and 
right panels) released from peripheral (PR) and central (CR) AP regions of suckled (S) rats and 
electroeluted from fractions 1-6 of SDS-PAGE. Data are means ± SEM. Letters (a-d) indicates P < 
0.05 for the difference of PRL content between electroeluted fractions. 
region of NS rats was incubated with the EE PRL variants from the peripheral AP region 
of NS rats, medium levels (about 10 ng/μl) of PRL variants 1 and 6, and medium to low 
levels to PRL variants 2, 3, 4, and 5 were released. As a result of these effects, high levels 
of total PRL were released from the peripheral but not from the central AP region; indeed, 
total PRL release from the central AP region was significantly depressed, below the initial 
level. 
In figure 2B, the PRL content of the EE control PRL variants released from the central AP 
region of NS rats was low in fractions 1, 2 and 4 of CM, and high (>10 ng/μl) in fractions 3, 5 
and 6. Also, with respect to the effect of incubating lactotrophs from the central AP region of 
NS rats with the EE PRL variants from the peripheral AP region, increased release occurred 
only of PRL variants 1 and 6; and low levels occurred to PRL variants 2-5 from the central 
AP region; and only the PRL variant 6 was above the zero level, i.e., about 10 ng/μl. Overall, 
significantly lower levels of PRL than those contained both in the EE PRL variants and in 
those released from the peripheral region, were released from lactotrophs of both the central 
and peripheral AP regions. 
4.1.3 .Effects of EE PRL variants released from AP regions of lactating non-suckled (NS) 
rats upon the in vitro release of PRL variants from lactotrophs of suckled (S) rat APs 
The effect of incubating lactotrophs from AP regions of S rats with EE PRL variants released 
from AP regions of NS rats is shown in figures 2 C-D. In figure 2 C the PRL level was low in 
fraction 2, but medium to high levels, (about 10 ng/ μl) in fractions 1, 3-6; the amount of PRL 
released from the same AP region of S rats was around zero in fractions 2-5; and low in 
fractions 1 and 6. Overall, significantly lower amounts of PRL were released from the 
peripheral AP region of S rats. Also, as shown in figure 2D, the amount of EE PRL released 
from the central AP region of NS rat APs was low in fractions 1, 2 and 4 and high in 
fractions 3, 5 and 6; the total amount of released PRL from the peripheral AP region was 
zero in all fractions, and thus, it was significantly lower than that of the EE PRL. With 
respect to the amount of PRL released from the central AP region, only fractions 2 and 6 
showed high levels and the levels of the other fractions were much lowers (1-3 ng/μl). Thus, 
as with the effect of CM from the PR of NS rats, the amount of released PRL from the 
peripheral AP region of S rats, was less than zero, i.e., lower than that of the EE control PRL, 
and of the still lower amount of PRL released from the central AP region, whose levels also 
were lower than those of the EE PRL. 
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Figure 2. (A-B). Effect of the PRL variants electroeluted (EE PRL) in fractions 1-6 from SDS-PAGE of 
CM from the peripheral (PR) (panel A), and central (CR) (panel B), AP regions of non-suckled (NS) 
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(AP) regions of non-suckled (NS) rats, and electroeluted (EE PRL) from fractions 1-6 of SDS-
PAGE. Data are means ± SEM. Letters (a-d) indicates P < 0.05 difference between fractions of EE 
PRL.  
(C-D). SDS-PAGE (left panels) and prolactin (PRL) content (ng/μl) of PRL variants (middle and 
right panels) released from peripheral (PR) and central (CR) AP regions of suckled (S) rats and 
electroeluted from fractions 1-6 of SDS-PAGE. Data are means ± SEM. Letters (a-d) indicates P < 
0.05 for the difference of PRL content between electroeluted fractions. 
region of NS rats was incubated with the EE PRL variants from the peripheral AP region 
of NS rats, medium levels (about 10 ng/μl) of PRL variants 1 and 6, and medium to low 
levels to PRL variants 2, 3, 4, and 5 were released. As a result of these effects, high levels 
of total PRL were released from the peripheral but not from the central AP region; indeed, 
total PRL release from the central AP region was significantly depressed, below the initial 
level. 
In figure 2B, the PRL content of the EE control PRL variants released from the central AP 
region of NS rats was low in fractions 1, 2 and 4 of CM, and high (>10 ng/μl) in fractions 3, 5 
and 6. Also, with respect to the effect of incubating lactotrophs from the central AP region of 
NS rats with the EE PRL variants from the peripheral AP region, increased release occurred 
only of PRL variants 1 and 6; and low levels occurred to PRL variants 2-5 from the central 
AP region; and only the PRL variant 6 was above the zero level, i.e., about 10 ng/μl. Overall, 
significantly lower levels of PRL than those contained both in the EE PRL variants and in 
those released from the peripheral region, were released from lactotrophs of both the central 
and peripheral AP regions. 
4.1.3 .Effects of EE PRL variants released from AP regions of lactating non-suckled (NS) 
rats upon the in vitro release of PRL variants from lactotrophs of suckled (S) rat APs 
The effect of incubating lactotrophs from AP regions of S rats with EE PRL variants released 
from AP regions of NS rats is shown in figures 2 C-D. In figure 2 C the PRL level was low in 
fraction 2, but medium to high levels, (about 10 ng/ μl) in fractions 1, 3-6; the amount of PRL 
released from the same AP region of S rats was around zero in fractions 2-5; and low in 
fractions 1 and 6. Overall, significantly lower amounts of PRL were released from the 
peripheral AP region of S rats. Also, as shown in figure 2D, the amount of EE PRL released 
from the central AP region of NS rat APs was low in fractions 1, 2 and 4 and high in 
fractions 3, 5 and 6; the total amount of released PRL from the peripheral AP region was 
zero in all fractions, and thus, it was significantly lower than that of the EE PRL. With 
respect to the amount of PRL released from the central AP region, only fractions 2 and 6 
showed high levels and the levels of the other fractions were much lowers (1-3 ng/μl). Thus, 
as with the effect of CM from the PR of NS rats, the amount of released PRL from the 
peripheral AP region of S rats, was less than zero, i.e., lower than that of the EE control PRL, 
and of the still lower amount of PRL released from the central AP region, whose levels also 
were lower than those of the EE PRL. 
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Figure 2. (A-B). Effect of the PRL variants electroeluted (EE PRL) in fractions 1-6 from SDS-PAGE of 
CM from the peripheral (PR) (panel A), and central (CR) (panel B), AP regions of non-suckled (NS) 
 
Prolactin 106 
lactating rats upon the in vitro release of PRL variants by lactotrophs from AP regions of NS lactating 
rats. Data are means ± SEM. *Differences P < 0.05 versus control (EE PRL). (C-D). Effect of the PRL 
variants electroeluted (EE PRL) in fractions 1-6 from SDS-PAGE of CM from the peripheral (PR) (panel 
A), and central (CR) (panel B), AP regions of non-suckled (NS) lactating rats upon the in vitro release of 
PRL variants by lactotrophs from AP regions of suckled (S) lactating rats. Data are means ± SEM. 
*Differences P< 0.05 versus control (EE PRL). 
4.1.4. Effects of electroeluted PRL variants released from AP regions of lactating suckled 
(S) rats upon the in vitro release of PRL variants from lactotrophs of suckled (S) rat APs 
The effect of incubating lactotrophs from AP regions of S rats, with EE PRL variants released 
from AP regions of S rats is shown in figures 3 A-B. As shown in figure 3A, the EE PRL content 
from the peripheral AP region (c.f. Fig. 1C-D) showed medium to high levels ( 5>20 ng/μl), in 
all fractions except fraction 2; the amount of PRL released from the peripheral AP region of S 
rats was medium to high in fractions 1, 3 and 6 and medium to low in fractions 2, 4 and 5; and 
with respect to the amount of EE PRL released from the central AP region of S rats, (figure 3B), 
low and medium levels (2 and 8-10 ng/μl), were found in fractions 1, 2 and 3-6, respectively; 
and with respect to the effect of incubating lactotrophs from the central AP region of S rats 
with EE PRL variants from the same AP region of S rats, the levels were low in fractions 1 and 
2 and higher (around 10 ng/μl) in fractions 3-6; and after incubation with the EE PRL, medium 
to low levels (1-6 ng/μl) occurred in fractions 1 and 2, reduced levels (-10 ng) in fraction 4 and 
higher levels (8-10 ng/μl) in fractions 3, 5 and 6 of PRL variants were released from the 
peripheral AP region of S rats, below zero levels were released from fraction 4 of the same AP 
region; and there was only a small stimulatory effect on PRL variants 1, 2, 3, 5, and 6. EE control 
PRL reduced the release of PRL variants from the central AP region to below zero levels in all 
fractions. As a result of these effects, the total amount of PRL released from the peripheral AP 
region, and particularly from the central AP region, was significantly lower than that of both 
the EE PRL variants and of the amount released from the peripheral AP region. 
4.1.5. Effects of electroeluted PRL variants, released from AP regions of lactating, suckled (S) 
rats, upon the in vitro release of PRL variants from lactotrophs of non-suckled (NS) rat APs 
The effect of PRL variants released from AP regions of suckled rats upon the release of PRL 
variants from lactotrophs of the peripheral and the central AP regions of non-suckled rats is 
shown in figures 3 C-D. In Fig. 3C, the PRL content of the EE fractions from the CM of the 
peripheral AP regions of S rats was low to medium in fractions 2 and 3, medium to high in 
fractions 1, 4 and 5, and particularly high in fraction 6; and, as a result of incubation, the 
amount of PRL released from lactotrophs of the peripheral AP region of NS rats was low in 
fractions 1, 4-6, and high only in fractions 2 and 3; and from the central AP region of these 
rats, the amount of PRL released was particularly high in fractions 1 and 6; medium in 
fractions 2 and 3, and low in fractions 1 and 4-5. As a result of these interactions, the amount 
of total PRL released from both AP regions was significantly lower than the amount 
electroeluted from SDS-PAGE, but higher than that shown from NS and S rat AP regions, 
(c.f. Figs. 2 A-B), due to the effect of CM from NS and S rats.  
Autocrine and Paracrine Regulation of Prolactin Secretion  
by Prolactin Variants and by Hypothalamic Hormones 107 
 
Figure 3. (A-B). Effect of the PRL variants electroeluted (EE PRL) in fractions 1-6 from SDS-PAGE of 
CM from the peripheral (PR) (panel A), and central (CR) (panel B), AP regions of suckled (S) lactating 
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lactating rats upon the in vitro release of PRL variants by lactotrophs from AP regions of NS lactating 
rats. Data are means ± SEM. *Differences P < 0.05 versus control (EE PRL). (C-D). Effect of the PRL 
variants electroeluted (EE PRL) in fractions 1-6 from SDS-PAGE of CM from the peripheral (PR) (panel 
A), and central (CR) (panel B), AP regions of non-suckled (NS) lactating rats upon the in vitro release of 
PRL variants by lactotrophs from AP regions of suckled (S) lactating rats. Data are means ± SEM. 
*Differences P< 0.05 versus control (EE PRL). 
4.1.4. Effects of electroeluted PRL variants released from AP regions of lactating suckled 
(S) rats upon the in vitro release of PRL variants from lactotrophs of suckled (S) rat APs 
The effect of incubating lactotrophs from AP regions of S rats, with EE PRL variants released 
from AP regions of S rats is shown in figures 3 A-B. As shown in figure 3A, the EE PRL content 
from the peripheral AP region (c.f. Fig. 1C-D) showed medium to high levels ( 5>20 ng/μl), in 
all fractions except fraction 2; the amount of PRL released from the peripheral AP region of S 
rats was medium to high in fractions 1, 3 and 6 and medium to low in fractions 2, 4 and 5; and 
with respect to the amount of EE PRL released from the central AP region of S rats, (figure 3B), 
low and medium levels (2 and 8-10 ng/μl), were found in fractions 1, 2 and 3-6, respectively; 
and with respect to the effect of incubating lactotrophs from the central AP region of S rats 
with EE PRL variants from the same AP region of S rats, the levels were low in fractions 1 and 
2 and higher (around 10 ng/μl) in fractions 3-6; and after incubation with the EE PRL, medium 
to low levels (1-6 ng/μl) occurred in fractions 1 and 2, reduced levels (-10 ng) in fraction 4 and 
higher levels (8-10 ng/μl) in fractions 3, 5 and 6 of PRL variants were released from the 
peripheral AP region of S rats, below zero levels were released from fraction 4 of the same AP 
region; and there was only a small stimulatory effect on PRL variants 1, 2, 3, 5, and 6. EE control 
PRL reduced the release of PRL variants from the central AP region to below zero levels in all 
fractions. As a result of these effects, the total amount of PRL released from the peripheral AP 
region, and particularly from the central AP region, was significantly lower than that of both 
the EE PRL variants and of the amount released from the peripheral AP region. 
4.1.5. Effects of electroeluted PRL variants, released from AP regions of lactating, suckled (S) 
rats, upon the in vitro release of PRL variants from lactotrophs of non-suckled (NS) rat APs 
The effect of PRL variants released from AP regions of suckled rats upon the release of PRL 
variants from lactotrophs of the peripheral and the central AP regions of non-suckled rats is 
shown in figures 3 C-D. In Fig. 3C, the PRL content of the EE fractions from the CM of the 
peripheral AP regions of S rats was low to medium in fractions 2 and 3, medium to high in 
fractions 1, 4 and 5, and particularly high in fraction 6; and, as a result of incubation, the 
amount of PRL released from lactotrophs of the peripheral AP region of NS rats was low in 
fractions 1, 4-6, and high only in fractions 2 and 3; and from the central AP region of these 
rats, the amount of PRL released was particularly high in fractions 1 and 6; medium in 
fractions 2 and 3, and low in fractions 1 and 4-5. As a result of these interactions, the amount 
of total PRL released from both AP regions was significantly lower than the amount 
electroeluted from SDS-PAGE, but higher than that shown from NS and S rat AP regions, 
(c.f. Figs. 2 A-B), due to the effect of CM from NS and S rats.  
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Figure 3. (A-B). Effect of the PRL variants electroeluted (EE PRL) in fractions 1-6 from SDS-PAGE of 
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rats upon the in vitro release of PRL variants by lactotrophs from AP regions of suckled (S) lactating 
rats. Data are means ± SEM. *Differences P < 0.05 versus control (EE PRL). 
(C-D). Effect of the PRL variants electroeluted (EE PRL) in fractions 1-6 from SDS-PAGE of CM from the 
peripheral (PR) (panel A), and central (CR) (panel B), AP regions of suckled (S) lactating rats upon the 
in vitro release of PRL variants by lactotrophs from AP regions of non-suckled (NS) lactating rats. Data 
are means ± SEM. *Differences P < 0.05 versus control (EE PRL).  
The PRL content of the electroeluted fractions from the central AP region of S rats was low in 
fractions 1 and 2, and high in fractions 3-6 of CM (Figure 3D). However, the amount of PRL 
released mainly from the peripheral, and in part also by the central AP region, was higher by 
the peripheral than the EE PRL variants in fractions 1, 2 and 5, 6; this level was about the 
same in fraction 3, and lower in fraction 4; and with respect to the amount of PRL released 
from the central AP region it was higher than the electroeluted hormone in fractions 1 and 2, 
lower in fraction 3 and 4, and about the same high level in fractions 5 and 6. As a result of 
these effects, an increased release of the hormone occurred from both AP regions, particularly 
from the peripheral region, whose levels, except from that of fraction 3, were significantly 
higher than those of the EE PRL as well as of that released from the central AP region, whose 
levels in fractions 1 and 2 were also higher than those of the EE PRL.  
4.2. Effects of hypothalamic hormones upon the release of PRL variants from AP 
regions of NS and S rats 
4.2.1. Dose-response effects of dopamine 
The effects of dopamine (DA) upon the release of PRL variants 1-6 from the lactotrophs of 
the peripheral and central AP regions of non-suckled (NS) and suckled (S) rats are shown in 
figures 4 A-D. As shown in Fig. 4 A, as compared with the amount of PRL released without 
DA, the low dose of DA (0.5 μM) inhibited the release of PRL variant 2 and stimulated PRL 
variants 3 and 5 of the peripheral AP regions of NS rats, and showed no effect upon the 
release of PRL variants 4 and 6 from the same AP region. Higher doses of DA increased the 
release of PRL variants in fractions 3 and 5, but 1.5 μM DA inhibited the release of PRL 
variants 1 and 6. As a result of these effects, the total amount of released PRL from the 
peripheral AP region of NS rats was decreased only by the highest dose of DA (1.5 μM) but 
not by the lower and intermediate doses. 
The effects of dopamine upon the release of PRL variants from lactotrophs of the central AP 
regions of non-suckled rats are shown in figure 4 B. The low dose of DA inhibited the 
release of the PRL variant 1 and showed no effect upon PRL variants 2 and 4, but it 
promoted a strong release of PRL variants 3, 5 and 6 from the central AP regions of NS rats; 
1.0 μM dopamine provoked decreased release of PRL variant 1, and increased release of 
PRL variants 2, 3, 5 and 6. With 1.5 μM DA, decreased release occurred in fraction 1, and 
increased release in fractions 3, 5 and 6. 
With respect to the effects of DA upon the release of PRL variants from the peripheral AP 
region of suckled rats APs, as shown in figure 4 C, at the low dose of DA inhibition occurred in 
fraction 3, stimulation of PRL in fractions 2, 5 and 6, and no effect on PRL variants in fractions 
Autocrine and Paracrine Regulation of Prolactin Secretion  
by Prolactin Variants and by Hypothalamic Hormones 109 
1 and 4. In the presence of 1.0 μM DA there was inhibition of PRL variants in fraction 3, no 
effect in fraction 4, and stimulation in fractions 2 and 5, 6. The total amount of PRL released 
from the peripheral AP region of S rats was decreased only by 1.0 and 1.5 μM DA, but not by 
the lower dose. The effects of DA upon the release of PRL variants from lactotrophs of  
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rats upon the in vitro release of PRL variants by lactotrophs from AP regions of suckled (S) lactating 
rats. Data are means ± SEM. *Differences P < 0.05 versus control (EE PRL). 
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are means ± SEM. *Differences P < 0.05 versus control (EE PRL).  
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the central AP region of suckled rats are shown in figure 4 D. The low dose of DA inhibited 
the release of PRL in fraction 1, had no effect upon the release of the PRL variant 3, but it 
promoted the release of PRL variants 2, 4 and 6; the intermediate dose of DA also inhibited 
the release of PRL from fraction 1, and promoted the release of fractions 2, 4 and 6; 1.5 μM 
DA inhibited the release of PRL fractions 1 and 2, but it promoted the release of fractions 3-6. 
4.2.2. Dose-response effects of TRH 
The effects of different doses of TRH, i.e., 0.1, 1.0 and 10 μM, upon the release of PRL 
variants from AP regions of NS and S rats are shown in Figs. 5 A-D and the values obtained 
after TRH, are compared with the control values of PRL that were released in the absence of 
TRH. As compared with control values, without TRH, 0.1 μM TRH provoked increased 
release, i.e., stimulation of PRL, in fractions 1, 3-6; and inhibition in fraction 2 from the 
peripheral AP region of NS rats (Fig. 5 A). The effect of 1.0 and 10 μM TRH was to increase 
the release of all PRL variants 1-6. 
The effect of TRH upon the release of PRL variants from the central AP region of NS rats is 
shown in Fig. 5 B. With 0.1 μM TRH, decreased release of PRL occurred in fraction 1, no 
change in fractions 2 and 4, and increased release in fractions 3, 5 and 6. Also, with respect 
to the effect of the higher doses of TRH, increased release occurred to PRL in all fractions 1-
6. Fig. 5 C, shows the effect of the low dose of TRH upon the release of PRL variants from 
the peripheral AP region of S rats. As shown there, release of PRL variants 1, 4, 5 and 6 was 
stimulated, and there was no effect on PRL variants 2 and 3; and with respect to the effect of 
the low dose of TRH upon the release of PRL variants from the central AP region of S rats 
(Fig. 5 D) a decreased release of PRL variant 1; increased release of PRL variants 3, 4 and 6, 
and no effect upon PRL variants 2 and 5 were observed.  
4.2.3. Dose-response effects of oxytocin 
The dose-response effects of oxytocin (OT) upon the release of PRL variants from NS rat 
APs are shown in Figs. 6 A-D. With 0.1 μM oxytocin, increased release of PRL, relative to the 
control, occurred only for PRL variants 3, 5 and 6 of the PR region of NS rat APs, but the 
release of PRL in fractions 1, 2 and 4 was inhibited. With respect to the effect of 1.0 μM of 
oxytocin upon the release of PRL variants from the peripheral AP region of NS rats (Fig. 6 
A), there was increased release of PRL variants 3, 5 and 6 and reduce release of PRL variants 
1, 2 and 4 from lactotrophs of the peripheral AP region. The high dose of OT, i.e., 10 μM 
resulted in increased release of PRL variants 2, 3, 5 and 6 from the peripheral AP region and 
to variants 1-6 from the central AP region of NS rats (Fig. 6 B); and with respect to the effect 
of the 10 μM OT upon the release of PRL from AP regions of S rats, increased release from 
the peripheral region occurred for PRL variants 1, 2, 5 and 6; whit no effect on release of PRL 
variants 3 and 4. Finally, with respect to the effect of the high dose of OT upon AP regions of 
NS rats, there was increased release of fractions 2, 3, 5 and 6 and no effect on fractions 1 and 
3 from the peripheral AP region of NS rats; and with the exception of fraction 5 in which 
there was no effect, increased release occurred in all the other fractions from the central AP 
region of the NS rats; and upon the effect of the same dose of oxytocin upon the release of 
PRL variants from the peripheral AP region of S rats, i.e., Fig. 6 C, also, increased release 
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occurred to PRL variant 5; inhibition to PRL variant 1, and no effect upon PRL variants 2, 3, 
4 and 6. And with respect to the effect of the same dose of OT i.e., 1.0 μM upon the release of 
PRL variants from the central AP region of suckled rats, i.e., Fig. 6 D, lower panel, increased 
release occurred to PRL variants 1, 2, 5 and 6, and no effect upon PRL variants 3 and 4; and 
with respect to the effect of the same dose of OT upon the release of PRL variants from the  
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release of PRL variants by lactotrophs from AP regions of NS and S lactating rats. Data are means ± 
SEM. *Differences P < 0.05 versus control (PRL content without TRH). 
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the central AP region of suckled rats are shown in figure 4 D. The low dose of DA inhibited 
the release of PRL in fraction 1, had no effect upon the release of the PRL variant 3, but it 
promoted the release of PRL variants 2, 4 and 6; the intermediate dose of DA also inhibited 
the release of PRL from fraction 1, and promoted the release of fractions 2, 4 and 6; 1.5 μM 
DA inhibited the release of PRL fractions 1 and 2, but it promoted the release of fractions 3-6. 
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release, i.e., stimulation of PRL, in fractions 1, 3-6; and inhibition in fraction 2 from the 
peripheral AP region of NS rats (Fig. 5 A). The effect of 1.0 and 10 μM TRH was to increase 
the release of all PRL variants 1-6. 
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shown in Fig. 5 B. With 0.1 μM TRH, decreased release of PRL occurred in fraction 1, no 
change in fractions 2 and 4, and increased release in fractions 3, 5 and 6. Also, with respect 
to the effect of the higher doses of TRH, increased release occurred to PRL in all fractions 1-
6. Fig. 5 C, shows the effect of the low dose of TRH upon the release of PRL variants from 
the peripheral AP region of S rats. As shown there, release of PRL variants 1, 4, 5 and 6 was 
stimulated, and there was no effect on PRL variants 2 and 3; and with respect to the effect of 
the low dose of TRH upon the release of PRL variants from the central AP region of S rats 
(Fig. 5 D) a decreased release of PRL variant 1; increased release of PRL variants 3, 4 and 6, 
and no effect upon PRL variants 2 and 5 were observed.  
4.2.3. Dose-response effects of oxytocin 
The dose-response effects of oxytocin (OT) upon the release of PRL variants from NS rat 
APs are shown in Figs. 6 A-D. With 0.1 μM oxytocin, increased release of PRL, relative to the 
control, occurred only for PRL variants 3, 5 and 6 of the PR region of NS rat APs, but the 
release of PRL in fractions 1, 2 and 4 was inhibited. With respect to the effect of 1.0 μM of 
oxytocin upon the release of PRL variants from the peripheral AP region of NS rats (Fig. 6 
A), there was increased release of PRL variants 3, 5 and 6 and reduce release of PRL variants 
1, 2 and 4 from lactotrophs of the peripheral AP region. The high dose of OT, i.e., 10 μM 
resulted in increased release of PRL variants 2, 3, 5 and 6 from the peripheral AP region and 
to variants 1-6 from the central AP region of NS rats (Fig. 6 B); and with respect to the effect 
of the 10 μM OT upon the release of PRL from AP regions of S rats, increased release from 
the peripheral region occurred for PRL variants 1, 2, 5 and 6; whit no effect on release of PRL 
variants 3 and 4. Finally, with respect to the effect of the high dose of OT upon AP regions of 
NS rats, there was increased release of fractions 2, 3, 5 and 6 and no effect on fractions 1 and 
3 from the peripheral AP region of NS rats; and with the exception of fraction 5 in which 
there was no effect, increased release occurred in all the other fractions from the central AP 
region of the NS rats; and upon the effect of the same dose of oxytocin upon the release of 
PRL variants from the peripheral AP region of S rats, i.e., Fig. 6 C, also, increased release 
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occurred to PRL variant 5; inhibition to PRL variant 1, and no effect upon PRL variants 2, 3, 
4 and 6. And with respect to the effect of the same dose of OT i.e., 1.0 μM upon the release of 
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release occurred to PRL variants 1, 2, 5 and 6, and no effect upon PRL variants 3 and 4; and 
with respect to the effect of the same dose of OT upon the release of PRL variants from the  
 
Figure 5. A-D. Effect of dose-response of the PRL variants electroeluted in fractions 1-6 from SDS-
PAGE of CM from the peripheral (PR) and the central (CR) regions of adenohypophysis (AP) of suckled 
(S) and non-suckled (NS) lactating rats incubated with 0.1, 1.0 and 10 μM of TRH, upon the in vitro 
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same, i.e., peripheral AP region of S rats, increased release occurred to PRL variants 1, 2 and 5, 
6; and no effect upon PRL variants 3 and 4. Finally, with respect to the effect of the high dose 
of OT upon the release of PRL from lactotrophs of the PR region of S rats, increased release 
occurred to PRL variants 1, 2, 5 and 6, with no change of PRL variants 3 and 4; the high dose of 
OT resulted in increased release of all PRL variant from lactotrophs of the central AP region. 
 
Figure 6. A-D. Effect of dose-response of the PRL variants electroeluted in fractions 1-6 from SDS-
PAGE of CM from the peripheral (PR) and the central (CR) regions of adenohypophysis (AP) of suckled 
(S) and non-suckled (NS) lactating rats incubated with 0.1, 1.0 and 10 μM of oxytocin (OT), upon the in 
vitro release of PRL variants by lactotrophs from AP regions of NS and S lactating rats. Data are means ± 
SEM. *Differences P < 0.05 versus control (PRL content without OT). 
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4.3. Electrical activity upon neurons 
4.3.1. Effect of conditioned medium from the lateral and central AP regions of S rats upon 
cultured sympathetic neurons 
Cultured sympathetic neurons, previously incubated with Fluo 4, to record variations of 
intracellular [Ca2+], showed clear increases of [Ca2+] within 60 sec of adding conditioned 
medium (CM) from lactating rats, thus indicating that these neurons were activated by the 
CM (Figure 7). These effects did not occurred when the neurons were incubated with 
medium from male rat APs (data not shown). 
 
Figure 7. Effect of 60 s exposure of conditioned medium from the peripheral region of suckled rat APs 
(CM PRS).upon intracellular calcium concentration in cultured sympathetic neurons. 
4.3.2. Effect of conditioned medium from the lateral AP region of suckled and of male rat 
APs upon electrical activity of male rat lactotrophs, and of astrocytes from the hippocampus 
and medial preoptic area 
As shown in Figures 8 A-D, CM of the peripheral region (CMPR) from male rat APs had no 
effect upon electrical activity of hippocampal astrocytes (Fig. 8A) whereas application of CM 
from lactating, suckled rats provoked a cationic inward current, shown as a downward 
deflection in male lactotrophs (Fig. 8C), as well as in astrocytes from the hippocampus and 
medial preoptic area (Figs. 8B, D). These responses remained for several seconds after 
washing CMPR out. 
4.3.3. Effect of conditioned medium from lactating and male rat APs upon [Ca 2+] 
concentration in astrocytes from the hippocampus 
As shown in Figure 9, CM from lactating, suckled rats (Fig. 9A), but not from male rat APs 
(Fig. 9B) or from non-suckled rats (data not shown) provoked an increased [Ca2+] in 
hippocampal astrocytes similar to that induced by application of 120 mM K+ (see Fig. 9C). 
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same, i.e., peripheral AP region of S rats, increased release occurred to PRL variants 1, 2 and 5, 
6; and no effect upon PRL variants 3 and 4. Finally, with respect to the effect of the high dose 
of OT upon the release of PRL from lactotrophs of the PR region of S rats, increased release 
occurred to PRL variants 1, 2, 5 and 6, with no change of PRL variants 3 and 4; the high dose of 
OT resulted in increased release of all PRL variant from lactotrophs of the central AP region. 
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Figure 8. (A-D). Effect of a 1 h incubation with conditioned medium (CM), from the peripheral region 
(PR) of male rats (A), and from suckled lactating rat APs (B-D) upon hippocampal astrocytes (B) , 
neurons from the preoptic area (D) and upon male rat lactotrophs (C). 
 
 
Figure 9. (A-C). Effect of conditioned media from the peripheral AP region of suckled lactating rats 
(CMPR) and of male rats upon intracellular calcium concentration in hippocampal astrocytes (A-B). 
Arrow in C indicates the application of 120 mM K+. Images in D are from astrocytes in A-C. 
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5. Conclusions  
This study confirms that PRL variants ranging from 7 to 97 kDa are released from tissue 
fragment of each AP region of the anterior pituitary gland of non-suckled and suckled lactating 
rats. When these variants are electroeluted from SDS-PAGE and then incubated with 
lactotrophs from each AP region of the same type of rats, they exert different effects (promotion, 
inhibition or no effect) upon the release of PRL variants from lactotrophs of both AP regions of 
NS and S lactating rats. In support of this was the fact that the immunoprecipitation of PRL 
contained in the CM from lactating rats, prevented the effects of PRL variants upon PRL 
release. Thus, these results indicate that autocrine regulatory effects are exerted by PRL 
variants upon the release of other variants of the hormone from lactating rat APs, and they are 
in accord with previous studies showing autoregulation of PRL secretion (Nagy et al., 1991; 
Nagy & Frawley, 1990; Diaz et al., 2002; Spies & Clegg, 1971; Hebert et al., 1979; Melmed et al., 
1980). Similar effects on male lactotrophs by CM from pregnant and lactating females and 
steroid-treated castrated males or females, but not by CM from intact males or by a PRL 
standard were reported previously (Huerta-Ocampo et al., 2007; Mena et al., 2010). 
Prior to fractionation the total PRL variants from both, the central and peripheral AP regions of 
NS rats stimulated the release of PRL from the peripheral region, but they inhibited its release 
from the central AP region. However, when CM from lactating rats was fractionated by SDS-
PAGE, eluates of fractions 5 and 6 containing 23-25 kDa PRL had the greatest effect on PRL 
release, although weaker immunoreactive bands with lower, or even inhibitory activity, were 
also detected in the upper gel fractions. In addition, separation by SDS-PAGE and 
electroelution of PRL variants indicated that CM from the lactating rat pituitary contains 37 to 
46 kDa PRL variants as well as 23 to 25 kDa PRL variants, that exert different effects upon the 
release of other PRL variants from the lactating rat pituitary and from APs of rats in different 
conditions Huerta-Ocampo et al., 2007; Mena et al., 2010). Therefore, the present study shows 
that the lactating rat pituitary produces PRL variants that are absent or deficient in the male 
pituitary gland and in the PRL Standard, even though the AP of male and of other types of 
rats, do respond to stimulatory factors released from the anterior pituitary of lactating rats 
(Mena et al., 2010). The results presented here, together with those in our previous study, also 
indicate that several PRL variants are produced and released by the lactating rat pituitary 
(Denef, 1988; Sinha 1992; Asawaroengchai et al., 1978); this hormonal heterogeneity may be 
physiologically very relevant in the context of autoregulatory mechanisms determining the 
wide range of PRL effects under different physiological conditions (Schwartz & Cherny, 1992; 
Schwartz, 2000; Sinha, 1992) and upon different structures (Ben-Jonathan et al., 2001; Lorenson 
& Walker, 2001; Ho et al., 1993; Celotti et al., 1997). 
In addition to the regulatory effects of PRL variants from lactating rats upon the release of 
the hormone, further evidence of these effects was obtained when CM’s from lactating rats 
were treated with phosphatase or with endoglycosidase which increased their ability, i.e., 
that of the PRL variants present in them to stimulate PRL release from lactating rat APs, 
similar to the effect shown previously upon male rat lactotrophs (Mena et al., 2010). These 
effects of dephosphorylation and deglycosylation of CM provide additional evidence that 
PRL variants in CM are responsible for the effects upon lactating rat lactotrophs. PRL 





Figure 8. (A-D). Effect of a 1 h incubation with conditioned medium (CM), from the peripheral region 
(PR) of male rats (A), and from suckled lactating rat APs (B-D) upon hippocampal astrocytes (B) , 
neurons from the preoptic area (D) and upon male rat lactotrophs (C). 
 
 
Figure 9. (A-C). Effect of conditioned media from the peripheral AP region of suckled lactating rats 
(CMPR) and of male rats upon intracellular calcium concentration in hippocampal astrocytes (A-B). 
Arrow in C indicates the application of 120 mM K+. Images in D are from astrocytes in A-C. 
Autocrine and Paracrine Regulation of Prolactin Secretion  
by Prolactin Variants and by Hypothalamic Hormones 115 
5. Conclusions  
This study confirms that PRL variants ranging from 7 to 97 kDa are released from tissue 
fragment of each AP region of the anterior pituitary gland of non-suckled and suckled lactating 
rats. When these variants are electroeluted from SDS-PAGE and then incubated with 
lactotrophs from each AP region of the same type of rats, they exert different effects (promotion, 
inhibition or no effect) upon the release of PRL variants from lactotrophs of both AP regions of 
NS and S lactating rats. In support of this was the fact that the immunoprecipitation of PRL 
contained in the CM from lactating rats, prevented the effects of PRL variants upon PRL 
release. Thus, these results indicate that autocrine regulatory effects are exerted by PRL 
variants upon the release of other variants of the hormone from lactating rat APs, and they are 
in accord with previous studies showing autoregulation of PRL secretion (Nagy et al., 1991; 
Nagy & Frawley, 1990; Diaz et al., 2002; Spies & Clegg, 1971; Hebert et al., 1979; Melmed et al., 
1980). Similar effects on male lactotrophs by CM from pregnant and lactating females and 
steroid-treated castrated males or females, but not by CM from intact males or by a PRL 
standard were reported previously (Huerta-Ocampo et al., 2007; Mena et al., 2010). 
Prior to fractionation the total PRL variants from both, the central and peripheral AP regions of 
NS rats stimulated the release of PRL from the peripheral region, but they inhibited its release 
from the central AP region. However, when CM from lactating rats was fractionated by SDS-
PAGE, eluates of fractions 5 and 6 containing 23-25 kDa PRL had the greatest effect on PRL 
release, although weaker immunoreactive bands with lower, or even inhibitory activity, were 
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rats, do respond to stimulatory factors released from the anterior pituitary of lactating rats 
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that of the PRL variants present in them to stimulate PRL release from lactating rat APs, 
similar to the effect shown previously upon male rat lactotrophs (Mena et al., 2010). These 
effects of dephosphorylation and deglycosylation of CM provide additional evidence that 
PRL variants in CM are responsible for the effects upon lactating rat lactotrophs. PRL 
released from the AP of lactating and non-lactating rats is phosphorylated and glycosylated 
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and thus, it is less bioactive than the dephosphorylated and deglycosylated variants (Ho et 
al., 1993a; Sinha, 1995, Ho et al., 1993b). 
In the present study we also analyzed whether the ability of the hypothalamic hormones 
dopamine, TRH and oxytocin, as established by many previous in vivo and in vitro studies 
(Mena et al., 1989), to regulate the release of AP PRL, would be manifest by their direct 
action upon the lactotrophs and interaction with the autocrine actions of PRL variants; and 
whether these effects would finally promote or inhibit the release of PRL variants, thereby 
regulating the release of the hormone. The results obtained showed that the effects of the 
hypothalamic hormones were exerted upon the lactotrophs both by interacting with the 
autocrine actions of the PRL variants, and also by regulating the release of PRL variants 
from these cells. Thus, when a high dose (1.5 μM) of DA was applied directly upon the 
lactotrophs of NS and S rats, the secretion of most PRL variants from both AP regions of 
non-suckled and suckled rats was inhibited, as previously reported by others (Nagy et al., 
1991), whereas the lower dose (0.5 μM) slightly stimulated the release of PRL variants, 
mainly from the central AP region of suckled rats. TRH provoked an increased release of 
some PRL variants from both the central and peripheral AP regions of NS and S rats, and 
OT at 1 and 10 μM, showed an intense stimulatory effect, particularly of 23-34 kDa PRL, 
from both AP regions of non-suckled and suckled lactating rat APs. Thus, these effects of 
hypothalamic hormones upon the release of PRL variants may also regulate, and thus 
interact with, the autocrine effects exerted by the PRL variants and lead to an integrative 
regulation of PRL secretion (Mena et al., 1989; Mena et al., 2011). 
This study shows that when pituitaries from male rats are incubated for a short period of 
time in conditioned media from each pituitary region of lactating rats, either suckled or non-
suckled, there is a significant dose-dependent increase of PRL release from male rat 
lactotrophs. Also, as shown previously (Mena et al., 2010) our results obtained by Western 
blotting confirm that CM from lactating rat pituitary contains several prolactin variants, i.e., 
37-46 kDa as well as 16-25 kDa, capable of stimulating PRL release from male rat pituitary. 
In addition, CM obtained from male rat pituitary regions as well as PRL standard have no 
significant stimulatory effect on PRL secretion of pituitary regions from either lactating or 
male rats (Huerta-Ocampo, 2007; Mena et al., 2010), this suggests that the male pituitary 
gland is deficient in the same PRL variants, and of other possible factors, that are released 
by the lactating rat AP, even though it does contain receptors for stimulating factors 
released from the anterior pituitary of lactating rats (Mena et al., 2011; Mena et al., 2012a).  
Based upon these results, it was of interest to determine whether production and release of 
pituitary prolactin variants contained in CM from lactating rats under different conditions, 
and their effects upon PRL release from incubated male AP regions, vary depending on the 
animal’s physiological condition, and whether CM’s from lactating or male rats exert effect 
upon brain structures, i.e., astrocytes in the hippocampus and medial preoptic area, and of 
sympathetic neurons (Fiordelisio & Hernandez-Cruz, 2002). The results obtained from 
Electrical recording of these astrocytes showed that astrocytic activation occurred upon 
exposure to CM from the lateral and central regions of lactating suckled rat APs 
(Hernández-Morales M & García-Colunga, 2009).  
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In conclusion, the results of the present and previous studies suggest that, in addition to 
regulation by hypothalamic and other influences, the release of PRL variants from the 
lactating rat AP is also regulated by autocrine influences exerted upon the gland by the 
previously released PRL variants; furthermore in parallel and interacting with such autocrine 
regulation, the effect of the hypothalamic hormones on PRL release is also regulated through 
the same mechanism i.e., the stimulation or inhibition of the release of PRL variants from the 
pituitary gland. Moreover, the present results confirm previous findings (Huerta-Ocampo, 
2007; Mena et al., 2010; Mena et al., 2011; Möderscheim et al., 2007, Mena et al., 2012a), that 
CM from lactating rats, contain prolactin variants capable of inducing rapid release of PRL 
from the untreated male rat pituitary, and that they can also activate of astrocytes and 
neurons in different areas of the central and peripheral nervous system (Mena et al, 2012b).  
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1. Introduction 
Light, being an environmental factor, has a significant effect on reproductive functions of 
animals exhibiting sensitivity to changes of the day length [1]. Among mammals there are 
many species displaying seasonality of reproduction, and given that, two models of seasonal 
sensitivity were distinguished. The first one refers to long-day animals (horses), in which 
reproductive processes are induced by lengthening days, i.e. in the spring. The other model 
concerns short-day animals, which include sheep, goats and deer; in these animals the 
reproduction system is stimulated and estrus takes place in the autumn and winter period 
[2]. In sheep the phenomenon of seasonality relates not only to reproduction but also to 
lactation. Following the process of mammogenesis in mammals, a mammary gland is 
developed, which is a complex cutaneous acinotubular gland [3]. The endocrine mechanism 
of entering and maintenance of lactation in sheep involves a number of hormones, which 
proves that the process relies basically on the activity of hypothalamus and pituitary gland 
[4,5,6]. One of the principal hormones conditioning both triggering and maintenance of 
lactation, synthesis of milk proteins, fat and immunoglobulins is prolactin (PRL), which is 
secreted chiefly by lactotroph cells of the anterior pituitary gland [7]. Prolactin is also 
produced locally by the mammary gland of mammals and does not differ immunologically 
from prolactin produced by the pituitary gland [8]. An important role in the process of 
mammogenesis and lactogenesis is assigned also to glycocorticoids, insulin and growth 
hormone and estrogens [9].  
The fundamental feature of all living organisms is the ability to receive and process 
information about changes in the environment. Succession of physiological changes is 
synchronized with changes of environmental conditions and conditioned by the activity of 
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the biological clock [10,11]. It is confirmed via seasonal changes of the activity of the 
hypothalamic-pituitary axis in animals kept under permanent light conditions. Thanks to 
constant and cyclical factors physiological processes can be synchronized with a relevant 
season of the year. The synthesis of melatonin is a biochemical signal informing the 
organism about changing light conditions [12,13,14]. Numerous studies go to show the 
existence of a molecular mechanism involved in deciphering of the melatonin signal which 
is found in the SCN (Suprachiasmatic Nucleus) and in the PT (Pars Tuberalis). Both in the 
SCN and PT there are several dozens of genes of the biological clock such as Per1, Per2 or 
Cry 1, Cry2, which are associated with each other [15,16]. The melatonin profile changing in 
a 24-hour cycle affects the rhythmical changes in the expression of the clock genes, which is 
reflected via their different amounts of mRNA in the PT and SCN. The maximum 
expression of the Cry1 gene occurs during the dusk period parallel to the growth of the 
melatonin concentration, whereas the expression of the Per1 gene is induced at dawn [17,18].  
2. The effect of diverse photoperiod and exogenous melatonin on the 
secretion of prolactin under in vivo conditions 
According to Misztal et al. (1999) [19] the modulating effect of melatonin on the secretion of 
prolactin can be exerted via two various mechanisms. The first one refers to the circadian 
rhythm and applies probably only to the prolactin stored in lactotrph cells of the pituitary 
gland. Tuberalin - a factor produced in the infundibular part of the gland probably triggers 
the expression of the PRL gene in lactotroph cells [20]. The daily secretion of prolactin is also 
controlled by the dopaminergic system because even the short-lasting growth of prolactin 
under the influence of melatonin is observed only in a situation when the activity of the 
dopaminergic system is weakened [21]. It must be stressed that the daily rhythm of 
prolactin displays a high seasonal variability; in the spring a higher concentration of the 
hormone is observed in morning and evening hours, and in the summer the daily secretion 
peak falls at night. In the autumn the rhythm has a two-phase character, like in the spring, 
whereas the concentration rises in morning and evening hours. In the winter, though, no 
specific release of prolactin is observed at all.  
The other mechanism for regulation of the prolactin secretion is related to its circannual 
secretion rhythm, when melatonin, owing to its lipophilic, exerts a direct effect on lactotroph 
cells of the pituitary gland and, accordingly, on the secretion of prolactin [19,22,23]. Under 
natural conditions the maximum PRL concentration in the sheep’s bloodstream is recorded 
in the long-day period; whereas at this time the melatonin level drops. The lowest level of 
prolactin is observed during short days, when the melatonin level is the highest [24,25] 
Shortening of the day length or prolonged administration of melatonin in the period of 
physiologically increased concentration of prolactin leads to a reduced secretion of this 
hormone [1,13]. Seasonal changes in the prolactin secretion in the lactation period in sheep 
undoubtedly affect milk yields. Rhythmical changes of the level of prolactin and melatonin 
throughout the year were observed mainly in barren sheep and rams; however, studies 
carried out in the group of sheep used for dairy production confirmed the presence of the 
 
The Effect of Physiological and Environmental Factors on the Prolactin Profile in Seasonally Breeding Animals 
 
123 
seasonal rhythm of these two hormones. The experiments demonstrated a definite influence 
of the day length on the parameters of ewes’ milk yields. Mothers entering lactation in the 
period of shortening days yielded 50% less milk as compared to ewes milked in the long-
day period. The drop in milk yields in the shortening photoperiod resulted from the change 
in the prolactin secretion. The highest PRL concentration in sheep milked in the long-day 
period was identified in May 312.6 ± 45.2 ng/ml, at this time the concentration of melatonin 
amounted to 33.5± 11.2 ng/ml. As lactation progressed and days became shorter, the 
concentration of prolactin declined, and that of melatonin increased (table 1).  
 
Months 
May June July August September 
x  SE x  SE x  SE x  SE x  SE 
Melatonin 
pg/ml 
133.5 11.3 77.8 18.9 73.3 15.1 124.7 21.6 91.3 22.2 
Prolactin 
ng/ml 
312.6 45.2 185.7 34.7 247.0 48.9 151.6 33.9 43.9 10.1 
Table 1. Changes in the concentration of melatonin and prolactin in sheep milked in the long-day 
period 
As regards sheep lambed and milked in the short-day period and kept under the natural 
photoperiod conditions the highest level of prolactin was observed in August, i.e. 124.0 ± 
48.8 ng/ml. In the first month of milking the concentration of prolactin in sheep 
corresponded to its seasonal rhythm and declined in subsequent months (table 2).  
 
Months 
August September October November 
x  SE x  SE x  SE x  SE 
Melatonin 
pg/ml 
87.8 15.5 82.3 15.0 77.5 16.1 93.2 17.4 
Prolactin 
ng/ml 
124.6 48.8 60.5 11.1 30.8 9.7 16.8 4.1 
Table 2. Changes in the concentration of melatonin and prolactin in sheep milked in the short-day period 
As the light day shortened, the secretion of PRL declined as the level of the hormone in 
September was lower by 15% as compared to the concentration observed in August. A 
distinct drop in the prolactin level was observed in the period of the last two months of 
lactation, i.e. in October and November, and amounted respectively to 30.8 ± 9.7 ng/ml and 
16.8 ± 4.1 ng/ml. The low concentration of prolactin already in the first month of milking and 
systematic growth of the melatonin secretion in the period of shortening days exerted an 
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September was lower by 15% as compared to the concentration observed in August. A 
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16.8 ± 4.1 ng/ml. The low concentration of prolactin already in the first month of milking and 
systematic growth of the melatonin secretion in the period of shortening days exerted an 





group of sheep kept under artificially simulated long-day conditions, 16 hours of light and 8 
hours of darkness (16L:8D), in the period from August to November, the concentration of 
PRL already in the second month of milking, i.e. from September to November, decreased. 
In October and November a sharp drop in the concentration of prolactin was observed. The 
parameters of milk yields of sheep kept under conditions of artificially extended light day 
decreased proportionately to the drop in the concentration of prolactin (table 3).   
 
Months 
August September October November 
x  SE x  SE x  SE x  SE 
Melatonin 
pg/ml 
60.4 19.8 17.6 7.6 4.4 1.1 17.0 5.5 
Prolactin 
ng/ml 
132.7 37.4 147.9 22.4 84.3 12.5 38.3 15.2 
Table 3. Changes in the concentration of melatonin and prolactin in sheep kept under simulated long-
day conditions -16L:8D 
In the short-day period even in lactating sheep it is highly difficult to maintain an 
appropriately high concentration of prolactin. Studies carried out by Molik et al. (2007) [26] 
demonstrated that in sheep under artificially extended long-day conditions (16L:8D) it is 
impossible to maintain a high concentration of prolactin as well as to maintain lactation 
during shortening days. 
Subsequent studies conducted on sheep milked in the long-day period showed that 
introduction of exogenous melatonin and initiation of artificial short-day conditions (16D:8L 
- 16 hours of darkness 8 hours of light) in the long-day period gave rise to reduction of the 
prolactin concentration (table 4). 
 
Months 
Concentracion of prolactin ng/ml 
May June July August September 
x  SE x  SE x  SE x  SE x  SE 
Control group 













192.8 9.3 82.8 4.2 163 6.2 78.6 8.6 52.8 2.7 
Table 4. Changes in the concentration of prolactin in sheep exposed to the effects of exogenous 
melatonin and simulated short-day conditions 16D:8L 
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In the first month of milking, in May, the highest concentration of prolactin was identified in 
sheep kept under natural day length conditions, with its level amounting to 220.52 ± 8.1 
ng/ml. As lactation progressed and days shortened, the secretion of prolactin dropped and 
in the last two months it amounted respectively to 125.7 ± 9.21 ng/ml and 84.3 ± 4.4 ng/ml. 
Use of subcutaneous melatonin implants in ewes caused a drop in the concentration of 
prolactin. Already in the first month of milking, in May, the concentration of prolactin 
amounted to 160.8 ± 5.6 ng/ml. In subsequent 60 days of lactation (June) a further bigger 
decrease of the concentration of prolactin was recorded, reaching the level of 82.8 ± 4.2 
ng/ml. As lactation progressed and melatonin implants started to exert their effects, a 
further drop in the secretion of prolatin was observed. In the group of sheep exposed to the 
effects of artificially simulated short-day conditions (16D:8L), the highest concentration of 
prolactin was identified in May, equaling 192.8 ± 9.3ng/ml. In subsequent months of 
lactation keeping sheep under 16D:8L conditions caused a drop in the secretion of prolactin. 
In the fourth and fifth month of milking the secretion of prolactin decreased again, reaching 
in August the level of 78.97± 8.63 ng/ml, and in September 52.83 ± 2.73 ng/ml. The studies 
revealed that simulation of the long signal of melatonin in the spring and summer period 
contributes to disturbance of the endogenous rhythm of prolactin. 
In studies carried out to date no differences have been identified as to the amount of milk 
obtained in the period of lambs rearing. In the early lactation period sucking is an important 
factor stimulating the PRL secretion in the mother’s organism [27]. The sucking impulse 
induces release of serotonin [28] and oxytocin in the central nervous system (CNS) which 
give rise to the release of prolactin from the pituitary gland into the peripheral blood [29]. 
Experiments conducted on lactating rat females demonstrated that intravenous 
administration of specific oxytocin antagonist (desGly-NH2-d(CH2)5[D-Tyr2,Thr4]OVT) 
completely inhibits the release of prolactin triggered by the sucking impulse [30]. Another 
important compound stimulating the release of prolactin induced by sucking is represented 
by salsolinol produced by the dopaminergic system in the lactation period. Infusion of 
exogenous salsolinol into the CNS in the group of lactating sheep gave rise to the release of 
prolactin into blood [31].  
With that in mind, further experiments were carried out, which aimed at determining changes 
in the secretion of prolactin in sheep feeding lambs in the period of lengthening and 
shortening days, and verifying the hypothesis that melatonin can modify the secretion of 
prolactin despite strong stimulation of the mammary gland by sucking in the early lactation 
period [32]. Results of these studies demonstrated that administration of exogenous melatonin 
to ewes feeding lambs in the long-day period caused a significant drop in the concentration of 
prolactin. The identified changes in the PRL concentration in sheep entering lactation in the 
long-day period are comparable with the studies by Rhind et al. (1991) [33] which proved that 
in mothers rearing lambs in the period of lengthening days the concentration of prolatin rises. 
The studies conducted showed that despite intensive sucking the secretion of prolactin in 
sheep with melatonin implants dropped significantly. It must be stressed that the melatonin 
signal, acting as a marker of the biochemical biological clock, is evolutionarily so strong that 
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Months 
Concentracion of prolactin ng/ml 
May June July August September 
x  SE x  SE x  SE x  SE x  SE 
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In the first month of milking, in May, the highest concentration of prolactin was identified in 
sheep kept under natural day length conditions, with its level amounting to 220.52 ± 8.1 
ng/ml. As lactation progressed and days shortened, the secretion of prolactin dropped and 
in the last two months it amounted respectively to 125.7 ± 9.21 ng/ml and 84.3 ± 4.4 ng/ml. 
Use of subcutaneous melatonin implants in ewes caused a drop in the concentration of 
prolactin. Already in the first month of milking, in May, the concentration of prolactin 
amounted to 160.8 ± 5.6 ng/ml. In subsequent 60 days of lactation (June) a further bigger 
decrease of the concentration of prolactin was recorded, reaching the level of 82.8 ± 4.2 
ng/ml. As lactation progressed and melatonin implants started to exert their effects, a 
further drop in the secretion of prolatin was observed. In the group of sheep exposed to the 
effects of artificially simulated short-day conditions (16D:8L), the highest concentration of 
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contributes to disturbance of the endogenous rhythm of prolactin. 
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factor stimulating the PRL secretion in the mother’s organism [27]. The sucking impulse 
induces release of serotonin [28] and oxytocin in the central nervous system (CNS) which 
give rise to the release of prolactin from the pituitary gland into the peripheral blood [29]. 
Experiments conducted on lactating rat females demonstrated that intravenous 
administration of specific oxytocin antagonist (desGly-NH2-d(CH2)5[D-Tyr2,Thr4]OVT) 
completely inhibits the release of prolactin triggered by the sucking impulse [30]. Another 
important compound stimulating the release of prolactin induced by sucking is represented 
by salsolinol produced by the dopaminergic system in the lactation period. Infusion of 
exogenous salsolinol into the CNS in the group of lactating sheep gave rise to the release of 
prolactin into blood [31].  
With that in mind, further experiments were carried out, which aimed at determining changes 
in the secretion of prolactin in sheep feeding lambs in the period of lengthening and 
shortening days, and verifying the hypothesis that melatonin can modify the secretion of 
prolactin despite strong stimulation of the mammary gland by sucking in the early lactation 
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to ewes feeding lambs in the long-day period caused a significant drop in the concentration of 
prolactin. The identified changes in the PRL concentration in sheep entering lactation in the 
long-day period are comparable with the studies by Rhind et al. (1991) [33] which proved that 
in mothers rearing lambs in the period of lengthening days the concentration of prolatin rises. 
The studies conducted showed that despite intensive sucking the secretion of prolactin in 
sheep with melatonin implants dropped significantly. It must be stressed that the melatonin 
signal, acting as a marker of the biochemical biological clock, is evolutionarily so strong that 





Introduction of melatonin implants for sheep rearing lambs in the short-day period did not 
cause significant changes in the profile of the prolactin secretion. By analyzing the profile of 
the PRL secretion in both sheep groups, a conclusion can be drawn that in sheep lambed in 
November the concentration of prolactin in the first control sample drawn was lower by 
50% as compared to the control sample drawn in March. In the long-day period the 
concentration of prolactin in the control group increased, and the secretion of melatonin 
decreased. In the autumn and winter period, though, as natural conditions set in, the 
concentration of melatonin increased and the level of prolactin dropped. The extending 
signal of melatonin observed in the autumn and winter period causes under natural 
conditions a decrease of the concentration of prolactin in sheep [34,35].  
3. The effect of the day length and exogenous melatonin on the secretion 
of prolactin under in vitro conditions  
Studies carried out on a group of lactating sheep under in vivo conditions showed 
modulating effects of melatonin with respect to the secretion of prolactin. The above 
mentioned relations demonstrate that melatonin can modulate the seasonal rhythm of the 
prolactin secretion affecting directly the pituitary gland. The highest concentration of 
melatonin receptors in the sheep’s pituitary gland was identified in the pars tuberalis [36]. 
This structure is located precisely between the eminentia medialis of the hypothalamus and 
the distal part of the gland, which enables its mediation in the communication of the brain 
with the pituitary gland. In the sheep’s PT only a MT1 melatonin receptor is found, and 
surgical separation of the pituitary gland from the hypothalamus does not have any 
influence on the concentration and location of this receptor and its sensitivity to binding 
melatonin [37]. Despite the fact that it was demonstrated that the activity of PT secretory 
cells is seasonal and melatonin-dependent, it was not to confirmed that it is involved in the 
control of seasonal changes in the sexual activity.  
The presence of melatonin receptor limited to the PT of the pituitary gland, and lack of 
direct effects of melatonin both on the prolactin gene expression and release of prolactin in 
cultures of lactotroph cells under in vitro conditions [38] suggests that melatonin regulates 
the seasonal secretion of prolactin by way of a specific compound synthesized in the PT. 
The presence of such a compound in the PT, with a peptide structure and stimulating 
secretion of prolactin from lactotroph cells of the pituitary gland, was confirmed in 
experiments, and the peptide itself was called tuberalin [36,39]. Own studies carried out 
under in vitro conditions demonstrated that both the day length and administration of 
exogenous melatonin affect the profile of the prolactin secretion. In vitro incubations of 
pituitary explants taken from sheep on 30th day of lactation were held in three periods: in 
the period of lengthening days (March), in the period of shortening days (August) and in 
the short-day period (November). The pituitaries taken were divided along the sulcus into 
two halves so that each one contained the adenohypophysis and the neurohypophysis. In 
vitro incubation was held during 3 hours in the Parker medium at a temperature of 370C. 
The control group (G1) was incubated in a medium without any hormonal additives, 
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whereas the experimental group (G2) was incubated in a medium with exogenous 
melatonin. The experiments performed demonstrated that administration of exogenous 
melatonin in the long-day period caused a decrease of the secretion of prolactin in the pars 
tuberalis (table 5) 
 
Group 
Secretion of prolactin    µg/ml 
March August November 
x  SE x  SE x  SE 
Parst tuberalis – control group 
(G1) 
145.4 21.2 65.4 15.7 13.1 2.8 
Parst tuberalis – with 
melatonin (G2) 
105.0 11.4 45.4 9.2 13.7 2.2 
Table 5. Effects of the day length and exogenous melatonin on the secretion of prolactin under in vitro 
conditions. 
The concentration of prolactin in the period of lengthening days (March) in the control 
group was at the level of 145.45 ± 21.2 µg/ml, whereas in the group incubated with 
melatonin it was lower and amounted to 105.06 ± 11.4 µg/ml. In the period of shortening 
days (August), the concentration of prolactin in the medium with exogenous melatonin was 
lower, equaling 45.4 ± 9.2 g/ml, as compared to the control group, being at the level of 65.4 
± 15.7 µg/ml. The lowest concentration of prolactin both in the control group and 
experimental one was recorded in the short-day period. The experiments conducted 
confirmed the seasonal rhythm of prolactin, because the highest concentration of this 
hormone was observed in the period of lengthening days (145.45 ± 21.2 µg/ml). At the same 
time the lowest one was recorded in the short-day period (13.1 ± 2.8 µg/ml). The 
experiments conducted under in vitro conditions showed that in the long-day period 
melatonin exerted a strong inhibitory effect on the secretion of prolactin. The studies 
confirmed also a direct influence of melatonin on cells of the sheep’s pars tuberalis. It was 
demonstrated that the secretory activity of lactotroph cells of the pituitary gland under in 
vitro conditions is closely linked to the day length, and at the same time to the secretion of 
melatonin. It must be stressed at this point that the obtained seasonal distribution of 
prolactin concentrations in lactating sheep resembles a seasonal rhythm of the prolactin 
secretion in barren sheep [19]. However, it should be noted that in the group of lactating 
sheep the secretion of prolactin is much more intensive. Melatonin administered on the 30th 
day of lactation contributed to the reduction of the prolactin secretion [40].  
4. The role of orexins and leptin in the regulation of the secretion of 
prolactin in sheep 
The process of entering and maintenance of lactation in sheep involves a great number of 
hormones, with prolactin playing a key role. In recent years, though, a focus has been placed 
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hormones, with prolactin playing a key role. In recent years, though, a focus has been placed 





neuropeptides was identified. It was demonstrated that they exert a significant influence on 
food intake, and in this manner they were dubbed orexins (Greek orexis – appetite) [41].  
Orexins derive from the same precursor – prepro-orexin, but they are a product of different 
posttranslational modifications. It is a protein built of 130 amino acid residues (mouse, rat) 
or 131 amino acid residues (human). In terms of the amino acid sequence a rat’s prepro-
orexin displays 83% homology with a human protein and 95% with a mouse’s protein [41]. 
Two forms of the newly discovered compounds are distinguished: orexin A (OxA) and 
orexin B (OxB), which are molecules whose amino acid composition is similar to the gut 
hormone - secretin [42]. Orexin A and orexin B bind specifically and activate two GPCR 
receptors (G-protein coupled receptors), which – before discovery of the ligands - were 
called orphan receptors, and now they are known as orexin receptors – 1 and – 2 (Ox1R and 
Ox2R). Studies carried out in 2000 by Date et al. [43] confirmed that matrix RNA of Ox1R 
and Ox2R exhibits strong expression in the middle, anterior (adenohypophysis) and 
posterior (neurohypophysis) lobe of the rats’ pituitary. At the same time it was noticed that 
in the anterior part of the pituitary gland Ox1R is subject to stronger expression than Ox2R. 
The observations go to show that the rat’s pituitary is a gland capable of receiving the orexin 
signal.  
Studies related to the synthesis of orexins and distribution of their receptors reveal that they 
are found in numerous brain sections and confirm the theory, according to which these 
compounds are regulatory proteins active in the central nervous system [41,44]. 
Experiments conducted on rats demonstrated that administration of exogenous orexin 
causes increased intake of food by animals [41]. OxA stimulates appetite in a dose-
dependent manner and this effect prevails even for up to 4 hours after injection. The effect of 
OxB injection does not prevail as long as that of OxA; after two hours stimulation of food 
intake is low. The longer effects of OxA probably are attributable to the molecular structure, 
thanks to which it is more resistant than OxB to an attack of inactivating peptidases [41].The 
experiments also displayed functions of orexins – other than the metabolic one. It was 
confirmed that orexins play a modulating role in the regulation of the hypothalamic-
pituitary-thyroid axis [45], - adrenal axis [46] and – gonadal axis [47].  
Results of in vivo studies conducted in 2000 by Russell et al. [48] showed for the first time 
that injection of orexin A reduced the level of prolactin in rats’ blood. Moreover, it was 
concluded that the mechanism is not connected with the activity of TIDA neutrons 
synthesizing dopamine (PRL inhibitor). In in vitro experiments it was proven that OxA 
exerts a direct influence on the secretory activity of explants of the hypothalamus and 
pituitary gland. Orexin A is also described as an inhibitor of the PRL secretion by lactotroph 
cells of the pituitary anterior lobe by Dusza and Ciereszko (2007) [49]. However, results of 
studies carried out on immature female rats under primary culture conditions are 
completely different as they reveal a statistically significant growth of the prolactin secretion 
depending on a dose and time of incubation of pituitary glands [50].  
The orexin gene expression in ruminants was defined for the first time only in 2002 and it 
was shown that the location of the mRNA of prepro-orexin in the hypothalamus in sheep 
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corresponds with the published pattern for rodents. Results of the studies confirmed also 
that the orexin gene expression is sensitive to changes in the day length (higher during 
shorter days). However, no starving-induced changes were identified, which questions the 
key role of orexins in the regulation of appetite in sheep [51,52]. 
In the light of the presented results of the studies orexins can be perceived as a link 
integrating the processes of maintaining energy, hormonal and reproductive balance. Orexin 
A can be of special importance to animals exhibiting sensitivity to changes in the day length, 
which include sheep. The process of entering and maintenance of lactation in the animals 
involves a number of factors, whereas the key role is attributed to prolactin and growth 
hormone. Unfortunately, mechanisms regulating secretion of these compounds in sheep in 
the lactation period still remain unclear. It is certain, though, that defining functions of 
orexins - above all - in the regulation of the prolactin secretion will make it possible to 
understand the process of maintaining lactation in sheep, in particular in the short-day 
period. Thus, the purpose of the initiated studies was to determine the role of orexin A in 
the regulation of the prolactin secretion in sheep under different day-length conditions in in 
vitro experiments.  
The experiments were performed on 15 sheep. Pituitary glands were taken from sheep on 
the 30th day of lactation in the long-day period (May n=5), in the period of shortening days 
(August n=5) and in the short-day period (December n=5). The pituitaries taken were 
divided along the sulcus into two halves so that each one contained the adenohypophysis 
and the neurohypophysis. In vitro incubation was held during 3 hours in the Parker medium 
at a temperature of 370C. The control group (G1) was incubated in a pure medium, whereas 
the experimental group (G2) was incubated in a medium with exogenous orexin A. Injection 
of exogenous orexin caused an increase of prolactin secretion already in the first hour of 
incubation (451.6±9.4 µg/ml) (table 6).  
 
Group 
Secretion of prolactin µg/ml 
Hours of incubation 
First hour Second hour Third hour 
x  SE x  SE x  SE 
Parst tuberalis – control group 
(G1) 
401.8 6.0 344.6 8.2 155.8 3.6 
Parst tuberalis – with orexin A 
(G2) 
451.6 9.4 346.5 7.0 196.3 4.7 
Table 6. Effects of orexin on the secretion of prolactin in the long-day period 
In the control group in the second hour of incubation the concentration of prolactin was 
lower (344.6±8.2 µg/ml) than in the group with orexin (346.5±7.0 µg/ml). But in the third 
hour of incubation the concentration of prolactin in the experimental group was higher by 
40.5 µg/ml than in the control group. In general, the PRL concentration in the long-day 
period during three-hour incubation in the group with orexin A equaled (331±15.2ng/ml) 
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demonstrated that irrespective of how the secretory capabilities of cells deteriorated in the 
course of incubation, exogenous orexin A stimulates the PRL secretion in the long-day 
period in lactating ewes (53).  
Studies conducted in the period of shortening days (August) showed that administration of 
orexin A can modulate prolactin secretion (table 7). 
 
Group 
Secretion of prolactin µg/ml 
Hours of incubation 
First hour Second hour Third hour 
x  SE x  SE x  SE 
Parst tuberalis – control group 38.05 12.1 32.1 9.6 19.2 7.3 
Parst tuberalis – with orexin A 40.6 13.5 38.7 10.1 28.6 9.7 
Table 7. Effects of orexin on the secretion of prolactin in the period of shortening days (August) 
While analyzing changes in the prolactin secretion in sheep during 3-hour incubation, the 
highest secretory activity of cells was observed in the first two hours of the experiment. In 
the first hour of incubation the concentration of prolactin in the group incubated with orexin 
A equaled (40.6±13.5 µg/ml) and was higher as opposed to the control group (38.05±12.1 
µg/ml). The concentration of prolactin in the second hour of the experiment was still higher 
than that in the control group and equaled respectively (38.7±10.1, 32.1±9.6 µg/ml). In the 
third hour of the experiment it was demonstrated that in the experimental group the 
concentration of prolactin was higher (28.6±9.7 µg/ml) as compared to the control group 
(19.2±7.3 µg/ml). 
In the period of shortening days, when the concentration of prolactin under natural 
conditions is reduced, administration of orexin A caused a growth of the prolactin secretion; 
similarly, injection of exogenous orexin A in the short-day period caused an increase of the 
prolactin secretion (table 8) 
 
Group 
Secretion of prolactin µg/ml 
Hours of incubation 
First hour Second hour Third hour 
x  SE x  SE x  SE 
Parst tuberalis – control group 135.1 8.4 107.8 7.5 65.7 5.9 
Parst tuberalis – with orexin A 158.9 9.2 164.8 7.5 79.9 7 
Table 8. Effects of orexin on the secretion of prolactin in the short-day period (December) 
In the first hour of incubation of the pituitaries in the short-day period it was observed that 
the prolactin secretion in the experimental group increased (158.9±9.2 pg/ml) as contrasted 
with the control group (135.1±8.4 pg/ml). In the second hour of incubation it was recorded 
that the concentration of prolactin in the experimental group grew (164.8±7.5 pg/ml), 
whereas in the control group the concentration of prolactin amounted to (107.8±4.0 pg/ml). 
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Results obtained in the third hour of incubation revealed that the concentration of prolactin 
in the control group equaled (65.7±5.9 pg/ml), whereas in the group treated with exogenous 
orexin it amounted to (79.9±7.0 pg/ml). Despite the fact that secretory capabilities of cells 
deteriorated in the course of incubation, the PRL concentration in the examined samples 
grew.  
The experiments conducted under in vitro conditions confirmed that the annual rhythm of 
the PRL secretion in sheep is characterized by a higher concentration in the long-day period 
(summer) and lower concentration in the short-day period (winter). 
Orexin exerts its effects on the PRL secretion in sheep, like in case of rodents, thanks to the 
presence of specific receptors Ox1R and Ox2R in the cytoplasmatic membrane of cells. Their 
existence in the sheep’s adenohypophysis was described in 2002 by Xu et al.[54], who 
identified a high homology of the structure of a gene encoding sheep’s Ox1R and a gene of 
the receptor in a rat (87%) and human being (89%). The presence of both of these forms of 
orexin receptors in the sheep’s pituitary gland was also confirmed by Zhang et al. in 2004 
[55]. 
Studies carried out to date with a view to explaining the relations between orexin and 
prolactin have been conducted mainly on rats. Thus, results of experiments on sheep in the 
period of lactation offer new information about the role of orexins in seasonally breeding 
animals. The conducted experiments proved that orexin A exerts a greater stimulating effect 
on the level of the PRL secretion in the summer season than in the winter season. The 
weaker response of sheep’s pituitaries to orexin during short days as compared to the 
response during long days is a phenomeon of resistance of lactotroph cells to the orexin 
signal. Such a reaction of endocrine cells can be explained by the seasonal rhythm of 
biosynthesis and secretion of orexin in sheep, regulated by the photoperiod. It was proven 
that under conditions of shortening light days the expression of the orexin precursor gene in 
these ruminants is on a higher level than during long days [51]. As a result, an increased 
concentration of the mRNA of prepro-orexin in the winter season is observed, followed by 
an increased concentration of orexin in the organism. It is probable that at this time the 
saturation degree of orexin receptors of lactotroph cells with endogenous ligand is so high 
that adding exogenous orexin A does not cause such a distinct response as that occurring 
during long days. While attempting to identify interactions between the secretion of 
prolactin and growth hormone and the level of melatonin in lactating sheep an analogous 
phenomenon was noticed. Despite the fact that ewes lambed in June were kept under 
artificial long-day conditions, as the day became shorter, a drop in the PRL level was 
observed. In consequence, it was concluded that the secretion of the hormones retained its 
endogenous seasonal rhythm. The effect of the loss of the pituitary cells’ sensitivity to the 
summer signal of the hormone of darkness repeating for too long does not allow for 
extension of sheep’s lactation to the autumn and winter period [57]. 
In experiments conducted in 2006 it was proven for the first time that leptin exerts an effect 
on the melatonin secretion both under in vitro [57] and in vivo [58] conditions. It was 





demonstrated that irrespective of how the secretory capabilities of cells deteriorated in the 
course of incubation, exogenous orexin A stimulates the PRL secretion in the long-day 
period in lactating ewes (53).  
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orexin A can modulate prolactin secretion (table 7). 
 
Group 
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First hour Second hour Third hour 
x  SE x  SE x  SE 
Parst tuberalis – control group 38.05 12.1 32.1 9.6 19.2 7.3 
Parst tuberalis – with orexin A 40.6 13.5 38.7 10.1 28.6 9.7 
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concentration of prolactin was higher (28.6±9.7 µg/ml) as compared to the control group 
(19.2±7.3 µg/ml). 
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similarly, injection of exogenous orexin A in the short-day period caused an increase of the 
prolactin secretion (table 8) 
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Parst tuberalis – control group 135.1 8.4 107.8 7.5 65.7 5.9 
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In the first hour of incubation of the pituitaries in the short-day period it was observed that 
the prolactin secretion in the experimental group increased (158.9±9.2 pg/ml) as contrasted 
with the control group (135.1±8.4 pg/ml). In the second hour of incubation it was recorded 
that the concentration of prolactin in the experimental group grew (164.8±7.5 pg/ml), 
whereas in the control group the concentration of prolactin amounted to (107.8±4.0 pg/ml). 
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orexin it amounted to (79.9±7.0 pg/ml). Despite the fact that secretory capabilities of cells 
deteriorated in the course of incubation, the PRL concentration in the examined samples 
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The experiments conducted under in vitro conditions confirmed that the annual rhythm of 
the PRL secretion in sheep is characterized by a higher concentration in the long-day period 
(summer) and lower concentration in the short-day period (winter). 
Orexin exerts its effects on the PRL secretion in sheep, like in case of rodents, thanks to the 
presence of specific receptors Ox1R and Ox2R in the cytoplasmatic membrane of cells. Their 
existence in the sheep’s adenohypophysis was described in 2002 by Xu et al.[54], who 
identified a high homology of the structure of a gene encoding sheep’s Ox1R and a gene of 
the receptor in a rat (87%) and human being (89%). The presence of both of these forms of 
orexin receptors in the sheep’s pituitary gland was also confirmed by Zhang et al. in 2004 
[55]. 
Studies carried out to date with a view to explaining the relations between orexin and 
prolactin have been conducted mainly on rats. Thus, results of experiments on sheep in the 
period of lactation offer new information about the role of orexins in seasonally breeding 
animals. The conducted experiments proved that orexin A exerts a greater stimulating effect 
on the level of the PRL secretion in the summer season than in the winter season. The 
weaker response of sheep’s pituitaries to orexin during short days as compared to the 
response during long days is a phenomeon of resistance of lactotroph cells to the orexin 
signal. Such a reaction of endocrine cells can be explained by the seasonal rhythm of 
biosynthesis and secretion of orexin in sheep, regulated by the photoperiod. It was proven 
that under conditions of shortening light days the expression of the orexin precursor gene in 
these ruminants is on a higher level than during long days [51]. As a result, an increased 
concentration of the mRNA of prepro-orexin in the winter season is observed, followed by 
an increased concentration of orexin in the organism. It is probable that at this time the 
saturation degree of orexin receptors of lactotroph cells with endogenous ligand is so high 
that adding exogenous orexin A does not cause such a distinct response as that occurring 
during long days. While attempting to identify interactions between the secretion of 
prolactin and growth hormone and the level of melatonin in lactating sheep an analogous 
phenomenon was noticed. Despite the fact that ewes lambed in June were kept under 
artificial long-day conditions, as the day became shorter, a drop in the PRL level was 
observed. In consequence, it was concluded that the secretion of the hormones retained its 
endogenous seasonal rhythm. The effect of the loss of the pituitary cells’ sensitivity to the 
summer signal of the hormone of darkness repeating for too long does not allow for 
extension of sheep’s lactation to the autumn and winter period [57]. 
In experiments conducted in 2006 it was proven for the first time that leptin exerts an effect 
on the melatonin secretion both under in vitro [57] and in vivo [58] conditions. It was 





of leptin directly in the sheep’s pineal gland, with an inhibitory effect of leptin on melatonin 
secreted by explants of the pineal gland in the period of lengthening days. However, during 
shortening days leptin stimulated the melatonin secretion by the gland explants [57]. Results 
of the in vitro experiments were confirmed in in vivo experiments, in which leptin was 
injected into the 3rd brain chamber. They demonstrated that exogenous leptin has an 
inhibitory effect on the concentration of melatonin during long days and a stimulating dose-
dependent effect – during short days [58].  
Seasonal insensitivity to leptin is observed in sheep in the spring and summer period, 
making it possible for the ruminants to make energy reserves, and despite increasing fatness 
intake of food in sheep is not reduced. Increased intake of food and a growth of the body 
weight during long days – LD (Long Days) spring - summer – is characterized by a high 
concentration of leptin in blood plasma, which “loses” then its anorectic features. In the 
short-day period – SD (Short Days) autumn - winter, when the availability of food dwindles, 
the sensitivity of centres regulating food intake in the hypothalamus to the concentration of 
leptin returns to normal. This paradox is explained by leptin resistance occurring during LD, 
whereas the neuroendocrinological basis of leptin resistance has not been fully understood 
yet. One of the phenomena underlying leptin resistance is auto-supression of the transfer of 
signal from the receptor to the cell centre resulting from the leptin-induced expression of 
SOCS-3 factors, being inhibitors of cytokine sygnalisation [58]. The phenomenon is observed 
in particular in the area of ventromedial hyopothalamus [58], where long-form receptors of 
leptin Ob-Rb are found in the highest concentration. 
Orexigenic and anorexigenic systems are linked in terms of morphology and functionality. It 
confirms the hypothesis about the existence of a nervous network regulating hunger, located 
in nervous centres of the hypothalamus. The area of receptors and nerve endings for 
orexigenic factors overlaps with the area of receptors for anorexigenic factors, which also 
reveals mutual interactions of the two systems. In animals with strong seasonal breeding 
characteristics the network of the above described relations overlaps additionally with 
effects of the photoperiod, which by way of a biological signal in the form of melatonin 
interferes with the developed relations. The suprachiasmatic nucleus (SCN), which is a part 
of the biological clock, generates signals adjusting food intake to the circadian rhythm. This 
element is considerably weakened in the primates, and in particular in humans, but it is 
very efficient in ruminants. The objective of the conducted experiments was to investigate 
interactions between the day length and leptin and orexin B in sheep under in vivo 
conditions.  
The experiments were carried out on 24 sheep of the Polish sheep breed. The first stage of 
experiments (n=12) was conducted in the period of lengthening days (spring – summer). The 
second stage (n=12) was held under conditions of shortening days (autumn – winter). Three 
weeks prior to the initiation of the planned experiments metal stainless cannulas were 
inserted surgically into the third brain chamber of ewes (using the stereotactic method by 
Traczyk and Przekop [1963] [59]). The tests were started at the sunset, and were continued 
during subsequent 6 hours. The experiments were performed so that each ewe received in a 
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2-week interval intraventricular infusion of Ringer-Locke’s fluid – control, recombinant 
sheep leptin (roleptin) – in a dose of 0.5 µg/kg body weight (Leptin 1), and roleptin in a dose 
of 1.0 ug/kg body weight (Leptin 2). On the day of the experiment animals were put in 
individual cattle crushes, the Ringer-Locke’s fluid (control) and roleptin were injected 
intraventricularly for the first time directly after drawing time-zero blood samples and in 
the 60th and 120th minute of the 6-hour experiment. During the experiment blood samples 
were drawn every 15 minutes. Blood was poured into test tubes containing 100 l of heparin 
solution (1000 IU/ml).  
During lengthening days the total PRL concentration in the plasma of control sheep was 
significantly higher (P < 0.001) than during shortening days (132.28  19.87 vs. 44.41  8.27 
ng/ml). Intraventricular infusions of two doses of exogenous leptin reduced the 
concentration of prolactin during SD (P < 0.001) as compared to the values observed in 
control ewes. It was concluded that the day length is one of the factors which modulate the 
effects of leptin on the prolactin secretion in sheep. It was observed that central infusions of 
leptin into the 3rd brain chamber significantly decreased the concentration of prolactin in 
sheep during short days in a dose-dependent manner; whereas the effect was opposite 
during a long photoperiod.  
In subsequent experiments a test of the hypothesis about season-dependent effects of leptin 
and orexin B on the endocrine activity of sheep was performed. Six weeks prior to the start 
of the experiments ewes were subjected to an ovariectomy procedure, and subcutaneous 
estradiol implants were inserted into each of them. Three weeks prior to the initiation of the 
planned experiments metal stainless cannulas were inserted surgically into the third brain 
chamber of ewes (using the stereotactic method by Traczyk and Przekop [1963] (59). Like in 
the previous experiment, the tests were started at the sunset, and were continued during 
subsequent 6 hours. The experiments were performed so that each ewe received in one-
week interval intraventricular infusion: 1. Control group (CG) - Ringer-Locke’s fluid 
(pH=7.4); 2. Experimental group 1 (Gr 1) – recombinant sheep leptin (PLR Laboratory, Israel) 
in a dose of 0.5 g/kg, the dose was selected based on experiments [58]; 3. Experimental 
group 3 (Gr 3) – orexins B (PolyPeptides Laboratories, Strasbourg, France) in a dose of 0,3 
µg/kg., 4. Experimental group 5 (Gr 5) - superantagonists of leptin (D23L/L39A/D40A/F41A; 
PLR Laboratory Israel) in a dose of 50 µg/kg, and then orexin B in a dose used previously. In 
the control group and experimental group 1, 2, and 3 infusions of selected factors were 
performed three times, every 60 minutes from the start of the experiment, in group 5 the 
leptin antagonist was infused twice, in the zero and 1st hour of the experiment, and 
ghrelin/orexin B was infused 15 and 60 minutes after administration of leptin antagonist. 
During the 6-hour experiment blood samples were drawn every 15 minutes. The average 
concentration of melatonin in the plasma of ewes from the control group was higher (P< 
0.001) during LD as compared to the values recorded in animals during short days (87.28  
1.2 vs. 59.70  3.1 pg/ml). In the seasons of lengthening days exogenous recombinant sheep 
leptin significantly reduced the concentration of melatonin (P< 0.001) in relation to the 
values observed in ewes from the control group, whereas during a short day it significantly 
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secreted by explants of the pineal gland in the period of lengthening days. However, during 
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individual cattle crushes, the Ringer-Locke’s fluid (control) and roleptin were injected 
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the 60th and 120th minute of the 6-hour experiment. During the experiment blood samples 
were drawn every 15 minutes. Blood was poured into test tubes containing 100 l of heparin 
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ng/ml). Intraventricular infusions of two doses of exogenous leptin reduced the 
concentration of prolactin during SD (P < 0.001) as compared to the values observed in 
control ewes. It was concluded that the day length is one of the factors which modulate the 
effects of leptin on the prolactin secretion in sheep. It was observed that central infusions of 
leptin into the 3rd brain chamber significantly decreased the concentration of prolactin in 
sheep during short days in a dose-dependent manner; whereas the effect was opposite 
during a long photoperiod.  
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and orexin B on the endocrine activity of sheep was performed. Six weeks prior to the start 
of the experiments ewes were subjected to an ovariectomy procedure, and subcutaneous 
estradiol implants were inserted into each of them. Three weeks prior to the initiation of the 
planned experiments metal stainless cannulas were inserted surgically into the third brain 
chamber of ewes (using the stereotactic method by Traczyk and Przekop [1963] (59). Like in 
the previous experiment, the tests were started at the sunset, and were continued during 
subsequent 6 hours. The experiments were performed so that each ewe received in one-
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(pH=7.4); 2. Experimental group 1 (Gr 1) – recombinant sheep leptin (PLR Laboratory, Israel) 
in a dose of 0.5 g/kg, the dose was selected based on experiments [58]; 3. Experimental 
group 3 (Gr 3) – orexins B (PolyPeptides Laboratories, Strasbourg, France) in a dose of 0,3 
µg/kg., 4. Experimental group 5 (Gr 5) - superantagonists of leptin (D23L/L39A/D40A/F41A; 
PLR Laboratory Israel) in a dose of 50 µg/kg, and then orexin B in a dose used previously. In 
the control group and experimental group 1, 2, and 3 infusions of selected factors were 
performed three times, every 60 minutes from the start of the experiment, in group 5 the 
leptin antagonist was infused twice, in the zero and 1st hour of the experiment, and 
ghrelin/orexin B was infused 15 and 60 minutes after administration of leptin antagonist. 
During the 6-hour experiment blood samples were drawn every 15 minutes. The average 
concentration of melatonin in the plasma of ewes from the control group was higher (P< 
0.001) during LD as compared to the values recorded in animals during short days (87.28  
1.2 vs. 59.70  3.1 pg/ml). In the seasons of lengthening days exogenous recombinant sheep 
leptin significantly reduced the concentration of melatonin (P< 0.001) in relation to the 
values observed in ewes from the control group, whereas during a short day it significantly 





concentration of melatonin during a short day, but it caused a significant growth (P< 0.05) of 
the concentration of melatonin on a long day.  
During a lengthening day the total PRL concentration in the plasma of sheep from the 
control group was markedly higher (P< 0.001) as contrasted with shortening days (132.28  
19.87 vs. 44.41  8.27 ng/ml). Intraventricular infusions of exogenous leptin reduced the 
concentration of prolactin during SD (P< 0.001) as compared to the values observed in ewes 
from the control group. The average concentration of endogenous orexin was higher (P< 
0.01) during short days (0.59  0.05 ng/ml) as opposed to LD (0.39  0.01 ng/ml) in the 
control group of sheep. Exogenous orexin caused a growth (P< 0.05) of the plasma 
concentration of endogenous orexin respectively on a long and short day (0.62  0.01 ng/ml 
and 0.71  0.03 ng/ml), whereas the effects of leptin reduced (P< 0.05) the concentration of 
orexin during LD and SD. Based on the conducted experiments it was concluded that orexin 
B and anorectic hormone – leptin directly interact closely with each other, regulating not 
only the processes of metabolism but influencing jointly release of melatonin and prolactin, 
and the interactions additionally depend on the prevalent photoperiod.  
5. Summary 
So far it has been believed that milk yields in mammals are determined by genetic and 
environmental factors. In recent years, though, a special focus has been placed on light, 
being the modulator of the prolactin level. In farm animals changes of the light day play a 
very important role as they determine their yields. The length of the light day, and in 
particular the melatonin profile, is of special importance in sheep as they determine 
reproductive processes, in which lactation is the last stage of reproductive physiology. 
Experiments carried out on sheep demonstrated that both the melatonin profile and 
prolactin profile retain features of a seasonal rhythm depending on the day length. The 
synthesis of melatonin by the pineal gland is a biochemical signal informing the organism 
about the break of the day or night. This hormone regulates activities of numerous organs. 
Until now the activity of melatonin has been associated with the impact on the reproductive 
system. Experiments carried out in recent years have shown that melatonin can modulate 
the level of prolactin. Under natural conditions the maximum concentration of prolactin in 
sheep blood is observed in the long-day period, and at this time the level of melatonin 
drops. The lowest concentration of prolactin is recorded during short days, when the level 
of melatonin is the highest. Shortening of the day length or long-term injection of melatonin 
in the period of physiologically increased concentration of prolactin leads to a reduced 
secretion of this hormone. Lactation in sheep involves a number of hormones, and for that 
reason in recent years a special focus has been placed on the role of orexins in the regulation 
of the prolactin secretion. Experiments conducted demonstrated that orexin A exerts a 
greater stimulating effect on the level of the PRL secretion in the summer season than in the 
winter season. The weaker reaction of sheep’s pituitaries to orexin during short days as 
compared to the response during long days is a phenomenon of resistance of lactotroph cells 
to the orexin signal. Such a reaction of endocrine cells can be explained by the seasonal 
rhythm of biosynthesis and secretion of orexin in sheep, regulated by the photoperiod.  
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During a lengthening day the total PRL concentration in the plasma of sheep from the 
control group was markedly higher (P< 0.001) as contrasted with shortening days (132.28  
19.87 vs. 44.41  8.27 ng/ml). Intraventricular infusions of exogenous leptin reduced the 
concentration of prolactin during SD (P< 0.001) as compared to the values observed in ewes 
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0.01) during short days (0.59  0.05 ng/ml) as opposed to LD (0.39  0.01 ng/ml) in the 
control group of sheep. Exogenous orexin caused a growth (P< 0.05) of the plasma 
concentration of endogenous orexin respectively on a long and short day (0.62  0.01 ng/ml 
and 0.71  0.03 ng/ml), whereas the effects of leptin reduced (P< 0.05) the concentration of 
orexin during LD and SD. Based on the conducted experiments it was concluded that orexin 
B and anorectic hormone – leptin directly interact closely with each other, regulating not 
only the processes of metabolism but influencing jointly release of melatonin and prolactin, 
and the interactions additionally depend on the prevalent photoperiod.  
5. Summary 
So far it has been believed that milk yields in mammals are determined by genetic and 
environmental factors. In recent years, though, a special focus has been placed on light, 
being the modulator of the prolactin level. In farm animals changes of the light day play a 
very important role as they determine their yields. The length of the light day, and in 
particular the melatonin profile, is of special importance in sheep as they determine 
reproductive processes, in which lactation is the last stage of reproductive physiology. 
Experiments carried out on sheep demonstrated that both the melatonin profile and 
prolactin profile retain features of a seasonal rhythm depending on the day length. The 
synthesis of melatonin by the pineal gland is a biochemical signal informing the organism 
about the break of the day or night. This hormone regulates activities of numerous organs. 
Until now the activity of melatonin has been associated with the impact on the reproductive 
system. Experiments carried out in recent years have shown that melatonin can modulate 
the level of prolactin. Under natural conditions the maximum concentration of prolactin in 
sheep blood is observed in the long-day period, and at this time the level of melatonin 
drops. The lowest concentration of prolactin is recorded during short days, when the level 
of melatonin is the highest. Shortening of the day length or long-term injection of melatonin 
in the period of physiologically increased concentration of prolactin leads to a reduced 
secretion of this hormone. Lactation in sheep involves a number of hormones, and for that 
reason in recent years a special focus has been placed on the role of orexins in the regulation 
of the prolactin secretion. Experiments conducted demonstrated that orexin A exerts a 
greater stimulating effect on the level of the PRL secretion in the summer season than in the 
winter season. The weaker reaction of sheep’s pituitaries to orexin during short days as 
compared to the response during long days is a phenomenon of resistance of lactotroph cells 
to the orexin signal. Such a reaction of endocrine cells can be explained by the seasonal 
rhythm of biosynthesis and secretion of orexin in sheep, regulated by the photoperiod.  
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1. Introduction 
In developed countries, the elderly population increases at an accelerated rate due to a 
decrease in the birth rate and the prolongation of life through medical development. 
Moreover, increases in the elderly population allow the prediction of an increase in 
hyperprolactinemia caused by aging. It is well known that hyperprolactinemia decreases 
libido and causes oligozoospermia [1]. On the other hand, hyperprolactinemia is caused by 
or associated with, a variety of pathogenic stages: pituitary adenoma, hypothalamic 
disorders, hypogonadism and hypothyroidism, and is detected in patients with infertility [2, 
3], impotence and hypogonadism [4]. PRL is a polypeptide hormone that is synthesized and 
secreted from mammotropes in the anterior lobe of the pituitary gland [5]. Many studies 
have documented a critical role of PRL in the maintenance of lactation in women and female 
animals [6, 7] as well as in immunregulation in both, males and females [8], however, its role 
in sexual behavior is not entirely clear [9-16].   
It has been also shown that DAerg agonists facilitate several aspects of copulatory behavior 
and ex copula genital responses [10]. DAerg neurons, locating in the medial preoptic area 
(MPOA), and the zona incerta (incertohypothalamic DAerg system) are the key centers in 
the stimulatory control of sexual functions [17-18]. (R)-salsolinol (SAL), a DA related and 
derived tetrahydroisoquinoline, has been recently identified as a strong candidate for being 
the endogenous PRL releasing factor (PRF) synthesized in both the hypothalamus and the 
neurointermediate lobe (NIL) of the pituitary gland. Analysis of SAL concentrations 
revealed parallel increase and decrease with the elevation and reduction of plasma PRL, 
respectively. SAL is sufficiently potent and selective in vivo to account for the massive 
discharge of PRL that occurs after physiological changes. At the same time, parallel with its 
DA depleting effect in sympathetically innervated peripheral organs, SAL can reduce 
testosterone secretion both in vivo and in vitro from Leydig cells [19-20]. Based upon all of 
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1. Introduction 
In developed countries, the elderly population increases at an accelerated rate due to a 
decrease in the birth rate and the prolongation of life through medical development. 
Moreover, increases in the elderly population allow the prediction of an increase in 
hyperprolactinemia caused by aging. It is well known that hyperprolactinemia decreases 
libido and causes oligozoospermia [1]. On the other hand, hyperprolactinemia is caused by 
or associated with, a variety of pathogenic stages: pituitary adenoma, hypothalamic 
disorders, hypogonadism and hypothyroidism, and is detected in patients with infertility [2, 
3], impotence and hypogonadism [4]. PRL is a polypeptide hormone that is synthesized and 
secreted from mammotropes in the anterior lobe of the pituitary gland [5]. Many studies 
have documented a critical role of PRL in the maintenance of lactation in women and female 
animals [6, 7] as well as in immunregulation in both, males and females [8], however, its role 
in sexual behavior is not entirely clear [9-16].   
It has been also shown that DAerg agonists facilitate several aspects of copulatory behavior 
and ex copula genital responses [10]. DAerg neurons, locating in the medial preoptic area 
(MPOA), and the zona incerta (incertohypothalamic DAerg system) are the key centers in 
the stimulatory control of sexual functions [17-18]. (R)-salsolinol (SAL), a DA related and 
derived tetrahydroisoquinoline, has been recently identified as a strong candidate for being 
the endogenous PRL releasing factor (PRF) synthesized in both the hypothalamus and the 
neurointermediate lobe (NIL) of the pituitary gland. Analysis of SAL concentrations 
revealed parallel increase and decrease with the elevation and reduction of plasma PRL, 
respectively. SAL is sufficiently potent and selective in vivo to account for the massive 
discharge of PRL that occurs after physiological changes. At the same time, parallel with its 
DA depleting effect in sympathetically innervated peripheral organs, SAL can reduce 
testosterone secretion both in vivo and in vitro from Leydig cells [19-20]. Based upon all of 
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these data, the aim of our present studies was to confirm the suppressive effects of 
hyperprolactemia induced by grafting pituitary glands under the kidney capsule and to 
investigate the effect of a single injection of SAL on the elevation of plasma PRL and on 
sexual behavior in male rats.  
Sexually experienced male rats of the Wistar-Imamichi strain (Imamichi Institute for Animal 
Reproduction, Tsuchiura, Japan), approximately 10 weeks old at the start of the 
experiments, were used. The animals were kept in a room with a temperature of 22-26 
Celsius and subjected to a light-schedule of 14 hrs light and 10 hrs darkness (lights off at 
19:00). They were provided with pellet diet CRF-1 (Charles River Laboratories Japan, 
Atsugi, Japan) and water ad libitum. Stimulus females of the same strain were rendered 
sexually receptive by treatment with estradiol benzoate (10μg/0.1 ml sesame oil, Sigma 
Chemical Co. Ltd., St. Louis, USA) 48 hrs prior to, and progesterone (500μg/0.1 ml sesame 
oil, Sigma Chemical Co. Ltd., St. Louis, USA) 4 hrs prior to exposure to males. 
One group of experimental animals were anesthetized with Nembutal (40 mg/kg, i.p.) and 
implanted one and two whole pituitaries from male donors with the same age in the same 
strain under the left kidney capsule [21]. Rats having 1 or 2 pituitary grafts were sacrificed 
by decapitation between 19:30 and 20:30 in a week after the test. It was carried out in 30 
seconds after taking animals out from their cages [22-23].  
In a separate group of animals, intravenous (i.v.) cannula have been inserted into the jugular 
vein of male Sprague-Dawley rats for injection of SAL, and being able to take blood 
samples. Saline or SAL (4 mg/kg body weight i.v.) have been injected to the animals prior to 
expose them to females being in estrus. 
Copulatory behavior test have been conducted four weeks after the surgery. After a male rat 
was placed in the semi-circular observation cage (radius 40, height 50 cm) faced with 
Plexiglass under low-level red-light illumination for a few minutes, a sexually receptive 
female was introduced to its cage. Tests lasted 60 min from the introduction of the female. 
Behavioral testing was conducted between 19:30 and 20:30. The behavior categories scored 
included the following [24]. Mounting frequency (MF): number of mounts without 
intromission preceding ejaculation. Intromission frequency (IF): number of mounts with 
intromission preceding ejaculation. Ejaculation frequency (EF): number of ejaculations during 
60 min. Mount latency (ML): time from the presentation of the female to the male’s first 
mount. Intromission latency (IL): time from the presentation of the male’s first intromission. 
Ejaculation latency (EL): latency from the first intromission until ejaculation. Post-ejaculatory 
interval (PEI): latency from ejaculation to the next intromission. 
Blood collected and centrifuged at 3,000 g for 15 minutes for the analysis of serum hormone. 
The serum was stored at -80 Celsius until analyzed by RIA for determination of serum PRL, 
LH and FSH. Serum concentrations of PRL, LH and FSH were measured by RIA using the 
method of Furudate et al. [25] with reagents provided from NIADDK. The standard 
references used were, rPRL-RP-3 for PRL, rLH-RP-2 for LH and rFSH-RP-2 for FSH. The 
intra- and inter-assay coefficients of variation were 9.6 and 15.9 for PRL, 3.5 and 5.3 for LH, 
and 5.3 and 9.8 for FSH, respectively. Testosterone levels were also measured by direct RIA. 
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All data are presented as mean ± SEs. The results from the copulatory behavior testing were 
analyzed using Fisher’s exact probability test and the Mann-Whitney U test and the data for 
hormone levels and organs weights were analyzed by Duncan’s multiple t-test. 
2. Effect of pituitary transplants induced hyperprolactinaemia on 
copulatory behavior 
The results of serum hormone levels in two pituitaries grafted and sham animals are shown 
in Table 1. Prolactin (PRL) concentration in rats having two pituitary grafts was significantly 
higher than sham operated animals (p < 0.05). There were no significant differences in the 
serum levels of luteinizing hormone (LH), folliculostimulating hormone (FSH) and 














1.3 ± 0.16 65.3 ± 13.60 31.1 ± 3.40a 2.1 ± 0.29 
Sham 
 
1.3 ±0.20 97.4 ± 9.84 7.2 ± 1.51b 2.6 ± 0.24 
All data represent mean ± S.E. 
*p<0.05 a vs. b 
Table 1. Serum hormone levels in grafted male rats 
As it is shown on Fig. 1, the mean number of mount in rats having one-, two grafted 
pituitaries and non was 76.5 ± 5.35, 66.8 ± 6.37 and 40.2 ± 3.43, respectively. The mount 
frequency (MF) showed a tendency to be higher in grafted, compared with sham-operated 
animals. The mean frequency of intromission (IF) was lower for one (18.0 ± 1.27) and two 
pituitaries grafted males (10.0 ± 2.00), compared to sham-operated controls (29.0 ± 2.00). 
There were significant differences in IF between two pituitaries grafted and sham-operated 
males (p < 0.05). Ejaculation could be detected in all one-pituitary grafted and sham-
operated males, while did not in 4 out of 6 two-pituitaries grafted males. The mean 
ejaculation frequency (EF) of one, two pituitaries grafted and sham males was 3.5 ± 0.33, 0.8 
± 0.20 and 5.2 ± 0.20, respectively. The EF of two pituitaries grafted males is significantly 
lower than sham males (P < 0.01).  
As shown on Fig. 2, having two pituitary grafts resulted in a significant prolongation in the 
mean latency of intromission, compared with sham-operated animals (1,014.4 ± 206.12 
versus 67.8 ± 7.72 sec, p < 0.05). The mean latency to the first ejaculation showed a tendency 
to extend in animals having one (652.1 ± 56.06 sec), two (1,367.5 sec) pituitary grafts, 
compared with sham-operated males (369.7 ± 25.28 sec). The post-ejaculatory interval (PEI) 
tended to extend in animals having one (425.7 ± 27.40 sec) or two (487.5 sec) pituitary grafts, 
compared with sham-operated animals (341.7 ± 3.27 sec).  
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MF: Mount frequency. IF: Intromission frequency. EF: Ejaculation frequency. *p<0.05:2 Grafts vs. Sham; **p<0.01:2 
Grafts vs Sham 
Figure 1. Copulatory behavior in pituitary-grafted male rats.  
 
MF: Mount frequency. IF: Intromission frequency. EF: Ejaculation frequency.PEI: Post-ejaculatory interval *p<0.052 
Grafts vs. Sham;  
Figure 2. Copylatory behavior in pituitary-grafted male rats 
3. Effect of SAL on copulatory behavior 
Plasma PRL concentrations of control and SAL groups at 15 min before exposure to females 
were 7.3 ± 2.0 and 8.0 ± 1.5 ng/ml, respectively. Moreover, plasma PRL concentrations in 
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males immediately after exposure to the females were 7.4 ± 1.2 and 68.0 ± 5.9 ng/ml, 
respectively. All (8 out of 8) of the control animals ejaculated in the presence of the female, 
whereas only 33% (2 out of 6) of the SAL group ejaculated. An increasing tendency for 
mount latency and intromission latency as well as a decreasing tendency for intromission 









Control 7.3 ± 2.0 7.4 ± 1.2a 100% 
SAL 8.0 ± 1.5 68 ± 5.9 b 33% 
All data represent mean ± S.E. 
*p<0.05 a vs. b 
Table 2. Effect of SAL on Plasma PRL levels and copulatory behaviour 
4. Discussion 
In male subjects, parallel with the age related testosterone depletion, there is a gradual 
increase of plasma PRL, generally referred as hyperprolactinemia, which is strictly related 
with a decrease of libido, erectile dysfunctions and oligozoospermia. It is an important issue 
in humans, because the proportion of elderly generation increases in developed countries, 
therefore, they also face to the same problems. Our data confirm previous results that only a 
mild but sustained elevation of PRL secretion is enough for inhibiting copulatory behavior. 
However, the exact neuronal and/or endocrine background of these age-related changes is 
not completely known. Our results underline the relationships between DA and its 
metabolite, SAL, in the regulation of sexual behavior and put a new player into the focus of 
this field. SAL cannot pass the blood-brain barrier, therefore, it likely affects copulatory 
behavior out of this barrier. In theory, anterior lobe of the pituitary gland may be one of the 
sites. In spite of the well documented PRL releasing activity of SAL in vivo, it has been also 
shown that SAL does not have a significant PRL releasing activity in vitro. Therefore, it can 
be hypothesized that SAL induces an elevation of plasma PRL as well as inhibition of the 
copulatory behavior through indirect pathways, which can communicate with each other. 
Short time elevation of plasma PRL that can be detected after SAL treatment just before 
copulation may be enough to inhibit copulatory behavior, but it needs further 
investigations. 
Interestingly enough, SAL is also supposed to be formed after taking alcohol, and negative 
effect of alcohol on sexual behavior is also well known. Based on all of these, if we can learn 
more about the role of SAL in the regulation of sexual behavior, it shall be advantageous not 
only for basic research but it may give a chance to find the way to use agonists or 
antagonists of this molecule for using them in the medical or clinical fields. Although some 
progress has been made in identifying neurotransmitter-receptor effects on behavioral 
components of the copulatory behavior, but it is rather complex, and no drug has been 
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1. Introduction 
Prolactin (PRL) is one of several hormones that are produced by the pituitary gland. PRL 
has many different roles throughout the body, and most of those are clearly shown as 
clinical symptom. Perhaps the most important classical role of prolactin is to stimulate milk 
production in women after the delivery of a baby. Prolactin levels increase during 
pregnancy causing the mammary glands to enlarge in preparation for breastfeeding and 
ready to secrete colostrums closely after delivery. Later on the elevated prolactin levels help 
with the sustained production of milk during nursing. The somatomammotrop cells of the 
anterior pituitary gland synthesize and secrete prolactin, which is under the control of 
hypothalamic factors, mainly the tonic inhibition of Dopamine (DA). There are several other 
sources of PRL-like substances in the periphery such as placental lactogens, (similar to 
pituitary PRL), mammary gland (produced within the mammary epithelial cells), or PRL 
variants of immune cell origin (that modulates the immune system). (Gellersen,1989; 
Andersen 1990; Lkhider, 1996; Kurtz,1993; Gala, 1994, Montgomery,1990; Ben-Jonathan 
1996; Yu-Lee LY 1997) 
It is important to underline that serum PRL in normal individuals is considered as almost 
entirely pituitary PRL sources, the above mentioned extra pituitary-PRL may contribute 
significant amounts but either carries as specific function and target mainly to the local 
environment acting via paracrine/autocrine manner. (Yu-lee 1997; Bachelot 2007) 
During the first several months of breastfeeding, the higher basal prolactin levels also serve 
to suppress ovarian cyclicity , through the inhibition of pituitary hormones, mainly via LH 
suppression (Taya 1982) This is the reason why women who are breastfeeding do not get 
their periods and therefore do not often become pregnant. In actively breastfeeding mothers 
the related hyperprolactinaemia persisting even over a year. It was observed that extended 
lactational amenorrhea is associated with low LH levels, and interestingly suckling induced 
PRL elevation as a response has a positive effect on prolongation. (Diaz 1991; Diaz 1995). 
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Menstruation and ovulation may only occasionally occur before the drop of elevated basal 
PRL levels. As time goes on with less frequent breastfeeding, e.g. during weaning however, 
the PRL levels do not stay as high and the woman may start to ovulate. In cases of 
nonlactating/ nonbreastfeeding mothers, that may happen between 2-3 month after delivery. 
(Baird 1979) 
Similarly, elevated PRL levels are shown during gestation, but mechanisms to inhibit 
ovulation is related to elevated estardiol and progesterone levels and a consequent 
depression of pituitary FSH secretion (Marrs 1981). 
Generally, the lactogenic hormones play role also in regulation of reproductive function. On 
one hand, PRL is essential to maintain regular oestrus cycles. PRL knock out mice are 
completely infertile (Horsemann 1997). One of the other actions of PRL is to stimulate 
ovarian production of progesterone. That is required in the process of preparation for 
embryo implantation and it is dependent on a continued estrogen and progesterone 
secretion by the corpus luteum, which is supported by a functional pituitary during the first 
half of pregnancy in rodents. (Binart 2000)  
On the other hand, high prolactin levels are associated with anovulation or may 
cause directly or indirectly infertility. In young women, hyperprolactinemia is probably one 
of the most common endocrine disorders related to pituitary function. Women who are not 
pregnant and are not breastfeeding should have lower levels of basal PRL (typically 10–28 
μg/L in women and 5–10 μg/L in men are defined as “normal levels”) If a non-pregnant 
woman has abnormally high levels of PRL, it may cause her difficulty in becoming 
pregnant. It is considered as the most frequent cause of anovulatory sterility, although 
spontaneous pregnancy may occur occasionally. The prevalence of hyperprolactinemia 
varies in different patient populations, stays below 1% (0.4% in an unselected normal 
population) but can be as high as 17% of women with reproductive disorders shown at the 
clinics (Crosignani 1999) 
The suppression of pituitary hormones by PRL, similar that described during lactation has 
an indirect anovulatory effect. PRL however, acts also directly on the ovary to inhibit the 
hCG-induced follicle rupture, resulting in the inhibition of ovulation. (Yoshimura 1989).  
Clinically significant elevation of PRL levels may cause infertility in several different ways. 
First, prolactin may stop a woman from ovulating. If this occurs, a woman’s menstrual 
cycles will stop. In less severe cases, high prolactin levels may only disrupt ovulation once 
in a while. This would result in intermittent ovulation or ovulation that takes a long time to 
occur. Women in this category may experience infrequent or irregular periods. Women with 
the mildest cases involving high prolactin levels may ovulate regularly but not produce 
enough of the hormone progesterone after ovulation. This is known as a luteal phase defect. 
Deficiency in the amount of progesterone produced after ovulation may result in a uterine 
lining that is less able to have an embryo implant. Some women with this problem may see 
their period come a short time after ovulation (Shibli-Rahhal,2011) 
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Hyperprolactinemia is commonly found in both female and male patients with abnormal 
sexual and/or reproductive function or with galactorrhea. If serum prolactin levels are above 
200 μg/L, a prolactin-secreting pituitary adenoma (prolactinoma) is the underlying cause, 
but if levels are lower, differential diagnoses include the intake of various drugs, 
compression of the pituitary stalk by other pathology, hypothyroidism, renal failure, 
cirrhosis, chest wall lesions, or idiopathic hyperprolactinemia. When a pituitary tumour is 
present, patients often have pressure symptoms in addition to endocrine dysfunction, such 
as headaches, visual field defects, or cranial nerve deficits (Wang, 2012). The objectives of 
therapy are to improve the symptoms associated with high PRL levels and to reduce the size 
of a pituitary tumour.  
Pharmacotherapy is available to reduce the tumour size and consequently decrease PRL 
levels. The large majority of patients with prolactinomas, both micro- and 
macroprolactinomas, can be successfully treated with dopamine D2 receptor agonists as 
first-line treatment, with normalization of prolactin secretion and gonadal function, and 
with significant tumour shrinkage in a high percentage of cases, to prevent the need for 
surgery. In cases when the only cause of infertility is chronic anovulation due to 
hyperprolactinemia, a 60-80% pregnancy rate can be achieved. Surgical resection of the 
prolactinoma is the option for patients who may refuse or do not respond to long-term 
pharmacological therapy. Radiotherapy and/or estrogens are also reasonable choices if 
surgery fails. In patients with asymptomatic microprolactinoma no treatment needs to be 
given and a regular follow-up with serial prolactin measurements and pituitary imaging 
should be organized (Asa 2002; Crosignani 1999, Molitch 2003). 
The most commonly used dopamine agonists are bromocriptine, pergolide, quinagolide and 
cabergoline. When comparing the plasma half-life, efficacy and tolerability of these drugs 
are different, there is also important to evaluate the risk/ benefits profile of each product. As 
the current clinical practice, pharmacological treatment with dopamine agonist plays an 
important role. The recommendations on the most effective dosages and the advantages of a 
long term efficacy of products have been evaluated summarizing the results of case histories 
of the last decades. 
2. Clinical diagnosis of hyperprolactinemia 
A variety of etiological factors including disorders of the hypothalamo-pituitary axis, 
interruption of dopamine synthesis, stress, pituitary tumours, polycystic ovary syndrome, 
primary hypothyroidism, and various medications may lead to hyperprolactinemia (5). 
Hyperprolactinemia in girls causes delayed puberty, hypogonadotropic hypogonadism, 
primary or secondary amenorrhea, and galactorrhea (Fideleff, 2000). Hyperprolactinemia in 
men may result in as a first signs of decreased libido or impotence, however also cause 
inefficient sperm production and infertility (Colao, 2004). 
As one of the fist signs in women with high prolactin levels may have irregular periods or 
no periods at all. Another common symptom is “galactorrhea”, which is the occurrence of a 
milky discharge from the breast in a woman who has not recently been pregnant. The 
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discharge is the result of persistant high PRL levels stimulating the mammary gland for milk 
production. Some women may see galactorrhea occur spontaneously. Others may see it only 
if they squeeze their nipples.  
As diagnostic practice, after signs and labtests have been evaluated the magnetic resonance 
imaging (MRI) of the pituitary gland should be performed in all patients. A pituitary 
adenoma with a diameter of less than 1 cm is defined as “microadenoma” and one above 1 
cm in diameter as “macroadenoma”.  
3. Measurement of prolactin 
Prolactin can be measured with a simple blood test drawn at the fertility doctor's office. In 
order to get accurate results, prolactin should be drawn first thing in the morning. Since PRL 
may serve as a hormone to affect reproductive functions, sexual contact, stimulation of 
nipples in human may cause a not just immediate but also next-day-long alterations of the 
PRL secretory pattern. (Kruger 2012) These fluctuations are measured on the next day to 
produce a PRL elevation around noon, additional of the regular circadian rhythm of PRL 
levels, as the peak on the morning. Accordingly it is important to note that the woman 
should have the instructions to eat nothing from the night before and to avoid any 
stimulation of the breast and nipples, included sexual intercourse as well, from the day 
before also. 
Since stimulation of the breast /nipples (stress such as physical exam) may cause immediate 
release of PRL one common mistake that doctors make is to draw a prolactin blood test 
immediately after a patient has had a breast exam in the office. These women will have high 
prolactin levels because of the exam and therefore they may show false (i.e. transient) 
increase of PRL levels. Prolactin should also be drawn early in the menstrual cycle - before 
ovulation. This is because prolactin levels are naturally higher after ovulation. 
A prolactin level of 5-20 ng/mL is considered normal in both sexes, according to some 
laboratories and test references the male and female (a bit higher) normal range may differ. 
A level above 20 ng/mL in two successive measurements is defined as hyperprolactinemia 
(7). According to WHO standards: 1 μg/L = 21.2 mIU/L. PRL levels > 250 ng/mL usually 
indication for prolactinoma, when PRL > 500 ng/mL it is considered as diagnosis for 
macroprolactinoma. (Melmed, 2011) 
There are cases when false positive and elevated PRL levels are measured: two high 
molecular mass forms of prolactin (PRL) in serum have been identified: macroprolactin (big-
big PRL, > 100 kDa) and big PRL (40-60 kDa). Big PRL is a consistent “normal” component 
of total serum PRL but rarely cause of hyperprolactinemia. Macroprolactin is usually a 
complex of PRL and IgG in composition, it is formed in the circulation from monomeric PRL 
with a molecular mass of 150-170 kDa, but may have some additional variability in 
composition. In labor tests the PRL in the complex remains reactive to a variable extent in 
immunoassays. Individuals may show a different pattern of % of these variants, or even can 
be a predominant immunoreactive component of circulating PRL and the cause of apparent 
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hyperprolactinemia, but it has minimal bioactivity in vivo and is not of pathological 
significance. As necessary the reference technique of gel filtration chromatography at the 
laboratory should be available for confirmation and request on investigation of samples to 
avoid confusion of diagnostics. (Fahie-Wilson 2005) 
4. Causes of high prolactin levels  
4.1. Pituitary tumours  
Pituitary adenomas are the most common tumour type in the pituitary gland. There is 
approximately 10% incidence was shown obtained by post-mortem autopsy, with similar 
ratio of male and female patients. The most frequently detected tumours (over 39%) are 
sparsely granulated PRL cell adenomas. The others types are GH cell or mixed PRL/GH 
adenoma, ACTH cell adenoma/Crooke’s cell adenoma (~14%) ; Gonadotroph cell adenoma 
(6.6%); Null cell adenoma/oncocytoma (~32%) and other or unclassified types (Buurman, 
2006).  
Invasive tumours with multiple recurrences are only classified as aggressive tumours or 
"atypical adenomas". Tumours with systemic metastasis must be considered as carcinomas, 
and “only” make up 0.1% to 0.2% of all pituitary tumours, but with very poor prognostics of 
66% mortality (Oh, 2012). However it was suggested that a full picture inlcuded clinical 
signs (gender, DA-resistant hyperprolactinemia, etc) , radiological status (invasive macro or 
giant tumour) and histological signs of angiogenesis, mitoses level, vascular invasion and 
molcular biology parameters (Ki-67 > 3 %, p53 positive, up-regulation of genes related to 
invasion and proliferation, and allelic loss of chromosome 11) should be taken into account 
considering the potential malignancy, prognosis of prolactin secreting tumours and identify 
the optimal therapy as early as possible. The key question is to identify factors associated 
with tumour aggressiveness. The approach combined genomic and transcriptomic analysis 
focus to the subtype of pituitary tumour able to identify molecular events associated with 
the aggressive and malignant phenotypes. Allelic loss in certain loci of chromosome 11 has 
been detected in tumours with signs of malignancy, potentially responsible for triggering 
the aggressive and malignant phenotypes. Within the recent years there are an increasing 
number of genes or molecular signs that has been associated with pituitary tumorigenesis to 
develop predictive and potential prognostic markers. (Zemmoura, 2012; Dworakowska, 
2012; Wierinckx 2011)  
About one-third of all pituitary tumours are not associated with hypersecretory syndromes 
but, rather, present with symptoms of an intracranial mass, such as headaches, nausea, 
vomiting or visual field disturbances. Only rare cases of pituitary tumours are considered as 
malignant prolactinoma. Tumours that produce growth hormone (GH) may also secrete 
prolactin in nearly 25% of cases. This is a common source of misdiagnosis, as the features of 
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hyperprolactinemia, but it has minimal bioactivity in vivo and is not of pathological 
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4.1.1. Characteristics of pituitary adenomas 
In some people, a small group of cells may form a cyst in the pituitary gland which 
produces elevated levels of prolactin. These cysts are called prolactinomas or pituitary 
adenomas. It is unclear exactly how these cysts get started. Recent investigations on 
pituitary tumours reported that approximately 12% of pituitary glands (obtained by autopsy 
of 3048 patients) are shown histologically diagnosed but clinically inapparent adenoma. 
Among the mean tumour size is approx 1.9mm. According to published data two-thirds of 
adenomas has a tumour size <3 mm, half of them were smaller than 1 mm in diameter and 
~23% was between 3-10mm. In this study only few (3/76) tumours were identified as 
macroadenomas corresponding to a tumour size >10 mm. (Buurman, 2006)  
The prevalence of clinically apparent prolactinomas ranges from 6–50/ 100,000 in reported 
populations (Daly, 2006; Fernandez 2010). The prevalence of “ever-treated“ 
hyperprolactinemia is approximately 20 /100,000 in male patients and approximately 90 
/100,000 in female patients. (Kars, 2009) 
The adenomas can be seen and measured using MRI and classified based on their size.  
Small adenomas are known as microadenomas. They measure less than one centimetre in 
diameter. This is the most common type of adenoma found. Microadenomas can even be 
present in healthy people who do not have high prolactin levels. Microadenomas can be 
treated with medication. They do not grow large and do not need to be treated if hormone 
levels are normal. Microprolactinomas usually follow a benign course and rarely progress to 
macroprolactinomas. However, in rare cases microadenoma may transform to other 
tumours. 
 A case history it was reported that a microadenoma transformed to macroprolactinoma 
within 10 month, probably due to estrogen therapy applied. The case report emphasizes 
the role of dopaminergic agonist in treatment of hyperprolactinemia. (Garcia, 1995) 
 A case history of a 22 -year-old woman with the signs of galactorrhea and slight 
hyperprolactinemia , showed 7-mm intrapituitary lesion which responded to treatment 
with cabergoline. This PRL-secreting microadenoma has a sudden change within 4 
years of diagnose. The case represents a rapid evolution from a microprolactinoma 
initially responding to dopamine agonists to a fatal pituitary carcinoma. 
(Guastamacchia, 2007) 
Adenomas larger than 1 centimetre are called macroadenomas. If untreated, 
macroadenomas can grow further and start to compress the nearby tissues and structures 
causing life-threatening events or even fatal outcome. The closest structures are the optic 
nerves, internal carotid arteries. If a macroadenoma causes compression of the optic nerves, 
partial blindness can result. For this reason, it is important to treat macroadenomas whether 
or not a woman is interested in getting pregnant. Medication can be used to treat them but if 
that fails, surgery may be necessary. 
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 According to a recent clinical study in Japan, treatment with Cabergoline achieved a 
high pregnancy rate with uneventful outcomes in infertile women with prolactinoma, 
independent of tumour size and bromocriptine resistance or intolerance. Over 90% of 
patients in the study conceived pregnancies, and one-third of the macroprolactinomas 
disappeared. Cabergoline monotherapy could serve as an alternative of the conventional 
combination bromocriptine therapy with surgery or irradiation in macroprolactinomas. 
(Ono, 2010) 
4.2. Hypothyroidism  
The hyperprolactinemia of hypothyroidism is related to several mechanisms. In response to 
the hypothyroid state, a compensatory increase in the discharge of central hypothalamic 
thyrotropin releasing hormone (TRH) results in increased stimulation of prolactin secretion. 
Although TRH was originally named for its ability to trigger the release of thyroid-
stimulating hormone (TSH) in mammals, it became apparent that TRH exerts multiple 
hypophysiotropic activities also in human. Stimulation with TRH will provide a diagnostic 
test to demonstrate a TSH release curve typical of the subclinic hypothyroidism. PRL is 
under tonic inhibition by the hypothalamus by way of the PRL inhibitory factor, DA. PRL-
releasing factors include TRH., Increased release of TRH may also cause a sustained 
stimulation of prolactin release from the pituitary gland. There are several clinical reports 
presented the correlation between subclinic hypothyroidism-hyperprolactinemia and 
sterility. Treatment with thyroid hormone supplements will result in correction of both the 
thyroid feedback and the high prolactin levels.  
4.3. Macroprolactinemia 
Asymptomatic patients with intact gonadal and reproductive function and moderately 
elevated prolactin levels may have macroprolactinemia (Vallette-Kasic, 2002). 
Hypersecretion of PRL by lactotroph cells of the anterior pituitary cause 
hyperprolactinemia. Patients with hyperprolactinemia may have radiologically undetected 
microprolactinomas, but some of them may present other causes of hyperprolactinemia 
characterised as a symptom of macroprolactinemia, with a predominance of higher 
molecular mass prolactin forms (big-big prolactin, MW > 150 kDa). This term should not be 
confused with macroprolactinoma, which refers to a large pituitary tumour greater than 10 
mm in diameter. 
The prevalence of macroprolactinemia varies between 15-46% in hyperprolactinemic 
populations, and it may because confusing tests results that could not be differentiated from 
true hyperprolactinemic patients, on the basis of clinical features alone. The 
pathophysiology of macroprolactinemia is based on a mechanisms of the increased 
antigenicity of these molecules, leading to the appearance of autoantibodies against PRL, 
which can consequently reduce the bioactivity of PRL and provide extended half-life. 
Therefore macroprolactinemia is manifested with less frequent clinical symptoms in 
macroprolactinemic patients and the tests results mainly due to the delayed clearance of 
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PRL. According to recent publications of Isik et al, evaluating over 300 hyperprolactinemic 
patients, over 26% of them resulted in elevated macroprolactin levels, with the less frequent 
signs of galactorrhea or abnormal MRI results compared those to patients with predominant 
monomer hyperprolactinemia. The other symptoms and frequency of amenorrhea, 
infertility, irregular menses, gynecomastia, and erectile dysfunction were similar in both 
groups. (Isik, 2012) 
Macroprolactinemic patients have no clinical symptoms of hyperprolactinemia and may 
have no pituitary adenomas. It is still controversial whether macroprolactinemia is a benign 
condition that does not need further investigation and treatment. Patients can be screened 
for macroprolactinemia by PEG (polyethylene glycol) precipitation as a standard laboratory 
test with a results of recovery of ≤40% to normal monomeric PRL level is used as an 
indication of macroprolactinemia (Tamer, 2012). The clinical importance of this test is based 
on the lower prevalence of pituitary adenomas in this group, compared to “true 
hyperprolactinemic” patients. 
4.4. PCOS (polycystic ovary syndrome)  
PCOS is a common problem that can cause infertility by inhibiting ovulation, affecting 3.5-
10% of the reproductive age of women. For unknown reasons, some women with PCOS 
may have slightly high PRL levels. PCOS similar to hypoprolactinemic are both common 
causes of secondary amenorrhoea in women. The relationship between PCOS and 
hyperprolactinemia so far has been reported still with controversial results: it seems that 
PCOS is very prevalent with hyperprolactinemia, nevertheless there are different reasons of 
altered regulation of gondotropin secretion, and suggests that these conditions have 
independent origins. Recent investigators using serial serum sampling have excluded 
transient elevations of PRL and have shown a less frequent association of these two 
disorders. According to clinical guidelines PCOS patients with increased PRL levels must be 
investigated for other causes of hyperprolactinemia, because hyperprolactinemia may be 
due to a reason of concomitant disease, but not proved the cause-relationship to PCOS. 
Treatment of infertility associated with PCOS has changed in the last decade due to the 
introduction of new medications such as insulin-sensitizing drugs, aromatase inhibitors, 
gonadotropin treatment etc. (Bracero 2001, Urman, 2006, Escobar-Morreale, 2004) 
 In a study conducted in Brazil, among the 82 PCOS women, 13 (16%) presented high 
PRL levels (over 100 microg/l). There were several reasons of hyperprolactinemia: 
pituitary adenoma; drug-induced hyperprolactinemia, or macroprolactinemia. The non-
hyperprolactinemic PCOS patients (over 80%) represented normal PRL levels. The 
authors concluded that hyperprolactinemia is not a clinical manifestation of PCOS. 
(Filho, 2007) 
4.5. Medications 
Some medications can cause higher levels of prolactin to be produced. The most common 
medications that do this are known as anti-psychotic medications. The antipsychotics mostly 
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act as dopaminergic neurotransmitters/ receptor blockers can also cause endocrine side 
effects, as hyperprolactinaemia and it is most common side effect of first-generation 
antipsychotics. The second- and thirdgeneration antipsychotics have a weaker affinity for 
D2 dopamine receptors, thus hyperprolactinemia is less common when such medication is 
used. (Uzun et al. 2005). The risk of side effects caused by antipsychotics is individual and it 
does not depend solely on the therapeutic dose and may have influence on some 
predisposing conditions. (Ružić 2011) 
Other medications which may increase prolactin levels: 
 Some types of anti-depressants, serotonin reuptake inhibitors, SRIs (fluvoxamine; 
fluoxetine; paroxetine, duloxetine etc) 
 Some types of sedatives 
 Catecholamine depletor 
 Dopamine synthesis inhibitor 
 Neuropeptides 
 Anticonvulsants 
 Opiates and opiate antagonists 
 Estrogen Oral contraceptives (birth control pills) 
 Some types of blood pressure medications (methyldopa, verapamil) 
 A medication for nausea (Reglan, metoclopramide) 
 Antacids (cimetidine) 
4.6. Stress 
A high prolactin level can sometimes be related to physical stress. Even drawing blood can 
by itself cause someone to produce and immediate prolactin-release. PRL eleveation can also 
detected in response to strong or sudden external stimuli in general, such as stressful 
environmental conditions, or can be related to physchological reasons. This latter can be 
evaluated by stress profile or measured by experimental conditions, such as “Screamer 
Index”, which is shown resulting in values to be parallel to levels of hyperprolactinemia in 
women. (Harrison, 1988; Cepisky, 1992). On the other hand, anxiety and irritability maybe a 
result of hyperprolactinemia. In rat models PRL increased the stimulatory effect of ACTH-
induced corticosterone secretion (Jaroenporn, 2007).  
 Endocrine abnormalities are frequently associated with a wide range of psychological 
symptoms. These symptoms may reach the level of psychiatric illness (mainly mood 
and anxiety disorders) or just being identified by the subclinical forms of assessment 
provided by the Diagnostic Criteria for Psychosomatic Research (DCPR). In a 
population study reported by Sonino et al, (2007), the majority of patients suffered from 
at least one of the three DCPR syndromes considered: irritable mood (over 45%), 
demoralization, persistent somatization. Long-standing endocrine disorders may imply 
a degree of irreversibility of the pathological process. Endocrine treatment may cause 
even the worsening of psychological symptoms. The methodology and assessment 
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score provided by DCPR tests have been demonstrated to be a valuable tool for 
psychological assessment in endocrine disease from diagnostic to follow-up periods. 
(Sonino 2007) 
 In clinical environment the variability of PRL concentration in random estimations 
underline the need for special testing to rule out stress-related hyperprolactinemia and 
diagnostic pitfalls. It was recommended by the results, that two or three serial PRL 
determinations in resting conditions provide more reliable results (Muneyyirci-Delale, 
1989). 
 In experimental conditions, hyperprolactinemia and stress interact differentially 
according to the length of the stimuli and that is connected to the immune response 
modulated by PRL. Surgical or restraint stress induce marked (2x- 4x) increase of 
plasma PRL of control rats, but interestingly did not change the PRL levels of 
hyperprolactinemic rats. In both cases the plasma glucose levels reported elevated 
(Reis, 1996). 
 It is suggested as a result of a retrospective observational study, that life events such as 
changes in subject’s social or personal environment indicated that these stressful 
conditions may provoke hyperprolactinemia. Even an exposure during childhood to a 
stressful environment maybe associated with hyperprolactinemia and/or galactorrhea 
later in life as a response to specific environmental changes (Sobrinho, 1984). Patients 
with hyperprolactinemia reported significantly more life events, these events rated as 
being of „moderate”, marked or severe „negative” impact compared with control 
subjects (Sonino, 2004).  
 There is evidence that several external stress-factors may contribute to the occurrence of 
hyperprolactinemia. In theory, stress might have been involved in facilitation of a clonal 
proliferation of a single mutated cell and cause prolactinomas. Patients in functional 
hyperprolactinemic status, stress might trigger neuroendocrine changes involving DA 
and/or serotonin, which both can consequently affect PRL release. (Verhelst, 2003; 
Freeman, 2000; Fava, 1981.) 
5. Hyperprolactinemia and infertility 
Prolactin is a pituitary-derived hormone that plays an important role in a variety of 
reproductive functions. It is an essential factor for normal production of breast milk 
following childbirth. Additionally, prolactin negatively modulates the secretion of pituitary 
hormones responsible for gonadal function, including luteinizing hormone and follicle-
stimulating hormone. Clnincally significant hyperprolactinemia may result in 
hypogonadism, infertility, and galactorrhea, or in some cases it may remain asymptomatic 
for a long period. (Klibanski 2010) The most commonly cited indications for treatment of 
microprolactinomas is infertility and hypogonadism. Hypogonadism and infertility 
associated closely with the treatment: DA agonists can restore normal PRL levels and 
consequently the normal gonadal function . According to the date of a meta-analyis, patients 
treated with bromocriptine had normalization of prolactin levels and it was successful in 
53% of patients with infertility. Studies with cabergoline showed similar results: cabergoline 
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was shown more effective than bromocriptine reducing PRL levels, or in symptoms of 
amenorrhea/oligomenorrhea, or in some of the patient-important outcomes. (Gillam 2006; 
Wang 2012)  
Prolactin is under dual regulation by hypothalamic hormones delivered through the 
hypothalamic–pituitary portal circulation. The differential diagnosis and causes of 
pathological hyperprolactinemia are summarized in Figure 1. 
The predominant signal is inhibitory, preventing prolactin release, and is mediated by the 
neurotransmitter dopamine. The stimulatory signal is mediated by the hypothalamic TRH. 
The balance between the two opposite signals determines the amount of prolactin released 




Figure 1. Prolactin is under dual control from the hypothalamus. 
6. Hyperprolactinemia management  
 The first steps in cases of signs of hyperprolactinemia should be a critical diagnosis, as 
discussed above, may involve dynamic testings, assessment for macroprolactinemia 
and further laboratory tests to eliminate false positive or negative results. 
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(Sonino 2007) 
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for a long period. (Klibanski 2010) The most commonly cited indications for treatment of 
microprolactinomas is infertility and hypogonadism. Hypogonadism and infertility 
associated closely with the treatment: DA agonists can restore normal PRL levels and 
consequently the normal gonadal function . According to the date of a meta-analyis, patients 
treated with bromocriptine had normalization of prolactin levels and it was successful in 
53% of patients with infertility. Studies with cabergoline showed similar results: cabergoline 
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was shown more effective than bromocriptine reducing PRL levels, or in symptoms of 
amenorrhea/oligomenorrhea, or in some of the patient-important outcomes. (Gillam 2006; 
Wang 2012)  
Prolactin is under dual regulation by hypothalamic hormones delivered through the 
hypothalamic–pituitary portal circulation. The differential diagnosis and causes of 
pathological hyperprolactinemia are summarized in Figure 1. 
The predominant signal is inhibitory, preventing prolactin release, and is mediated by the 
neurotransmitter dopamine. The stimulatory signal is mediated by the hypothalamic TRH. 
The balance between the two opposite signals determines the amount of prolactin released 




Figure 1. Prolactin is under dual control from the hypothalamus. 
6. Hyperprolactinemia management  
 The first steps in cases of signs of hyperprolactinemia should be a critical diagnosis, as 
discussed above, may involve dynamic testings, assessment for macroprolactinemia 
and further laboratory tests to eliminate false positive or negative results. 
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 Consider other underlying causes, such as suspected drug-induced hyperprolactinemia, 
hypothyroidism, elimination/renal failure, other persistent pituitary and parasellar 
tumours, etc. 
 Identify the size of pituitary tumour and other anatomical circumstances. 
 Apply pharmacotherapy treatment specified to patient 




Figure 2. Approach to diagnosis of hyperprolactinemia. 
7. Recommendations for the diagnosis of hyperprolactinemia  
Specific recommendations for diagnosis of hyperprolactinemia include the following 
(Melmed 2011): 
 A single measurement of serum prolactin level can confirm the diagnosis if the level is 
above the upper limit of normal and the serum sample was obtained without excessive 
venipuncture stress. Dynamic testing of prolactin secretion is not recommended to 
diagnose hyperprolactinemia. 
 Macroprolactin evaluation is recommended in patients with asymptomatic 
hyperprolactinemia. 
 When there is a discrepancy between a very large pituitary tumour and a mildly 
elevated prolactin level, serial dilution of serum samples is recommended to eliminate 
the "hook effect," or an artifact that can occur with some immunoradiometric assays 
leading to a falsely low prolactin value. 
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8. Recommendations for drug-induced hyperprolactinemia 
Specific recommendations for management of drug-induced hyperprolactinemia are as 
follows (Melmed 2011): 
 In a symptomatic patient with suspected medication-induced hyperprolactinemia, the 
drug should be discontinued for 3 days or an alternative drug substituted, and the 
serum prolactin measurement should then be repeated. However, the patient's 
physician should be consulted before an antipsychotic agent is discontinued or 
substituted. If the drug cannot be discontinued and the onset of the hyperprolactinemia 
does not coincide with starting therapy, magnetic resonance imaging (MRI) of the 
pituitary gland may distinguish medication-induced hyperprolactinemia from 
symptomatic hyperprolactinemia caused by a pituitary or hypothalamic mass. 
 Patients with asymptomatic medication-induced hyperprolactinemia should not be 
treated. Estrogen or testosterone can be used in patients with long-term hypogonadism 
(hypogonadal symptoms or low bone mass) caused by medication-induced 
hyperprolactinemia. 
 If it is not possible to stop the drug causing medication-induced hyperprolactinemia, 
cautious administration of a dopamine agonist should be considered, in consultation 
with the patient's physician. 
9. Treatment of hyperprolactinemia 
As noted above, prolactin levels can often be corrected by stopping suspected medication or 
switching to a different medication type. Correction of hypothyroidism is also effective and 
specific to reduce PRL levels. If prolactin levels are persistently high, they can be effectively 
treated with a group of medications known as dopamine agonists. 
According to our clinical practice patients with macroadenoma suggested to undergo 
transsphenoidal pituitary surgery. Medical treatment is given to the subjects with 
microadenoma, persistent postoperative hyperprolactinemia, and to those cases of 
hyperprolactinemia when it is caused by other medications.  
From the available mediactions Bromocriptine 2.5 mg (Parlodel®, Novartis) once or twice a 
day or cabergoline 0.5 mg (Dostinex®, Pharmacia) once or twice a week is given as 
prolactin-lowering drug. 
9.1. Bromocriptine (Parlodel) 
Parlodel is an effective and inexpensive medication for high prolactin levels. Parlodel is 
usually taken at bedtime with a snack. This is because Parlodel will occasionally cause 
dizziness or stomach upset, so taking it before sleep and with food will reduce those side 
effects. Generally with time, the side effects stop anyway.  
The prolactin levels can be rechecked in about three weeks. If the levels are still elevated the 
dose can be increased or a different medication can be tried. The administration of Parlodel 
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can be stopped upon diagnosis of pregnancy. However, if a woman has a macroadenoma, 
Parlodel should be continued through pregnancy and delivery. 
Due to the side effects, some women can not tolerate Parlodel. For these women, they may 
try alternatives, e.g. vaginal bioadhesive suppositories or inserted the pills vaginally instead 
of taking them orally.  
9.2. Cabergoline (Dostinex) 
Because it is more expensive, cabergoline is not usually the first choice for treatment of high 
prolactin levels. It is usually used when Parlodel is ineffective or a woman cannot tolerate 
the side effects. Cabergoline is a longer acting medication. It is usually given twice a week 
instead of every day. 
The Endocrine Society has released a new clinical practice guideline for the diagnosis and 
treatment of patients with hyperprolactinemia (Melmed, 2011). The new recommendations 
for management of elevated levels of the PRL, which is associated with infertility, low sex 
drive, and bone loss, are listed. 
10. Recommendations for the treatment of prolactinoma 
Specific recommendations for management of prolactinoma are as follows (Melmed 2011):: 
 Dopamine agonist therapy is recommended to reduce prolactin levels and tumor size 
and to restore gonadal function in patients with symptomatic prolactin-secreting 
microadenomas or macroadenomas. Compared with other dopamine agonists, 
cabergoline is more effective in normalizing prolactin levels and in shrinking pituitary 
tumours. 
 Dopamine agonists are not recommended for asymptomatic patients with 
microprolactinomas. However, patients with microadenomas who have amenorrhea 
can be treated with a dopamine agonist or oral contraceptives. 
 In patients treated with dopamine agonists for at least 2 years who no longer have 
elevated serum prolactin levels or visible tumour on MRI, careful clinical and 
biochemical follow-up therapy may be tapered and perhaps discontinued. 
11. Recommendations for resistant, malignant prolactinoma 
Specific recommendations for management of resistant and malignant prolactinoma are as 
follows (Melmed 2011): 
 For symptomatic patients in whom normal prolactin levels are not achieved or who 
have significant shrinking of the tumour size while receiving standard doses of a 
dopamine agonist, the dose should be increased rather than referring the patient for 
surgery. 
 Patients resistant to bromocriptine should be switched to cabergoline. 
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 Symptomatic patients with prolactinomas who cannot tolerate high doses of 
cabergoline or who are unresponsive to dopamine agonist therapy should be offered 
trans-sphenoidal surgery. Patients intolerant of oral bromocriptine may respond to 
intravaginal administration. Radiation therapy is recommended for patients in whom 
surgical treatment fails or for those with aggressive or malignant prolactinomas. 
 Temozolomide therapy is recommended for patients with malignant prolactinomas. 
12. Recommendations for pregnant women with prolactinoma 
Specific recommendations for management of prolactinoma during pregnancy are as 
follows (Melmed 2011): 
 Women with prolactinomas should discontinue dopamine agonist therapy as soon as 
pregnancy is recognized, except for selected patients with invasive macroadenomas or 
adenomas abutting the optic chiasm. 
 Serum prolactin measurements should not be performed during pregnancy. 
 Unless there is clinical evidence for tumour growth, such as visual field impairment, 
routine use of pituitary MRI during pregnancy is not recommended in patients with 
microadenomas or intrasellar macroadenomas. 
 Women with macroprolactinomas that do not shrink during dopamine agonist therapy 
or women who cannot tolerate bromocriptine or cabergoline should be counselled 
regarding the potential benefits of surgical resection before attempting pregnancy. 
 Pregnant women with prolactinomas who experience severe headaches and/or visual 
field changes should have formal visual field assessment followed by MRI without 
gadolinium. 
 Bromocriptine therapy is recommended in patients who experience symptomatic 
growth of a prolactinoma during pregnancy. 
Hyperprolactinemia has been proposed to block ovulation through inhibition of GnRH 
release. Kisspeptin neurons, which express prolactin receptors, were recently identified as 
major regulators of GnRH neurons. A recently published study demonstrated 
that hyperprolactinemia in mice induced anovulation, reduced GnRH and gonadotropin 
secretion, and diminished kisspeptin expression. Kisspeptin administration restored 
gonadotropin secretion and ovarian cyclicity, suggesting that kisspeptin neurons play a 
major role in hyperprolactinemic anovulation. This study indicate that administration of 
kisspeptin may serve as an alternative therapeutic approach to restore the fertility of 
hyperprolactinemic women who are resistant or intolerant to dopamine agonists (Sonigo, 
2012). 
To sum up, the systematic reviews and meta-analyses affirm the use of dopamine agonists 
in treating hyperprolactinemia and reducing associated morbidity. Cabergoline was found 
to be more effective than bromocriptine in achieving normoprolactinemia and resolving 
amenorrhea/oligomenorrhea and galactorrhea. Radiotherapy and surgery are efficacious in 
patients with resistance or intolerance to dopamine agonists (Wang, 2012). 
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 Symptomatic patients with prolactinomas who cannot tolerate high doses of 
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intravaginal administration. Radiation therapy is recommended for patients in whom 
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Hyperprolactinemia is defined as higher-than-normal blood levels of the hormone prolactin. 
This hormone is made by the pituitary gland, which is located at the base of the brain. The 
main function of prolactin is to stimulate breast milk production after childbirth. High 
prolactin levels are normal during pregnancy and breastfeeding. In other cases, prolactin 
can become too high because of a disease or the use of certain medications. Often, the cause is 
a prolactin-producing tumour in the pituitary gland, called a prolactinoma. This tumour is 
mostly benign (adenomas), meaning not invasive (invasive tumours with multiple recurrences 
are “atypical adenomas”), and not metastatic (malignant tumours, carcinomas). It is more 
common in women than men. Rarely, children and adolescents develop prolactinomas. Other 
brain tumours may also cause the pituitary gland to make too much prolactin. 
Prolactin-secreting pituitary tumours are a common cause of amenorrhea and infertility in 
premenopausal women. The goals of therapy are to normalize prolactin, restore gonadal 
function and fertility, and reduce tumour size, and dopamine agonists are the preferred 
therapy. Clinically significant tumour enlargement during pregnancy is uncommon and 
dependent on tumour size and pre-pregnancy treatment. 
Accroding to over 180 clinical study reports (across 3000 patients) treatment with 
bromocriptine or with cabergoline are both effective in normalization of prolactin levels and 
also successful in restoration of fertility over 53% of patients. Cabergoline was shown more 
effective than bromocriptine in persistent hyperprolactinemia, and reducing the symptoms 
of amenorrhea/oligomenorrhea. At our institution patients with symptomatic 
prolactinomas, both micro- and macroadenomas, are treated with cabergoline as the first-
line approach. In the small group of patients who do not respond to this treatment, or who 
refuse long-term therapy, surgery is offered. Radiotherapy is given if both pharmacologic 
therapy and surgery fail. 
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1. Introduction 
A consensus view developed over the last decades holds that the basal secretion of PRL from 
the anterior lobe (AL) is spontaneous (i.e., occurs without stimulation by the hypothalamus) 
(Neill 1994; Freeman 2000) since PRL is secreted from lactotropes with a high secretory rate for 
prolonged periods after disconnecting the hypothalamic influence (when it transplanted to a 
site distant from the hypothalamus under the kidney capsule or when cultured in vitro). 
Consequently, PRL secretion appears to be severely restrained by the hypothalamus in vivo as 
the main source prolactin inhibiting factor (PIF). Results of the extensive research of the last 
decades have clearly demonstrated that the withdrawal of DA tone is not sufficient to account 
for the surge of PRL secretion observed in response to the suckling (physiological) stimulus 
during lactation. Similarly, DAerg tone would not completely recover the chronic elevation of 
PRL during pregnancy, lactation or in other pathophysiological stages. The research has 
subsequently included the search for putative prolactin-releasing factors (PRF) controlling PRL 
peaks occurring after mating or triggered by ovarian steroids. These can be termed by central 
(i.e hypothalamic) or peripheral (within the pituitary gland) sites of actions. However, it may 
be better to classify them by the levels of control mechanisms to regulate PRL secretion: (i) 
action on hypothalamic DAerg neurons; (ii) binding to specific receptors on lactotrophs in the 
pituitary gland; (iii) paracrine/autocrine compounds.  
i. The hypothalamic regulating factors acting on hypothalamic DAergic neurons may have 
direct activation or inhibition of their activity, or alter DA, resulting in a consequent 
changes in PRL secretion (Freeman, 2000; Ben-Jonathan, 2008). The final common 
pathways of the central stimulatory and inhibitory control are the neuroendocrine 
neurons producing DA available to be delivered into the hypophyseal portal vessels or 
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the main source prolactin inhibiting factor (PIF). Results of the extensive research of the last 
decades have clearly demonstrated that the withdrawal of DA tone is not sufficient to account 
for the surge of PRL secretion observed in response to the suckling (physiological) stimulus 
during lactation. Similarly, DAerg tone would not completely recover the chronic elevation of 
PRL during pregnancy, lactation or in other pathophysiological stages. The research has 
subsequently included the search for putative prolactin-releasing factors (PRF) controlling PRL 
peaks occurring after mating or triggered by ovarian steroids. These can be termed by central 
(i.e hypothalamic) or peripheral (within the pituitary gland) sites of actions. However, it may 
be better to classify them by the levels of control mechanisms to regulate PRL secretion: (i) 
action on hypothalamic DAerg neurons; (ii) binding to specific receptors on lactotrophs in the 
pituitary gland; (iii) paracrine/autocrine compounds.  
i. The hypothalamic regulating factors acting on hypothalamic DAergic neurons may have 
direct activation or inhibition of their activity, or alter DA, resulting in a consequent 
changes in PRL secretion (Freeman, 2000; Ben-Jonathan, 2008). The final common 
pathways of the central stimulatory and inhibitory control are the neuroendocrine 
neurons producing DA available to be delivered into the hypophyseal portal vessels or 
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to be released to pituitary neurointermediate (NIL) lobe in order to reach ultimately the 
anterior lobe (AL). 
 Prolactin itself, bombesin, gastrin-releasing peptide (GRP), neuromedins B and C, 
neurotensin, neuropeptide Y, acetylcholine (Ach), PACAP, angiotensin II, 
calcitonin, atrial natriuretic peptide (ANP) family members demonstrated to 
stimulate tyrosine-hydroxilase (TH) activity, increase DA release and a consequent 
depression in PRL secretion. 
 Others induce opposite effect, such as opioids, norepinephrine, somatostatin, CCK, 
serotonin, and GABA act as inhibitors on TH activity of TIDA cells and associated 
with PRL release.  
 Several compounds (e.g. TRH, oxytocin, VIP, neurotensin, neuropeptide Y, 
histamine, acetylcholine, somatostatin, CCK) may have different central or 
peripheral effect or exert dual phase actions on PRL release.  
ii. The other group of regulators of PRL secretion act directly on lactotrophs. These 
hypothalamic releasing/inhibiting factors bind to specific receptors on pituitary 
lactotrophs, cause alterations in expression or release of PRL resulting in changes of 
secretion pattern. PIF and PRF from the neuroendocrine neurons can be released either at 
the level of median eminence (ME) into the long portal veins or at the level of NIL, which is 
indirectly connected to the anterior lobe of the pituitary gland by the short portal vessels.  
iii. Additional to the hypothalamic PRF and PIF factors, lactotrophs are also influenced by 
compounds that released from the surrounding cells and act as a paracrine regulation or 
potentially from the lactotrophs themselves via autocrine regulation. These putative 
paracrine or autocrine factors or combined interactions are potentially also responsible 
for regulation of PRL release, but the robust and dynamic regulation of PRL secretion 
more likely controlled and strongly relies on hypothalamic factors (vide supra). 
On the other hand, there is an ever-growing list of peptides with the potential to act as 
intrapituitary agent to control PRL secretion, and even more of those which may have dual 
features: enhance or suppress PRL release in the presence/ absence of other factors. That is a 
challenge for researchers to demonstrate the presence and to prove the precise mode of 
actions, since data obtained from in vitro, in vivo or ex vivo experiments may have 
discrepancies in results. The effect of a putative autocrine-paracrine control is also hard to 
demonstrate, since the active substance may have an extremely low local level. Detection 
however, on a single cell level of PRL release; or by presence of those factors using 
immunocytochemistry and in situ hybridization, or a combination of these techniques has 
been found successful. The list of proved factors that act as a local regulator on pituitary 
lactotroph cells considered as a cumulative contributions of “Pros and Cons” over the last 
two-three decades (Freeman 2000; Wenger 1999; Takaya 2000; Brogilo, 2008; Ondo, 1989; 
Schettini, 1990; Ben-Jonathan, 2008; Toth 2001; Rettori, 2011): 
Suppress/ inhibit PRL secretion:  
 dopamine (DA),  
 somatostatin (SST), cortistatin (CST), 
 gamma-aminobutyric acid (GABA),   
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 calcitonin (in vitro) 
 prolactin (PRL), 
 TGF- isoforms, 
 endothelin-like peptides, ET1, 
 acetylcholine (ACh), 
 glucocorticoids, 
 cannabinoids, 
 adenosine or analogues (in vitro). 
Stimulate/enhance PRL secretion:  
 VIP, 
 TRH (locally in anterior pituitary), 
 oxytocin (OT), 
 dopamine (DA, in certain low concentrations only)  
 cytokines/ IL6, IL1, 
 EGF, 
 vasopressin (VP), 
 angiotensin (ANG) II, 
 galanin (GAL), 
 Substance P, 
 bombesin/ gastrin-releasing peptide (GRP), 
 neurotensin (NT), 
 serotonin (5-HT), 
 GnRH, 
 -MSH, 
 estradiol (E2), 
 ghrelin and growth hormone secretagogue (GHS), 
 adenosine (icv), 
 salsolinol, 
 ethanol (alcohol). 
1.1. Anatomy of hypothalamic structures in control of PRL secretion 
The established hypothalamic hypophysiotropic inhibitor of PRL secretion is DA produced 
by the arcuate-periventricular nucleus and travels from the median eminence (ME) to the 
anterior lobe (AL) via the long portal vessels. The well known hypophysiotrophic DAergic 
neurons in the hypothalamus consist of at least two different areas (named as ‘A12’ and 
‘A14’) by anatomical location. Despite the extensive supportive evidences for this simplistic 
view, it has recently proven to be incomplete. It has been demonstrated, that the early 
studies failed to account for an important source of DA reaching the AL through the short 
portal vessels from the neurointermediate lobe (NIL). It was clarified that these DAergic 
neurons can be divided into three distinct systems based on functionality due to the 
anatomical distribution of neurons and the terminals within the pituitary and sensitivity of 
internal control mechanisms (summarized in Table 1.). 
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a. Tuberoinfundibular DAergic (TIDA) neurons located mainly in the middle and 
posterior portion of the arcuate nucleus (‘A12’), project to the ME, and the functions are 
well accepted as a physiological regulator of hypophysial PRL secretion.  
b. The periventricular-hypophysial dopaminergic (PHDA, ‘A14’) neurons’ branched axons 
terminate in the intermediate lobe (IL), (but not in the neural lobe) (Ben-Jonathan 1980; 
Peters 1981; Ben-Jonathan, 1982; Goudreau, 1995). Taken together that hypothalamic 
neurons release DA into portal blood flow (rather than into synaptic clefts)  and also the 
fact that no DA autoreceptors found in TIDA neurons, both assist to abolish the effect of 
the negative feedback by secreted DA on tyrosine-hydroxilase (TH) activity in DA 
neurons themselves and consequently maintain the high DA output. These cells are not 
affected by stimuli of nonselective DA agonists, which cells otherwise increase or 
decrease the DA output and provide consequent change in PRL secretion as a response 
by selective D1 or D2 agonist’s actions, respectively (Ben-Jonathan, 2001).  
c. Experimental evidences have been presented to prove that DA derived from the 
tuberohypophysial DAergic (THDA, ‘A12’) system also may serve as an important 
regulator of PRL secretion. Neurons of this THDA system are located in the most rostral 
part of the arcuate and periventricular nucleus and axons terminate in the NIL of the 
pituitary gland rather than in the ME of the hypothalamus (Holzbauer, 1978; 
Holzbauer, 1985; Ben-Jonathan, 1982, Ben-Jonathan, 1985; Neill 1994; Freeman 2000). 
Due to the anatomical situation that axon terminals branch in NIL, the amount of DA 
released by THDA neurons would not be present in pituitary stalk blood. These cells 
carry different functionality and interestingly no differences in activities between males 
and females were recognized compared these characteristics to neurons of the TIDA 
system (Higuchi 1992; Freeman 2000). 
From the regulatory aspects, DA concentrations reaching the AL, measured in portal blood 
only may have been underestimated. Indeed, removal (Ben-Jonathan, 1982; Peters, 1981; 
Ben-Jonathan, 1985) or denervation (Vecsernyes, 1997) of the NIL elevates basal PRL 
secretion in cycling or lactating females, but also in males. Hypothalamic regions of the 
main DAergic control (i.e. TIDA neurons) in arcuate nucleus, keep the balance of 
stimulation and inhibition and maintain the regularly low basal PRL secretion, due to 
combined action of putative control mechanisms (vide infra). On the other hand, elevated 
PRL levels during pregnancy and lactation mediate actions also in other hypothalamic 
regions such as the paraventricular nucleus (PVN), rostral preoptic area (rPOA) as 
demonstrated by Sapsford et al. (2012). The observation that electrochemically detectable 
DA in the AL is reduced after surgical removal of the NIL was found to be consistent with 
this finding (Mulchahey, 1985). Thus, DA of hypothalamic origin which is delivered to the 
AL by way of the long and the short portal vessels (from TIDA or THDA, respectively) 
together, seems quantitatively sufficient to account for inhibition of PRL release (Nagy, 1992; 
Freeman, 1993; Nagy, 1990).  
The aim of this summary is to review the evidences accumulated to date and outline several 
new aspects of the regulation and the tonic inhibitory role of DA on PRL secretion in various 
physiological stages.  
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1.2. Physiology of responsiveness: The balance 
The feedback interaction in which the released PRL controls its own secretion called “short 
loop feedback”, only partially has been characterized. Due to the primary influence as 
inhibition on PRL release by hypothalamic structures, the mechanism of this feedback is 
considered fairly complex in process to change the activity of TIDA or PHDA/THDA 
neurons and trigger effect of immediate reactions, or in course of the physiological 
regulation, such as estrus cycle or by chronic increase of PRL levels, such as pregnancy or 
lactation. Elevation of serum PRL levels consequently increases hypothalamic DA synthesis 
and DA release into hypophysial-portal blood to complete the negative feed-back loop 
(Gudelsky, 1980). Since hypothalamus is within the brain, PRL that released to circulation 
should be transferred through the blood-brain barrier (BBB) in order to reach and manifest a 
feedback to TIDA cells, potentially by an uptake of the choroid plexus (Mangurian, 1992).  
For the action of PRL on TIDA neurons several potential mechanisms have been proposed: 
such as control of TH expression by activation of PRL-receptor in DA neurons (Gonzalez, 
1988) or activation of early genes, nerve growth factors (NGF-1), etc (Sagrillo, 1998). Since 
PRL receptors are found in all the three described subpopulations i.e. TIDA, THDA and 
PHDA neurons in hypothalamus, the short PRL feedback supported by the relevance of 
potential activation in all three systems (DeMaria, 1999). Alternatively, PRL can be 
synthesized de novo locally within the hypothalamus, by the stimuli of estrogens may have 
other functions and questionable the direct action controlling of TIDA neurons (DeVito, 
1992; DeVito, 1993; Freeman 2000; Ben-Jonathan 2001). Interestingly, subpopulations of 
oxytocin neurons in the hypothalamus were also found to be differentially sensitive to PRL, 
and may have effect controlling PRL secretion, as PRF (Kennett, 2012). 
According to the most recent report of Lyons et al. (2012) in which they focused on rapid 
electrophysiological changes induced by PRL within the hypothalamic TIDA neurons utilizing 
a whole-cell current- and voltage-clamp recordings. The presence of relatively high doses of 
PRL in arcuate nucleus resulted in a change to tonic inhibition, manipulating mainly those 
rapid mechanisms of depolarization on the spontaneously oscillating DA secreting cells. 
Experiments on slices of hypothalamus, tested to ion substitution and pharmacological 
manipulations proved that the transparent switch to tonic discharge and consequent APs are 
composed of low- and high-voltage components: activation of a transient receptor potential-
like current and the change of a calcium ion-dependent BK-type K+-current as a slow 
component, then broadened APs increase terminal Ca2+ influx, and change the vesicular DA 
release at the terminals in the median eminence. The PRL-induced depolarization is reversible 
and dose dependent; it involves direct, postsynaptic actions because it persists when AP 
discharge is blocked by TTX. PRL levels (higher than the physiological range of circadian 
rhythm) that required for normal reproduction (may be out of the normal range) have been 
effective in these electrophysiological actions. Accordingly this feedback „option” may 
primarily play a role during pathophysiological elevations of PRL. (Lyons, 2012) 
Perhaps the most intriguing aspect of this neuroendocrine reflex mechanism is the dramatic 
change in responsiveness of lactotrophs due to a brief application of the suckling stimulus 
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(Nagy, 1990; Hill, 1991; Nagy, 1991). Previously we have provided experimental evidences 
that these responsiveness changes (induced by 10 minutes suckling in vivo) can be detected 
in primary cultures prepared from dissected ALs (Nagy, 1990; Hill, 1991; Nagy, 1991; 
Murányi, 1997; Murányi, 1998; Horváth, 1999). Pituitary cells from non-suckled rats 
(separated for 4 hours) exposed to various concentrations of DA exhibit only a dose-
dependent inhibitory effect and TRH or Angiotensin II (AII) cannot release PRL. In striking 
contrast, lactotrophs derived from suckled rats are less responsive to the inhibitory actions 
of DA as well as more responsive to the stimulatory effects of TRH and AII. The suckling-
induced changes in responsiveness related to decrease in protein phosphatase-2A (PP2A) 
activity which possibly plays a role in the uncoupling of D2 receptors on lactotrophs  from 
the tonic inhibitory influence of DA (Murányi, 1998). Parallel with these, 10 minutes 
suckling stimulus applied immediately before sacrifice rendered PRL cells to respond with 
an increase of PRL release to picomolar concentrations (10-10 M-10-12 M) of DA. Thus, a brief 
suckling stimulus primes pituitary lactotrophs to respond with an increase of PRL secretion 
to low dose of DA (Nagy, 1990). 
Another distinct advantage of this experimental model (non-suckled and suckled rats) is 
that it also shows a striking difference in the effectiveness of DA removal-induced increase 
of PRL release. It is well known, that dissociation of DA from its receptor induces PRL 
release. AL cells have been dispersed from non-suckled and suckled mothers then subjected 
to treatment of the inhibitory dose of DA for 2 hours. In the next step DA has been washed 
out before initiating the plaque assay by infusing the PRL antibody. Withdrawal of DA has 
clearly induced release of PRL compared to the medium pretreated cells obtained from non-
suckled mothers. In contrast, the DA removal signal has been completely missing on cells 
from suckled animals (Nagy, 1991; Horváth, 1999; Murányi, 1998). Being able to distinguish 
between dissociation- and stimulation-induced elevation of PRL release is a critical part of 
the interpretation of these mechanisms. 
Salsolinol (SAL), isolated from the NIL is present in the hypothalamic neuroendocrine 
dopaminergic system, appears to be a selective and potent stimulator of PRL secretion rat in 
vivo and with a moderate effect in vitro (Toth, 2001). It seems that SAL does not act through 
the dopamine D2 receptors, but utilize receptor independent mechanisms to stimulate PRL 
High affinity binding sites for this putative PRF have been detected in median eminence 
where TIDA projects and the NIL that are known terminal fields of THDA/PHDA DAergic 
systems (Toth; 2002; Homicsko, 2003). Reserpine pretreatment (blocking VMAT) prevented 
the effect of SAL on PRL release. Within the similar experimental model, suckling stimulus 
increased SAL content of NIL, but there was no change in SAL binding in the anterior lobe. 
Moreover, structural analogue of SAL (1-methyl-3,4-dihydroisoquinoline) can block 
salsolinol-induced release of PRL, but does not affect PRL release in response to TRH, TH 
inhibitors or D2 receptor antagonist domperidone (Homicsko, 2003). Taken together these 
results suggested that D2 receptor independent mechanisms can play a pivotal role in 
regulation of PRL secretion in reflection to suckling induced physiological stimuli (Toth, 
2002; Bodnar, 2003). 
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1.3. Tonic inhibition of prolactin secretion 
The PRL production and release to circulation is under a predominant inhibitory control of 
DA. Without the sustained regulation by hypothalamic DA dispersed pituitary cells increase 
the basal secretion and similarly, disconnected pituitary gland increase the released PRL 
(Neill, 1982; Leong, 1983; Vecsernyes, 1997; Murányi, 1998). Since most of experimental 
reports discuss the role of DA in females, it should be noted here that there are marked 
sexual differences in activity of TIDA (not relevant with PHDA and THDA) neurons and 
responsiveness to physiological and pharmacological stimuli, even though similar density 
nerve terminals found in both sexes (See also Table 1.). Higher basal activity of these 
neurons is seen in females that suppressed by removal of ovaries (OVX) and restored by 
treatment with E2. The opposite, i.e. control of lower basal activity of TIDA neurons in males 
effected by presence of testosterone and may be due also to tonic inhibition by endogenous 












External zone of 
the median 
eminence (EM) 
around long portal 
vessels 
 
- Main physiological 
regulator of PRL 
secretion.  
- Daily rhythm by SCN 
. PRL surges in estrus 
cycle 
- Response to suckling 
stimulus.  
- Sensitive to feedback to 
PRL levels. 
 
- Discharge in a highly 
robust and synchronized 
oscillations. 
- Significant difference in 
activity b/w male and 
females. 
- Activity increased by 






the neural lobe 
(NIL) 
- Response to suckling 
stimulus.  
- Activated by 
dehydration. 
- Release of DA to AL 
through the short portal 
vessels. 
-No sex differences in 
activities,  
- function is independent 






- tonic inhibition -MSH 
and on basal PRL 
- Release of DA to AL 
through the short portal 
vessels. 
-No sex differences in 
activities,  
- function is independent 
from gonadal steroids 
Table 1. Dopaminergic neurons in control of PRL secretion 
 
Prolactin 172 
(Nagy, 1990; Hill, 1991; Nagy, 1991). Previously we have provided experimental evidences 
that these responsiveness changes (induced by 10 minutes suckling in vivo) can be detected 
in primary cultures prepared from dissected ALs (Nagy, 1990; Hill, 1991; Nagy, 1991; 
Murányi, 1997; Murányi, 1998; Horváth, 1999). Pituitary cells from non-suckled rats 
(separated for 4 hours) exposed to various concentrations of DA exhibit only a dose-
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contrast, lactotrophs derived from suckled rats are less responsive to the inhibitory actions 
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to low dose of DA (Nagy, 1990). 
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that it also shows a striking difference in the effectiveness of DA removal-induced increase 
of PRL release. It is well known, that dissociation of DA from its receptor induces PRL 
release. AL cells have been dispersed from non-suckled and suckled mothers then subjected 
to treatment of the inhibitory dose of DA for 2 hours. In the next step DA has been washed 
out before initiating the plaque assay by infusing the PRL antibody. Withdrawal of DA has 
clearly induced release of PRL compared to the medium pretreated cells obtained from non-
suckled mothers. In contrast, the DA removal signal has been completely missing on cells 
from suckled animals (Nagy, 1991; Horváth, 1999; Murányi, 1998). Being able to distinguish 
between dissociation- and stimulation-induced elevation of PRL release is a critical part of 
the interpretation of these mechanisms. 
Salsolinol (SAL), isolated from the NIL is present in the hypothalamic neuroendocrine 
dopaminergic system, appears to be a selective and potent stimulator of PRL secretion rat in 
vivo and with a moderate effect in vitro (Toth, 2001). It seems that SAL does not act through 
the dopamine D2 receptors, but utilize receptor independent mechanisms to stimulate PRL 
High affinity binding sites for this putative PRF have been detected in median eminence 
where TIDA projects and the NIL that are known terminal fields of THDA/PHDA DAergic 
systems (Toth; 2002; Homicsko, 2003). Reserpine pretreatment (blocking VMAT) prevented 
the effect of SAL on PRL release. Within the similar experimental model, suckling stimulus 
increased SAL content of NIL, but there was no change in SAL binding in the anterior lobe. 
Moreover, structural analogue of SAL (1-methyl-3,4-dihydroisoquinoline) can block 
salsolinol-induced release of PRL, but does not affect PRL release in response to TRH, TH 
inhibitors or D2 receptor antagonist domperidone (Homicsko, 2003). Taken together these 
results suggested that D2 receptor independent mechanisms can play a pivotal role in 
regulation of PRL secretion in reflection to suckling induced physiological stimuli (Toth, 
2002; Bodnar, 2003). 
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1.3. Tonic inhibition of prolactin secretion 
The PRL production and release to circulation is under a predominant inhibitory control of 
DA. Without the sustained regulation by hypothalamic DA dispersed pituitary cells increase 
the basal secretion and similarly, disconnected pituitary gland increase the released PRL 
(Neill, 1982; Leong, 1983; Vecsernyes, 1997; Murányi, 1998). Since most of experimental 
reports discuss the role of DA in females, it should be noted here that there are marked 
sexual differences in activity of TIDA (not relevant with PHDA and THDA) neurons and 
responsiveness to physiological and pharmacological stimuli, even though similar density 
nerve terminals found in both sexes (See also Table 1.). Higher basal activity of these 
neurons is seen in females that suppressed by removal of ovaries (OVX) and restored by 
treatment with E2. The opposite, i.e. control of lower basal activity of TIDA neurons in males 
effected by presence of testosterone and may be due also to tonic inhibition by endogenous 
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All of our recent data clearly indicate that wherever this signal originates and whatever is its 
nature, suckling-induced desensitization/sensitization of pituitary tissue to PRL-release 
inhibiting stimuli is manifested at the cellular level of lactotrophs as a proportional increase 
of subpopulation of those cells less sensitive to inhibition by high doses and more sensitive 
to stimulatory effect by low doses of DA. The mechanism(s) leading to these suckling-
induced changes in DA responsiveness of lactotroph cells is (are) currently only in parts 
clarified. Efforts have been made to determine the mechanism(s) of this change in 
responsiveness have indicated that it is mediated through the D2 dopamine receptors 
(Horváth, 1999; Murányi, 1997). There are certain theories in hormonal- and receptor-level 
or intracellular signaling cascades-related, which may serve as potential explanation for the 
complexity of responsiveness to external stimuli and internal controls of pituitary cells 
during physiological and stress reactions.  
TIDA cells form a network that discharges rhythmically in a robust 0.05 Hz synchronized 
oscillations. Thyrotropin-releasing hormone (TRH), which stimulates PRL release at the 
level of pituitary, cause transition from phasic pattern to tonic firing at the level of TIDA-
cell. The results of these electrophysiology experiments are in concert with earlier findings 
on dispersed pituitary cell, suggesting a useful model for PRL regulation. TIDA network 
switches from oscillations to sustained discharge converting DA at high concentrations to a 
functional agonist as the net DA output decreases. (Lyons, 2010; Nagy, 1991) 
Utilizing the analogy that has been reported by Conductier (2011) on hypothalamic 
neuronal populations, may serve as another potential explanation of this dose-dependent 
biphasic regulatory process of DA. The theory is based on the observation that certain 
biological actions believed to be associated with DA are not due to activation of DA 
receptors, but likely mediated via other receptors (such as 2-noradrenergic) and a 
subsequent action to open G-protein activated inward rectifier K+ (GIRK) channels, which 
leads to hyperpolarization of cells (vide infra). It is also possible that DA modulates other 
hypothalamic inputs in a complex and biphasic manner: at low concentrations DA activates 
D2-like receptors, promoting presynaptic activity and upregulation, but high concentration 
of DA activates the D2-like receptors resulting in inhibition, which consequently blocks the 
presynaptic activity. (Conductier, 2011) 
It has been recently discovered that sustained presence of the ligands of G-protein-coupled 
receptors (GPCRs) can promote specific intracellular signaling adaptation mechanisms 
parallel with the internalization process of the receptors. The receptor desensitization or 
“tolerance” is based on these mechanisms. Desensitization has been described in the AL of 
pituitary gland as well, where dopamine D2 receptors are permanently activated on 
lactotrophs. Ceasing of the dopaminerg inhibition is essential for the maintenance of the 
high secretory rate of PRL in lactotrophs during lactation.  
2. Receptor mechanisms regulating lactotroph cells 
Among those cellular and variety of receptor mediated mechanisms that regulating the 
pituitary hormone secreting cells only the key elements in this chapter that may have direct 
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impact on PRL release, will be highlighted. DA released from the specific DAerg nerve 
terminals and bind to its appropriate receptors located at the post-synaptic membrane is the 
main down-stream process. However, the potential effects of presynaptic receptor 
mechanisms in regulation can not be completely ruled out. To achieve biological response in 
cellular level, it is necessary to activate the G-protein-coupled receptors (GPCRs), which 
described with five distinct but closely related subunits that carry different and versatile 
subcellular messenger functions. A new concept of GPCR receptor theory describes the 
options of modified ligand selectivity and alternative intracellular responses on the same 
receptor type, increasing the down-stream effector mechanisms.  
2.1. Dopamine receptors in mammotrop cells 
The two major groups of receptors are the D1 and D2 classes:  D1 class (D1 and D5 
subtypes) has a stimulatory effect on intracellular signaling pathways, while D2 class (D2, 
D3 and D4 subtypes) has mainly inhibitory influence on cAMP. The predominant D2 type 
receptor in pituitary lactotroph cells exists in two alternatively spliced isoforms, termed D2-
short (D2S) and D2-long (D2L) receptors, which differ from each other in the insertion of 29 
amino acids of the third cytoplasmic loop. To date, there are no specific ligands to 
discriminate the D2S from D2L actions, only KO animal models in use to identify isoform 
specific effects. (Beaulieu, 2011; Vallone, 2000; Ben-Jonathan, 2001; Radl, 2011). The receptor 
isoforms exhibit fairly similar pharmacological properties, activation in rat lactotrophs 
mediates DA suppression of the PRL gene (McChesney, 1991). These two isoforms of D2 
dopamine receptor are both present on lactotroph cells. Because each form is selectively 
coupled to different G proteins, they serve different functions: (i) inhibition of adenylyl 
cyclase, (ii) activation of voltage-gated calcium channels, and (iii) inhibition of potassium 
channels in a similar manner but only the D2S coupled to the phospholipase signaling 
pathway. (The Gi/Go family of proteins is not involved in this pathway, since insensitive to 
PTX) (Senogles, 2000).  
D2L is the main isoform present in the anterior pituitary both in rat and in human 
(Guivarc’h, 1995) and instead of D2S, the D2L isoform is expressed in an elevated manner 
level during estradiol-induced PRL secretion and cell proliferation in mammotrop cell. 
However, in cells contained only D2L form, (lactotroph-derived PR1 cells, with no D2S) 
there was only diminished response to the same stimuli demonstrated. It was concluded 
that D2S-receptor regulates the Gi3 inhibitory action on Gs; also D2S is more efficient for 
inhibiting adenylyl cyclase than D2L, thus could serve as mechanism controlling the PRL 
release and proliferation of mammotrop cells (Sengupta, 2012). The role of D2 receptor is 
essential to maintain the physiological PRL levels. In receptor knock-out (KO) mice pituitary 
hyperplasia and persistent hyperprolactinemia is seen. Other data suggest some additional 
function associated with DA, describing it not just a major inhibitor of PRL secretion and 
cell proliferation, but also induces apoptosis of mammary cells (Kelly 1997). 
Experimental data support the hypothesis that D2S and D2L receptors are functionally 
distinct in terms of coupling to MAPK pathways, since DA-induced apoptosis in neurons in 
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oscillations. Thyrotropin-releasing hormone (TRH), which stimulates PRL release at the 
level of pituitary, cause transition from phasic pattern to tonic firing at the level of TIDA-
cell. The results of these electrophysiology experiments are in concert with earlier findings 
on dispersed pituitary cell, suggesting a useful model for PRL regulation. TIDA network 
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functional agonist as the net DA output decreases. (Lyons, 2010; Nagy, 1991) 
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receptors, but likely mediated via other receptors (such as 2-noradrenergic) and a 
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hypothalamic inputs in a complex and biphasic manner: at low concentrations DA activates 
D2-like receptors, promoting presynaptic activity and upregulation, but high concentration 
of DA activates the D2-like receptors resulting in inhibition, which consequently blocks the 
presynaptic activity. (Conductier, 2011) 
It has been recently discovered that sustained presence of the ligands of G-protein-coupled 
receptors (GPCRs) can promote specific intracellular signaling adaptation mechanisms 
parallel with the internalization process of the receptors. The receptor desensitization or 
“tolerance” is based on these mechanisms. Desensitization has been described in the AL of 
pituitary gland as well, where dopamine D2 receptors are permanently activated on 
lactotrophs. Ceasing of the dopaminerg inhibition is essential for the maintenance of the 
high secretory rate of PRL in lactotrophs during lactation.  
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Among those cellular and variety of receptor mediated mechanisms that regulating the 
pituitary hormone secreting cells only the key elements in this chapter that may have direct 
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impact on PRL release, will be highlighted. DA released from the specific DAerg nerve 
terminals and bind to its appropriate receptors located at the post-synaptic membrane is the 
main down-stream process. However, the potential effects of presynaptic receptor 
mechanisms in regulation can not be completely ruled out. To achieve biological response in 
cellular level, it is necessary to activate the G-protein-coupled receptors (GPCRs), which 
described with five distinct but closely related subunits that carry different and versatile 
subcellular messenger functions. A new concept of GPCR receptor theory describes the 
options of modified ligand selectivity and alternative intracellular responses on the same 
receptor type, increasing the down-stream effector mechanisms.  
2.1. Dopamine receptors in mammotrop cells 
The two major groups of receptors are the D1 and D2 classes:  D1 class (D1 and D5 
subtypes) has a stimulatory effect on intracellular signaling pathways, while D2 class (D2, 
D3 and D4 subtypes) has mainly inhibitory influence on cAMP. The predominant D2 type 
receptor in pituitary lactotroph cells exists in two alternatively spliced isoforms, termed D2-
short (D2S) and D2-long (D2L) receptors, which differ from each other in the insertion of 29 
amino acids of the third cytoplasmic loop. To date, there are no specific ligands to 
discriminate the D2S from D2L actions, only KO animal models in use to identify isoform 
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isoforms exhibit fairly similar pharmacological properties, activation in rat lactotrophs 
mediates DA suppression of the PRL gene (McChesney, 1991). These two isoforms of D2 
dopamine receptor are both present on lactotroph cells. Because each form is selectively 
coupled to different G proteins, they serve different functions: (i) inhibition of adenylyl 
cyclase, (ii) activation of voltage-gated calcium channels, and (iii) inhibition of potassium 
channels in a similar manner but only the D2S coupled to the phospholipase signaling 
pathway. (The Gi/Go family of proteins is not involved in this pathway, since insensitive to 
PTX) (Senogles, 2000).  
D2L is the main isoform present in the anterior pituitary both in rat and in human 
(Guivarc’h, 1995) and instead of D2S, the D2L isoform is expressed in an elevated manner 
level during estradiol-induced PRL secretion and cell proliferation in mammotrop cell. 
However, in cells contained only D2L form, (lactotroph-derived PR1 cells, with no D2S) 
there was only diminished response to the same stimuli demonstrated. It was concluded 
that D2S-receptor regulates the Gi3 inhibitory action on Gs; also D2S is more efficient for 
inhibiting adenylyl cyclase than D2L, thus could serve as mechanism controlling the PRL 
release and proliferation of mammotrop cells (Sengupta, 2012). The role of D2 receptor is 
essential to maintain the physiological PRL levels. In receptor knock-out (KO) mice pituitary 
hyperplasia and persistent hyperprolactinemia is seen. Other data suggest some additional 
function associated with DA, describing it not just a major inhibitor of PRL secretion and 
cell proliferation, but also induces apoptosis of mammary cells (Kelly 1997). 
Experimental data support the hypothesis that D2S and D2L receptors are functionally 
distinct in terms of coupling to MAPK pathways, since DA-induced apoptosis in neurons in 
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lactotrophs, via p38 MAPK. Similarly, cabergolin-induces apoptosis of lactotrophs in the 
presence of E2. The effect of DA on apoptosis is reverted by a p38 MAPK inhibitor in 
primary cultures and in PR1-D2S (D2S predominant, transfected pituitary tumor) cells, 
indicating that p38 MAPK is involved in the apoptosis of lactotrophs induced by D2 
receptor activation. Alterations in the proportion of D2L and D2S isoform expression could 
be involved in the clinical resistance of D2R agonist therapies (i.e. cabergoline). In addition, 
estrogens sensitize anterior pituitary cells to different proapoptotic behavior. The 
phosphorylation of p38 MAPK induced by DA seems to be a necessary but not a sufficient 
event to induce apoptosis of lactotrophs, and moreover the hormonal milieu could affect the 
action of D2R agonists in patients with prolactinomas (Radl, 2011). 
2.2. GIRK channel in lactotroph cells 
The theory that a G-protein activated inward rectifier K+ (GIRK) channel can be considered 
as a physiological cellular level effector of DA action in pituitary lactotroph cell has been 
proposed by Gregerson et al (2001). The experiments focused on specific hormonal changes 
on days of estrus cycle in rat, associated with DA sensitivity and effects of dispersed cell in 
vitro. In proestrus and not on other days of the reproductive cycle in rats, the functional 
expression of this DA-activated channel could be observed in lactotrophs isolated from 
female rats. (Gregerson, 1989, Gregerson, 2001)    
This experimental design demonstrated that estradiol (E2) up-regulates the GIRK channel 
subunits and controls the functional activation of the D2R-GIRK pathway on mammotrop 
cells. The functional D2R-GIRK pathway is the pertussis toxin (PTX)-sensitive heterotrimeric 
G-protein complex. The ability of DA to activate the GIRK channel of lactotroph 
demonstrated on isolated cells prepared from animals on different days of estrus cycle 
seems to be regulated by the hormonal status and property of the cells obtained only of the 
day of proestrus. Rising levels of circulating E2 during the transition from diestrus result in a 
functional switch in DA signaling to include GIRK channel activation. On the morning of 
proestrus DA activates membrane hyperpolarization. This negative membrane potential 
“primes” the lactotroph population by removing inactivation of voltage-gated Ca2+ channels 
(VGCC). The drop of hypothalamic DA levels in portal vessels, i.e. on the afternoon of 
proestrus, the primed lactotrophs depolarize, initiating increased Ca2+ influx through VGCC 
and a consequent PRL release. (Gregerson, 1989; Gregerson, 2001)    
E2 does not have a direct effect on D2 receptor, but may influence the expression of G 
protein βγ subunit isoforms, which are known to bind and potentially activate the GIRK 
channel. A receptor antagonist that competes with E2 for binding at both ERα and Erβ 
blocks the induction of GTPγS-activated GIRK current. It was concluded, that there are 3 
„essential components” work in synergy regulating the mammotrop cells during the 
hormonal changes of estrus cycle:  
 D2 receptor, which couples to Gαi and thereby inhibits adenylate cyclase (AC), decrease 
in density on the afternoon of proestrus or with exposure to high concentrations of E2. 
(Enjalbert 1983; Pasqualini 1984) 
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 D2R-GIRK pathway: a pertussis toxin-sensitive heterotrimeric G protein complex, 
where the dissociated βγ complex directly binds to GIRK proteins to open the K+ 
channel. (Krapivinsky 1996; Yamada 1998) 
 GIRK channel itself: E2 significantly increase the percentage of lactotrophs with 
detectable levels of GIRK transcripts in the rat AP gland, measured by single-cell RT-
PCR. (Christensen 2011 
2.3. DA transporter (DAT) 
This member of the Na+/Cl−-dependent transporter superfamily displays the characteristic 
twelve transmembrane domains and actively transports DA. It there is a bi-directional 
mechanism behind, since DAT can not only remove DA from the synaptic cleft but under 
certain conditions can also pump DAT out of cells which is generally referred to as the 
“reverse transport” (Barnes 2008). The functionality of dopamine transporter of TIDA 
neurons that is effective in regulating PRL secretion, but the transporter effective in THDA 
and PHDA neurons as well. Within the dynamics of DA secretion, the termination of DA 
action is primarily achieved by its reuptake utilized a dopamine transporter (to inwards) 
located on the terminals of dopaminergic neurons. Dopamine is translocated from the 
cytoplasm into the vesicles by the vesicular monoamine transporter (VMAT). DA is stored 
in synaptic vesicles at extremely high at a 100- to 1000-fold higher concentration than 
neuropeptides, which is near its limit of solubility. These vesicles intend to store and protect 
DA from degradation but also prevent leakage and control precise release from the synaptic 
vesicles (Ben-Jonathan, 2001). 
DAT-knock-out mice have increased dopaminergic tone and anterior pituitary hypoplasia, 
and decreased number of lactotroph cells with down-regulation of the PRL gene (Bosse, 
1997). „Clinically” the signs summarized as increased DA, consequent reduction (70-80%) in 
pituitary PRL content, the lack of milk production (since no PRL) and the inability to lactate 
(since no suckling-induced PRL release). Interestingly, the DAT-KO mice has the basal PRL 
level unchanged, which is probably due to activated compensatory mechanisms either in 
DA terminals, or at the lactotroph level. (Ben-Jonathan, 2001; Ben-Jonathan, 2008)  
DAT is a common target of several drugs used in both the therapeutic field of psychiatry 
(psychostimulants, antidepressants), and subjects of drug abuse (like cocaine or 
amphetamine). Manipulations with the function of DAT and its potential influence on DA 
levels might have regulatory potential, but more likely causing side-effect of drugs or in 
certain cases the drug abuse. 
2.4. Non DA related receptor mechanisms 
2.4.1. Endothelin receptors 
The alternative path in regulation of PRL secretion is the actions of endothelins (ETs) in 
pituitary cells: all members of the mammalian endothelin family of peptides exert significant 
effects on PRL release in vitro that mediated by ETA receptors (ET-AR). ET-AR is encoded by 
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levels might have regulatory potential, but more likely causing side-effect of drugs or in 
certain cases the drug abuse. 
2.4. Non DA related receptor mechanisms 
2.4.1. Endothelin receptors 
The alternative path in regulation of PRL secretion is the actions of endothelins (ETs) in 
pituitary cells: all members of the mammalian endothelin family of peptides exert significant 
effects on PRL release in vitro that mediated by ETA receptors (ET-AR). ET-AR is encoded by 
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an intron-containing gene. Selective ETA receptor antagonist can block the effects of the ETs in 
a competitive manner (Samson, 1992). Functional ETA receptors are expressed in all five 
secretory pituitary cell types included lactotrophs. The ET receptors are connected to both 
stimulatory and inhibitory (Gs, Gi/o, Gz) G-protein pathways (Tomic, 2002; Andric, 2005).  
Generally in lactotrophs and also in somatotrophs, ETs activate the Ca2+ -mobilization pathway 
and transiently can stimulate hormone release. There is a post transient inhibitory effect of 
PRL release observed for several hours, underlining the importance of desensitization period. 
Endothelin, similar to D2 receptors coupled to Gi/o, in a picomolar concentration range 
inhibits adenylyl cyclase (AC) activity in a dose-dependent manner and consequently the PRL 
release from cultured anterior pituitary cells (Kanyicska, 1992; Samson, 1990). However, this 
inhibition of basal cAMP production does not abolish spontaneous firing of PRL cells, and 
only partially inhibits basal PRL release (Stojilkovic 2009). 
2.4.2. Adenosine receptors 
The presence of adenosine has been identified in the anterior pituitary gland. The 
experimental results and the direct effect of adenosine are controversial and depend on site 
of administration or the experimental conditions (Ondo, 1980; Schettini, 1990; We, 1998). 
As it was revealed earlier, adenosine inhibits the basal adenylate cyclase activity in a dose-
dependent manner and decreased PRL secretion. Adenosine and analogues affects the basal 
as well as stimulated secretion of PRL in pituitary cells, in vitro cell culture. It has a biphasic 
pattern of effect: low concentrations inhibit both AC activity and that affect the PRL release 
from primary pituitary cells; high concentrations may restore the action. The mechanisms 
involve the action on the cAMP coupled adenosine receptors at the level of pituitary gland 
(Schettini, 1990) or the short-loop negative feedback of released PRL.  
The adenosine receptor subtypes (A1, A2a, A2b, and A2) are involved in mechanisms of action 
and in regulation of cell proliferation: A1 receptors have been shown to activate Gi inhibitory 
G-proteins that decrease intracellular calcium concentrations which decrease the activity of 
NOS and lower the NO. NO activatins guanylate cyclase that synthesizes cGMP from GTP, 
and increase the level, which leads to inhibition of PRL release. Since the A1 and A2 receptor 
blockers did not alter PRL release adenosine plays no role in basal PRL release in vitro (We, 
1998). There subtypes of purinergic G protein-coupled adenosine receptors (AR), the 
adenosine nucleotide-controlled receptors (P2YR) and ion-conducting receptor-channels 
(P2XR) have been characterized in the pituitary by Koshimizu  et al. (2000). Lactotrophs cells 
express three subtypes of P2XR channels, and homomeric and/or heteromeric receptors may 
utilize also the extremely complex but effective mechanisms to activate the cell- and 
receptor-specific Ca2+ signaling patterns (Koshimizu, 2000; Zemkova 2010).  
2.4.3. Cannabinoid receptors 
Preclinical studies suggest a predominantly inhibitory effect of cannabinoids on PRL 
secretion and some other pituitary hormones like GH, THS. The cannabinoid receptors (CB-
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1R) are found in hypothalamic regions (Murphey, 1998; Wenger 1999) and in pituitary 
(Yasuo, 2010), co-localized with DA receptors in hypothalamic DA projections and modulate 
the DA transmission that regulates the PRL secretion (Rodríguez De Fonseca, 2001). 
Treatment with specific endogenous ligand of cannabinoid receptor anandamide inhibited 
the postnatal development of hypothalamo-pituitary axis in offspring (Wenger, 1999). 
Anandamide blocks human breast cancer cell proliferation through CB1-like receptor-
mediated inhibition of endogenous PRL action by suppressing the levels of the long form of 
the PRL receptor (Petrocellis, 1998). In human, however, Δ-9-THC did not change plasma 
PRL levels across a wide range of relevant doses presented in a study by Ranganathan 
(2009), however frequent users may have lower baseline plasma PRL levels relative to 
healthy controls. Accordingly, clinical evidence suggesting effects by dose dependent and 
the development of tolerance and a long-term adaptation to several cannabinoid effects in 
association with chronic exposure (Block, 1991). 
2.4.4. Ghrelin and GHS receptors 
Expression of functional growth hormone secretagogue receptors (GHS-R) and the co-
expression of the two GHS-R isoforms (Ia and Ib) was found in GH-, GH-PRL- and PRL-
secreting adenomas and in pituitary cells. (Lanfranco, 2010). The PRL mRNA is co-localised 
with GHS-R mRNA. Triple in-situ hybridization showed co-localization of GHS-R mRNA 
with messengers of GH and PRL, conjointly or separately, in individual cells of 
somatotroph, somatomammotroph, and lactotroph adenomas (Barlier, 1999).  
The administration ghrelin, serves as an endogenous ligand for the GHS-receptor (and 
primarily expressed in stomach and hypothalamus), as a direct action on 
somatomammotroph cells significantly stimulates PRL secretion in in human (Takaya, 2000; 
Lanfranco, 2010), but may exert inhibitory effects in prepubertal rats (Tena-Sempere, 2004). 
On the other hand, synthetic cortistatin-derived ghrelin receptor ligand (CST-8) does not 
modify the stimulatory endocrine responses to acylated ghrelin or hexarelin in humans and 
seems devoid of any modulatory action on either spontaneous or ghrelin-stimulated 
lactotrophs (Prodam, 2008). 
3. Intracellular regulation of PRL secretion 
Over the last two-three decades number papers discussing the signal transduction 
mechanisms have been presented describing the direct or the indirect regulatory effects of 
dopaminergic inhibition (or stimulation in certain circumstances) of PRL secretion. DA 
connected through its D2 receptors to G proteins and subunits to control the cAMP levels, 
but also activates various ion channels, triggering potassium current; influences voltage-
activated calcium and potassium currents that induce changes in membrane depolarization, 
or cause hyperpolarization (Enjalbert, 1983; Freeman 2000). Most of these plasma membrane 
channels have been characterized in PRL secreting cells, but the mechanism underlying their 
extracellular Ca2+-dependent action potentials and pacemaking activity is still not fully 
understood. The cAMP signaling pathway is probably in control of pacemaking, voltage-
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(P2XR) have been characterized in the pituitary by Koshimizu  et al. (2000). Lactotrophs cells 
express three subtypes of P2XR channels, and homomeric and/or heteromeric receptors may 
utilize also the extremely complex but effective mechanisms to activate the cell- and 
receptor-specific Ca2+ signaling patterns (Koshimizu, 2000; Zemkova 2010).  
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mediated inhibition of endogenous PRL action by suppressing the levels of the long form of 
the PRL receptor (Petrocellis, 1998). In human, however, Δ-9-THC did not change plasma 
PRL levels across a wide range of relevant doses presented in a study by Ranganathan 
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modify the stimulatory endocrine responses to acylated ghrelin or hexarelin in humans and 
seems devoid of any modulatory action on either spontaneous or ghrelin-stimulated 
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3. Intracellular regulation of PRL secretion 
Over the last two-three decades number papers discussing the signal transduction 
mechanisms have been presented describing the direct or the indirect regulatory effects of 
dopaminergic inhibition (or stimulation in certain circumstances) of PRL secretion. DA 
connected through its D2 receptors to G proteins and subunits to control the cAMP levels, 
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gated Ca2+ influx and also the PRL release are PKA-independent mechanisms (Gonzalez-
Iglesias, 2006). The highlights of key intracellular mechanisms regulating PRL secretion in 
lactotroph cells discussed below.  
3.1. G-protein signaling pathways 
The classical dopaminergic inhibition of PRL release from the anterior pituitary mediated 
through both the adenylate cyclase (AC) and Ca2+ mobilization/phosphoinositide pathways. 
D2 receptors are functionally associated with pertussis toxin (PTX)-sensitive G proteins (i.e. 
affected by activation of PTX-sensitive blockade). Activation of these receptors via Gi-3α 
causes inhibition of basal AC activity and consequent inhibition of cAMP production. 
Concomitantly D2 receptors trigger the voltage-sensitive potassium channels (via Goα) and 
inhibit the voltage-sensitive calcium channels. The Gγ-subunits can enhance the activity of 
type II AC, influencing the several other intracellular pathways. These complex intracellular 
messenger mechanisms alter the cAMP levels and a consequent PKA activity. PKA then in 
the cascade phosphorylates cytoplasmic and nuclear proteins and this also regulates ion 
channel function and may cause a desensitization of G protein coupled receptors. 
Accordingly, both Ca2+ and cAMP play important roles also in controlling the fusion of 
secretory vesicles with the plasma membrane to trigger the release hormones in these 
endocrine cells. (Lledo 1992; Freeman 2000)   
That is in concert with the earlier observations, demonstrated the signaling through G 
protein-dependent pathways resulting in decreased cAMP levels. The Gi/o signaling 
pathway is involved in DA-related inhibition, since resulted in depressed cAMP production. 
On the other hand, inhibition of basal cAMP production in pituitary lactotrophs does not 
completely abolish the spontaneous firing of APs and only partially inhibits basal PRL 
release (Gonzalez-Iglesias 2006). Similar to D2 DA receptor coupled subunits, the endothelin 
(ETA) receptors are also connected to both stimulatory and inhibitory (Gs, Gi/o, Gz) G-
protein pathways. (Tomic, 2002; Andric 2005). 
The original theory discussed the activated heterotrimeric guanine nucleotide-binding (G) 
proteins dissociated Gα and Gβγ subunits resulting in activate or inhibit various 
downstream effector molecules, impact the consequence of receptor activation in the same 
fashion (i.e. G-protein coupling, receptor desensitization, internalization, or trafficking). 
Utilizing frontiers in scientific approach supported by recent experimental evidences (Nb: 
not specified all cell types of pituitary gland to date) evolved a new concept for receptor 
theory of multiple active receptor states. That concept has critical implications since leaves 
room for alternative mechanisms of signaling; for the optimal receptor conformation of G 
protein activation that differs between G protein pools and that synthetic ones; or for cases 
when ligands can selectively promote different coupling conformations of the receptors. It is 
possible that only subsets of potential G protein partners being activated or induction of G 
protein coupling happens without triggering desensitization. On the other hand, receptor 
antagonists can cause receptor desensitization or initiate G protein-independent signals 
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without producing detectable activation of heterotrimeric G proteins. As concluded, 
receptor dimerization and interactions with scaffolding or signaling proteins can specifically 
modify ligand selectivity and determine the intracellular response from alternatives. 
Accordingly even within a single cell, multiple copies of the same receptor, may have 
coupled to different signal transduction cascade (especially if the receptor is susceptible to G 
protein switching induced by heterologous desensitization or capable of signaling through 
β-arrestins), so they can activate different down-stream effectors in response to the same 
ligand. (Maudsley, 2005) 
The conclusion of recent reports on activation of G-protein coupled receptors (GPCR) by 
Stojilkovic et al (2009) outlined the complexity of actions of ETA and D2 receptors in 
inhibition of basal PRL release. Pertussis toxin could only partially reverse the action of DA 
agonist induced inhibition of PRL release indicating the place for the pathway that 
independent from the Gi/o pertussis toxin blocking effect. This PTX insensitive step in 
agonist-induced inhibition of PRL release is not affected by inhibition of PI3-kinase and 
GSK-3, but reversed at least partially by down-regulation of the Gzα expression. Moreover, 
the parallel activation of sensitive and insensitive pathways is affecting the PRL release 
through actions blocking electrical activity and also by desensitizing calcium-secretion 
coupling. (Stojilkovic 2009) 
3.2. G-protein independent pathways 
Update on mechanisms of intracellular events related with D2-dopamine receptor may help 
to understand several conflicting results that exist in the regulation of pituitary PRL 
secretion. In 2004, a new, D2-receptor coupled signaling was described in the mouse 
striatum that involves the ser/thr protein kinase Akt (protein kinase B) and was used to 
study efficiency of psychotropic drugs and lithium. This alternative vs. “canonical” (Gi-
cAMP-PKA) signaling pathway is regulated mainly by β-arrestin2, a ubiquitous molecule of 
receptorial desensitization. The arrestin type 1 has been associated with the dark-adaptation 
of the retinal cones. The GPCR-β-arrestin2-Akt-PP2 complex plays a dual role: It can 
terminate the G-protein-mediated signaling of the receptor and initiates a G-protein 
independent signaling through different downstream phosphorilation cascades (e.g. 
Glycogene Synthase Kinase-3, GSK-3) (Beaulieu, 2005; Beaulieu, 2008; Csercsik 2008).  
The expression of D2 receptor was found to be associated with filamin-A (FLNA). Recently 
Pervelli et al (2012) demonstrated reduced FLNA and D2R expression in DA-resistant 
tumors in human samples in vitro experimental conditions. According to clinical results, a 
subset of patients is resistant to DA probably D2 receptor alterations. The results indicate 
that (Peverelli, 2012): (i) FNLA is crucial for D2 receptor expression, (ii) depression of FNLA 
expression resulted in loss of inhibitory effect of DA due to decreased D2 receptor 
expression in 60%, in those prolactinomas that characterized as originally DA-sensitive; (iii) 
in DA-resistant prolactinomas forced FLNA expression restored D2 receptor expression and 
consequently the responsiveness to DA 
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agonist induced inhibition of PRL release indicating the place for the pathway that 
independent from the Gi/o pertussis toxin blocking effect. This PTX insensitive step in 
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GSK-3, but reversed at least partially by down-regulation of the Gzα expression. Moreover, 
the parallel activation of sensitive and insensitive pathways is affecting the PRL release 
through actions blocking electrical activity and also by desensitizing calcium-secretion 
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study efficiency of psychotropic drugs and lithium. This alternative vs. “canonical” (Gi-
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tumors in human samples in vitro experimental conditions. According to clinical results, a 
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in DA-resistant prolactinomas forced FLNA expression restored D2 receptor expression and 
consequently the responsiveness to DA 
 
Prolactin 182 
3.3. Voltage-gated calcium channels 
Dopamine exerts diverse effects on lactotroph, however the two most rapid events are: (i) 
the membrane hyperpolarization leading to inactivation of voltage-gated calcium channels, 
and resulting in a reduced intracellular free calcium ([Ca2+]i ) and a consequent inhibition of 
PRL release from secretory granules; and (ii) suppression of AC activity and inositol 
phosphate metabolism resulting in diminished of PRL expression of the cells (Ben-Jonathan 
2001). All other events associated to DA actions are more redundant on the time-scale, 
assuming that controls exerted via calcium channels play a critical role in immediate actions 
of PRL regulations.   
The speed that noticed in electrophysiology experiments in the action of DA inhibiting PRL 
release also underline the involvement of ion channels and harmony in interplay between 
sodium current, T- and L-type calcium channels and calcium-dependent potassium 
channels. All of these membrane and ion-concentration related effects contribute to the 
generation of spontaneous, voltage dependent action potentials (APs) at frequencies 
between 0.2 and 0.5 Hz and a resting membrane potential -40 to -60 mV. However it should 
be noted, that a certain population of cells are considered as „quiescent” cells with a stable 
membrane potential, characterized with lack of changes in electrical activity, compared to 
„active” cells with higher basal PRL release. As it was reported earlier calcium is required to 
release PRL from the secretory granules. Action of DA induces a rapid change in cytosolic 
[Ca2+]i concentration, particularly in those spontaneously active lactotrophs, as proposed via 
D2 receptor coupled with voltage-gated calcium channels and consequent 
phosphorylation/dephosphorylation or via indirect action on GIRK and resulting in a 
marked decline in intracellular calcium. (Corrette, 1995; Ho, 1996; Curtis, 1985; Nastainczyk, 
1987; Ben-Jonathan, 2001; Gregerson, 2001) 
As the membrane potential (Vm) of cultured anterior pituitary cells oscillates from a 
baseline and when it reaches the threshold level, pituitary cells fire action potentials (APs). 
The types of “active “ secretory pituitary cells differ with respect to the pattern of electrical 
activity and AP-driven calcium signaling and secretion in vivo and in vitro. Cultured 
lactotrophs and somatotrophs frequently exhibit larger Vm oscillations, on top of which the 
depolarizing plateau and bursts of APs are generated, with spikes that do not usually reach 
the reverse potential. The differences in the patterns of spontaneous firing of APs among 
secretory pituitary cells are reflected in their respective pattern of calcium signaling. In 
elegant experiments of Stojilkovic (2009), measuring simultaneously the Vm and intracellular 
calcium concentration ([Ca2+]i) the lactotrophs cell have been characterized. Generally in 
lactotroph-somatotroph cells the slow resting Vm oscillations superimposed with bursts of 
APs, with an average duration of seconds shown high amplitude calcium transients, which 
reflects the increases in intracellular calcium concentration ([Ca2+]i  (Stojilkovic 2009). 
The in vitro basal PRL secretion from lacto-somatotroph pituitary cells is high and is 
dependent on the extracellular calcium concentration. Basal hormone secretion is dependent 
also on the duration of the AP wave form, since that is the volume to drive calcium through 
voltage-gated calcium (Cav) channels. These non-stimulated cells secrete in a „constitutive 
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and regulated manner”, since handled by Ca2+ influx and resulted in Ca2+-dependent 
exocytosis. The voltage-gated calcium influx however, triggers secretion in lactotrophs, 
resulting in an organized superimposition of APs, so called „plateau-bursting” action 
potentials that generate high amplitude calcium signals. Since the firing of spontaneous APs 
depends on the presence of calcium in extracellular medium the transient removal of 
calcium leads to cease spiking and accompanied by abolition of basal hormone release. 
These results indicate that a specialty of these „active” lactotroph cells (i.e. the extended 
duration of the AP wave due to the high amplitude [Ca2+]i signals) probably is the main 
reason for their high level of basal PRL secretion profile. (Van Goor 2001)  
That is in accordance of earlier results which has been part of experimental protocols also in 
our laboratory that animals bearing ectopic pituitary grafts (e.g. under kidney capsules) in 
vivo, release high levels of PRL for a prolonged period. It is also plausible that a well-balanced 
control mechanism is necessary to regulate the PRL release in a precise manner during the 
different physiological stages, such as needed during the estrus cycle, peaks of diurnal rhythm 
during pregnancy, suckling induced PRL release, etc. DA serves as the hypothalamic 
controlling agent, regulating the spontaneous release by the cascades of Gi/o-coupled receptors 
for inhibition, controlling ion-channels for immediate action, but in addition to support need 
for release stimulation via Gs-coupled receptors mobilizing Ca2+ is also utilized.  
3.4. Cyclic nucleotides in signaling 
As discussed above the hypothalamo-hypophyseal system, or more generally the 
neuroendocrine and also immune systems are prominently regulated by G-protein coupled 
receptors that utilize the cAMP signal transduction cascade. Increases in cAMP lead to 
functional activation of PKA by binding to the regulatory subunits and liberating the 
catalytic subunits, phosphorylates cytoplasmic and nuclear proteins, and desensitize the G 
protein coupled receptors. Decrease in cAMP suppresses PKA by maintaining it in an 
inactive conformation and moreover in the presence of secretagogues, that potentially 
mediates other cellular responses of lactotrophs in relation to DA activation. Involvement of 
different membrane enzymes in the context of varied levels of activation of G-proteins as 
well as Ca2+- and protein kinase C-dependent processes are equally important to generate 
the characteristic cAMP signal and cut-off at certain level by the cAMP-degrading 
phosphodiesterases. (Antony, 2000; Diamond 1999; Gonzalez-Iglesias, 2006)  
The level of  Ca2+  concentration in cytosol and the cyclic nucleotide signaling pathways are 
connected in regulation of physiological processes through messenger generation and also 
influencing additional other signaling pathways and vice versa, there is a distinct  molecular 
machinery responsible to modulate the calcium concentration ([Ca2+]i) (Bruce  2003). 
 From one side, the intracellular calcium concentration influences cAMP levels and 
balance, may also activates or inhibits some isoforms of adenylyl cyclase (AC), 
moreover the calcium concentration ([Ca2+]i), and selectively stimulates some 
phosphodiesterase (PDE) subtypes. Besides the cAMP, calcium also affects cGMP 
levels, NO synthase, etc through the activation of Ca2+-sensitive phosphodiesterases.  
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3.3. Voltage-gated calcium channels 
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and regulated manner”, since handled by Ca2+ influx and resulted in Ca2+-dependent 
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 From the other side, the cyclic nucleotide intracellular levels and activity of their kinases 
can influence membrane potential (Vm) and Ca2+ balance by Ca2+ influx via channels, 
and also the Ca2+ clearance. (Gonzalez-Iglesias 2006) 
This machinery of the cyclic nucleotides and the kinases may serve as a regulator or a 
pacemaker for hormone secretion of pituitary cells. It was demonstrated by in vitro models, 
that: 
 plasma membrane channels involved in action potential spiking; 
 basal cyclic nucleotides could contribute to the modulation of firing activity in 
lactotrophs; 
 both the cyclic nucleotide-dependent and -independent pathways controlling 
spontaneous VGCI and the level of exocytosis; 
 basal cAMP production controls the VGCI and PRL release by modulating electrical 
activity of the cell; 
 VGCI should be accountable for inhibition of intrinsic AC activity, since VGCI 
attenuates the intrinsic AC activity in intact cells independently of the status of PDEs. 
This regulation in lactotroph pituitary cells contributes only to the control of spontaneous 
electrical activity and basal PRL release, whereas the AC-independent action potential 
secretion coupling accounts for the majority of basal PRL release. Partial dependence of 
basal PRL release on cyclic nucleotides and partial inhibition of AC activity by spontaneous 
VGCI are the findings that consistent with reciprocal modulation of cyclic nucleotides and 
VGCI in spontaneously firing pituitary lactotrophs. (Gonzalez-Iglesias 2006). 
3.5. Role of protein phosphorylation-dephosphorylation in the extracellular 
signals mediated secretory function of lactotrophs 
Since virtually all types of extracellular signals (either those affecting second messenger-
dependent activation or inactivation of protein kinases (PKs) or those that use a direct 
activation or inactivation of an ion channel) converge to a final common system of 
fundamental importance in biological regulation, called PROTEIN PHOSPHORYLATION, 
one of the main objectives of this review is to summarize the role of this final messenger 
system. In recent years, significant advances have been made in our understanding of the 
role of protein phosphorylation-dephosphorylation in the extracellular signals mediating 
secretory function of different cells (Murányi 1997; Muranyi 1998; Lefkowitz, 1993; 
Shenolikar, 1988).  
Given the complexity and diversity of intercellular communication between hypothalamic 
releasing/inhibiting factors and hormone secreting pituitary cells (neuroendocrine 
communication) or between different cells of the pituitary gland itself (paracrine/autocrine 
communication), it would not be surprising that many of these systems use reversible 
protein phosphorylations. In this “third messenger” system, phosphorylation of the 
appropriate target or substrate proteins is tightly controlled by the activities of 
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phosphorylating PKs and dephosphorylating protein phosphatases (PPs). While the 
functions of PKs in the pituitary gland have been widely explored (Beretta, 1989; Leighton, 
1993; Chneiweiss, 1992), the role of the PPs has been mostly ignored. Significance of 
dephosphorylation in such regulatory mechanisms has been already demonstrated in the 
CNS (Leighton, 1993; Chneiweiss, 1992; Nestler, 1983; Shenolikar, 1994; Nestler, 1994) 
including control of neurotransmitter synthesis and release (Leighton, 1993), signaling 
through the neurotransmitter receptors (Nestler, 1983; Shenolikar, 1994) and ion channels 
(Shenolikar, 1994; Nestler, 1994) or various aspect of gene expression (Nestler, 1994; 
Mumbby, 1993; Wera 1995).  
4. Overview: control mechanisms of PRL secretion 
The hypophysiotrophic (inhibitory) DAergic neurons in the hypothalamus consist of three 
distinct groups of neurons: the tuberoinfundibular (TIDA), tuberohypophysial (THDA) and 
the periventricular-hypophysial (PHDA) dopaminergic systems. DA reaching the AL via 
short portal vessels from the neurointermediate lobe (NIL) accounts for an alternative 
regulatory aspect of basal and tonic PRL release besides the main physiological regulator 
TIDA neurons. The stimulatory and inhibitory factors influencing PRL secretion have 
multiple sites of action at least in two levels: (i) hypothalamic level as neurotransmitter on 
DA neurons; (ii) at the pituitary as a neurohormone acting on lactotrophs, or other factors 
may act as an autocrine or paracrine modulator. Well defined external effects (circadian 
patterns, noise, stress, etc) or neuronal stimuli have been identified to modulate PRL 
secretion, however the main components are endogenous substances that can affect the 
activity of neuroendocrine dopaminergic and PRF neurons and/or pre-synaptically regulate 
neural inputs to these neuroendocrine cells; alternatively act directly on pituitary cells.  
The predominant dopamine receptor is the D2 type in pituitary lactotroph cells, which exists 
in two alternatively spliced D2-short (D2S) and D2-long (D2L) isoforms, co-expressed in the 
same cells. Due to selective coupling to G-proteins, these receptor isoforms serve different 
functions: (i) inhibition of adenylyl cyclase, (ii) activation of voltage-gated calcium channels, 
and (iii) inhibition of potassium channels. D2L is the main isoform present in the anterior 
pituitary both in rat and in human. Alterations in the proportion of D2L/D2S could be the 
reason of resistance in D2R agonist therapies treating prolactinomas in clinical practice. 
The G-protein-coupled receptors carry the mainstream of biological responses, utilizing 
subunits that carry different and versatile subcellular messenger functions increasing the 
flexibility of the down-stream effector mechanisms according to the endocrine milieu. Gi/o 
signaling pathway is involved in DA-related inhibition of PRL secretion and results in 
depressed cAMP production. D2 receptors trigger the voltage-sensitive potassium channels 
(via Goα) and inhibit the voltage-sensitive calcium channels. Both Ca2+ and cAMP play 
important role to trigger the hormone release. Inhibition of basal cAMP production 
lactotrophs does not completely abolish the spontaneous firing of APs and only partially 
effect the basal PRL secretion. The PTX insensitive step in agonist-induced inhibition of PRL 
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release parallel with an activation of the sensitive pathways are affecting the PRL release 
through actions blocking electrical activity. 
The physiology of pituitary cells reflecting to suckling stimulus or separation from pups, 
controlled by various concentrations of DA: due to suckling stimulus with low dose of DA 
to PRL release or exhibit dose-dependent inhibitory effect. This experimental model (non-
suckled versus suckled) serves to demonstrate manipulations on concentrations of DA or 
receptors of DA in vivo or in vitro moreover, able to distinguish between ligand dissociation, 
and stimulation-induced elevation of PRL release. The suckling-induced 
desensitization/sensitization of pituitary cells is manifested at the cellular level by an 
increase of subpopulation of those cells less/ more sensitive to high/low dose ranges of DA. 
The receptor mediated intracellular mechanisms leading to these suckling-induced changes 
in DA responsiveness of lactotrophs is still not fully understood. It is possible that DA 
modulates the inputs in a biphasic manner: at low concentrations DA activates D1-like 
receptors, but higher concentrations activate the D2-like receptors resulting in inhibition. 
The receptorial desensitization or “tolerance” is based on the mechanisms, in which ligands 
of G-protein-coupled receptors (GPCRs) can promote specific intracellular signaling 
adaptation mechanisms parallel with the internalization process of the receptors. Estradiol 
up-regulates the GIRK channel subunits and controls the functional activation of the D2R-
GIRK pathway on mammotrop cells for the DA action. The negative membrane potential 
“primes” the lactotroph population by removing inactivation of voltage-gated Ca2+ 
channels. 
The intracellular mechanisms of DA activation connected to D2 receptors and G-proteins 
coupled subunits to control the cAMP levels and various ion channels: triggering potassium 
current influences voltage-activated calcium and potassium currents. Most of these plasma 
membrane channels have been characterized, but the mechanism connected to Ca2+-
dependent action potentials and pacemaking activity is still not fully understood. The cAMP 
signaling pathway is probably in control of pacemaking, voltage-gated Ca2+ influx and PRL 
release is a PKA-independent mechanism. The parallel activation of PTX-sensitive and 
insensitive pathways are affecting the PRL release through changes in electrical activity or 
modulate voltage-gated calcium channels. A specialty of these „active” lactotroph cells that 
this voltage-gated calcium influx resulting in an organized superimposition of APs, so called 
„plateau-bursting” action potentials that generate high amplitude calcium signals triggers 
secretion in lactotropes.  
The complexity and diversity of intercellular and paracellular communication suggests a 
common theory of a “third messenger” system: phosphorylation of the appropriate target or 
substrate proteins controlled by the activities of phosphorylating PKs and 
dephosphorylating by protein phosphatases (PPs). Significance of dephosphorylation has 
been already demonstrated in the CNS, signaling through the neurotransmitter receptors 
and ion channels, but role of PPs has been still left some uncertainty. In recent years efforts 
have been made to understand the role of protein phosphorylation-dephosphorylation in 
processing extracellular signals to mediate secretory functions.  
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1. Introduction 
Prolactin (PRL) is a polypeptide hormone secreted by the anterior pituitary responsible for the 
growth and differentiation of the normal mammary gland and plays a role in breast cancer. It 
functions systemically as an endocrine factor, but PRL may also act in an autocrine/paracrine 
fashion in a number of other tissues. Studies in both pre- and post-menopausal women have 
determined a significant increased risk for breast cancer for those with serum PRL in the 
highest quartile [6, 7]. PRL, acting through its receptors, has been shown to increase cell 
proliferation and decrease apoptosis in breast cancer cells in vitro [3, 8]. PRL also acts as a pro-
angiogenic factor in mammary tissues [9]. PRL exerts its effects by binding to its receptors on 
the surface of normal human breast epithelial and cancer cells, initiating the Jak2/Stat5, PI3K, 
and mitogen-activated protein kinase (MAPK) signaling pathways [3]. 
The PRL receptor (PRLR) is a member of the class I cytokine/hematopoietic receptor 
superfamily. A single hydrophobic transmembrane region separates the extracellular 
ligand-binding domain from the intracellular signaling domain. Five cell-associated PRLR 
isoforms differ only in their C-terminal cytoplasmic domains [1, 3]. The three major isoforms 
(long, LF; short 1a and 1b, SF1a and SF1b, respectively) are regulated by PRL itself. LF 
signals for many functions including growth and differentiation, whereas SF1a and SF1b act 
as dominant-negatives for differentiation [1, 2]. The role of the short forms in breast cell 
growth remains to be determined. 
2. Problem statement 
Studies from our laboratory [1] and from others [2] have demonstrated that three specific 
isoforms of the PRLR are expressed in both normal and cancerous breast cells and tissues. 
We recently developed and characterized PRLR isoform specific polyclonal antibodies that 
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1. Introduction 
Prolactin (PRL) is a polypeptide hormone secreted by the anterior pituitary responsible for the 
growth and differentiation of the normal mammary gland and plays a role in breast cancer. It 
functions systemically as an endocrine factor, but PRL may also act in an autocrine/paracrine 
fashion in a number of other tissues. Studies in both pre- and post-menopausal women have 
determined a significant increased risk for breast cancer for those with serum PRL in the 
highest quartile [6, 7]. PRL, acting through its receptors, has been shown to increase cell 
proliferation and decrease apoptosis in breast cancer cells in vitro [3, 8]. PRL also acts as a pro-
angiogenic factor in mammary tissues [9]. PRL exerts its effects by binding to its receptors on 
the surface of normal human breast epithelial and cancer cells, initiating the Jak2/Stat5, PI3K, 
and mitogen-activated protein kinase (MAPK) signaling pathways [3]. 
The PRL receptor (PRLR) is a member of the class I cytokine/hematopoietic receptor 
superfamily. A single hydrophobic transmembrane region separates the extracellular 
ligand-binding domain from the intracellular signaling domain. Five cell-associated PRLR 
isoforms differ only in their C-terminal cytoplasmic domains [1, 3]. The three major isoforms 
(long, LF; short 1a and 1b, SF1a and SF1b, respectively) are regulated by PRL itself. LF 
signals for many functions including growth and differentiation, whereas SF1a and SF1b act 
as dominant-negatives for differentiation [1, 2]. The role of the short forms in breast cell 
growth remains to be determined. 
2. Problem statement 
Studies from our laboratory [1] and from others [2] have demonstrated that three specific 
isoforms of the PRLR are expressed in both normal and cancerous breast cells and tissues. 
We recently developed and characterized PRLR isoform specific polyclonal antibodies that 
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revealed that the three isoforms, LF, SF1a, and SF1b, are differentially expressed in ductal 
and lobular carcinomas [5]. These two most common histological types of breast cancer 
originate from the terminal ductal lobular unit and may be difficult to classify. However, 
distinct differences were observed in PRLR expression in normal, benign, and malignant 
breast tissue which may have prognostic significance [10, 11]. The development and 
characterization of PRLR isoform specific monoclonal antibodies will provide a near 
limitless supply of reagent to continue to examine how and where these isoforms interact 
both in normal breast development and in breast cancer. 
3. Application area  
The identification of estrogen receptor (ER) and progesterone receptor (PR) in the current 
testing of breast cancer has advanced the field. Other hormones/growth factors are also 
involved; for example, PRL and its receptor isoforms. If their roles are more clearly 
identified with the use of specific antibodies then there may be a practical need for them in 
the diagnosis of this disease. Examining normal breast development could give clues to the 
relevance of PRLR isoforms in cancer. Not only do these apply to the breast, but may also be 
of value to studying ovarian and prostate cancers where PRL may play a role/function. 
PRLR isoform specific antibodies could be powerful tools in this quest. 
4. Methods 
4.1. Preparation of the PRLR isoform specific monoclonal antibodies 
Synthetic peptides were designed based on the regions of unique intracellular sequences of 
the PRLR splice variants and synthesized (AnaSpec, Inc., San Jose, CA) by the solid-phase 
method. Peptides (4 mg) were conjugated to bovine serum albumin (10 mg) with 1mM DSS 
overnight at room temperature and sent to Epitomics (Burlingame, CA) for immunization of 
rabbits. Initially, a total of 76 clones were received (54 clones for SF1a, 22 clones for SF1b) 
and screened for reactivity to their respective antigens by Western blot analysis. Briefly, 
lysates of CHO-K1 cells expressing either SF1a or SF1b were separated by SDS-PAGE, and 
transferred to PVDF. Membranes were blocked for 1 hr at room temperature in 5% non-fat 
dairy milk diluted in TBST+0.1% sodium azide. Subsequently, the clonal supernatants were 
diluted 1:1 in 10% non-fat dairy milk (diluted in TBST+0.1% sodium azide) and incubated 
for 3 hr at room temperature. Membranes were washed and probed with goat anti-rabbit 
Alexa680 (1:4000) prior to visualization using a LiCOR Odyssey reader. Supernatants from 
positively reacting clones were re-screened prior to selection for subcloning. In total, four 
SF1a and six SF1b rabbit monoclonal antibodies were put into production. The rabbit sera 
were initially purified by MEP Hypercel (PAL) chromatography, followed by size-exclusion 
chromatography to further purify the antibodies. Final pools of antibody were produced 
and protein concentration determined by the Pierce 660nm assay. 
For LF, 6 mg peptide was conjugated to 3 mg keyhole limpet hemocyanin overnight at room 
temperature using glutaraldehyde. Peptide conjugates were sent to Green Mountain 
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Antibodies (Burlington, VT) for generation of mouse monoclonal antibodies. Initially, 120 
clones were screened by Western blot as described above using CHO-K1 cells expressing LF 
with the exception that the antibodies were diluted 1:100 in 5% non-fat dairy milk (diluted 
in TBST+0.1% sodium azide) and incubated overnight at 4o C. Secondary antibody and 
imaging were essentially as described above. Supernatants of positively reacting clones 
were re-screened by Western blot and examined by fluorescence microscopy (to confirm 
appropriate localization) prior to selection for production. In total, 10 positive clones were 
selected for this process, 8 of which produced IgG. Antisera was purified as described for 
SF1a and SF1b antibodies. Final pools of antibody were produced and protein concentration 
determined by the Pierce 660nm assay. 
4.2. Cell culture and transfection  
Chinese hamster ovary cells (CHO-K1, ATCC, Manassas, VA) were maintained in -MEM 
(Invitrogen, Gaithersburg, MD) supplemented with 5% fetal bovine serum (FBS, Invitrogen) 
and penicillin/streptomycin (100 U/ml and 100 g/ml respectively, Invitrogen). Transfections 
were performed using FuGENE 6 (Roche Applied Science, Indianapolis, IN) at a ratio of 1 
g DNA to 3 l FuGENE. The PRLR isoform specific cDNA constructs were previously 
described [1]. Cells were transfected for 48 hr, then allowed to grow for an additional 48 hr.  
T47D, ZR75-1, MDA-MB-231, MDA-MB-468, MCF7, and SK-BR-3 breast cancer cell lines 
were obtained from ATCC. T47D, ZR75-1, MDA-MB231, and MDA-MB468 cells were 
maintained in RPMI1640 (Invitrogen). MCF7 cells were grown in DMEM and SK-BR-3 cells 
were maintained in McCoys 5a media. All media were supplemented with 5% heat inactivated 
FBS, 10 g/ml bovine insulin (Sigma, St. Louis, MO), and penicillin-streptomycin (100 U/ml 
and 100 g/ml respectively, Invitrogen). Where indicated, breast cancer cell lines were plated 
on 8-well glass chamber slides (Nunc, Rochester, NY) in normal growth media, and allowed 
to attach overnight. The media were replaced and the cells were treated for the indicated 
times with 500 ng/ml recombinant human PRL in media where the FBS was replaced with 
1% charcoal stripped serum, then fixed in 10% normal buffered formalin prior to Duolink 
assay. 
All cells were maintained at 37 °C in a humidified atmosphere with 5% CO2. Cells were 
passaged using trypsinization (0.05% trypsin-EDTA, Invitrogen) and counted on a 
hemocytometer using trypan blue exclusion 
4.3. Western blot analysis  
Transfected CHO cells were collected and whole cell lysates were prepared in Complete 
Buffer (Roche Applied Science) according to the manufacturer’s instructions. Total protein 
was estimated according to Bradford [12]. Protein (100 g) was subjected to 10-20% SDS-
PAGE (Invitrogen). Proteins were transferred to nitrocellulose membrane and probed with 
PRLR isoform specific antibodies (10 g/ml for LF, 6 g/ml for SF1a or SF1b). Reactivity was 
detected using ECL Plus (GE Healthcare Life Science, Pittsburgh, PA). Molecular size 
determinations were made using BenchMark Protein Ladder (Invitrogen). 
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revealed that the three isoforms, LF, SF1a, and SF1b, are differentially expressed in ductal 
and lobular carcinomas [5]. These two most common histological types of breast cancer 
originate from the terminal ductal lobular unit and may be difficult to classify. However, 
distinct differences were observed in PRLR expression in normal, benign, and malignant 
breast tissue which may have prognostic significance [10, 11]. The development and 
characterization of PRLR isoform specific monoclonal antibodies will provide a near 
limitless supply of reagent to continue to examine how and where these isoforms interact 
both in normal breast development and in breast cancer. 
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testing of breast cancer has advanced the field. Other hormones/growth factors are also 
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identified with the use of specific antibodies then there may be a practical need for them in 
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4. Methods 
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Antibodies (Burlington, VT) for generation of mouse monoclonal antibodies. Initially, 120 
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(Invitrogen, Gaithersburg, MD) supplemented with 5% fetal bovine serum (FBS, Invitrogen) 
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described [1]. Cells were transfected for 48 hr, then allowed to grow for an additional 48 hr.  
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were obtained from ATCC. T47D, ZR75-1, MDA-MB231, and MDA-MB468 cells were 
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were maintained in McCoys 5a media. All media were supplemented with 5% heat inactivated 
FBS, 10 g/ml bovine insulin (Sigma, St. Louis, MO), and penicillin-streptomycin (100 U/ml 
and 100 g/ml respectively, Invitrogen). Where indicated, breast cancer cell lines were plated 
on 8-well glass chamber slides (Nunc, Rochester, NY) in normal growth media, and allowed 
to attach overnight. The media were replaced and the cells were treated for the indicated 
times with 500 ng/ml recombinant human PRL in media where the FBS was replaced with 
1% charcoal stripped serum, then fixed in 10% normal buffered formalin prior to Duolink 
assay. 
All cells were maintained at 37 °C in a humidified atmosphere with 5% CO2. Cells were 
passaged using trypsinization (0.05% trypsin-EDTA, Invitrogen) and counted on a 
hemocytometer using trypan blue exclusion 
4.3. Western blot analysis  
Transfected CHO cells were collected and whole cell lysates were prepared in Complete 
Buffer (Roche Applied Science) according to the manufacturer’s instructions. Total protein 
was estimated according to Bradford [12]. Protein (100 g) was subjected to 10-20% SDS-
PAGE (Invitrogen). Proteins were transferred to nitrocellulose membrane and probed with 
PRLR isoform specific antibodies (10 g/ml for LF, 6 g/ml for SF1a or SF1b). Reactivity was 
detected using ECL Plus (GE Healthcare Life Science, Pittsburgh, PA). Molecular size 
determinations were made using BenchMark Protein Ladder (Invitrogen). 
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4.4. Fluorescent immunocytochemistry 
CHO cells were plated on 8-well glass chamber slides (Nunc) and transfected as above. 
After blocking with 5% normal goat serum (Jackson Laboratories, Bar Harbor, ME) prepared 
in PBS-0.1% Triton, slides were incubated with the PRLR isoform specific monoclonal 
antibodies (10 g/ml for LF, 6 g/ml for SF1a or SF1b) overnight at 4o C. In all cases no 
primary antibody served as the negative control. Slides were washed four times with PBS-
0.1% Triton followed by incubation for 1 hr with either red fluorescent tagged goat anti-
mouse secondary antibody for the PRLR-LF or red fluorescent tagged goat anti-rabbit 
secondary antibody for the PRLR-SF (AlexaFluor 594, 1:500, Invitrogen) in the dark. After 
extensive washing with PBS containing Triton, slides were mounted with Prolong Gold 
antifade reagent with DAPI (Invitrogen). The fluorescent staining pattern of the receptor 
isoforms was evaluated using an Olympus BX40 fluorescence microscope (Olympus 
America, Center Valley, PA). 
4.5. Fluorescent immunohistochemistry  
Fresh breast samples were supplied by either the Cooperative Human Tissue Network, a 
NCI supported resource that supplies human biospecimens to IRB approved researchers, or 
from patient samples collected in accordance with the guidelines of the National Cancer 
Institute Review Board, protocol 02-C-0144. Breast tissue was obtained from 15 pre-
menopausal reduction mammoplasty patients; each sample was determined free from 
hyperplastic growth by a pathologist. Samples were fixed in 10% normal buffered formalin, 
embedded, cut into four micron sections, deparaffinized, and stained as above. For dual 
labeling studies, sections were incubated overnight at 4o C with LF (10 g/ml) and either 
SF1a or SF1b (6 g/ml) monoclonal antibodies. Red fluorescent anti-mouse secondary 
antibody (AlexaFluor 594, 1:500) was used for LF; green fluorescent anti-rabbit secondary 
antibody (AlexaFluor 588, 1:500) was used for SF1a and SF1b. 
An additional eight samples were also snap-frozen and stored at -80o C for OCT embedding 
and sectioning. Frozen tissue sections were thawed for 30 to 60 sec and fixed in ice-cold 
methanol:acetone (1:1) for 10 min. After washing twice with PBS, sections were blocked for 
30 min with 10% normal goat serum in IF buffer (PBS containing 0.05 mg/ml sodium azide, 
0.1 mg/ml BSA, 0.02% Triton X, and 0.05% Tween 20). Sections were incubated with either 
LF (10 g/ml) and SF1a or SF1b (6 g/ml) PRLR isoform specific monoclonal antibodies 
overnight at 4o C. Sections were extensively washed with PBS, then incubated with red 
fluorescent anti-mouse secondary antibody (AlexaFluor 594, 1:500) for LF and green 
fluorescent anti-rabbit secondary antibody (AlexaFluor 588, 1:500) for SF1a and SF1b. 
Sections were washed again and mounted with Prolong Gold antifade reagent with DAPI.  
The fluorescent staining patterns of the PRLR isoforms were assessed using an Olympus 
BX40 fluorescent microscope. For both paraffin-embedded and frozen tissue sections, 
photographs were immediately taken under the violet, green, and blue channels to detect 
DAPI, red, and green fluorescence, respectively. Images were merged in order to observe 
PRLR isoform localization patterns.  
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Nine samples of paraffin-embedded breast tumor tissue were stained and analyzed as 
above. 
4.6. Measurement of fluorescence intensity  
Because serial sections for the breast specimens were used, the same region of each tissue 
could be measured for fluorescence intensity using Adobe Photoshop (Adobe Systems Inc., 
Beaverton, OR). Nearly every cell in positive samples showed some level of PRLR isoform 
expression; as a result, red fluorescence intensity was used to compare levels of isoform 
expression between samples. In order to do this, the same fluorescent areas were selected 
from each serial section using the lasso and rectangular marquee tools. Selected sections 
were analyzed using the histogram function through the red channel, which gave the mean 
red intensity of the selected section. Photoshop assigns intensity values between 0 and 255 
to each pixel in the selected area and then averages these intensities. The distribution of 
these means was analyzed and used to divide samples into four intensity classes: negative 
(less than 10 intensity), low (between 11 and 30 intensity), medium (between 31 and 50 
intensity), and high (greater than 51 intensity).  
4.7. Generation of ProbeMaker probes for Duolink  
Antibodies against the various PRLR isoforms were directly conjugated using the 
ProbeMaker protocol as described by the manufacturer (OLINK BioScience, Upsala, 
Sweden). Briefly, 2 l ProbeMaker conjugation buffer was added to 20 g of each antibody 
(starting antibody concentration, 1 mg/ml) prior to addition of the antibody to the 
lyophilized oligonucleotides (PLUS and MINUS probes). Incubation with oligonucleotides 
proceeded overnight at room temperature, followed by addition of 2 l of ProbeMaker Stop 
Reagent and incubation for 30 min at room temperature to conclude the labeling reactions. 
Unreacted oligonucleotides were rendered inactive during this step, preventing spurious 
signals from being generated. For storage of the antibody-oligonucleotide conjugates, 24 l 
ProbeMaker storage buffer was added. The final concentration of the antibody-
oligonucleotide conjugates were ~0.4 mg/ml and stored at 4o C until use. 
4.8. In situ proximity ligation assay  
Cultured cells were plated onto 8-well chamber slides (Millipore) in media for one day prior 
to stimulation as described above. Cells were stimulated for 0, 5, 10, or 60 min with PRL, 
washed twice in PBS, then fixed in 4% paraformaldehyde for 10 min. Fixed cells were 
subsequently washed twice with PBS, dried and frozen at -20o C.  
On the day of the experiment, slides were thawed at room temperature and rehydrated in 
PBS for 10 min at room temperature. All steps of the Duolink protocol were performed as 
open droplet reactions on the chamber slides, using 30 l volume per chamber to ensure 
complete coverage of the cells. Cells were then permeabilized in PBS+0.1% Triton X-100 for 
10 min at room temperature, washed twice in PBS, and blocked in 1X Duolink Blocking 
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America, Center Valley, PA). 
4.5. Fluorescent immunohistochemistry  
Fresh breast samples were supplied by either the Cooperative Human Tissue Network, a 
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embedded, cut into four micron sections, deparaffinized, and stained as above. For dual 
labeling studies, sections were incubated overnight at 4o C with LF (10 g/ml) and either 
SF1a or SF1b (6 g/ml) monoclonal antibodies. Red fluorescent anti-mouse secondary 
antibody (AlexaFluor 594, 1:500) was used for LF; green fluorescent anti-rabbit secondary 
antibody (AlexaFluor 588, 1:500) was used for SF1a and SF1b. 
An additional eight samples were also snap-frozen and stored at -80o C for OCT embedding 
and sectioning. Frozen tissue sections were thawed for 30 to 60 sec and fixed in ice-cold 
methanol:acetone (1:1) for 10 min. After washing twice with PBS, sections were blocked for 
30 min with 10% normal goat serum in IF buffer (PBS containing 0.05 mg/ml sodium azide, 
0.1 mg/ml BSA, 0.02% Triton X, and 0.05% Tween 20). Sections were incubated with either 
LF (10 g/ml) and SF1a or SF1b (6 g/ml) PRLR isoform specific monoclonal antibodies 
overnight at 4o C. Sections were extensively washed with PBS, then incubated with red 
fluorescent anti-mouse secondary antibody (AlexaFluor 594, 1:500) for LF and green 
fluorescent anti-rabbit secondary antibody (AlexaFluor 588, 1:500) for SF1a and SF1b. 
Sections were washed again and mounted with Prolong Gold antifade reagent with DAPI.  
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photographs were immediately taken under the violet, green, and blue channels to detect 
DAPI, red, and green fluorescence, respectively. Images were merged in order to observe 
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Nine samples of paraffin-embedded breast tumor tissue were stained and analyzed as 
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expression; as a result, red fluorescence intensity was used to compare levels of isoform 
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(less than 10 intensity), low (between 11 and 30 intensity), medium (between 31 and 50 
intensity), and high (greater than 51 intensity).  
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Antibodies against the various PRLR isoforms were directly conjugated using the 
ProbeMaker protocol as described by the manufacturer (OLINK BioScience, Upsala, 
Sweden). Briefly, 2 l ProbeMaker conjugation buffer was added to 20 g of each antibody 
(starting antibody concentration, 1 mg/ml) prior to addition of the antibody to the 
lyophilized oligonucleotides (PLUS and MINUS probes). Incubation with oligonucleotides 
proceeded overnight at room temperature, followed by addition of 2 l of ProbeMaker Stop 
Reagent and incubation for 30 min at room temperature to conclude the labeling reactions. 
Unreacted oligonucleotides were rendered inactive during this step, preventing spurious 
signals from being generated. For storage of the antibody-oligonucleotide conjugates, 24 l 
ProbeMaker storage buffer was added. The final concentration of the antibody-
oligonucleotide conjugates were ~0.4 mg/ml and stored at 4o C until use. 
4.8. In situ proximity ligation assay  
Cultured cells were plated onto 8-well chamber slides (Millipore) in media for one day prior 
to stimulation as described above. Cells were stimulated for 0, 5, 10, or 60 min with PRL, 
washed twice in PBS, then fixed in 4% paraformaldehyde for 10 min. Fixed cells were 
subsequently washed twice with PBS, dried and frozen at -20o C.  
On the day of the experiment, slides were thawed at room temperature and rehydrated in 
PBS for 10 min at room temperature. All steps of the Duolink protocol were performed as 
open droplet reactions on the chamber slides, using 30 l volume per chamber to ensure 
complete coverage of the cells. Cells were then permeabilized in PBS+0.1% Triton X-100 for 
10 min at room temperature, washed twice in PBS, and blocked in 1X Duolink Blocking 
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solution for 30 min at 37o C in a humidity chamber to prevent evaporation. PRLR primary 
antibody-oligonucleotide conjugates were diluted in PLA Probe Diluent to 5 g/ml, and 
applied to slides overnight at 4o C in a cooled humidity chamber. On the second day, slides 
were washed 3 times in 1X Duolink Wash Buffer A to remove excess antibody-
oligonucleotide conjugates. Bound antibody-oligonucleotide conjugates were ligated 
together for 30 min at 37o C according to the manufacturer’s instructions. Subsequently, 
ligated templates were amplified for 2 hr at 37o C according to the manufacturer’s protocol, 
washed twice for 10 min in Duolink 1X Wash Buffer B, and once for 1 min in 0.1X Wash 
Buffer B prior to mounting with Duolink Fluorescence mounting media (which also contains 
DAPI for nuclear counterstaining) and observation under a fluorescent microscope. 
Image acquisition was performed using a Zeiss Axioscope M1 under 40X magnification and 
an AxioCam HR. Image analysis was performed using the Duolink ImageTool software 
according to the instructions provided by OLINK. 
5. Results 
5.1. Characterization of PRLR isoform specific monoclonal antibodies 
We have recently prepared and characterized PRLR isoform specific polyclonal antibodies 
[5]. However, a limitless source of polyclonal antibody is restricted because it is generated 
by repeated immunization of a rabbit. Each antibody preparation has the potential to vary in 
its specificity as well. Monoclonal antibodies are more homogeneous and can produce a 
near inexhaustible supply of reagent. We used the same peptide sequence as for the 
preparation of isoform specific polyclonal antibodies and, again, demonstrate specificity for 
the individual isoforms. CHO cells were transiently transfected with cDNA containing the 
individual PRLR isoforms; western blot analysis from cell lysates indicate that the 
antibodies detect the corresponding protein without cross-reactivity (Figure 1A).  
By immunocytochemical analysis using transiently transfected CHO cells, we were able to 
positively stain for isoform specific PRLR. As shown in Figure 1B, no cross-reactivity was 
identified using the antibodies on cells transfected with non-corresponding PRLR cDNA. By 
both western and immunochemical analysis we were able to demonstrate the specificity of 
the PRLR isoform specific monoclonal antibodies. 
5.2. Immunofluorescent staining of human breast tissue  
Once we determined the specificity of the isoform specific monoclonal antibodies on 
transfected cells, we tested them on histosections obtained from reduction mammoplasty 
specimens. In order to examine the localization patterns of the PRLR, we stained the tissues 
simultaneously with LF and either SF1a or SF1b antibodies. Similar, striking, distribution of 
isoform expression was observed, regardless of whether paraffin-embedded or frozen 
sections were used. As seen in Figure 2, LF expression appeared primarily basal, whereas SF 
localized more luminally. 
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Figure 1. Characterization of PRLR isoform antibodies. A. Western blot analysis indicating specificity of 
monoclonal antibodies. CHO cells were transiently transfected with isoform specific PRLR cDNA as 
described. Cell lysates were prepared and proteins separated by PAGE. Each isoform specific lysate was 
probed with each isoform specific antibody. Western blot analysis was performed twice with separate 
lysates. Data shown are a representative autoradiogram. Molecular weights are marked as indicated: LF 
= 93kDa, SF1a = 55kDa, SF1b = 43kDa. B. Fluorescent immunocytochemical analysis. CHO cells were 
transiently transfected with isoform specific PRLR cDNA as described. Specific staining was observed. 
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Figure 2. Fluorescent immunohistochemical analysis from normal breast tissues. Representative photos 
taken from breast reduction mammoplasty specimens. Images in left panels are taken from paraffin 
embedded tissues; middle panels are imaged from frozen sections; right panels are taken from paraffin 
embedded normal lactating mammary tissues. Negative control indicates no primary antibody used. LF 
is indicated by green fluorescence; SF is indicated by red fluorescence. LF = long form; SF = short form. 
Magnification 40X. 
However, the expression patterns localized quite differently in cancer tissue. The PRLR 
isoforms appeared to colocalize, but were only present in specific areas (Figure 3). The 
pattern seemed more random, concentrated in “hot spots,” particularly for SF1a. 
5.3. In situ proximity ligation assay monitors PRLR dimerization  
The Duolink reagents allow for specific protein-protein interactions to be examined in situ. 
Using antibodies to PRLR-LF, SF1a and SF1b we generated PRLR isoform-specific PLA 
probes in order to monitor every possible dimer combination using the OLINK ProbeMaker 
kit. This kit allows for the direct conjugation of the oligonucleotide (PLUS or MINUS end) to 
the primary antibody, which is essential for examining homodimers. Using these probes, we 
examined the six possible dimer pairings (LF/LF, SF1a/SF1a, SF1b/SF1b, LF/SF1a, LF/SF1b, 
SF1a/SF1b) in six established breast cancer cell lines: T47D, ZR75-1, MDA-MB-231, MDA-
MB-468, MCF7, and SK-BR-3 in the absence and presence of PRL stimulation. In addition to 
the specific antibodies, we included non-specific isotyped control antibodies as negative 
controls (i.e. LF/NSR, where NSR is a non-specific rabbit IgG in place of a specific rabbit 
antibody against PRLR). After the proximity ligation reaction has taken place, a single 
fluorescent red dot is observed. This dot represents a single molecular interaction between 
the two proteins being interrogated.  
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Figure 3. Fluorescent immunohistochemical analysis from breast cancer tissues. Representative photos 
taken from breast tumor specimens. LF is indicated by green fluorescence; SF is indicated by red 
fluorescence. LF = long form; SF = short form. Magnification 40X. 
With the exception of the MDA-MB-231 cells, similar patterns of expression were observed 
in all breast cell lines tested. In the ER positive MCF7 cells, dimers of all six potential 
combinations were observed in the absence of stimulation, and were maintained throughout 
the stimulation with PRL (Figure 4A). However, in the ER negative MDA-MB-231 cells, a 
much more complex pattern appeared (Figure 4B). We observed changes in the levels of 
several dimers over the course of PRL stimulation, suggesting that the different dimer 
pairings may be utilized by the cell to mitigate responses to prolonged PRL stimulation.  
While performing these experiments, we noticed a significant amount of PRLR dimers at 
either the perinuclear or nuclear region of the cell. Several receptors in the mammary gland 
have been shown to undergo nuclear translocation including EGFR, FGFR, and GHR [13]. 
However, there is little information known about the nuclear localization of PRLR. Several 
reports in the literature have offered contradicting evidence for PRLR nuclear translocation 
[19-21].  
In a preliminary study of PRLR isoform nuclear translocation, MDA-MB-231 cells were 
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embedded tissues; middle panels are imaged from frozen sections; right panels are taken from paraffin 
embedded normal lactating mammary tissues. Negative control indicates no primary antibody used. LF 
is indicated by green fluorescence; SF is indicated by red fluorescence. LF = long form; SF = short form. 
Magnification 40X. 
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Figure 4. Duolink analysis of breast cancer cell lines for PRL-dependent PRLR dimerization. 
Representative images are shown for each dimer pairing in both MCF7 (panel A) and MDA-MB-231 
(panel B) cells at 0, 5, 10 and 60 min post-stimulation with PRL. Magnification 40X. Nuclei stained 
(shown in blue) with DAPI, Duolink signal shown in red. Each red dot represents a single dimerization 
event. 
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6 hr prior to Duolink analysis to examine steady-state nuclear localization of PRLR dimer 
formation using confocal microscopy (Figure 5). Of the various combinations of PRLR 
isoform dimers that were examined, nearly all exhibited some nuclear localization. The 
exception was for SF1a/SF1a homodimers, which formed perinuclear rings but showed little 
to no nuclear localization (Figure 5B). Homodimers of the two short forms or a heterodimer 
of the two short forms (Figure 5B, SF1a/SF1a; Figure 5C SF1b/SF1b; Figure 5D, SF1a/SF1b) 
exhibited significantly higher levels of nuclear localization while LF homodimers (Figure 
5A) and the two LF-short form heterodimers (Figure 5E, LF/SF1a; Figure 5F, LF/SF1b) 
showed modest levels of nuclear localization. These results confirm that nuclear 
localization exists for the human prolactin receptor isoforms and may suggest a new role 
for them as potential transcriptional regulators. Pathways indicating the intranuclear 
transport and function of PRL and its receptor targeting intracellular actions, such as 
transcription, have been demonstrated [13]. Increases in transcription may effect cell 
proliferation and/or differentiation. However, the function of perinuclear localization has 
yet to be explored. 
 
 
Figure 5. PRLR isoform dimers exhibit different localization patterns. MDA-MB-231 cells were 
stimulated for 6 hr with 500 ng/ml recombinant human PRL, fixed and examined by confocal 
microscopy for PRLR dimer localization using Duolink. Dimer combinations: A. LF/LF; B. SF1a/SF1a; C. 
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6. Discussion and further research  
Prolactin signaling through the LF of the PRLR has been well studied [13]. Two short forms 
of the PRLR (SF1a and SF1b) share common extracellular and transmembrane domains with 
the LF, yet contain different cytoplasmic sequences due to alternative splicing of exon 11 
[1,2]. The role of these short forms in PRLR function remains elusive, in part due to a lack of 
specific reagents. Both SF1a and SF1b contain the Box1 binding site for Jak2 and MAPK 
proteins, yet lack the Box 2 site (and downstream phosphorylation sites) required for STAT 
binding [2, 14]. By lacking part of intracellular signaling domain, the short forms of the 
PRLR act as dominant negatives of the LF in transfected cells and its effects most likely 
occur through heterodimerization with LF [5]. While both short forms can function as a 
dominant negative, SF1b is the more potent negative regulator of LF function. 
To facilitate the study of the PRLR short forms, we generated isoform-specific polyclonal 
antibodies and demonstrated a breast cancer specific pattern of expression. While all tumor 
biopsies expressed both LF and SF1b equally, the presence of SF1a was detected mainly in 
ductal breast carcinoma biopsies and not in those derived from lobular carcinomas [5]. 
These data suggest diagnostic potential for the PRLR short forms.  
The mere expression profiles of these proteins may not serve as sufficient biomarkers, as 
PRLR dimers are the functional unit for PRL-mediated events. Therefore, an analysis of the 
ratios of the various potential dimers may be needed to generate a more complete 
understanding of PRLR signaling. Techniques such as BRET and FRET have been used to 
examine PRLR dimer formation [14-17]. However, these techniques collectively constrain 
the user to cells that express tagged constructs and prevent analysis of tissue samples. Co-
immunoprecipitation has been used with moderate success for PRLR dimer analysis and 
avoids the need for tagged constructs, but lacks quantitation, requires specific antibodies, 
and is devoid of any cellular localization information. To overcome these technical 
challenges, we employed an in situ proximity ligation assay developed by OLINK. This 
technique allows for the sensitive detection of protein-protein interactions in unmodified 
cells and tissue. Using the newly generated rabbit and mouse monoclonal PRLR isoform-
specific antibodies, we examined PRLR dimer formation in breast cancer cell lines in the 
absence and presence of PRL stimulation. Due to the flexibility of the method, we were able 
to monitor all possible homo- and hetero-dimers concurrently.  
We were able to confirm that PRLR homo- and hetero-dimers form in the absence of PRL, 
similar to reports by others [14, 17]. Similar reports have shown that members of the EGFR 
family can form dimers in the absence of ligand [18]. In total, we observed homodimers of 
LF/LF, SF1a/SF1a, and SF1b/SF1b and heterodimers of LF/SF1a, LF/SF1b, and SF1a/SF1b in 
two different, but well-established breast cancer cell lines, MCF7 and MDA-MB-231. While 
SF homodimerization has been shown, heterodimerization of the short forms has been 
examined but not proven [16]. However, these assays utilized PRLR receptors C-terminally 
tagged with GFP or Rluc to perform BRET analysis, which may somehow block the 
detection of the SF heterodimer. The functional consequence of the SF1a/SF1b heterodimer is 
not known. Given that both short forms lack the majority of the intracellular domain, this 
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dimer may be formed to limit the inhibitory activity of each monomer towards the LF by a 
yet-to-be discovered mechanism. 
In addition to confirming the existence of all possible dimer pairings, we were able to show 
that the different PRLR dimers peaked at different times during the PRL time course. These 
data suggest that upon stimulation with PRL, regulatory events occur within the cell to 
favor a particular signaling outcome. For example, an increase in LF/SF1b dimers is 
predicted to sequester otherwise functional LF monomers into inactive dimers with SF1b. 
These dimers (and similarly LF/SF1a dimers) would be capable of binding PRL, but would 
most likely be unable to transmit the signal from ligand binding to the intracellular milieu. 
Thus, the dominant negative nature of the PRLR short forms could occur by isolating PRLR 
LF monomers and also result in diminished effects of PRL on cells. Further studies would be 
required to better understand the dimerization time course for PRLR in these and other 
breast cancer cell lines. 
The confirmation of the nuclear localization of PRLR dimers is an important finding. 
Conflicting reports were found in the literature [13, 19, 20], however our study confirms that 
PRLR dimers can be found in the nucleus of cultured breast cancer cells. Interestingly, the 
amount of nuclear localized PRLR was different for the various dimer pairings tested in 
MDA-MB-231 cells. In general, the SF dimer combinations (SF1a/SF1a, SF1a/SF1b, and 
SF1b/SF1b) exhibited higher levels of nuclear localization than dimers containing at least 
one monomer of LF. In addition, only SF1a homodimers localized to a perinuclear region, 
and appeared as rings around the nucleus. Together these data suggest a potential 
transcriptional role for PRLR. Recent work performed in the Walker laboratory [21] 
demonstrated that, in prostate cancer, the expression of SF1b was upregulated after 
treatment with the PRL inhibitor S179D. This increase in repression also led to an 
upregulation of p21 and the vitamin D receptor (VDR), both known to affect differentiation 
and apoptosis. In vitro studies also confirmed that long-term overexpression to SF1b 
decreased the growth and migration of prostate cancer cells, in addition to enhancing cell-
matrix interactions and cell-cell aggregation [22]. Abnormalities in the vitamin D endocrine 
system have been linked to many disorders, including cancer [23]. Strong epidemiological 
associations were made between vitamin D deficiency and breast and prostate cancers. The 
VDR system may arrest the tumor cell cycle at G1/G0 through several mechanisms such as 
by induction of p21 gene transcription [24] or by inducing the synthesis and/or stabilization 
of p27 [25]. Recent work in tumor-derived endothelial cells has implicated VDR as an anti-
proliferative factor inducing cell cycle arrest in G1/G0 and tumor angiogenesis [26]. Loss of 
VDR in this system or in mammary epithelial cells may affect differentiation and apoptosis 
or modulate intracellular signaling routes. These changes in the tumor microenvironment 
could potentially result in aberrant angiogenic signaling pathways, possibly even enhancing 
angiogenesis for a more efficient delivery of chemotherapeutic drugs. PRL and its signaling 
pathways could be exploited to search for more effective therapies in prostate and breast 
cancer [27]. Potential synergy with various chemotherapeutics may be another aspect of the 
importance of dimerization and localization of PRL and its receptors in breast cancer. 
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As discussed herein, our laboratory has recently published the utility of PRLR isoform-
specific antibodies in characterizing breast cancer samples as either lobular or ductal in 
nature [5]. The generation of monoclonal antibodies to the various PRLR isoforms provides 
a more renewable and reliable supply of these antibodies, and were crucial to the 
dimerization studies. To our knowledge, this is the first time that the Duolink in situ 
proximity ligation assay enabled detection of all possible PRLR dimer combinations. The 
technique is robust, quantitative and relatively easy to use.  
With the advent of the tissue microarray (TMA) [28, 29], researchers are able to examine 
large populations of tissues from patients on a single glass slide. There are many 
commercially available TMAs as well, including arrays for breast cancer patients. These 
arrays have typically been evaluated for ER/PR/HER2 status and, in many cases, have both 
normal and diseased tissue for each patient. Given that OLINK provides a Brightfield 
Duolink kit, several studies could be envisioned. First, since the Duolink assay can also be 
used to obtain quantitative total expression of a target, the application of this technique to 
TMAs would provide a significantly better means of analyzing the expression levels of 
targets (rather than high, medium, and low expression). These data could also be combined 
with expression profiles of the PRLR dimer complexes and ultimately compared with other 
markers to identify more specific breast cancer signatures. Further correlations could be 
made with the levels of the hormone PRL itself, which could help further diagnose patients. 
The “hormonal responsiveness” of breast cancer has been known for a long time. 
Unfortunately, this phrase has only been used to indicate responsiveness to estrogen (E) and 
progesterone (P). However, several other hormones including PRL, growth hormone, and 
thyroid hormone have been shown to play roles in normal breast development and function 
and their various roles in breast cancer are being investigated. The complex interplay of the 
three major hormones involved in normal breast development, E, P, and PRL, is well 
documented. In model systems that include human breast cancer cells in culture as well as 
rodent models, E, P, and PRL have all been shown to stimulate growth. In fact, when 
compared directly with E acting on MCF-7 human breast cancer cells, PRL is a more potent 
mitogen than E [8]. 
Additionally, these model systems have demonstrated that each of these hormones acts as 
more than just a mitogen. Complex systems of inter-regulation exist between these steroids, 
PRL and their receptors. PRL stimulates growth through both an endocrine as well as an 
autocrine/paracrine mechanism. The expression of autocrine PRL in human breast cancer 
cells is regulated by E through action on the PRL promoter [30]. Expression of the PRL gene 
is regulated by two promoters, the proximal promoter utilized primarily in the pituitary and 
the distal promoter utilized in breast cancer cells. E directly induces hPRL gene expression 
in T47D human breast cancer cells through the action of a functional non-canonical E 
response element (ERE) and an AP1 site on the distal promoter. Both the ERE and AP1 sites 
are required for full induction of promoter activity through the alpha form of the ER. 
Similarly, the interplay of P and PRL is well established in various models. PR and PRLR are 
co-expressed temporally and spatially in the developing mouse mammary gland. In 
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mammary glands from ovariectomized female mice lacking both E and P, neither P nor PRL 
stimulate DNA synthesis in epithelial or adjacent stromal cells. However, simultaneous 
injection of P and PRL results in a significant synergistic effect on DNA synthesis in both cell 
types [31]. Similarly, disruption of expression and distribution of PR in the mammary gland 
results in a parallel disruption of expression and distribution of the PRLR suggesting inter-
regulation of these receptors [32]. Expression of the PRLR in human cells is regulated 
through a complex system of promoters. The PRLR gene in humans has six exon 1s, the 
most generic of which (PRLR promoter region III) is functional in human breast cancer cells. 
T47D human breast cancer cells treated with P overexpress the PRLR and activate PRLR 
promoter III. This promoter lacks a classical P response element. Thus P acts through the 
cooperative interaction of the PR with the transcription factors C/EBP and an adjacent Sp1A 
site to confer P responsiveness leading to increased expression of the PRLR [33]. 
These examples of the complex interactions of E, P, and PRL underscore the importance of 
understanding all three hormones’ actions and their receptor interactions, distribution, and 
functions in the normal human breast and in breast cancer. Effective tools for these studies 
are now available. 
7. Conclusion 
Just as the identification of the ER and PR are now routinely performed on all clinical breast 
cancer samples, screening for PRLR status and isoform profile may also one day become a 
routine procedure in the characterization of breast cancers. Isoform specific antibodies to the 
PRLR can be powerful tools in detection and characterization of breast and other cancers 
and provide valuable insights into the important PRLR signaling pathways that could be 
effective targets for prevention and treatment. 
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1. Introduction 
Human prolactin is a single-chain polypeptide hormone. It has a molecular weight of 
approximately 22,500 Da (figure 1). It takes part in lactation through physiological and 
biochemical events.  
Its polypeptide chain consists of 198-200 amino acid remainders which complete sequence is 
unknown. Over 80% of the first 50 amino acids are identical or equivalent to the bovine 
prolactin. 
The prolactin molecule is arranged in a single chain of amino acids with three intra 
molecular disulfide bonded between six cysteine residues (Cys4-Cys11, Cys58-Cys174, 
Cys191-Cys199 in humans). The sequence homology can vary from the striking 97% among 
primates to as low as 56% in rodents (1) 
The sequence of the first 23 amino acid remainders corresponding to the N-terminal extreme 
NH2-leu-pro-ile-cys-pro-gly-ala-ala-arg-cys-gln-val-thr-leu-arg-asp-leu-phe-asp-arg-ala-val 
It’s secreted by the anterior part of the hypophysis, the adenohypophysis (figure 2) that 
stimulates the milk production in the mammary glands and the progesterone synthesis in 
the corpus luteum. 
Although the major form of prolactin found in the pituitary gland is 23 kDa, variants of 
prolactin have been characterized in many mammals, including humans. Prolactin variants 
can be results of alternative splicing of the primary transcript, proteolytic cleavage and other 
posttranslational modifications of the amino acid chain (1) 
 The Author(s). Licensee InTech. This chapter is distributed under he terms of the Creative Commons 
Attribution License http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, 
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Source: Originally from en.wikipedia; description page is/was here. 
Author: Original uploader was BorisTM at en.wikipedia 
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Figure 1. Prolactin´s structure 
 
This image is propriety of our laboratory and created by us. 
Figure 2. Prolactin’s secretion. 
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It was discovered in 1928 in a cow´s hypophysis and it is phylogenetically considerated  as 
the oldest known hormone in the animal kingdom. It has been detected in insects, 
amphibian, fish and mammals. Its luteotrophic activity was not discovered until 1945 (2-4). 
Its isolation was difficult due to its structure, which is similar (in a 16%) to the growth 
hormone (GH) structure. Both are located in the hypophysis, but the GH is present in higher 
concentration. Its existence was demonstrated through a trial series performed between 1965 
and 1971, it was discovered, as well, the way its secretion is performed, where some 
physiological factors are positive and negative hypothalamic neurohormonal compounds  
(5-6). 
Studies on the secondary structure of prolactin have shown that 50% of the amino acid chain 
is arranged in α-helices, while the rest of it forms loops. Although it was predicted earlier, 
there are still no direct data about the three-dimensional structure of prolactin. The tertiary 
structure of prolactin was predicted by homology modeling approach, based on the 
structural similarities between prolactin and other helix bundle proteins, especially growth 
hormone. 
According to the current three-dimensional model, prolactin contains four long α-helices 
arranged in antiparallel fashion (1).  
It shows a synergic effect with the following hormones: estrogens, progesterone and GH. 
 
This image is propriety of our laboratory and created by us. The data was taken from Benavides IZ, Castillo AP, 
Montemayor I, DeEstrada R,Onatra W, Posso H. Biorritmo de prolactina en mujeres de edad reproductiva 
vs.Perimenopáusicas.Rev Coloma Menop.2003;9:153–8.[16 Sep 2009].  
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Figure 3. Prolactin’s circadian rhythm 
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The nipple suction during breastfeeding favors a bigger amount of hormone synthesis. 
Besides, it’s one of the few physiological systems that have positive feedback, so the 
presence of prolactin in the organism favors this peptide production. 
Nipple and areola´s terminal nerves are stimulated when suction occurs. This stimulus 
travels via afferent nerve pathways to the hypothalamus, proving the prolactin release, by 
inhibition of the release of dopamine. (5-9) 
Prolactin levels during pregnancy rise from its normal value up to 200 or 400 ng/ml. This 
increase starts around the 8th week in a simultaneous way with the estrogen increasing. The 
rising in prolactin secretion is due to the suppression that estrogens provoke over dopamine 
and the direct stimulation of the transcription of the prolactin gene in the hypophysis. (8) 
Prolactin shows a circadian and pulsatile rhythm (figure 3) that starts raising 90 minutes 
after sleep beginning, with maximum peaks at 4-5 hours and it can stay high two hours after 
waking up (7-9). 
It is known that its discharges are 20-30 minutes intervals and the mean life is 20-30 minutes 
(7-11). 
The main circulating form is the monomeric prolactin (little prolactin) or native prolactin 
which is a non-glycosylated monomer that makes up the 80-90% of the total amount of 
prolactin in a normal individual. 
Another circulating form in the big prolactin (big PRL) which consist in glycosylated dimers 
or trimers of 40.000-50000 daltons molecular weight, which is supposed to be a deposit form 
which is rarely detected in serum and which biological activity is nearly non-existent. 
However, it is detected in hyperprolactinemia without any pathological clinical signs. 
Finally, big-big prolactin or macroprolactin wich is a dimer form of the big-PRL joined to 
IgG immunoglobulin with a molecular weight over 100000 daltons and without any 
biological activity (10-12). 
2. Effects 
The prolactin´s main function in women is to stimulate and maintain the puerperal 
breastfeeding, direct action over acidophilic cells known as lactotrophs cells of the 
mammary glands (6, 13). Estrogens, GH, corticoids, placental lactogenic hormones and 
prolactin are needed to increase the ductal system. Estrogens, progesterone and prolactin 
are needed to develop the lobuloalveolar system, so levels of these hormones should be 
considered in pathological states as fibrocystic mastopathy, mastodynia (breast pain), 
mammary carcinoma, etc. 
Among its effects over the mammary alveolar cells there is an increase of the lactose 
synthesis and a higher production of lactose proteins as casein and lactalbumin. 
It is related with the reproductive cycle, the pregnancy maintenance and the fetal growth, 
through an effect over the mother metabolism acting over different effector organs to 
facilitate its functions through synergy or inhibition of other hormones.  
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It shows a synergism with the gonadal steroid hormones  in the continuance of the corpus 
luteum and progesterone production, with action in the reproductive processes, according 
to some researches that revealed the presence of specific prolactin receptors in the 
mammal´s ovaries, transferring part of the progesterone function which, among other 
functions, stimulates the formation of membrane receptors for the follicle stimulating 
hormone (FSH) and the luteinizing hormone (LH) for the follicle growth and the estradiol 
synthesis. It was found, in the little antral follicles, a prolactin concentration 6 times higher 
than in circulation, when the follicle is 6-8 mm of diameter the levels drop, getting close to 
the basal blood levels near the ovulation (3, 4, 12, 14). 
Some secondary functions or less powerful have been reported, being related to 
androgenesis that takes part in the suprarenal cortex reticular area, where some specific 
receptors for prolactin have been found, the joint with those receptors stimulates the 
secretion of dehydroepiandrosterone and its sulfate.  
Prolactin has also an inhibitory effect over the gonadotropin secretion, so its hypersecretion 
can cause oligomenorrhea or amenorrhea in women (3,4, 14). 
In men, the prolactin behavior can affect the adrenal function, the electrolytic balance, 
gynecomastia, galactorrhea sometimes, libido decreasing and sexual impotence and some 
other actions in prostate, seminal vesicles and testicles (15-17). 
Prolactin serum levels have daily and circadian variations, its secretion is pulsatile, as 
described by Sassin et al, measuring blood levels every 20 minutes with raises up to 50% 
(13). 
It shows a circadian rhythm with increases or secretory peaks during the sleep, started 
between 10 minutes and one hour after sleep beginning and reaching the highest values 
mainly in the deepest stages. These values do not go down in the next two hours after 
waking up and decrease slowly by the end of the afternoon, without any tendency to be 
repeated in the same individual in the days after, once in circulation prolactin mean life is 
estimated around 14 minutes. 
It seems that variation during time and sleep are due to the hypothalamus dopaminergic 
stimulus modifications, the circadian fluctuation is not affected by the use of oral 
contraceptives (10-15). 
3. Limits of reference 
In blood, prolactin can be found from the 16th week of fetal life, increasing its levels due to 
active secretion, as in birth it shows higher amounts to the ones recorded in the mother. 
The normal described limits (figure 4 y 5) for healthy population are the following: 
 Men: 2 - 18 ng/mL 
 Non-pregnant women: 1 - 46 ng/mL 
 Pregnant women: 35 - 600 ng/mL 
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The nipple suction during breastfeeding favors a bigger amount of hormone synthesis. 
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It shows a synergism with the gonadal steroid hormones  in the continuance of the corpus 
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Figure 4. Prolactin’s limits of reference (I) 
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The limits of reference change according to the studied population showing very 
pronounced individual variations, even in age and sex groups. 
In fertile women the levels show a light elevation during ovulation and the luteinic phase, 
concerning to the follicular phase, corresponding to the endogenous estrogens liberated by 
the ovaries, which reduce the prolactin inhibitory factor in the hypothalamus increasing the 
amount of lactotroph cells as demonstrated in rats by stimulation although that effect 
depends on the dose and duration of the application, but it used to be shown by 24 hours (3, 
12-15). 
In postmenopausal woman and elderly men, levels go down, it is not clear if it is due 
pituitary deficiency or gonadal insufficiency, showing some role in gonadal function and 
aging. 
The presence of different nonspecific stimulus, as the coitus, exercises, stress situations as 
surgery, insulin hypoglycemia course….can cause variations in prolactin secretion, some of 
the can have an adaptive nature, as them one occurred in hypoglycemia (12). 
Because of what we mentioned previously, it is recommended to take from 2 to 3 samples to 
determine the prolactin level after 9 am to avoid late effects at night and hypoglycemia. 
4. Hyperprolactinemia 
As it has been described before, prolactin is secreted by lactotroph cells from the anterior 
hypophysis and it is subjected to the dopamine inhibitory effect in the hypothalamus. Any 
cause which interferes in its synthesis, the transport to the pituitary gland or the action over 
the dopamine receptors can produce hyperprolactinemia (Table 1). 
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Antipsychotics: phenothiazine (chlorpromazine, perphenazine, fluphenazine, thorazine, 
promazine, fluoperazine, trifluoperazine, etc.), haloperidol, butyrophenone. 
Other dopaminergic blockers: metoclopramide, sulpiride, domperidone, cisperidone, 
cisapride. 
Antidepressant: monoamine oxidase inhibitors (imipramine), amoxapine, Tryciclic 
antidepressants. 




Opiates: cocaine, morphine, heroine. 
Benzodiazepine 
Cimetidine (iv) 




Adrenergic receptor antagonists (medroxalol) 
Neurogenic causes
Thoracic wall lesions 




Chronic renal insufficiency 
Liver cirrhosis 
Suprarenal insufficiency 
Polycystic ovary syndrome 
Convulsions 
Idiopathic macroprolactinemia 
GABA: Gamma-aminobutyric acid 
HRT: Homone replacement therapy 
Iv: intra-venous 
Table 1. Hyperprolactinemia causes 
The most important cause of hyperprolactinemia is the secretory pituitary adenoma. 
Nevertheless, the most common cause are drugs and, when it is possible, the serum 
prolactin determination should be done once those are suspended. 
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5. Physiological causes 
1. Pregnancy 
Serum prolactin rises in a progressive way during gestation, but in a variable manner (18-
19). At the end, the mean value is around 200 ng/ml but the range is 35-600. 
Around the 6th week from the labor the normoprolactinemia is restored. Although the 
prolactin concentration is high before the labor, the milk secretion only takes place after it, 
because the high presence of estrogens and progesterone in pregnant women has an 
inhibitory effect over the milk secretion. When these hormones levels drop after the labor, 
lactation is produced. 
During gestation the prolactin levels in the amniotic liquid can reach the 1000 ng/ml, higher 
concentration that any other organic fluid, this happens around the 15th and the 20th week of 
gestation and it drops slowly until the end of the pregnancy to 450 ng/ml. It is supposed to 
be produced by the fetal and the mother´s hypophysis, with a possible function of fetal 
osmoregulation to survive in the intrauterine liquid environment, helping and contributing 
to the pulmonary maturing raising the content of phospholipids and changes in the lecithin-
sphingomyelin ratio (20). 
2. Breast stimulation 
Nipple suction, probably by neural via, during breastfeeding, rises the serum values of 
prolactin, especially in the first weeks after giving birth in direct relation to the lactotroph 
hypertrophy by the estrogenic stimulus of the pregnancy (18-20) 
3. Stress 
Any kind of stress, physical or psychical, can cause hyperprolactinemia, which is normally 
slight, and rarely over 40 ng/ml. 
4. Sexual contact 
There is a dopamine decreasing after orgasm, immediately, the prolactin rises, in men and 
women, acting as a sexual satiation mechanism (21). In men, without any doubt contributes 
to the “turn around and snore” phenomenon. In women, its effects can be delayed. 
Kruger TH et al have demonstrated that sexual intercourse with orgasm induced not only 
the well-established immediate prolactin increasing of 300% but also an additional prolactin 
elevation around noon of the next day. These fluctuations were measured on top of regular 
circadian rhythm (22). 
6. Pathological causes 
Pathological hyperprolactinemia can be caused by: lactotroph hyperplasia, lactotroph cells 
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1. Lactotroph hyperplasia 
Lactotroph hyperplasia derives, in most cases, from the decrease of the dopamine 
inhibitory tone over the lactotroph cells. Hypothalamic and pituitary stalk lesions can 
cause light or moderated hyperprolactinemia, normally less than 150 ng/ml (18-19, 23). 
The most common cause of hyperprolactinemia are the drugs. Any substance that acts 
over the central nervous system can, potentially, change the prolactin serum levels. 
Generally, the serum prolactin concentration increase a few hours or days after the drug 
administration and it gets normal from 2 to 4 days after its suspension.  
Drugs can be divided in two big groups: drugs that act over the hypothalamus altering 
the dopamine metabolism and the drugs that act directly over the hypophysis. These 
last ones are more powerful and its action mechanism is dopamine antagonist, 
displacing it from its receptor in the lactotroph cell. Examples of these are the 
metoclopramide, sulpiride and domperidone. The Antihypertensives as reserpine and 
methyldopa act in the hypothalamus. Cimetidine and similar substances stimulate the 
receptor H2 and provoke the hyperprolactinemia. 
The hyperprolactine grade depends on the drug, for example, haloperidol can provoke 
rises lower than 20 ng/ml, but the risperidone can raise it over 100 ng/ml (19). 
Estrogens rise the prolactin secretion and explain the higher response of prolactin in 
women in the presence of the different physiological stimulus. 
Besides, up to a 30% of the patients with polycystic ovary syndrome show a light 
hyperprolactinemia, and the treatment with dopaminergic agonists can, in some cases, 
normalize the menstrual cycle. 
The primary hypothyroidism is associated with a slight increase of the prolactin serum 
concentration in a 40% of the patients, but values over 25 ng/ml appear in less of the 
10% (19, 23). 
2. Lactotroph cells adenoma: prolactinoma 
It is the most frequent secretory pituitary tumor and it represents a 60% of the operating 
tumors. The 90% of the prolactinomas are intrasellar microadenomas (<10 nm). 
In women, over 90% are microadenomas, especially between 20 and 40 years old (2, 3). 
In male, the 60% are macroadenomas and it is because the poor symptoms, the delay of 
the medical visit for erectile dysfunction or a higher growth rate (19). 
Prolactinomas are the most common pituitary tumors and they are, normally, benign. 
They are more frequent in women, but they can also appear in men. The symptoms that 
they cause, if the symptoms appear, are related to prolactin excess and so, the milk 
production in non-pregnant women, which is called galactorrhea. 
Prolactinoma, the same as other pituitary neoplasms, comes from a monoclonal expansion 
of a cell that has mutated (18, 19, 23). It is usually sporadic and benign and it is rarely 
malign and metastatic. 
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Sometimes, it takes part of the type one multiple endocrine neoplasms (MEN). It is the only 
pituitary tumor with an effective medical treatment. 
The prolactinoma natural history shows that over 90% of the microadenomas do not grow 
and they do not progress to macroadenomas, that suggest that these have a different 
biological behavior to the microadenomas (19, 24-27), Most of the times the lactotroph 
cells are the only ones affected but up to a 10% can alter, as well, the somatotropes or 
the mamosomatotropes, and a prolactin and growth hormone (GH) co-secretion is 
produced. 
Prolactinoma can lead to: 
- Interruption of the pulsatile secretion of the gonadotropin releasing hormone (GnRH) 
with inhibition of the gonadal steroids production and can provoke infertility and 
hypogonadism. 
- Compression over adjacent structures. 
- Deleterious effects over the organism, specifically the skeleton.  
Prolactin secretion by the prolactinoma is characterized by: 
1. Its efficiency: even small tumors, smaller than 1 cm, can produce significant 
hyperprolactinemia. 
2. Its proportionality: usually, the prolactin serum concentration rises in direct relation to 
the adenoma size: 
- < 1cm is associated with serum prolactin values under 200 ng/ml. 
- Between 1 and 2 cm usually leads to values between 200 and 1000 ng/ml. 
- > 2 cm leads to prolactinemia over 1.000 ng/ml. 
Discrepancies are frequent: 
1. Big tumors with light hyperprolactinemia: they are usually atipic prolactinomas, worse 
differentiated and, so, less sensitive to therapy  with dopaminergic agonists and more 
susceptible to surgical treatment. 
2.  Hook effect: very high levels of prolactin secreted by the macroadenoma saturate the 
assays and lead to an apparently low value (between 20 and 200 ng/ml), which could 
confuse the macroprolactinoma with a non-secretory macroadenoma. It is produced by 
interferences in the enzime inmunoassays for prolactin and it can be settled by serum 
dilution to 1:100, which will show the real prolactin serum values secreted by the tumor 
(19, 28-29). 
7. Miscellaneous 
1.  Decrease of the prolactin clearing: 
a. Chronic renal insufficiency. (CRI) 
The hyperprolactinemia appears in most of the patients with CRI and dialysated. When 
these patients take medication that can alter the hypothalamic regulation of the 
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prolactin, this can take to serum values over 2000 ng/ml. It is produced by a decrease of 
the glomerular filter, although a pituitary primary defect associated to a renal failing 
cannot be dismissed. 
b. Macroprolactinemia.  
In some patients with hyperprolactinemia without a perceptible cause or idiopathic, 
this could be due to an excess of macromolecules of prolactin, known as macroprolactin 
or big prolactin. The macroprolactin is a complex of prolactin joined to an IgG antibody 
with a low bioactivity but with a higher mean life than normal prolactin, of 23 kDa, 
which condition its lower clearing and the consequent accumulation of high serum 
concentrations. 
To distinguish it from other causes, some samples of serum with polyethylene glycol 
should be precipitated (13, 19-20). 
This prolactin variety can be present in over 10% of the patients with 
hyperprolactinemia, and its presence should be suspected in every hyperprolactinemia 
without a defined etiology, with poor or nonexistent symptomatology, despite of the 
high prolactin serum concentrations and with poor or nonexistent response to normal 
therapy with dopaminergic agonists (13,19-20, 28-30).  
This situation can lead to unsuitable diagnosis and treatments in patients with 
hyperprolactinemia, but usually without clinical significance. Every hyperprolactinemia 
assay should consider the possible presence of macroprolactinemia (19, 30). 
When the cause is not found and the imaging tests are negative, the hyperprolactinemia 
is defined as idiopathic. In most of the cases they are small microadenomas. A 10% of 
them will be visible between 2 and 6 years. In other cases it is a transitory and self-
limited disorder that can be solved spontaneously (19,31). 
2. Hyperprolactinemia related to psychotropic drugs 
Prolactin determinations will not be needed in individual under psychotropic treatment, but 
if there is indicative clinical symptoms of hyperprolactinemia. 
However, in a patient with hyperprolactinemia under psychotropic drugs, among others, 
subsequent studies (hormonal and imaging) will be performed only if: 
- There are clinical symptoms derived from hyperprolactinemia. 
- There are prolactin serum concentrations over 6 times the normal value. 
The assessment of the new patient should be done ideally 3 months after the medication 
suppression or, if not possible, the possibility of a substitutive medication that does not 
provoke hyperprolactinemia should be assessed, always under psychiatric control. 
It is normally not recommended the dopaminergic agonists use in a combined 
form to psychotropic or dopaminergic antagonist drugs because of the undesirable effects. 
(19,20). 
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8. Assessment and diagnosis of the hyperprolactinemia 
Because the secretion of the prolactin is pulsatile, it is advisable to determine the serum 
prolactin in, at least, 2 times or more. 
To the most of the clinical laboratories, the normal serum concentration is less than 25 ng/ml 
in women and 20 ng/ml in men. 
(Note: conversion factor: mU/l × 0,0472 =ng/ml; ng/ml × 21,2 = mU/l.) 
The determination should be done, ideally, in a basal situation, under rest conditions and 
after suppression of any medication that can interfere in its quantification. 
The clinical records are determinant to the hyperprolactinemia treatment: 
- The data collection, especially about drugs, must be meticulous. 
- Other non-pituitary causes should be dismissed: pregnancy, thyroid, renal, hepatic and 
adrenal dysfunction. 
- We should investigate the existence of compressive symptomatology like cephalalgia, 
chiasmatic syndrome, liquorrhea and pituitary dysfunction data related to the pituitary 
tumor presence. 
Values of serum prolactin can lead to the diagnosis (figure 6): 
- Serum concentrations slightly raised (20-40 ng/ml) require confirmation before 
cataloguing the hyperprolactinemia state. 
- Prolactin serum values between 20 and 200 ng/ml can appear in iatrogenic or 
extrapituitary hyperprolactinemia. 
- Serum values between 40 and 100 ng/ml appear in secondary and idiopathic causes and 
less frequently in some microprolactinomas. 
- Serum concentrations between 100 and 200 ng/ml, ruled out the pregnancy, are 
characteristic of a prolactinoma. 
- Values over 200 ng/ml appear in macroprolactinomas. 
It is convenient to insist in the importance of differentiate between the big pituitary non-
secretory macroadenomas, that apply compression to the pituitary stalk and can curse with 
prolactin serum values that are not too high, generally lower than 200 ng/ml (pseudo-
prolactinoma) from the real macroprolactinomas, which usually show prolactin serum 
concentrations over 200 ng/ml. 
The first ones are susceptible of surgical treatment, while the prolactinomas are treated, 
most of them, with medical treatment. In a same way, low prolactin serum concentrations 
can coexist with uncovered small tumors in an incidental way, and they can lead to false 
diagnosis of microprolactinoma (19, 33). 
Nevertheless, values between 20 and 200 ng/ml, in presence of a macro-lesion, obliged to 
reassess the samples using a dilution of 1:100 to dismiss the hook effect described previously 
and according to it very high values of serum prolactin saturate the assays and lead to an 
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apparently low value, that could confuse the macroprolatinoma with a non-secretory 
macroadenoma (31). 
 
This image is propriety of our laboratory and created by us. 
Figure 6. Diagnosis of the hyperprolactinemia 
The dynamic tools of suppression or stimulation of prolactin (TRH, L-dopa, etc.) offer 
inconsistent results and should be rejected (19). In the study of the pituitary gland 
functionalism, in the case os a microadenoma, the determination of the basal pituitary 
hormones would be normally enough. 
On the other hand, the presence of a macroadenoma would make advisable a deepest 
anterior hypophysis study. 
9. Protocol of samples extraction to determine the serum prolactin 
Prolactin measurement is subjected to a very careful extraction protocol, because most of the 
errors happen in the pre-analytic stage (between 53-75%) (20, 32). 
Due to some physiological stimulus that rise prolactin levels, it is recommended to use 2-3 
samples obtained at different times to assure that a patient suffers hyperprolactinemia (19-
20). 
Some clinical guides as the “Pituitary Society Guidelines” (35) recommend the 
macroprolactin screening under certain conditions (moderate increase of prolactin levels 
and the patient should not show typical symptoms associated to hyperprolactinemia). Other 
authors recommend the macroprolactin screening performing to all those samples that show 
high prolactin concentrations (19, 20, 36). 
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Our work team has developed a protocol to optimize the samples extraction and the 
monomeric prolactin measurement, when values are above the reference limits (19). This 
procedure has shown to reduce the amount of false hyperprolactinemias if compared to the 
direct puncture technique, because this eliminates the possible increase of prolactin due to 
stress puncture. 
In our protocol (figure 7), patient visit us at 8.00 a.m., following the pre-analitic 
requirements for prolactin measurement (table 2). Then we place a micro-diffusor 
(canalizing the vein, which stays permeable, salinizing the blood vessel puncture). Once it 
has been 60 minutes since the micro-diffuser placement, we will extract the blood sample. 
 
 
This image is propriety of our laboratory and created by us. 
Figure 7. Protocol of extraction samples to determine the serum prolactin 
 
 Being awake 2 hours before extraction and without making any physical effort. 
 Avoid high-protein diet from the day before the extraction 
 Avoid high-fat diet from the day before the extraction. 
 Avoid breast stimulation from the day before the extraction. 
 Be 8-10 hours of fasting prior to extraction. 
 Do not take medications that may increase or decrease prolactin. 
 Be relaxed and rested for at least 30 min before extraction. 
 Do not be under stress.
Table 2. Conditions for the extraction of prolactin 
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The monomeric fraction determination was performed when we found high prolactin levels 
after 60 minutes, then we perform the macroprolactin precipitation through PEG 6000 
(20, 36) 
Polyethylene glycol was mixed in equal parts with the patient serum, then it was stirred and 
centrifuged. Prolactin was measured in the supernatant (monomeric prolactin). 
We show in our report the prolactin measure at 60 minutes, the percentage of recuperation 
after precipitation with PEG 6000 and the monomeric prolactin (we add in a note this is the 
fraction that has biological activity). 
10. Imaging techniques 
Neuro-imaging studies must be performed with any hyperprolactinemia degree that cannot 
be explained with the purpose of dismiss the hypothalamic-pituitary diseade. 
The Magnetic resonance imaging (MRI) with gadolinium gives the most precise anatomical 
details, and let us measure the tumor size and its relation to the optical chiasma and the 
cavernosus sinus, that is why this is, nowadays, the best imaging technique (19, 32). If MRI 
is normal, after excluding other hyperprolactinemia causes, we should talk about idiopathic 
hyperprolactinemia. 
Computed tomography with intravenous contrast is less efficient than MRI in small 
adenomas diagnosis and the definition of big tumors, but it can be used if MRI cannot be 
used or if it is contraindicated. The rest of the image techniques that are more usual like X-
Rays and isotope techniques are not recommended. (37). 
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